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Abstract 
The genetic composition of arboviruses is a critical determinant of viral infectivity and the 
capacity for  virus dissemination in arthropod vectors. Due to concerns related to a hypothetical potential 
for loss of attenuation,  the supression of   vector infection and dissemination is a  critical component for 
the rationale-based design of  live-attenuated flavivirus vaccine candidates. The yellow fever virus (YFV) 
17D vaccine virus is not only attenuated in vertebrates, but also has low infectivity for Aedes agypti 
mosquitoes and since it does not disseminate, it is not transmissible.  Using a reverse genetics system,  the 
mutations  present in the envelope protein  YFV 17D virus were characterized in Ae. aegypti to determine 
the role of mutations in limiting the viral infectivity and dissemination capacity.   This knowledge would 
contribute to the rational design of live attenuated vaccines with the desirable phenotype of being non-
transmissible by arthropod vectors. 
The upper lateral portion of the YFV 17D envelope (E) protein domain III (EDIII) habors the 
T380R mutation in the FG loop. Experiments demonstrated that the  T380R mutation was associated with  
the viral infectivity phenotype for mosquitoes, but did not influence  dissemination into the secondary 
tissues. The G52R mutation in the molecular hinge region that is located between E protein domains I 
(EDI) and II,  significantly reduced  viral infectivity for mosquitoes. In contrast, when cloned into the 
Asibi wildtype virus genetic backbone, the T173I mutation in the loop structure between the G0 and H0 β-
strands did not  attenuate  viral infection and dissemination. The double mutant virus  containing both  the 
G52R and T173I mutations in the E protein, showed a  similar attenuated reduced infectivity to the single 
G52R mutant.  The M299I mutation in the linker region between EDI and EDIII resulted in a significantly 
lower viral infectivity at the initial phase of viral infection at 7 days post-infection in Ae. aegypti. 
In conclusion, the characterization on four mutations in the YFV 17D vaccine E protein have 
demonstrated three genetic loci, that can influence  the process of YFV infection in Ae. aegypti. These 
results provide  new knowledge and understanding which may  have broad applications for the rationale 
design of safe flavivirus vaccines, via  targeting  genetic loci and  introducing specific  mutations that 
preclude infection of, and transmission by arthropod vectors.   
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mutations  present in the envelope protein  YFV 17D virus were characterized in Ae. aegypti to determine 
the role of mutations in limiting the viral infectivity and dissemination capacity.   This knowledge would 
contribute to the rational design of live attenuated vaccines with the desirable phenotype of being non-
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T380R mutation in the FG loop. Experiments demonstrated that the  T380R mutation was associated with  
the viral infectivity phenotype for mosquitoes, but did not influence  dissemination into the secondary 
tissues. The G52R mutation in the molecular hinge region that is located between E protein domains I 
(EDI) and II,  significantly reduced  viral infectivity for mosquitoes. In contrast, when cloned into the 
Asibi wildtype virus genetic backbone, the T173I mutation in the loop structure between the G0 and H0 β-
strands did not  attenuate  viral infection and dissemination. The double mutant virus  containing both  the 
G52R and T173I mutations in the E protein, showed a  similar attenuated reduced infectivity to the single 
G52R mutant.  The M299I mutation in the linker region between EDI and EDIII resulted in a significantly 
lower viral infectivity at the initial phase of viral infection at 7 days post-infection in Ae. aegypti. 
In conclusion, the characterization on four mutations in the YFV 17D vaccine E protein have 
demonstrated three genetic loci, that can influence  the process of YFV infection in Ae. aegypti. These 
results provide  new knowledge and understanding which may  have broad applications for the rationale 
design of safe flavivirus vaccines, via  targeting  genetic loci and  introducing specific  mutations that 
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Chapter 1 - Introduction to Arbovirology 
 1.1 Definition and biology of arboviruses 
According to the World Health Organization (WHO), arthropod-borne viruses (arboviruses) 
are defined as “viruses which are maintained in nature principally, or to an important extent, 
through biological transmission between susceptible vertebrate hosts by hematophagous 
arthropods” (WHO 1967). The  term  being  “arthropod-borne” with respect to pathogen 
transmission was first  used for animal viruses that cause encephalitis in infected vertebrate hosts 
in 1942 and the term of “arbovirus” was officially recommended by the International 
Subcommittee on Viral Nomenclature in 1963 (WHO 1967, WHO 1985). Over 500 arboviruses 
have been recognized and more than 130 of them cause human diseases with a broad spectrum of 
clinical manifestations (CDC 1975). Among those with human and veterinary public health 
significance, the majority of them belong to different virus families including Togaviridae, 
Flaviviridae, Bunyaviridae, Reoviridae and Rhabdoviridae.  
Arthropods are classified under the kingdom Animalia, phylum Arthropoda, class Arachnida 
and Insecta. The first demonstration of a pathogen being transmitted by an arthropod was the 
transmission of filarial nematodes by mosquitoes by Sir Patrick Manson in 1876. Subsequently, 
groups of arthropods that were found competent for the transmission of arboviruses include ticks 
(class Arachnida, order Ixodida, families Ixodidae and Argasidae); mosquitoes (class Insecta, 
order Diptera, family Culicidae); biting midges (class Insecta, order Diptera, family 
Ceratopogonidae); black flies (class Insecta, order Diptera, family Simuliidae); sand files (class 
Insecta, order Diptera, family Psychodidae) and tabanid flies (class Insecta, order Diptera, family 
Tabanidae) (Eldridge and Edman 2003, Marquardt and Kondratieff 2005). Although the early 
definitions of arboviruses required the virus to be maintained in nature through biological 
transmission, the modes of transmission can also be mechanical transmissions. In biological 
transmission, the propagation or the development of the pathogens take place in the vector prior 
to the transmission to another vertebrate host. Biological transmission also includes other 
variants such as transovarial transmission, which has been demonstrated primarily among the 
members of the family of Bunyaviridae (Watts, Pantuwatana et al. 1973, Borucki, Kempf et al. 
2002). The contamination in the mouthpart of arthropod vectors by pathogens leads to the 
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mechanical transmission, where mosquitoes serve as “flying syringes” for arboviruses. However, 
both modes are not mutually exclusive or inclusive. The mechanical transmission by arthropods 
also has been reported in pathogens that are not known to be classified as arboviruses(Eldridge 
and Edman 2003).  
Pathogen transmission between vertebrates typically involves arthropods that feed on blood 
i.e. are hematophagous. Although hematophagy occurs in many arthropod groups, not all blood-
feeding arthropods are competent for the biological transmission of pathogens due to the 
requirement of permissive cells for the propagation of pathogens in vivo. To be classified as 
competent vectors for arboviruses, the permissive arthropod species in nature fulfill  the 
epidemiological and ecological definitions of disease vectors, including:  the isolation or 
detection of the pathogens in the absence of visible blood in the digestive system, the infection 
after the acquisition of viremic body fluid either from vertebrate hosts or artificial apparatus, the 
transmission of pathogens by inoculating the saliva through the bites, and having a proven role 
with respect to the epidemiological association with diseases and the ecological association with 
susceptible vertebrate hosts (WHO 1967, WHO 1985). The competence of pathogen vectors is 
subjected to the control over multiple factors that influence the efficiency of the transmission 
including the innate susceptibility to the pathogens, the longevity through adverse environmental 
and climate conditions prior to the transmission to vertebrate hosts, the abundance of the vector 
population and the susceptible vertebrate hosts and the likelihood of physically in contact with 
the vertebrate hosts. Mosquitoes are considered one of the most important vectors for various 
arboviruses with medical or public health importance. The members of both the subfamilies of 
Anophelinae and Culicinae are competent of transmitting specific arboviruses by feeding on 
vertebrate hosts. The propagation of arboviruses in the permissive tissues in the midgut cuboidal 
epithelial cells and the dissemination into secondary tissues occur before the transmission of 
arboviruses. The presence of infectious virus in the saliva due to the replication of virus in 
salivary gland acinar cells and the release into the salivary ducts leads to the transmission of the 
arboviruses as the vector feeds on the vertebrate. The time required for the propagation and the 
development of arboviruses, from initial feeding on an infected host to release of virus in the 
saliva, is defined as extrinsic incubation period. Throughout the virus transmission cycle, several 
barriers that may limit infection and dissemination in the vectors have been proposed. A midgut 
infection barrier determines the susceptibility of specific vector species to arboviruses and the 
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midgut escape barrier governs the successful dissemination into other tissues. The efficiency of 
infection amongst specific vectors is also determined by the viremic titers of the vertebrate 
hosts(Barnett 1956, Gubler and Rosen 1976, Tesh, Gubler et al. 1976). The details of the biology 
of mosquitoes and mosquito-virus interactions is further described in Section 1.2. 
The complexity of the field of arbovirology is in part due to the nature of the arbovirus 
transmission cycle depending on alternation between the vertebrate hosts and arthropod vectors. 
Although the tools available for the studies in the laboratory and field have led to significant 
advancement in the knowledge on both the viruses and vectors, critical gaps in our knowledge 
still exists. It has long been known that only certain species of arthropod can transmit a given 
pathogen, and indeed even within a species, there is considerable variation in the susceptibility to 
infection with that pathogen and ability to transmit. Intuitively, it has been assumed that genetics 
of the arthropod control this variation in competence as a vector, but other factors including 
pathogen genetics and environmental factors also play a role. Despite publication of papers that 
suggested an understanding of vector competence, we still do not know the basis of species 
specificity for any mosquito-virus relationship. Vector competence for arboviruses is determined 
by several intrinsic and extrinsic factors including the environmental conditions, the genetics and 
the physiological conditions of the vectors (Tabachnick 1994). Using western equine encephalitis 
virus (WEEV) and Culex tarsalis as an experimental model, it was proven that the viral 
replication and dissemination in the infected mosquitoes can be impaired at relatively  higher 
extrinsic incubation temperature of 32˚C(Kramer, Hardy et al. 1983). Additional factors that 
influence vector competence were also reported including the nutritional conditions at the larval 
stage and the variations in the viral population (Miller and Adkins 1988, Kay, Edman et al. 
1989). The quasispecies nature of RNA viruses also led to observed variations in vector 
competence. The variants of YFV selected based on the plaque morphologies demonstrated the 
different capacity of dissemination in Ae. aegypti (Miller and Adkins 1988). There have been 
several lines of evidence suggesting that the same vector species obtained from different 
locations displays significant variation in vector competence for arboviruses including Ae. 
aegypti collected from various locations with the different ability of transmitting dengue viruses 
(DENV) and YFV (Gubler and Rosen 1976, Tabachnick, Wallis et al. 1985). The 
characterization of the underlying genetic basis in the laboratory that controls vector competence 
was initially performed by selecting susceptible and refractory strains of mosquitoes, and mating 
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between strains of different susceptibility (Hardy, Apperson et al. 1978, Wallis, Aitken et al. 
1985, Bosio, Beaty et al. 1998). Although the mating experiments suggested that the 
susceptibility is genetically linked, the identification of single genetic loci that govern the vector 
competence has not been accomplished. Some progress has been made with the advancement of 
molecular techniques to manipulate viral genomes and more recent characterization of vector 
genetics. The revolutionary technique polymerase chain reaction has allowed the amplification of 
the genetic materials of mosquito vectors, which can be subsequently subjected to the genetic 
polymorphisms analysis. For Ae. aegypti and dengue virus serotype 2 (DENV-2), the 
quantitative trait loci analysis, which was based on the quantitative traits established by either the 
continuous distribution of the virus titers in infected tissues of mosquitoes or the percentage of 
viral infection and dissemination,  has  provided evidence that vector competence is determined 
by multiple genetic loci (Bosio, Beaty et al. 1998, Bosio, Fulton et al. 2000). Characterization of 
the genomic sequences in multiple mosquito species is expected to ultimately provide the critical 
knowledge on the preferential association of the members under the subfamily of Culicinae for 
the transmission of small enveloped RNA viruses in the families of Flaviviridae and 
Togaviridae. With respect to this goal, the genomic sequences of Anopheles gambiae, Ae. 
aegypti and Cx. quinquefasciatus have now been completely determined (Holt, Subramanian et 
al. 2002, Nene, Wortman et al. 2007, Arensburger, Megy et al. 2010). In contrast to the approach 
taken by analyzing the ampilicons of randomly probed or specific genes, the availability of 
genomic data has provided some critical details on the ecology of flaviviruses. For example, the 
largest number of olfactory-receptor-related genes encoded in the genome of Cx. 
quinquefasciatus may contribute to the opportunistic feeding behaviors on multiple vertebrate 
animals and explains the zoonotic nature of West Nile virus (Arensburger, Megy et al. 2010). 
Similarly, the wide host range of Cx. quiquefasciatus is also reflected by the presence of several 
unique proteins present in the saliva, which allows the acquisition of bloodmeals from humans, 
birds and other mammals (Ribeiro and Arca 2009). However, the currently available knowledge 
is still insufficient to define the specific genetic determinants required for the vector competence 
or refractoriness of arboviruses among the mosquitoes in nature. An impetus for such studies has 
been the idea that new control methods for vector-borne disease could be developed based on 
manipulation of the vector genome to effectively reduce competence. The approach can be taken 
by introducing genetic components that prevents the mosquitoes from completing the lifecycle 
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followed by the selection based on the selectable markers such as chemical compounds or 
fluorescent proteins at laboratory rearing facilities. With the remarkable success of the 
elimination of New World screwworm, a modified Sterile Insect Technique (SIT) has been 
devised for mosquitoes to produce laboratory-reared genetically altered male arthropods that 
compete with the wildtype male and produce no or fewer progeny. Ae. aegypti was transformed 
to contain the genetic lethality, which is suppressed by tetracycline under laboratory conditions, 
and the males were released to introduce the lethal gene to the populations in nature in order to 
suppress the vector population (Phuc, Andreasen et al. 2007). The other method utilizes the 
obligatory intracellular bacteria Wolbachia. The mating between an infected male Ae. aegypti 
and an uninfected female results in the embryonic lethality and the elimination of uninfected 
mosquitoes in the population. Additionally, the infection of Wolbachia led to the phenotypic 
changes of mosquitoes by not only shortening the life span but also by  reducing the 
susceptibility to arboviruses (Walker, Johnson et al. 2011). Another approach that has been 
considered is to utilize the innate immunity components of mosquitoes targeting the viral genetic 
materials. The transformation of Ae. aegypti with the short sequences which are transcribed into 
the siRNA products targeting the DENV-2 prM gene. These have been shown to be effective to 
introduce resistance to DENV-2 (Franz, Sanchez-Vargas et al. 2006). However, the resistance 
was later reported to be transient within the limited generations after the transformation (Franz, 
Sanchez-Vargas et al. 2009). The development of novel tools for the potential control and 
prevention of arboviral diseases targeting both the viral and vector components have been 
actively and continuously conducted. It provides an alternative approach to block the 
transmission of arboviruses at the stage of mosquitoes in addition to the control of vector 
populations. In spite of all the efforts, the options for prophylaxis and antivirals remain limited. 
The public health measures for disease control and prevention still rely heavily on vaccines and 
the vector control. 
The list of arboviruses has rapidly expanded with the advancement of tools developed for 
the molecular detection and identification of new viruses. It is unlikely to provide an up-to-date 
comprehensive list of arboviruses or mosquito-borne viruses. The following paragraphs and table 
(Table 1.1) provide a list of selected mosquito-borne viruses of human or veterinary public 
health importance. 
Genus Name Major vector(s)  Geographic distribution 
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Flavivirus  Dengue viruses 
(DENV-1~4) 
Ae. aegypti 
Ae. albopictus 
Old world: Africa, Asia 
New world: America 
Japanese encephalitis 
virus 
Cx. tritaeniorhynchus Old world: eastern and 
southern Asia 
New world: northern 
Australia 
West Nile virus  Cx.tarsalis 
Cx. pipiens 
quiquefasciatus 
Old world: western Asia 
and Europe 
New world: north 
America 
St. Louis encephalitis 
virus 
Cx. pipiens 
quiquefasciatus 
New world: America 
Yellow fever virus Ae. aegypti New world: America 
Old world: Africa 
Alphavirus Chikungunya virus Ae. aegypti 
Ae. albopictus 
Old world: Africa and 
Asia 
New world: America 
Eastern equine 
encephalitis virus 
Culiseta melanura New world: America 
O’nyong-nyong virus Anopheles spp. Old world: Africa 
Sindbis virus Ae. aegypti Old world: Asia. Africa, 
eastern Europe 
Venezuela equine 
encephalitis virus 
Culex melanoconion 
spp. 
New world: America 
Western equine 
encephalitis virus 
Cx. tarsalis 
Cx. pipiens 
quiquefasciatus 
New world: America 
Orthobunyavirus California serogroup 
viruses 
Aedes spp. 
Culiseta spp. 
New world: North 
America 
Old world: Europe 
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Phlebovirus Rift Valley fever virus Aedes spp. Old world: Africa 
 
Table 1.1 Selected mosquito-borne arboviruses with human or veterinary public health 
importance 
 
 A. Flaviviruses 
Under the family of Flaviviridae, the genus of flavivirus consists of arthropod-borne viruses 
mainly transmitted by mosquitoes and ticks (Gould and Solomon 2008). Collectively, the 
flaviviruses are public health threats for over half of the global population, and become the 
category of arboviruses that have the highest human public health significance (Gubler 2002). 
The group of mosquito-borne flaviviruses, which display homology of their genome structures 
and virion morphologies, contains two major groups of viruses distinguished by their clinical 
presentations including; viral encephalitis caused by Japanese encephalitis virus (JEV) group and 
viral hemorrhagic fever caused by the DENV and YFV group. JEV, West Nile virus (WNV) and 
St. Louis encephalitis virus (SLEV), which all belong to the Japanese encephalitis group, are 
able to cause severe neurological diseases amongst infected individuals. The members of the 
JEV group infect multiple vertebrate species including equine species, avian species and human 
species through the bites of different vectors (Gould and Solomon 2008).  DENV consists of four 
serotypes of dengue virus (DENV-1, 2, 3, 4), which are transmitted mainly by Ae. aegypti and 
Ae. albopictus and cause a wild spectrum of diseases from febrile illness to severe diseases such 
as dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) without any currently 
available vaccines or antiviral therapies (WHO 2009). The members of the YFV and DENV are 
maintained by transmission between the susceptible primates and the vector species.  
 B. Alphaviruses 
Alphaviruses are mosquito-borne viruses categorized under the genus of Alphaviruses in the 
family of Togaviridae. There have been seven complexes identified based on the antigenic 
characteristics of the alphaviruses. Pathogenic alphaviruses in the old world tend to cause rash 
and arthritis whereas the new world alphaviruses lead to the encephalitic symptoms amongst 
infected humans. The analyses on the nucleotide and amino acid sequences and the antigenic 
properties suggested the homology in the secondary structures amongst different alphaviruses 
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(Knipe and Howley 2013). Although the number of reported human infections by alphaviruses is 
substantially lower than for flaviviruses, the significance of alphaviruses in human and 
veterinary public health is established based on its characteristics in nature often as emerging and 
zoonotic pathogens. For example, the total number of reported chikungunya virus (CHIKV) 
cases in Oceania and Asia since 2005 has exceeded 1.9 million (WHO 2014).  Sindbis virus 
which causes fever, rash and arthritis in humans has also been used as a genetic expression 
system through the genetic engineering of the subgenomic promoter in both vertebrate and 
invertebrate systems (Higgs, Powers et al. 1993). O’nyong-nyong virus (ONNV) is the only 
known alphavirus infecting the malaria vector Anopheles gambiae and causes large outbreaks 
(Williams, Woodall et al. 1965). Chikungunya virus recently has been spread rapidly and causing 
several epidemics in the Indian ocean and the southeast Asia due to the A226V mutation of the 
E1 protein, which has altered the vector specificity and epidemic potential (Tsetsarkin, 
Vanlandingham et al. 2007). Recently, CHIKV has also been detected as an emerging pathogen 
in the new world (Albuquerque, Marandino et al. 2012). Venezuela equine encephalitis virus 
(VEEV) causes high viremia in infected equine species and occasional human cases mainly 
reported in Latin America (Weaver and Barrett 2004). Western equine encephalitis virus was 
first isolated in California in 1930 and is transmitted primarily by Cx. tarsalis in its enzootic 
cycle and other bridging vectors, which feed on humans or equine species. Eastern equine 
encephalitis virus  (EEEV) with its geographic distribution along both the Atlantic coast and the 
gulf coast and in the mid-west causing a higher mortality in horses than WEEV through the 
transmission by Aedes, Coquilletidia and Culex species which feed on humans and horses (Zacks 
and Paessler 2010). 
 Although alphaviruses are classified under Togaviridae, alphaviruses and flaviviruses 
share the similar receptor binding and membrane fusion mechanisms classified as type II fusion 
protein.(Harrison 2008) The research on alphaviruses in mosquitoes provided several examples 
with respect to how viral genetics can determine the choice of vector species among related 
viruses in the same complex and alter the vector competence among the different strains of a 
single virus. The monoclonal-antibody-1A3B-7-resistant VEEV variant was shown to lose its 
capacity in the infection and dissemination in Ae. aegypti.(Woodward, Miller et al. 1991) In the 
study described by Brault et al., the S218N mutation in the E2 glycoprotein was identified as a 
genetic substitution which increased the viral infectivity of VEEV in  Ochlerotatus 
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taeniorhynchus.(Brault, Powers et al. 2004) Between the two closely related ONNV and CHIKV, 
which are vectored by Anopheles gambiae and Ae. aegypti, respectively, the genetic mapping 
between the genomes of ONNV and CHIKV demonstrated the choice of vector species is due to 
the distinct sequences in the structural genes. (Vanlandingham, Tsetsarkin et al. 2006) Such 
studies provided the mechanistic evidence that the different genetic composition of arboviruses 
are critical for the choice of vector species and the vector competence. 
 C. Bunyaviruses 
Most bunyaviruses can be transmitted by arthropod vectors except for Hantaviruses, which 
are mainly transmitted by rodents. Members of the genera of Orthobunyavirus and Phlebovirus 
have been described to be transmitted by mosquitoes; whereas members of the genus of 
Nairovirus are exclusively transmitted by ticks in nature (Knipe and Howley 2013). In the genus 
of Orthobunyavirus, the California serogroup viruses contain a large number of viruses present 
in various geographic locations and are mostly vectored by Aedes mosquitoes.  La Crosse virus 
(LAC) leading to encephalitic cases in infected children is maintained in rodents which can 
potentially develop high-titered viremia with limited symptoms and transmitted by Ae. triseriatus 
mosquitoes. Additionally, the infection of mosquito eggs is utilized as one of the strategies of 
overwintering. Horizontal transmissions also have been described from female mosquitoes to 
male mosquitoes (Watts, Pantuwatana et al. 1973). Members of the Phlebovirus genus are found 
worldwide except for Australia. Rift Valley fever virus (RVFV) infects both humans and 
livestock and utilizes Aedes mosquitoes as its vector in Africa. Large epizootic epidemics of 
RVFV cause serious economic loss due to the high abortion rates amongst infected ruminants 
(Weaver and Reisen 2010).  
 1.2 General biology of mosquitoes and mosquito-virus interactions 
 A. Taxonomy, morphology and evolution 
In the family of Culicidae under the order of Diptera, mosquitoes are classified under the 
suborder of Nematocera.  Mosquitoes are classified into three major groups known as the 
anophelines, the culicines and the aedines. The hematophagous feeding strategy renders 
mosquitoes the most important arthropod vectors with respect to human and veterinary public 
health. It is suggested the blood feeding behavior emerged independently during the course of 
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evolution and has become the significant approach utilized by pathogens to increase the mobility 
amongst various host species (Grimaldi and Engel 2005). All three groups of mosquitoes have a 
pair of wings, which is the major characteristic of the members in the order of Diptera. The 
morphology of the proboscis in female mosquitoes is distinct from that of the male mosquitoes. 
The long slender proboscis in female mosquitoes is required for the penetration of skin and the 
acquisition of blood from the host whilst the male mosquitoes are adapted to the acquisition of 
sugars from various sources. 
There have been at least six independent emergences of hematophagy during the 
evolution. It is believed that the evolution of hematophagy has been closely associated with 
vertebrate hosts in the environment. The hematophagy of mobile aerial insects may emerge as an 
occasional event in the presence of vertebrates and later transform to obligatory hematophagy. 
 B. Classification 
The subfamilies Anophelinae and Culicinae within the Culicidae are the two subfamilites of 
great public health significance. The Culicinae subfamily contains two tribes, which are Culicini 
(culicines) and Aedini (aedines). The third subfamily Toxorhynchitinae does not obtain blood 
from vertebrate hosts but has been used as a biological control agent based on its predaceous 
behavior at its larvae stage to other mosquito larvae. 
Complete metamorphosis occurs amongst all mosquitoes with an egg stage, four larval 
stages, a single pupal stage and the adult. The eggs of Culicine mosquitoes are held together by a 
concave raft on the surface of the water compared to the individual floating eggs deposited by 
the Anophelines. The Aedine mosquitoes utilize moist substrates to deposit eggs which hatch 
during the later flooding conditions. (Figure 1.1 (a))  Both the larvae of culicine and aedine 
mosquitoes have an elongated air tube for air exchange. The larvae of anopheline mosquitoes 
obtain oxygen by lying right underneath the surface of water without the air tube. (Figure 1.1 
(b)) The appearance of the pupae of most mosquito species is similar with very limited value for 
identification. 
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Figure 1.1 Eggs and larvae of mosquitoes 
(a) The individual eggs of anophelines, adenine and culicine mosquitoes are listed in the 
upper section of figure 1.1(a). The multiple eggs of Anopheline and Aedine mosquitoes and 
the egg raft of culicine mosquitoes are listed in the bottom section of figure 1.1(a) (b) The 
larvae of Anopheline, Aedine, and Culicine mosquitoes. (adapted from (Littig 1966))  
The relative importance of different vector species is based on the pathogens transmitted by 
the mosquitoes. The combinations of vectors and pathogens are also subjected to human 
behavior changes such as the increase of aviation transportation and deforestation. Ae. aegypti 
serves as the vector for viruses in both the family of Flaviviridae and Togaviridae including 
YFV, DENV and CHIKV amongst the tropical and subtropical regions worldwide (Rao 1964). 
There have been more than 40 species of Anopheles demonstrated to be able to transmit malaria 
parasites (Enayati and Hemingway 2010). Culex quinquefasciatus is responsible for the 
transmission of the lymphatic filariasis species and several other arboviruses (Simonsen and 
Mwakitalu 2013). St. Louis encephalitis virus  and WNV in North America and Tahyna virus in 
Europe utilize the same vector within the Cx. pipiens complex. Culex tarsalis is responsible for 
the transmission of western equine encephalitis virus and SLEV in western North America 
(Weaver and Barrett 2004). In Asia, the transmission of JEV depends on Cx. tritaeniorhynchus 
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as its vector (van den Hurk, Ritchie et al. 2009). Aedes (Neomelaniconion) macintoshi is 
important for the transmission of RVFV in Africa (Weaver and Reisen 2010).  
 C. Life cycle 
The time required for the development from larvae to adult varies from 10 days or less. It is 
subjected to the conditions of water including temperature, the abundance of nutrients and the 
larval densities. The larvae molt three times in order to progress to the fourth-stage larvae. The 
development to adult mosquitoes from pupae generally requires one or two days from the 
emergence of pupae.  
The plant nectar is the primary source of carbohydrates, which are subsequently stored in 
the crop or ventral diverticulum of both male and female adults(Marquardt and Kondratieff 
2005). Anautogenous mosquitoes require the blood meals for oviposition after the release from 
the arrest stage of oogenesis in the ovaries; whereas, the autogenous mosquitoes only require 
facultative bloodmeals (Spielman 1971). The behaviors of oviposition are subjected to multi-
factorial controls including chemical, physical and environmental factors. The extrinsic light 
cues are important stimuli for the Ae. aegypti, which lay the eggs towards the later afternoon 
(Surtees 1967). The oviposition patterns vary among species. Anopheles spp. lay individual eggs 
on the surface of aqueous bodies. The Culex spp. mostly produce egg rafts floating on the surface 
of the water. The deposit of individual eggs of Aedes spp. takes place on the most surface of 
substrates or vegetation (Bentley and Day 1989). The embryogenesis takes place along with the 
hardening and darkening of the chorion after oviposition.  
The process of blood-feeding, digestion and oviposition is referred to as the gonotrophic 
cycle, which is largely temperature dependent. The search of vertebrate hosts for blood feeding is 
a critical component for the transmission cycle of all vector-borne pathogens. The infected hosts 
serve as the source of pathogens, which render the vectors infectious and competent for the 
transmission to the next host. Therefore, the chance of transmitting the pathogens increases with 
the frequency of taking blood meals from the hosts. The acquisition of multiple bloodmeals 
during one single gonotrophic cycle has been reported in both malarial and arboviral mosquito 
vectors (Scott and Takken 2012).  
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 D. Host-seeking behavior 
The blood feeding behavior is not initiated until 1-2 days after eclosion (emergence of the 
adult from the pupa). Such period is defined as the previtellogenic period when the fat body 
matures and synthesizes the precursors of the yolk proteins (Deitsch, Chen et al. 1995, 
Sappington, Kokoza et al. 1996). The development of the blood feeding behavior amongst Cx. 
pipiens is controlled by the release of juvenile hormone (JH) (Spielman 1974). On the other 
hand, the development of host-seeking behavior of Ae. aegypti is JH-independent. The 
development of the midgut of the female Ae. aegypti is not complete until three days post 
eclosion making it less likely to consume blood (Bowen and Davis 1989, Marquardt and 
Kondratieff 2005).  
Mosquitoes respond to various chemical, physical and environmental stimuli as clues for 
locating the vertebrate hosts (Eldridge and Edman 2003, Marquardt and Kondratieff 2005). 
Carbon dioxide (CO2) has been considered the universal attractant for vectors. The change in the 
CO2 concentration triggers the behavioral changes of the mosquitoes through the CO2 receptors. 
The species-specific differential responses to CO2 may be the determinant of the preference of 
the host species (Dekker and Takken 1998). Synergistic effects of other volatile compounds such 
as lactic acid, acetone, and octenol in the presence of CO2 also assist the host-seeking behavior. 
The host-seeking behavior relies heavily on olfaction. Numerous cuticular sensilla on the 
segmented antennae and the maxillary palps are responsible for receiving the external stimuli. In 
spite of the diversity in the morphologies and the structures, the scaffold underneath the cuticle 
structure is well-conserved. The bipolar neurons function as olfactory receptors with the 
dendrites extending into the sensillum shaft. Other supportive cellular structures such as 
trichogen and tormogen cells are responsible for both the integrity of the structure and the 
synthesis of components required in the aqueous lymph. The odorant molecules diffuse through 
the pores and initiate the signal transduction by its binding to the receptors. It’s been postulated 
that the water-soluble odorant-binding proteins functions as the carriers to facilitate the 
movement and binding of odorant molecules. The intracellular signaling relies on the GTP-
binding proteins, which govern the downstream enzymatic synthesis of secondary messengers 
cyclic AMP (cAMP) and inositol 1,4,5-triphosphate (IP3) (Zwiebel and Takken 2004). The 
secondary messengers trigger the action of ion channels and lead to cellular depoloarization and 
the electropysiological signals to CNS. Negative regulation in the signaling pathway by reducing 
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the numbers of receptors on the cell surface and the decoupling of the active G-protein 
complexes can control the sensory response. Additionally, the degradation of odorant molecules 
by the biotransformation enzymes can thus control the olfactory process. Taken together, the 
host-seeking behavior of mosquitoes are regulated with multiple receptors and signaling 
pathways. The understanding at the molecular-, cellular- and systematic-level is still being 
developed. 
 E. Mechanisms of acquisition of blood meals 
The mouthpart of the mosquitoes is used to pierce through the outer epidermis and the 
inner dermis.  The mouthpart consists of the fascicle and the labium. The fascicle penetrates the 
skin during the acquisition of the blood whilst the labium is progressively bent during the 
process of probing (Marquardt and Kondratieff 2005). The blood vessels are later ruptured 
leading to the vasoconstriction, the formation of platelet plugs,  activation of coagulation 
mechanisms, the host pain and inflammation. Therefore, the saliva of mosquitoes contains 
several macromolecules such as anti-coagulant, immunomodulator and vasodialator (Schneider 
and Higgs 2008). Additionally, the secretion of the saliva during blood feeding allows the 
transmission of pathogens to take place. Ae. aegypti utilizes a salivary gland-specific apyrase 
which belongs to the 5’-nucleotidase family to impair the aggregation of platelets (Cupp, Ribeiro 
et al. 1998). It has also been reported the genome of An. albimanus encodes the salivary 
peroxidase/ catechol oxidase which promotes the vasodilation (Ribeiro and Valenzuela 1999). 
By degrading adenosine to inosine and ammonia, the adenosine deaminase of Ae. aegypti 
therefore delays the initiation of pain and the inflammation (Ribeiro, Charlab et al. 2001). It has 
also been suggested the neurotransmission is also impaired by the anaesthetic components of the 
Ae. aegypti saliva. The secretion of various macromolecules leads to the depletion of the salivary 
glands and promotes the resynthesis of the components of saliva (Hudson, Bowman et al. 1960).  
The cibarial and pharyngeal pump muscles facilitate the intake of the blood (Eldridge and 
Edman 2003, Marquardt and Kondratieff 2005). The ingestion of blood fills the hind most part of 
the midgut followed by the expansion of the anterior portion until the abdomen is filled. The 
determinants of the final location of the ingested meals have been suggested to be the 
components in the meals. Increase in the glucose concentration led to the dispatchment into the 
diverticulum (Day 1954). The blood-feeding action is driven by phagostimulants derived from 
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the cellular fractions of the host such as adenine nucleotides in the blood of the vertebrate hosts 
(Hosoi 1958, Friend and Smith 1977, Galun, Vardimon-Friedman et al. 1993). Ae. agypti 
responds to ATP during the gorging process. Removal of the phosphate groups reduced the 
gorging behavior. The binding of ATP induces the opening of the membrane channels to allow 
the influx of sodium. The acquisition of blood meal will continue up to the average intake of 
blood which weighs the same as the unfed body weight. The estimated volume of the blood meal 
can be over four microliter. The acquisition of blood leads to the mechanical stretch of receptors 
in the abdomen and the suppression of the blood-feeding drive. The stretch receptors in the 
abdominal also prevent the over-distention during blood meals (Gwadz 1969).  The large-volume 
blood meals have been considered an effective strategy to reduce the opportunity of being 
swatted by the hosts. However, multiple blood meals can still occur due to the interruptions 
during blood feeding and other further nutritional needs. Due to the high water content in each 
blood meal, blood-sucking insects also utilize the epithelium that is adapted for the rapid 
excretion of water in the midgut. 
 F. Midgut of adult mosquitoes 
The anatomy of the insect guts generally can be differentiated into three sections; the 
foregut, the midgut and the hindgut. The midguts of blood-sucking insects can be classified into 
two groups based on the structure of the alimentary canal for the storage of the blood meal. The 
structure of the midgut of Hemiptera (true bugs) and Siphonaptera (fleas) is characterized of a 
simple tube with no diverticulae. Members of the diptera have one or multiple diverticulae as an 
additional structure for fluid storage (Eldridge and Edman 2003, Marquardt and Kondratieff 
2005). The midgut with the cardia as its opening can be further divided into two different 
regions, the anterior midgut and the posterior midgut. The cardia is located at the junction of the 
foregut and midgut and consists of the tissues from the intersuscepted foregut and the midgut. 
The midgut is composed of a layer of epithelium above the basolateral membrane. The anterior 
midgut (AMG) contains densely packed microvilli and basal labyrinth upon the continuous layer 
of basal lamina. It has been suggested that the AMG is the absorptive epithelium with microvilli 
for the sugar from the diverticulum (Billingsley 1990, Zieler, Garon et al. 2000). The posterior 
midgut (PMG) exhibits the properties of both secretory and absorptive tissues. The apical surface 
of the PMG epithelium contains organized microvilli structure whilst the basal surface lies above 
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the basal membrane with polarized distribution of mitochondria. The abundant intracellular 
membrane organelles such as rough endoplasmic reticulum (rER) and Golgi reveals its capacity 
of secreting macromolecules. The digestion and absorption of blood meals in mosquitoes take 
place in the posterior midgut, which harbors the alkaline digestive conditions (Billingsley 1990, 
Marquardt and Kondratieff 2005). Starvation or feeding on an exclusive sugar diet led to the 
degeneration of such structures. The degeneration caused by starvation was irreversible (Bauer, 
Rudin et al. 1977). Additionally, histological observations also demonstrated the storage function 
of the PMG with the presence of glycogen and lipid deposits (Billingsley 1990). The digestion 
was performed simultaneously over the entire surface of the food bolus described as the batch 
system.  
The biological functions of midgut can also be defined by the presence of different cell 
types and their morphologies. The epithelial cells confer the digestive functions by secreting 
large quantities of digestive enzymes. The morphologies of the membrane organelles in the PMG 
epithelium suggested the secretory functions of the midguts with the presence of large quantities 
of rER, especially in response to blood meals (Hecker and Rudin 1981). The morphologies of 
epithelial cells appear to be columnar prior to the ingestion of the blood meal. The cells undergo 
a substantial morphological change and turn squamous with convex internal border while the 
mosquito is engorged (Gooding 1972). The integrity of the cellular and tissue structures is 
maintained by the continuous junctions (zonula continua) on the later surface of the epithelium 
(Reinhardt and Hecker 1973). The formation and reorganization of the intracellular whorl 
structures have been suggested to be important for the synthesis and secretion of digestive 
macromolecules and peritrophic matrix (Bertram and Bird 1961, Zhou, Isoe et al. 2011). 
Additionally, the microvillar structure maximizes the surface which can be utilized to absorb 
nutrients. However, both the secretory and absorptive cell types are unable to be distinguished 
based on the histological morphologies. Alternatively, the other two additional cell types also 
exist in the midgut including the endocrine and regenerative cells. In Ae. aegypti, there are more 
than 500 endocrine cells making the midgut the largest endocrine organ with unknown 
physiological functions.  Despite the presence of the regenerative cells, there is no active cell 
division in the midgut. Interestingly, the distribution of the endocrine cells has been reported to 
be concentrated on the PMG and found adjacent to the regenerative cells (Brown, Raikhel et al. 
1985, Brown, Crim et al. 1986, Glattli, Rudin et al. 1987). Immunoelectron microscopic staining 
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demonstrated the cells with electron-lucent cytoplasm produce the vertebrate pancriptic 
polypeptide in Ae. aegypti (Glattli, Rudin et al. 1987). The other peptide hormone identified was 
FMRF-amide, which can also be found in the nervous tissue (Brown, Crim et al. 1986).  
There is considerable knowledge on the digestive mechanisms required for the process of 
blood meals. The lysis of the red blood cells is one of the most important parts in digestion in 
order to obtain the high protein content in the meal. Ae. aegypti lacks the cibarial armatures 
required for the mechanical disruption of the red blood cells and achieves haemolysis by 
chemical means (Geering and Freyvogel 1975, Eldridge and Edman 2003, Marquardt and 
Kondratieff 2005). Haemolysins can be produced in the midgut or alternatively secreted by the 
salivary glands. Due to the high protein concentration of the blood meals, proteases and 
peptidases are the predominant digestive molecules released in the midgut. Multiple trypsin 
genes have been identified in the genome of Ae. aegypti (Kalhok, Tabak et al. 1993). Other 
enzymes such as chymotrypsins also facilitate the digestion of the blood meal (Jiang, Hall et al. 
1997). The production of digestive enzymes occurs in large quantities after the blood meals and 
is regulated by the concentrations of the proteins in the blood meal (Noriega, Edgar et al. 2001). 
After the degradation of the protein components, the amino acid transporters are responsible to 
transport the amino acids through the midgut epithelial cells for other physiological processes 
(Evans, Aimanova et al. 2009). In spite of the negligible concentration of lipids in the blood 
meals, the triacylglycerol lipases have been identified in Ae. aegypti. The lipid components of 
the eggs were found to derive from the conversion of the amino acids into lipids (Geering and 
Freyvogel 1975).  
 1.3 Flaviviruses 
 A. Epidemiology and ecology 
There have been at least 53 species identified and classified under the genus of flavivirus.  
According to the type of hematophagous arthropod vectors, the members of the flavivirus genus 
can be classified as mosquito-borne, tick-borne or no-known-vector flaviviruses. Based on the 
clinical manifestations, flaviviruses can further be categorized into two major groups, the 
encephalitic flaviviruses and the viscerotropic/hemorrhagic flaviviruses. The tick-borne 
flaviviruses consist of one major complex- the tick borne encephalitis virus (TBEV) complex 
infecting mammals with other members infecting seabirds (Gould and Solomon 2008).  
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The encephalitic group of mosquito-borne flaviviruses are mainly transmitted by Culex 
mosquitoes. In addition to the mammalian hosts, which are considered incidental low-viremic 
dead-end hosts, the avian species infected by the encephalitic mosquito-borne flaviviruses serve 
as the amplification hosts, which develop high-titer viremia to sustain the transmission. The 
transmission cycle of the viruses is summarized in Figure 1.2. 
 
Figure 1.2 Transmission cycle of flaviviruses under the JEV-serocomplex 
There are at least five mosquito-borne encephalitic flaviviruses associated with human 
diseases including JEV, WNV, SLEV, Kunjin virus (KUNV) and Murray Valley encephalitis 
virus (MVEV). JEV is estimated to cause 30,000-50,000 cases and 10,000 deaths per 
year.(“WHO | Water-related diseases,” n.d.) Culex tritaeniorhynchys serves as the primary vector 
in Asia. The unique ecology of JEV requires the swine species as the amplification host 
characterized by the high infection rate and the high viremia in the epidemic area and the 
maintenance host in the endemic area. Additionally, there have been more than 90 domestic and 
wild avian species that can be infected by JEV. There are three available vaccines- the live-
attenuated 14-14-2 vaccine, the formalin-inactivated vaccine and the ChimeriVax-JE vaccine. 
(van den Hurk, Ritchie et al. 2009).  
In North America, there have been several encephalitic arboviruses identified since 1930s. 
St. Louis encephalitis virus was once the most important mosquito-borne flavivirus throughout 
Canada and the United States (Weaver and Barrett 2004). Recently, SLEV has been reported to 
have a further expanded distribution to countries where to date, no known outbreaks were 
documented including  Columbia and Argentina in Latin America (Mattar, Komar et al. 2011, 
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Valinotto, Barrero et al. 2012). Culex spp. mosquitoes have been shown to have varied 
susceptibility to SLEV. In western United States, it is believed that Culex tarsalis is the principle 
vector for SLEV; whereas Culex pipiens quinquefasciatus and Culex nigripalpus may be 
responsible for the transmissions in the east coast (Weaver and Barrett 2004). West Nile virus 
has become one of the most significant arboviruses for the human and veterinary public health in 
North America since its emergence in New York in 1999. There have been multiple species of 
Culex mosquitoes demonstrated to be competent for the transmission in North America. The 
transmission occurs most frequently in warmer months from July to October. The most common 
clinical presentation of WNV infection can be febrile illness. The incidence of its severe 
neurological diseases increases with age and the immunosuppression (Mackenzie 2002).  
There are also two arboviruses, Murray Valley encephalitis virus (MVEV) and Kunjin 
virus (KUNV), in the JEV serocomplex isolated in Australia. Murray Valley encephalitis virus 
was described to be the potential etiological agent for the Australian X disease in the 1910s and 
1920s. The maintenance of the virus relies on the enzootic cycle between the Culex annulirostris 
and the migratory waterbirds in the northern tip of west Australia. The spread of the virus is 
subjected to the flooded area due to the heavy rainfall and the routes of migratory birds. MVEV 
infection leads to febrile illness with the incidence of severe neurological diseases including fatal 
encephalitis between one in five hundred to one in one thousand cases (Knox, Cowan et al. 
2012). The other etiological agent, KUNV, was first detected in northern Queensland in 1960 
and is considered a subtype of WNV. However, asymptomatic infections and milder forms of 
diseases are more frequently seen in infected animals and humans. Severe fatal encephalitis is 
considered rare amongst the infected individuals. Kunjin virus  also shares the vector Culex 
annulirostris with MVEV (Hall, Scherret et al. 2001).  
The viscerotropic/hemorrhagic mosquito-borne flaviviruses cause significant mortality in 
the tropical and subtropical regions throughout the world. The two medically important viruses 
of such kind are DENV and YFV. Both viruses are transmitted by Ae. aegypti in its urban 
transmission cycle and have been reported to maintained in the sylvatic and jungle transmission 
cycles.(Figure 1.3) The jungle transmission cycle is maintained between the non-human 
primates as vertebrate hosts and jungle vectors that feed on non-human primates. The sylvatic 
transmission cycle is maintained by the vectors that feed on both non-human primates and 
humans, which come into contact with the vectors. The virus in the urban transmission cycles 
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alternates between humans and urban vectors. Although the sylvatic transmission is considered a 
critical component for the ecology of YFV, infections with DENV have largely been reported to 
be associated with urban transmission. Increased transmission, i.e. emergence and reemergence, 
have been attributed to rapid urbanization and other factors (Guzman, Halstead et al. 2010). The 
isolation of sylvatic DENV has only been described in specific locations in Brazil, Malaysia and 
West Africa, where the endemicity of DENV still lead to the higher number of cases in urban 
transmission (Diallo, Ba et al. 2003, Cardosa, Ooi et al. 2009, de Figueiredo, de et al. 2010).  
 
Figure 1.3 Transmission cycles of flaviviruses in YFV- serocomplexes 
YFV is the first arbovirus transmitted by mosquitoes and considered to have public health 
significance. The virus can be transmitted in two ecologically distinct cycles, the urban cycle and 
the sylvatic cycle, both in Africa and central and south America. The mammalian hosts including 
nonhuman primates and humans are infected via the competent mosquito vectors which have 
previously fed on viremic hosts. In Africa, the sylvatic cycle can be maintained by sylvatic Aedes 
species such as Ae. africanus; whereas, the Haemagogus mosquitoes are the principle vectors for 
the sylvatic cycle in the central and south America (Monath 2001, Barrett and Higgs 2007).  
The members of TBEV complex transmitted by ixodid ticks have been reported in both 
Europe and Asia. The biological transmission occurs through the secretion of contaminated 
saliva secreted by ticks. Six of the TBEV serocomplex members cause human diseases including 
the encephalitic Louping ill virus (LIV), tick-borne encephalitis virus (TBEV), the Langat virus 
(LGTV), Powassan virus (POWV) and the hemorrhagic  Kyasanur Forest disease virus (KFDV) 
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and Omsk hemorrhagic fever virus (OHFV) (Gould and Solomon 2008). In addition to the 
infection through the blood meals from viremic hosts, the transmission of tick-borne viruses and 
pathogens can further be complicated by the prolonged period of feeding by ticks. Naïve ticks 
have also been reported to acquire the viruses through co-feeding on the same infected host 
(Labuda, Danielova et al. 1993, Hudson, Norman et al. 1995). Given the long lifespan of tick 
species, the infection can persist up to two years in infected ticks.  
Since its first isolation in Russia leading to the name Russia spring and summer 
encephalitis virus (Levkovich 1945), there have been three subtypes of TBEV reported including 
the European TBEV-Eu transmitted by Ixodes ricinus, the Siberia (TBEV-Sib) transmitted by Ix. 
persulcatus, and Far Eastern (TBEV-FE) transmitted by Ix. persulcatus. TBEV causes the 
biphasic disease in humans. After the incubation period, the first viremic phase leads to the 
febrile symptoms, myalgia, general malaise and thrombocytopenia. The second phase is 
manifested by neurological symptoms from mild meningitis to severe encephalitis. Severe forms 
of the disease have been frequently reported in eastern Russia (Gould and Solomon 2008, 
Lindquist and Vapalahti 2008).  
 POWV is endemic in Canada and other parts of North America. The virus has been 
isolated from tick species in North America such as Ixodes spp. and Dermacentor andersoni 
(Hinten, Beckett et al. 2008). The virus can also be found in the Russian Far East although the 
actual mode of spread between two continents remains unclear (Deardorff, Nofchissey et al. 
2013). LIV, the only tick-borne encephalitis virus in the British isles, is considered as a 
descendent of TBEV infecting sheep and red grouse through Ix. ricinus with limited numbers of 
human cases reported. However, the pathology of infected vertebrate hosts resembled that of 
human TBEV-infected cases (Davidson, Williams et al. 1991). Similar viruses have also been 
isolated in other parts of the European continent such as Spain and Greece (Gonzalez, Reid et al. 
1987, Papa, Pavlidou et al. 2008). OHFV was first isolated in the Omsk region of Russia and can 
be isolated from Dermacentor pictus causing febrile illness, hemorrhage and leukopenia amongst 
infected individuals (Ruzek, Yakimenko et al. 2010). KFDV was first isolated from captured 
monkeys in India in 1957. It has been suggested the virus is maintained between the 
haemaphysalis spp. ticks and the forest animals (Gould and Solomon 2008, Holbrook 2012).   
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 B. Intracellular lifecycle and molecular biology of flaviviruses 
The transmission cycle of flaviviruses requires the viral particles to utilize cellular 
molecules and pathways that are expressed in arthropods, mammals and avians for virus entry 
and exocytosis. The successful establishment of infection by flaviviruses is initiated by the 
receptor binding through the viral envelope (E) protein followed by the viral and cellular 
membrane fusion in the acid endosomes (Chen, Maguire et al. 1997, Harrison 2008). The entry 
of flaviviruses has been demonstrated to predominantly depend on the clathrin-mediated 
endocytosis pathway (Krishnan, Sukumaran et al. 2007, Acosta, Castilla et al. 2008).  
For single-stranded positive-sense RNA viruses, the viral genomes allow the translation of 
the host machinery in order to form the replication complex for the subsequent production of 
progeny virions. The 11-kilobase (kb) viral genome of flaviviruses encodes three structural 
genes, capsid (C), pre-membrane (prM), and E, and seven nonstructural (NS) genes, NS1, NS2A, 
NS2B, NS3, NS4A, NS4B and NS5. The 5’ end of the viral genome is modified with the viral 
RNA cap structure but the 3’ end of the viral genome lacks the polyA structure, which is 
common among the eukaryotic mRNA. The cap structure increases the stability of viral genome 
against the host nuclease digestion and functions as the immunomodulator antagonizing the host 
antiviral innate immunity (Daffis, Szretter et al. 2010). (Figure 1.4(a)) The structure genes are 
the predominant components of the viral particles containing the viral genetic material. The 
nonstructural proteins function as enzymatic machineries for the propagation of the progeny 
viruses and antagonists for viral immunity. The translation of the genomic RNA leads to the 
production of a polyprotein, which is subjected to the cleavage of viral and host proteases 
(Chambers, Hahn et al. 1990).(Figure 1.4(b))   
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Figure 1.4 Genome organization and proteolytic processing of flaviviruses 
The biochemical characterization has led to the discovery of several key enzymatic 
components for the viral replication complexes. The NS2B-NS3 complex forms the serine 
protease that is involved in the process of the viral polyprotein (Chambers, Weir et al. 1990, 
Chambers, Grakoui et al. 1991). The NS3 protein also has additional functions as RNA helicase 
and triphosphatase (Arias, Preugschat et al. 1993, Warrener, Tamura et al. 1993). The NS5 
protein encodes the methylatransferase and the RNA-dependent RNA polymerase that catalyze 
the synthesis and modification of the viral genetic materials (Grun and Brinton 1986, Grun and 
Brinton 1987). The available evidence from immunostaining of the viral proteins and 
ultrastructure identified the replication complex of flaviviruses is likely to be located in the 
cytoplasm of infected cells, especially the perinuclear area and triggers the extensive formation 
of intracellular convoluted and vesicular membrane structures. However, several critical 
questions for functions of NS1, NS2A, NS4A and NS4B proteins remain unanswered. Although 
the large quantities of NS1 produced in vitro and in vivo and the antibody responses targeting the 
NS1 protein have been well documented in the available literature, its biological functions and 
contribution to disease pathogenesis remain unclear (Muller and Young 2013). NS2A, NS4A and 
NS4B proteins have been reported as immunomodulators that target the IFN-mediated antiviral 
signaling in the vertebrate hosts (Munoz-Jordan, Sanchez-Burgos et al. 2003). The membrane 
topology of NS2A protein has recently been reported and indicated its function is also critical for 
the viral particle assembly (Xie, Gayen et al. 2013). NS4B has been further demonstrated to 
block the transcription activation function of STAT1 protein in response to type-II IFN treatment 
(Munoz-Jordan, Sanchez-Burgos et al. 2003). Similarly, the degradation of STAT2 protein is 
mediated by the NS5 protein and the proteasomal degradation pathway (Ashour, Laurent-Rolle 
et al. 2009).  
Virions are assembled in the endoplasmic reticulum (ER) and subsequently to the Golgi 
complex (Welsch, Miller et al. 2009). The gradient of pH between ER and the trans-Golgi 
network will allow the maturation of the viral particle and the cleavage of the pr peptide from the 
prM protein by furin will lead to the formation of the mature infectious viral particles ready for 
the release into the extracellular space (Zhang, Ge et al. 2013).  
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 C. Envelope protein of flaviviruses 
The flavivirus E proteins play significant roles in several steps of virus life cycle and have  
been extensively characterized. The protein consists of three discontinuous domains, domain I 
(EDI), domain II (EDII) and domain III (EDIII), based on the locations and functions (Rey, 
Heinz et al. 1995). The fusion property of flavivirus E proteins resembles other viral structural 
proteins under the category of class II fusion proteins (Harrison 2008). Although the crystal 
structure of YFV E protein has not yet been determined, the structures of several flaviviruses 
have been published. Although the overall structures of flavivirus E proteins resemble one 
another, minor and distinct variations in the structures exist. Functional characterization of the 
different domains of flavivirus E proteins provides the information critical for the understanding 
of the biology of the viruses as well as its application to develop preventive and therapeutic 
measures for the diseases. The pH-dependent conformational changes of E proteins in different 
cellular compartments are critical for the viral entry and the secretion of viral particles. 
As the predominant component of the viron surface, 180 copies of E protein are arranged in 
the dimeric conformation in mature viral particles. In addition to the dimeric arrangement, the 
surface of viral particles contains 3-fold and 5-fold symmetrical units throughout the surface 
(Kuhn, Zhang et al. 2002). (Figure 1.5) The detailed 3D structure of flavivirus E protein is 
displayed and annotated in Figure 1.6. The EDI of flavivirus E proteins acts as a structurally 
central component, which has two β-sheets stabilized by the interior hydrophobic amino acids. 
The external β-sheet contains four β-strands C0D0E0F0 with a short A0 β-strand that is parallel to 
the C0 β-strand. The interior β-sheet faces the viral membrane and consists of four β-strands 
G0H0I0B0 (Kuhn, Zhang et al. 2002, Zhang, Zhang et al. 2004). EDII stabilizes two neighboring 
monomers through the dimerization domain and contains the fusion peptide that mediates the 
viral membrane fusion. The finger-like structure of EDII consists of the two large loop regions 
between β-strands D0 and E0 as well as H0 and I0. The base component of EDII contains five 
short β-strands GFEAH arranged in the antiparallel fashion and two α-helices αB and Αa; 
whereas, the elongated structure is stabilized by three disulfide bonds within the three-β-strands 
sheet BDC. Most importantly, the fusion loop is located in the cd loop at the tip of the domain 
and largely conserved among flaviviruses with its hydrophobicity (Rey, Heinz et al. 1995, 
Allison, Schalich et al. 2001). The binding of cellular receptors is mediated by EDIII (Chen, 
Maguire et al. 1997).  The overall structure of EDIII shares an IgG-like fold and contains three β-
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sheets. The NMR structure of YFV EDIII has been available and showed the gross similarity to 
other flaviviruses with minor differences. The first β-sheet is made of four β-strands ABDE and 
faces domain I and domain II. Two short β-strands Cx and Dx form the second β-sheet. And, β-
strands CFG form the third β-sheet (Volk, Gandham et al. 2007, Volk, May et al. 2009).  
 
Figure 1.5 Structures of the flavivirus virion based on the Cryo-electron microscope (Cryo-
EM) reconstructed images. (adapted from Zhang et al., 2004))  
The surface of the virion is covered by 180 copies of flavivirus E protein monomers, which 
are dimerized to create 90 copies of dimers and the two-fold symmetric units. The three-
fold and five-fold symmetric units can also be found by the neighboring monomers of 
flavivirus E protein. Three distinct domains displayed above are labeled with three 
different colors. EDI, the central domain, is labeled in red. EDII, the dimerization domain, 
is labeled in yellow with the fusion loop structure highlighted in green. EDIII, the receptor-
binding domain is labeled in blue.  
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Figure 1.6 The crystal structure of flavivirus E protein (adapted from Modis et al., 2004) 
The crystal structure of flavivirus E protein is displayed as the dimerized structure. Three 
domains are labeled with distinct colors, EDI in red, EDII in yellow and EDIII in blue. The 
two β-sheets of EDI, C0D0E0F0 and G0H0I0B0, are annotated. EDII is composed of two β-
sheet structures, GFEAH and BCD, and two α-helices, αA and αB. The two major β-sheets, 
ABED and CFG, of EDIII are labeled in blue. 
The viral entry requires the transition from the dimeric conformation to the trimeric 
conformation in the endocytosis pathway. Such conformational change is triggered by the acidic 
environment of the endosomes and allows the insertion of the fusion peptide to protrude from the 
viron surface into the cellular membrane in order to bring both viral and cellular membranes into 
close proximity (Nawa 1997, Harrison 2008). The fused membranes allow the release of viral 
genome into the host cells. 
The viral particles are assembled first in the immature form with the envelope proteins 
arranged in trimeric conformations. The fusion peptide is protected by the pr peptide of the prM 
protein. The prM protein functions as a chaperon protein for the E protein in the process of virion 
maturation. The maturation process is mainly triggered by the decrease of pH in the secretory 
pathways and critical for the production of infectious viral particles (Yu, Zhang et al. 2008). In 
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the acidic environment of trans-Golgi network, the viral particle is covered by the dimers of E 
protein on its smooth surface as oppose to the spiky virion surface in the immature virions 
(Zhang, Corver et al. 2003). Prior to the release into the extracellular space, the host furin 
protease removes the pr peptide producing the infectious viral particles. 
Given its importance of viral infectivity and particle assembly in both mosquitoes and 
vertebrates in vitro and in vivo, the E proteins have been extensively tested for the vector 
competence. The genetic determinants of viral infection and dissemination have been found in 
flavivirus E proteins. The YFV E protein was demonstrated to contain the determinants for viral 
infection and dissemination in Ae. aegypti. Chimerization of the EDI and EDII region of YFV 
17D strain to the backbone of Asibi strain reduced the viral infectivity; whereas, the EDIII of the 
Asibi strain was found critical for the viral dissemination in orally infected mosquitoes 
(McElroy, Tsetsarkin et al. 2006). For WNV, in addition to the potential alterations in amino 
acid sequences and secondary structures, the N154I mutation which abolished the N-linked 
glycosylation site, led to the reduced viral infection and dissemination in Cx. quiquefasciatus 
(Moudy, Payne et al. 2011). The T329A mutation in the EDIII of DENV-1 selected by the 
antibody escape was shown to increase the viral infectivity in Ae. aegypti (Shrestha, Austin et al. 
2012). The EDI-EDII molecular hinge region and the FG-loop in EDIII were mapped to be the 
critical parts of the viral infectivity of DENV-2 in Ae. aegypti (Erb, Butrapet et al. 2010, 
Butrapet, Childers et al. 2011).  
In addition to the importance in the cellular, molecular and structural biology of 
flaviviruses, the flavivirus E proteins have also been studied extensively as an immunogen for 
the humoral immunity response in vertebrate hosts. The study of B-cell epitopes on the flavivirus 
E proteins was first performed on yellow fever virus in order to distinguish the vaccine and wild-
type viruses (Schlesinger, Brandriss et al. 1983). Flaviviruses E proteins, especially EDIIIs, later 
have been proved to elicit the protective antibody responses, which were further utilized to 
develop the therapeutic humanized monoclonal antibodies or subunit vaccine candidates 
(Oliphant, Engle et al. 2005, Clements, Coller et al. 2010, Shrestha, Brien et al. 2010, Sukupolvi-
Petty, Austin et al. 2010). The studies were further expanded to other flaviviruses and the cross-
reactive antibodies targeting the homologous sequences and structures of flavivirus E proteins 
(Gould, Buckley et al. 1985). The B-cell epitopes on YFV E protein have been found critical for 
the attenuation of YFV 17D strains. These vaccine epitopes are the determinants for the 
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virulence of various YFV strains in vivo (Sil, Dunster et al. 1992, Ryman, Xie et al. 1997). 
Interestingly, the immunogenicity of YFV 17D strains led to the repertoire of antibodies that 
target multiple neutralization epitopes, which retained the neutralizing capacities towards the 
neutralization escapes of 17D strains that contain several genetic substitutions (Daffis, 
Kontermann et al. 2005).  
The extensive studies on flavivirus E proteins are expected to generate the information 
which is critical for vaccine development. The reverse genetic systems of flaviviruses based on 
the cDNA infectious clones and the infectious positive-sense viral RNA have also further 
fostered the functional characterization and mechanistic studies at the level of individual 
domains or amino acids. The currently available flavivirus vaccines and vaccine candidates are 
reviewed in the section 1.3.D. The reverse genetics system of flaviviruses is reviewed in the 
section 1.3.E. 
D. Vaccines for flaviviruses 
Currently, there are no specific antiviral therapies targeting mosquito-borne arboviruses. 
Therefore, vaccination and vector control still remain as the most effective public health 
measures for disease control and prevention. Several vaccines have been used to successfully 
control disease mortality and morbidity. The first success in generating live-attenuated flavivirus 
vaccines took place in 1937 through the serial passage of virulent YFV Asibi strain (Theiler and 
Smith 1937). Members of JEV serocomplex have been recognized as threats to both human and 
animal health and three human vaccines for JEV and several animal vaccines for WNV have 
been available. However, with the most significant amount of disease burden, mortality and 
economical loss, different DENV vaccine candidates are still in various stages of clinical trials. 
The currently available vaccines and vaccine candidates for flaviviruses are summarized in table 
1.2. 
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Virus  Vaccine Availability  
YFV Live-attenuated YFV17D strains produced from 
chicken embryos 
Manufactured and available 
worldwide for human use 
JEV Live-attenuated SA14-14-2 strain Manufactured in China and 
available in Asia for human 
use 
Inactivated Ixiaro® vaccine based on SA14-14-2 
strain 
Licensed in the United States 
and the European Union for 
human use 
Inactivated JEBIKV® vaccine and ENCEVAC® 
based on Beijing-1 strain 
Manufactured and approved in 
Japan for human use 
DENV Live-attenuated chimeric vaccine based on 
ChimeriVax® 
Phase III clinical trial in 
progress 
Live-attenuated tetravalent chimeric vaccine based 
on DENVax® 
Phase II clinical trial in 
progress 
Live-attenuated tetravalent chimeric vaccine based 
on DENV-4-3’-Δ-30 
Phase II clinical trial in 
progress 
WNV Formalin-inactivated WNV Available in the United States 
for equine use 
Recombinant WNV based on the poxvirus vector Available in the United States 
for equine use 
TBEV Formalin-inactivated TBEV purified from chicken 
embryos 
Available in western Europe 
and Russian for human use 
 
Table 1.2 The list of current available vaccines or vaccine candidates for flaviviruses 
The YFV 17D vaccine was attenuated from its parental virulent Asibi strain through 176 
passages in mouse brain and chicken tissues. The 17D vaccine strain has lost its viscerotropism 
in both non-human primates and vacinees (Smith and Theiler 1937, Theiler and Smith 1937, 
Theiler and Smith 1937). Additionally, the 17D vaccine strain has been repeatedly showed to be 
non-biologically transmissible by Ae. aegypti; whereas, the Asibi strain rapidly disseminates into 
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the salivary glands and is readily infectious to immunologically naïve non-human primates 
(Whitman 1937, Miller and Adkins 1988, McElroy, Tsetsarkin et al. 2005). The human immune 
responses to the 17D vaccine strain can potentially persist up to 35 years demonstrated by the 
presence of neutralizing antibodies (Poland, Calisher et al. 1981). There have been more than 
540 million doses of the YFV 17D vaccine administered worldwide in human history. Although 
the vaccine-associated adverse effects have been report, the YFV 17D vaccine is still considered 
the one of the most successful live-attenuated vaccines in human history (Barrett and Teuwen 
2009). The use of the YFV 17D vaccine has been further expanded to the field of viral vaccine 
candidates with molecular manipulations (Van Epps 2005).  However, YFV 17D vaccine strain 
is not the only vaccine developed for YFV. Several other YFV vaccine viruses, including YFV 
17DD and YFV FNV have also been developed and will be discussed in the section 1.4.B. 
There have been two vaccines available for JEV, the mouse-brain-derived vaccine and the 
SA14-14-2 live-attenuated vaccine. The mouse-brain-derived JEV vaccine requires three doses to 
achieve acceptable immunogenicity with several cases of vaccine-associated adverse effects 
(Darwish and Hammon 1966). The live-attenuated SA14-14-2 vaccine has been given to more 
than 120 million children with negligible transient reactogenicity (0.2~6%) in China alone. In the 
United States, Australia and Europe, the IC51 vaccine obtained by passaged in primary dog 
kidney cells for eight times has been licensed and manufactured in the serum-free format. The 
SA14-14-2 strain has also been used as the strain providing genetic materials for the development 
of the chimeric JEV vaccine candidate based on the backbone of the YFV 17D vaccine strain 
(Halstead and Thomas 2010). Since the introduction of WNV into the United States in 1999, 
there have been several veterinary vaccines approved for use in  equine species including the 
formalin-inactivated whole-virus vaccine (WN-Innovator®; Fort Dodge Animal Health, KS, 
USA), the recombinant canarypox-vectored vaccine (Recombitek®equine Rwnv; Merial, GA, 
USA), the YFV-17D-based chimeric vaccine (PreveNile®; Invertec Inc., DE, USA) and the DNA 
vaccine expressing the prM and E proteins of WNV (West Nile-Innovator®DNA; Fort Dodge 
Animal Health, KS, USA). The human vaccines for WNV are currently undergoing different 
phases of trials including the YFV-17D-based chimeric vaccine (ChimeriVax®-WN02, Sanofi-
Pasteur), the live-attenuated vaccine based on the DENV-4 backbone (WN/DENV-4-3’∆30; 
National Institute of Allergy and Infectious Diseases(NIAID), MD, USA), the WNV prM-E 
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DNA vaccine (Vical Inc., PA, USA and NIAID), and the subunit truncated E protein vaccine 
(HBV-002; Hawaii Biotech, HI, USA) (Beasley 2011).  
Due to the frequent epidemics, high number of cases and wide geographic distribution, 
vaccines development for DENV has been a priority but for various reasons has been 
problematic. Several candidate vaccines are still being tested at different phases in various 
locations worldwide. The vaccine candidates that are currently evaluated in different phases of 
clinical trials are summarized in table 1.3. The recombinant ChimeriVax dengue tetravalent 
vaccine (Sanofi Pasteur) based on the YFV 17D vaccine backbone has recently completed the 
phase 3 clinical trial but requires the extended dosing schedule in order to achieve the level of 
protection. However, the tetravalent vaccine only provides partial protection to three of the four 
serotypes of DENV (Guy, Barrere et al. 2011, Sabchareon, Wallace et al. 2012). Similarly, 
NIAID has also utilized the recombinant DNA technology to produce the chimeric tetravalent 
vaccine based on the DENV-4 virus with the deletion in its 3’ untranslated region (UTR), which 
is currently undergoing the Phase 2 clinical trial with specific formulations (Durbin, Kirkpatrick 
et al. 2013). The other molecular-biology-based tetravalent vaccine based on the cDNA 
infectious clone of the attenuated DENV-2 16681-PDK53 strain as its backbone is tested at the 
stage of the Phase 1 clinical trial (Osorio, Huang et al. 2011). In addition to the reverse-genetics-
based vaccine candidates, the subunit vaccine based on the N-terminal 80% region of the E 
protein of four serotypes of DENV (Hawaii Biotech, HI, USA) is going through Phase 1 clinical 
trial (Clements, Coller et al. 2010).  
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Vaccine candidates Property Platform Progress in clinical 
trials 
ChimeriVax® dengue 
tetravalent vaccine 
Live-attenuated ChimeriVax® 
technology based on 
YFV 17D strain 
Phase III clinical trial 
DENVax® dengue 
tetravalent vaccine 
Live-attenuated DENVax® 
technology based on 
DENV-2 PDK53 
strain 
Phase II clinical trial 
TV003 dengue 
tetravalent vaccine 
Live-attenuated DENV-4-3’-Δ-30 
attenuated strain 
based on the deletion 
of 3’ UTR 
Phase II clinical trial 
80E dengue tetravalent 
vaccine 
Subunit Insect cell expression 
of N-terminal 80% of 
the E protein 
Phase I clinical trial 
D1ME100 dengue DNA vaccine Naked plasmid DNA 
containing DENV-1 
prM and E genes 
Phase I clinical triall 
Table 1.3 The vaccine candidates currently undergo clinical trials 
The complicated process of developing flavivirus vaccines has led to the important 
discoveries and advancement in knowledge and experience that are also applicable to the 
production of vaccines against other mosquito-borne viruses primarily under Togaviridae and 
Bunyaviridae. Such vaccines and vaccine candidates are briefly discussed in the following 
paragraphs. 
Similar to the YFV 17D vaccine strain, the VEEV TC83 vaccine strain virus was also 
attenuated by 83 in vitro passages through the guinea pig heart cells. However, the limited 
numbers of mutations throughout the viral genome has led to the potential concern of reversion. 
Additionally, the TC83 vaccine strain virus has been reported to be isolated from the vectors in 
nature.(Pedersen, Robinson et al. 1972) Currently, the TC83 vaccine of VEEV is limited for 
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human use as investigational new drug (IND) in the United States (Berge, Gleiser et al. 1961). 
Chikungunya virus  strain AF15561, originating from strain 15561was plaque-to-plaque purified 
in the MRC-5 cells in order to produce the attenuated strain CHIK 181/clone25 (Levitt, 
Ramsburg et al. 1986). The attenuated strain completed the Phase 1 and the Phase 2 of its clinical 
trial but led to arthralgia in 8% of the vaccinees despite of the fact that the vaccine showed the 
advantage of the limited potential of being transmitted by mosquitoes (McClain, Pittman et al. 
1998, Edelman, Tacket et al. 2000).  
The demand from both the perspectives of human and veterinary public health has led to 
several vaccine candidates for RVFV with different strategies. The formalin-inactivated TSI-
GSD-200 vaccine has been given to veterinarians and laboratory personnel who are at the risk of 
exposure. However, the vaccine has not achieved the immunogenicity as the live-attenuated viral 
vaccines and requires a six-month schedule for initial vaccination followed by the annual 
boosters (Kark, Aynor et al. 1982, Kark, Aynor et al. 1985, Pittman, Liu et al. 1999). The MP-12 
live-attenuated vaccine for RVFV was produced by the serial passage of the ZH548 virulent 
strain in the presence of 5-fluorouracil (Caplen, Peters et al. 1985, Morrill, Carpenter et al. 
1991). The vaccine protected the animals from the subsequent challenges in experimental 
animals. Recently, the vaccine was evaluated in the Phase 2 clinical trial for potential human 
adverse effects. The Clone13 isolate carrying deletion in the NSs genomic fragment is currently 
being tested for the use as a veterinary vaccine. The clone13 reassortant R566 strain which 
contains the L and M genomic fragments of the MP12 vaccine has also been evaluated for its 
veterinary use (Dungu, Louw et al. 2010).  
The unique transmission cycles of flaviviruses and other arboviruses complicates the issue 
of disease control, especially with the presence of natural reservoirs and disease vectors. 
Although several vaccines have been available in different formats, the two live-attenuated 
vaccines, YFV 17D vaccines and JEV SA14-14-2 vaccine, are still the most efficacious tools and 
lead to long-term protective immunity. Therefore, the development of live-attenuated vaccine 
candidates for flaviviruses has become one of the most important fields of virology and 
vaccinology. As detailed below, the reverse genetics systems now available has further 
facilitated the advancement in the field with the newly developed approaches to chimerize and 
introduce immunogenic components on the backbones of several attenuated flaviviruses such as 
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ChimeriVax® and DENVax®.(Pugachev, Guirakhoo et al. 2005) The reverse genetics systems for 
flaviviruses are reviewed in the following section.  
 E. Reverse genetics systems for flaviviruses 
The positive-sense genomic RNA of flaviviruses and other small RNA viruses allow the 
production of viral particles by the transfection of viral RNA derived from cDNA infectious 
clones. The production of viral RNA can often be achieved by the in vitro transcription of cDNA 
fragments that contains the viral genome with bacteriophage DNA-dependent RNA polymerases 
and the appropriate promoters. The bacterial plasmid or artificial chromosome systems allow the 
propagation of such cDNA materials and the manipulation of specific residues or fragments of 
the genetic materials. The cDNA infectious clone of poliovirus was the first reverse genetics 
system available for the molecular manipulation of genomes amongst human single-stranded 
positive-sense RNA viruses (Racaniello and Baltimore 1981).  Several variants of the 
methodologies such as the multi-plasmid systems coupled with in vitro ligation of nucleic acids 
and the introduction of intron sequences have been developed to overcome technical obstacles 
including the toxicity of viral genetic materials to the bacterial system and the instability of the 
sequences propagated in bacteria (Sumiyoshi, Hoke et al. 1992, Yamshchikov, Mishin et al. 
2001, Messer, Yount et al. 2012).  
The current one-plasmid reverse genetics system for YFV was modified from the original 
two plasmid system (Rice, Grakoui et al. 1989). The two-plasmid system was adopted due to the 
toxicity of the viral genome to the bacterial host and the laborious procedures for the λ phage-
based full-length YFV cDNA clones. The stable infectious clone was established based on the 
cDNA derived from the YFV 17D strain and the low-copy pANCR1180 plasmid (Bredenbeek, 
Kooi et al. 2003). Through the amplification of the cDNA of the Asibi virus, the infectious clone 
of the virulent Asibi strain was developed and characterized. The phenotype of the Asibi virus 
derived from the infectious clone resembled the phenotype of the original virus (McElroy, 
Tsetsarkin et al. 2005). In addition to its application in studying the pathogenesis and the biology 
of YFV, the reverse genetics system of YFV has also been used to develop the chimeric 
flavivirus vaccines for various flaviviruses (Monath, Soike et al. 1999).  
Shortly after the infectious clone of YFV was available, the infectious clones of DENV 
were developed. The viral genome of DENV-4 strain 814669 was the first cloned into the 
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pBR332 plasmid for the development of its infectious clone (Lai, Zhao et al. 1991). The neuro-
adapted DENV-2 New Guinea C strain was also recovered from the T7-promoter-based in vitro 
transcribed RNA (Kapoor, Zhang et al. 1995). The infectious clone of DENV-2 16681 strain and 
the attenuated PDK-53 strain were developed and utilized as the backbone for the chimeric live-
attenuated vaccines for other serotypes of DENV (Kinney, Butrapet et al. 1997).  
The construction of infectious clones for JEV-serocomplex members was initially 
performed on multi-plasmid systems and in vitro ligation. The first JEV cDNA infectious clone 
was developed by in vitro ligating two cDNA fragments followed by the transcription of the full-
length cDNA. However, the genome of JEV was found highly unstable in E. coli and the 
infectious clones of JEV were further optimized by the introduction of intron and the use of very-
low-copy-number plasmid (Yamshchikov, Mishin et al. 2001, Zhao, Date et al. 2005). Similarly, 
WNV infectious clones have also been developed with the low-copy-number plasmids 
(Yamshchikov, Wengler et al. 2001, Shi, Tilgner et al. 2002).  
The reverse genetics systems of flaviviruses provide a convenient platform for the 
production of viruses that can be easily manipulated in the genomic sequences. It has been used 
in the production of vaccine candidates for different flaviviruses by chimerizing the structural 
genes of flaviviruses with the backbone of YFV 17D strain or DENV-2 PDK-53 strain (Monath, 
Soike et al. 1999, Osorio, Huang et al. 2011). Several mechanistic studies based on the cDNA 
infectious clones and mutagenesis techniques have also provided the critical knowledge in 
identifying the genetic determinants for the disease pathogenesis. 
  
 1.4 Yellow fever virus 
 A. Epidemiology 
Historically, yellow fever (YF) has also been described in various terms such as “black 
vomit”, “yellow jack”, and “king of terrors”, which describe the severity of diseases and 
symptoms as well as the consequences of infection in humans (Calisher 2013). Whilst the 17D 
vaccines are readily available, its etiological agent YFV is still categorized under the risk group 
three and required to be handled in the biosafety level 3 laboratories by the National Institutes of 
Health and Centers for Disease Control and Prevention (Chosewood, Wilson et al. 2009). The 
estimated numbers of YFV infection and fatal cases are 200,000 and 30,000 worldwide by WHO. 
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Currently, 900 million people are living at the risk of contracting the disease in the endemic 
tropical regions of Africa and Latin America (WHO 2014).  
YFV was first hypothesized to be transmitted through mosquito bites by Carlos Finlay and 
subsequently became the first arbovirus recognized to be medically important (Chamberlain 
1982). In a series of experiments by the U.S. Army yellow fever commission led by Walter Reed 
and others, the transmission was proved to require two key factors, the feeding of disease vectors 
on viremic hosts and the extrinsic incubation period prior to the transmission to another immune-
naïve host (Bauer and Hudson 1928). Multiple vertebrate and mosquito species are involved in 
the maintenance and transmission of YFV and the epidemiological studies of yellow fever virus 
demonstrated the virus is maintained in three cycles in Africa and two cycles in south America, 
respectively (Barrett and Monath 2003, Barrett and Higgs 2007). In the urban cycle, the major 
vector for its transmission is Ae. aegypti feeding on viremic humans. The laboratory transmission 
of YFV by Ae. aegypti led to the misconception that YF is exclusively an urban disease, 
however, this was prior to the discovery of the jungle and sylvatic intermediate cycles. Other 
Aedes and Haemagogus spp. feeding on non-human primates in the jungle are responsible for the 
transmission of the jungle cycle reported in Africa and South America (Anderson and Osorno-
Mesa 1946, Smithburn and Haddow 1946, De Rodaniche, Galindo et al. 1957).  
The primates in the jungle cycles of Africa and South America are responsible for the 
maintenance of the virus in nature but show distinct consequences of infection. In Africa where 
YFV originated, non-human primates normally do not succumb to the infection; whereas, in  
South American where YFV was introduced in the 1800, infection of the indigenous primate 
species is typically fatal. Serological surveys demonstrated the high prevalence of YFV 
antibodies in baboons (Papio spp.) and grivet monkeys (Cercopithecus spp.) in Africa (Taylor, 
Haseeb et al. 1955). Colobus monkeys in Africa have also been demonstrated to be susceptible to 
YFV infection (Woodall, Dykes et al. 1968). Although Galago species exist in high abundance, 
the low seropositive rates suggested the less involvement of transmission (Taylor, Haseeb et al. 
1955). The repeated virus isolation and high antibody prevalence in South American howler 
monkeys showed their importance in supporting virus transmission in the jungles of South 
America (Laemmert and Kumm 1950, Downs, Anderson et al. 1955, Mendez, Parra et al. 2007). 
The jungle cycle is primarily sustained by the biting behaviors of canopy-dowelling mosquitoes 
and primates. The jungle cycle in Africa has been found to be maintained by the principal vector 
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Ae. africanus (Smithburn, Haddow et al. 1949, Henderson, Metselaar et al. 1970). In 1938, H. 
leucocelaenus and H. capricorni were first reported to be susceptible to YFV infection 
(Shannon, Whitman et al. 1938). Sabethes chloropterus, H. janthinomys and other Haemagogus 
mosquitoes were later found to be vectors for the jungles of South America (De Rodaniche, 
Galindo et al. 1957). Human infections can be incidental and sometimes considered an 
occupational disease amongst people with histories working in the forest.  
In addition to the jungle cycle, transmissions in the intermediate cycles in Africa happen in 
the areas with the presence of both human and non-human primates characterized by the focal 
outbreaks spaced by the areas without the presence of humans. The intrusion of human activities 
into areas where the jungle cycles take place initiates the spillover of virus from primates to 
humans. Ae. luteocephalus, Ae. furcifer, Ae. metallicus, Ae. vittatus, Ae. opok, Ae. taylori and 
members of Ae. simpsoni complex have been discussed in the literatures for the potential as 
vectors in the intermediate cycle (Lee and Moore 1972, Germain, Francy et al. 1980, Barrett and 
Higgs 2007).  
The mechanisms that are responsible for the absence of YF outbreaks in Asia remain 
unclear. Although Ae. aegypti has been known as the vector for both DENV and YFV and the 
Ae. aegypti in Asia has been found susceptible to YFV, other epidemiological and ecological 
conditions ought to be taken into account (Tabachnick, Wallis et al. 1985). Gould et al. has 
proposed several hypotheses including the lack of sylvatic YFV transmission and the differences 
in disease severities which may impede the long-distance transmission of YFV (Gould, de 
Lamballerie et al. 2003). The experimental evidence of the viscerotropic YFV hamster model 
suggested that cross protections can also provide a plausible explanation, especially with the high 
incidence of DENV and JEV in Asia (Xiao, Guzman et al. 2003). Other alternatives were also 
proposed based on the relative viral fitness between DENV and YFV in vitro (Amaku, Coutinho 
et al. 2011). However, other evidence also challenge the hypothesis, for example,  the reports of 
sylvatic transmissions of DENV and other flaviviruses suggesting the presence of potentially 
susceptible vectors and non-human primates due to the genetic homology between DENV and 
YFV and the shared use of vector species. However, the vertebrate hosts and the proposed 
vectors for the sylvatic transmission of DENV have not been challenged with YFV and whether 
the vertebrate hosts are susceptible to YFV or the vectors are competent for transmission remains 
unclear. 
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 B. History of YFV 
Although it is now regarded as a rare and exotic disease for the United States, historically  
epidemics caused by YFV were documented as far north as Boston and other parts of New 
England throughout the history of United States. However, the geographic distributions of the 
diseases were mostly restricted to the southern United States, especially the major port cities 
(Patterson 1992). One of the earliest notable outbreaks of YFV took place in Philadelphia, which 
was the largest city in the United States, in 1793. However, prior to such epidemic, the city has at 
least three epidemics in 1699, 1741 and 1762 (Foster, Jenkins et al. 1998). In 1874, Memphis 
Tennessee experienced the largest YF outbreak in the history of United States leading to 20,000 
cases distributed along the Mississipi River (Wright 2001). The most recent notable outbreak 
happened in New Orleans Louisiana in 1905. 
Prior to the 1930s in the 20th century, the virus has been isolated and subsequently used for 
the tests for the vaccine development and human immunity. The etiological agent was further 
confirmed using the laboratory model of Macacus sinicus that succumbed following  the 
inoculation of viremic blood and had no detectable Leptospira icteroides (Stokes, Bauer et al. 
2001). Two of the most important strains for vaccine production, the Asibi strain from a West 
African survivor of YF infection and the French viscerotropic strain, were isolated in 1920s. The 
Asibi strain later became the starting material in the serial passage experiments by Max Theiler 
to produce the attenuated 17D strain (Smith and Theiler 1937).  
In 1949, the first isolation of YFV in 43 years took place in Panama followed by the 
expansion towards the border between Guatemala and Mexico in 1957, leaving 315 identified 
cases (Elton 1955). Interestingly, this epidemic also led to the discovery that the Haemagogus 
vectors are competent for the transmission in the western hemisephere in the laboratory 
established by the Rockefeller foundation in Trinidad. During this period, YFV epidemics were 
absent due to the comprehensive immunization campaigns in the French West and Equatorial 
Africa (Peltier 1947). However, the immunological naïve population in the British colonies 
including Ghana and Nigeria suffered from the outbreaks between 1950 and 1952 leading to at 
least 12,000 cases and 500-600 deaths during the single outbreak in the Jos Plateau (WHO 
2014). In this epidemic, the knowledge that Ae. africanus feeds at the ground level and can be 
isolated in the household was established. In the early 1960s, the southwestern Ethiopia of East 
Africa was swept by the virus causing about 30,000 fatal cases with the estimated infection rate 
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at 10% of the total population in two years and recognized as the largest outbreak in history 
(Tignor, Casals et al. 1993). In West Africa, the termination of the vaccination with the French 
neurotropic vaccine amongst the children at the age of 10 led to the decision of reformulation for 
the pediatric vaccines to the 17D vaccine due to the severe neurological adverse effects 
(Macnamara 1953, Frierson 2010). The decade was concluded with an extensive epidemic 
affecting parts of Mali, Burkina Faso, Togo, Ghana and Nigeria leaving an estimated number of 
100,000 infections in the area. Throughout the 1960s, in addition to the Ae aegypti which 
constantly was responsible for the transmission, the vectoring by Ae luteocephalus, Ae africanus 
and Ae vittatus was also observed (Lee and Moore 1972, Germain, Francy et al. 1980). In Latin 
America, the traditional boundaries of YFV were challenged in the 1960s by the reported cases 
between Brazil and Argentina due to the epizootic outbreaks. The jungle cycle of YFV can only 
be partially controlled by the vaccination among residents in the rural areas; whereas, the control 
of the urban YF can be achieved by the eradication of Ae. aegypti in the cities (Monath 1999). 
The control measures based on eliminating the breeding sites of Ae. aegypti were initiated by the 
International Health Commission of the Rockefeller Foundation, proved highly successful for 
disease control in Ecuado in 1918 (Strode and Rockefeller Foundation. International Health 
Division. 1951). Since the 1930s, the initiation of Ae. aegypti eradication has originated from 
Brazil and further expanded to other countries in the Americas. The success of joint disease 
control efforts by the Brazilian federal government and the Rockefeller Foundation was 
compromised by the reinfestation of border territory by Ae. aegypti, which further led to the 
proposal for much wider collaborative effort of vector eradication in multiple countries in 1947. 
The multinational campaign was approved by the Pan America Health Organization and 
maintained due to the constant threat of jungle YF reported in five to eight countries each year 
(Soper 1963, Soper 1967). Such campaigns were not only helpful for the control of YF but also 
led to the control of other arboviral diseases, especially dengue fever (DF) (Schliessmann 1967).  
In 1971, the virus reemerged in Angola after its long period of silence for the last 99 years 
leaving 65 cases with 42 deaths. However, the serological evidence suggested the 
underestimation by finding at least 13% of the urban population were seropositive (Pinto and 
Filipe 1971). In Gambia between 1978 and 1979, the Chinese contract physicians first reported 
the jaundice and fatal cases leading to the discovery of an epidemic causing at least 8,400 cases 
and 1,600 deaths. It was the first outbreak providing the epidemiological insight of the 
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asymptomatic and symptomatic infections of YFV, the vulnerability of the immunologically 
naïve Gambian population to the epizootic virus from eastern Senegal, and the spillover of the 
virus leading to the transition of the vector choice from the sylvatic Ae. furcifer to the urban Ae. 
aegypti in eastern Gambia (Germain, Francy et al. 1980). In the Americas, the reemergence of 
sylvatic YFV from the Brazilian jungle started in 1972-1973 extending its distribution south to 
Paraguay and Bolivia. Additionally, the reinfestation of areas by Ae aegypti also posted 
significant concern on the spread of the epizootic YFV to the west of the Panama Canal (WHO 
1985, Barrett and Higgs 2007).  
In 1983, the massive outbreak transmitted by the sylvatic vector Ae. furcifer in Burkina 
Faso and Ghana caused 15,000 infections, amongst which 10% of the cases developed jaundice 
and 4% of the cases died (Robert, Lhuillier et al. 1993). In 1986, an even larger epidemic spread 
by the rural vector Ae. africanus occurred in eastern Nigeria leading to 10,000 jaundice cases and 
5,000 fatal cases (De Cock, Monath et al. 1988). In 1987, the city of Ogbomosho in western 
Nigeria was struck by another epidemic transmitted by Ae. aegypti leaving twenty percent of the 
population infected (Nasidi, Monath et al. 1989). Cases have been reported in Bolivia, Brazil, 
Columbia, Ecuador and Peru between 1985 and 1994. In 1995, the largest epidemic in Peru since 
1950s was reported (Barnett 2007).  
Currently, there have been five genotypes reported to circulate in different regions of 
Africa whilst two genotypes have been found in Latin America (Mutebi and Barrett 2002, Barrett 
and Higgs 2007). The changing epidemiology and the reemergence of YFV have posted 
significant public health threat since 1980s. In Africa, the transmissions in the sylvatic cycle 
allow the virus to circulate between non-human primates and mosquitoes in spite of the 
vaccination. The vaccination has become the emergency strategy in order to control the outbreak. 
The pause of the routine vaccination coincided with the report of YF cases in 93% of the 
countries in West Africa in early 2000 (Barrett and Higgs 2007). With the rapid urban 
development in Africa, the non-vaccinated individuals have substantially increased the number 
of the susceptible populations to YFV infection in the urban areas (Barrett and Higgs 2007, Ellis 
and Barrett 2008, Gardner and Ryman 2010). Although the eradication of Ae. aegypti in the 
Americas since 1930s and 1940s temporarily suppressed the outbreaks of YF, the lack of 
persistent control measures led to the more extensive reestablishment  of such vector species. 
Such reinfestation not only led to the reemerging threats of YFV in the urban area but also has 
41 
 
been further complicated by the rapidly expanding geographic distribution of the other flavivirus, 
dengue virus, which also utilizes Ae. aegypti as its primary vector (Guzman, Halstead et al. 
2010). With the increase frequency of aviation travels, the epidemics of YFV in Africa or South 
America can easily be spread to other parts of the world, where the susceptible hosts and 
competent vectors exist. The imported case of YFV in Texas from Amazonas, Brazil in 2002 
was considered a good example that the import of arboviruses through unvaccinated travelers 
becomes a significant public health issue in the United States (Centers for Disease and 
Prevention 2002).  Additional challenges have also emerged due to the shortage of the YFV 
vaccine. Since 2013, the shortage has been reported in both the United States and the United 
Kingdom due to the failures in manufacturing procedures.  The shortage of the vaccine limits the 
coverage for travelers who plan on traveling to high-risk areas and the capacity of health 
authorities in response to disease epidemics (CDC 2014).  
 C. Clinical Diseases 
As the prototype of viral hemorrhagic fever, YF can result in up to 50% case mortality if 
the patients are not properly treated. The progression of the disease can be divided into three 
stages, infection, remission and intoxication. The severe human pathology and diseases are 
primarily documented as the lesions in the liver and other viscerotorpic symptoms, especially 
jaundice (WHO 2014).  
The development of the viremic phase generally requires three to six days from the start of 
the infection by the wild-type YFV strains. The typical symptoms in the viremic phase resemble 
other viral hemorrhagic fevers and viral diseases such as high fever up to 39Ԩ, myalgia, malaise 
and vomiting (Nassar Eda, Chamelet et al. 1995, Lefeuvre, Marianneau et al. 2004). Virus 
isolation can often be performed from the biopsy or serum samples from infected individuals 
(Pinto and Filipe 1971, Carey, Kemp et al. 1972). The stage of remission is characterized by the 
clearance of infectious virions in the blood. The patients may recover without further clinical 
signs or symptoms in the case of abortive infections. However, 15-25% of cases are likely to 
develop profound bleeding symptoms including jaundice, major bleeding, coffee-ground 
haematemesis, melaena or metrorrhagia (Monath 2001).  
Biochemical laboratory tests have been found particularly helpful for the diagnosis of YF. 
The elevated levels of serum alanine transaminase (ALT) and aspartate transaminase (AST) are 
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the most common characteristics for the liver damages caused by YF (Francis, Moore et al. 
1972). Although the hematological characteristics vary among patients, thrombocytopenia, 
prolonged clotting times and platelet dysfunction have also been reported (Francis, Moore et al. 
1972, Monath 2001). The mortality of patients with hepatorenal diseases can range from 20 to 
50% and deaths in the recovery phase has also been described in the past. In addition, the 
neutropenia and renal damage may lead to the superimposed bacterial infections, pneumonia or 
require dialysis due to the necrosis in the renal tissues (Lefeuvre, Marianneau et al. 2004). The 
disease incidence and mortality can be 1000-fold greater than those caused by Ebola virus 
leading to the name of the most lethal virus infections known to human (Van Epps 2005).  
Two forms of YF-related diseases  have been observed associated with  vaccine adverse 
effects (Barrett and Teuwen 2009). Although the recent reviews have discussed the incidence of 
the diseases related to the YFV 17D vaccines occurred as early as 1973, the concept of the 
vaccine-associated effects in the literature was not introduced until 2002 (Centers for Disease 
and Prevention 2002). The incidence rates of the viscerotropic form (YEL-AVD) and 
neurotropic form (YEL-AND) of vaccine adverse effects are estimated to occur at 0.013 and 
0.016 per 100,000 doses when the vaccines are used in endemic areas (Breugelmans, Lewis et al. 
2013). The vaccine-associated viscerotropic disease is rare and mostly occurs in elderly 
vaccinees (≥65 years old). The disease symptoms mostly resemble those infected by the wildtype 
YF with viremia, jaundice and elevated ALT and AST. Case fatalities have been reported in 
severe cases with multiple organ failure. The liver pathology is commonly manifested with 
necrosis, acidophilic degeration, Kupffer cell hyperplasia and microvesicular fat. Antigens of 
YFV can often be detected in multiple organs (Centers for Disease and Prevention 2002, 
Kitchener 2004, Monath 2010). Multiple forms of neurological symptoms have been reported in 
YEL-AND cases including encephalitis, acute disseminated encephalomyelitis (ADEM) and 
Guillain-Barre Syndrome (GBS) (Kitchener 2004, McMahon, Eidex et al. 2007).  
 D. Yellow fever vaccines 
There have been several approaches to describe the approaches to attenuate YFV. In the 
1930s, two vaccines, the 17D vaccine and the French neurotropic vaccine, were developed 
concurrently. However, the reactogenicity of French neurotropic vaccine has been repeatedly 
reported since 1950s and its production and use have been discontinued (Macnamara 1953).  
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Prior to the era of YFV vaccines, laboratory-acquired infections repeatedly caused death in 
laboratory workers. The earlier attempt of vaccination among the laboratory personnel was made 
with the French neurotropic virus mixed with human immune serum (Sawyer, Kitchen et al. 
1932). Theiler et al. showed the cultivation of YFV by intracerebral inoculation into mice was 
able to reduce the virulence in monkeys (Laemmert and Kumm 1950). The development of the 
17D vaccine by the cultivation of the virulent Asibi strain in vitro was first proved to lose the 
viscerotropism in primates and further found non-transmissible in mosquitoes (Theiler and Smith 
1937, Miller and Adkins 1988). Additional experimental evidence demonstrated the passage 
through chicken embryos led to the more efficient attenuation than the passage in either mouse 
embryonic tissues or testicles. The prolonged culture of the Asibi virulent strain in mouse 
embryonic tissues followed the minced chicken embryos with minimal brain and spinal cord for 
a total of 176 passages led to the attenuated phenotype of 17D vaccine strain. Such serial passage 
approach was first found to cause reduced neurovirulence in mice compared to the viruses passed 
through mouse embryonic tissues. Inoculation of rhesus monkeys showed reduced viremia and 
led to the production of neutralizing antibodies. Further attempts to vaccinate humans 
demonstrated the safety and the immunogenicity desired for the live-attenuated vaccines (Smith 
and Theiler 1937, Theiler and Smith 1937).  
Immunization of YFV 17D vaccine causes self-limited viremia and induces both innate and 
adaptive immune responses. The vaccine is able to elicit innate and adaptive responses through 
the activation of Toll-like receptor signaling followed by the production of proinflammatory 
cytokines (Querec, Bennouna et al. 2006). In addition to the humoral immunity which persisted 
over a decade, the vaccination also led to CD8(+) T-cell memory responses by the T cell 
epitopes on the nonstructural proteins (Poland, Calisher et al. 1981, Akondy, Monson et al. 
2009). Currently, the YFV 17D vaccines are based on two substrains, 17D-204 and 17DD 
strains. The 17D-204 substrain was obtained based on the 204th passage and the 17DD substrain 
was further passaged in eggs in South America from the 195th passage (Barrett 1997).  
The French neurotropic vaccine (FNV) strain was derived from the serial passage of the 
French viscerotropic virus (FVV) isolated from Syrian in 1927. The parental virus underwent 
128 passages in mouse brain in order to achieve the attenuation and the scale of vaccine 
production (Wang, Ryman et al. 1995, Barrett 1997, Frierson 2010). FNV was given to 80 
million residents of French-speaking regions of Africa along with the smallpox vaccine through 
44 
 
scarification (Peltier 1947). Although FNV was more immunogenic than 17D vaccines, the 
production of FNV has been discontinued in 1980 due to the unacceptable high incidence of 
vaccine-associated encephalitis with mortality rate up to 40%, especially amongst vaccinated 
children under the age of 14 (Wang, Ryman et al. 1995, Barrett 1997, Frierson 2010).  
17D vaccines have also been reported to cause adverse effects amongst the vaccines 
(Barrett and Teuwen 2009). The vaccine-associated neurotropic disease (YEL-AND) has been 
described and led to less than 5% case fatality rate (McMahon, Eidex et al. 2007). The other 
form of the vaccine-associated adverse events, the vaccine-associated viscerotropic disease 
(YEL-AVD), has first been described in 2002 and could be further dated back to 1973 (Centers 
for Disease and Prevention 2002, Monath 2010). The epidemiological analysis has identified 
several risk factors for YEL-AND including age, males and the history of thymus disease with a 
thymectomy (Barrett and Teuwen 2009). Due to the limited samples of YEL-AVD cases, the 
mechanistic evidence has been very limited centering the hypothesis on the disconnection 
between innate and adaptive immune responses. Fatal cases shared similar hematological 
characteristics with viremia similar to YFV infected individuals. Multiorgan failure, the 
elevation of liver enzymes and the impairment of coagulation have also been observed 
(Breugelmans, Lewis et al. 2013).  
The other attempt of attenuating virulent YFV has also been reported in the passages 
through HeLa cells. The attenuated viruses have been described for multiple times in different 
literatures (Hearn, Soper et al. 1965, Barrett, Monath et al. 1990). The attenuated Asibi-LP-CDC 
HeLa p6 virus lost its viscerotropism in primates and reduced its neurovirulence in mice with 
fewer mutations identified in the genomes (Dunster, Wang et al. 1999). Most interestingly, the 
Asibi LP-CDC HeLa p6 virus was also found non-transmissible in Ae. aegypti (Miller and 
Adkins 1988).  
Whilst the phenotypes of attenuated FNV and 17D strains had distinct safety profiles, the 
amino acid sequences of FVV and the Asibi strain have two nearly identical genomes, differing 
at only 9 amino acids and 23 nucleotides (Wang, Ryman et al. 1995). However, the distinct 
passage histories between two vaccines led to only two consensus mutations, the LeuPhe 
mutation at the residue 36 of the prM protein and the IleMet mutation at the residue 94 of the 
NS4B protein.  
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Between the Asibi and 17D strains, our research focuses on comparing the different genetic 
composition and delineating the mechanisms leading to the distinct phenotypes of two viruses in 
Ae. aegypti. The sequence analysis identified 67 nucleotide changes leading to 31 amino acid 
substitutions between the Asibi strain and the 17D-204 strain, the critical determinants for viral 
attenuation have not yet been identified. The overall divergence is 0.623% and 0.94% at the 
nucleotide level and amino acid level, respectively. The envelope (E) protein contains the most 
amino acid mutations amongst the viral genes; whereas, the mutation rates were found to be 
highest in NS2A and NS2B (Hahn, Dalrymple et al. 1987). The genetic differences between the 
wildtype Asibi strain and the 17D strains are listed in table 1.4. Although it has been proved that 
the 17D vaccines contain a heterogeneous population of viruses that lead to different plaque 
morphologies and phenotypes, the recent report from the deep sequencing of the wildtype Asibi 
strain and the 17D-204 strain demonstrated the relative diversity of quasispecies can be a critical 
characteristic for viral attenuation. The phenotypes of 17D vaccines were derived from the 
accumulation of attenuating mutations (Beck, Tesh et al. 2014).  
 
Gene Position (nt) Asibi 17D-204 17DD Position(aa) Asibi 17D-204 17DD 
C 304 G A A     
370 U C U     
M 854 C U U 36 L F F 
 883 A G A     
E 1127 G A A 52 G R R 
 1140 C U C 56 A V A 
 1482 C U U 170 A V V 
 1491 C U U 173 T I I 
 1572 A C C 200 K T T 
 1750 C U U     
 1819 C U U     
 1870 G A A 299 M I I 
 1887 C U U 305 S F F 
 1946 C U C 325 P S P 
 1965 A G G 331 K R R 
 2112 C G G 380 T R R 
 2219 G A G 416 T A T 
 2356 C U U     
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NS1 2687 C U U 79 L F F 
 2704 A G G     
 3274 G A A     
 3371 A G G 307 I V V 
 3613 G A A     
NS2A 3817 G,A G G     
 3860 A G G 61 M V V 
 3915 U,A U U     
 4007 A G G 110 T A A 
 4013 C U C 112 L F L 
 4022 A G G 115 T A T 
 4054 C U C     
 4056 C U U 126 S F F 
NS2B 4289 A C C 37 I L L 
 4387 A G G     
 4505 A C C 109 I L L 
 4507 U C C     
NS3 4612 U C U     
 4864 A,G G G     
 4873 U G U     
 5131 U,G G G 187 I,M M M 
 5153 A G A 195 I V I 
 5194 U C C     
 5431 C U U     
 5473 C U U     
 5641 G A G     
 6013 C U U     
 6023 G A A 485 D N N 
 6448 G U U     
 6529 U C C     
NS4A 6758 A G A 107 I V I 
 6829 U C C     
 6876 U C C 146 V A A 
NS4B 7171 A G G 95 I M M 
 7571 C A C     
 7580 U C C 232 Y H H 
NS5 9605 A G A 657 N D N 
47 
 
 10075 G,U G G 814 M,I M M 
 10142 G A A 836 E K K 
 10243 G A A     
 10285 U C C     
 10312 A G G     
 10316 U,C U U 894 S,P S S 
 10338 C U U 900 P L L 
3’ NCR 10367 U C C     
 10418 U C C     
 10454 A G A     
 10550 U C U     
 10800 G A A     
 10847 A C C     
 
Table 1.4 Genetic mutations between the wildtype Asibi strain and 17D vaccine strains at 
nucleotide (nt) and amino acid (aa) level 
 
Efforts on characterizing mutations in YFV 17D genomes have been performed in mice 
and mosquitoes in the laboratory. The attenuated phenotypes of YFV 17D strains will be 
described in section 1.4.E and 1.5. With the neurovirulent variant of 17D Porterfield strain, 
several point mutations were identified and can potentially alter the virulence of YFV in vivo. 
Mutations in EDIII including the ArgThr reversion at the residue 380 to the Asibi sequence led 
to the neuroinvasive phenotype (Nickells and Chambers 2003). Together with the report from 
Lee et al., the positive charges on the lateral surface of YFV EDIII are the critical determinants 
of the heparin binding sensitivity in vitro and the neurovirulence of YFV in mice (Lee and 
Lobigs 2008). The other critical region which was reported to be critical for the viral spread was 
the ValAla mutation at the residue 260 of the molecular hinge region between EDI and EDII 
of neuroadapted YFV 17D strain. The mutation changed the cell penetration capacity by altering 
the efficiency of the fusion process (Vlaycheva, Nickells et al. 2004). Although such change did 
not occur in the attenuation process from the Asibi strain, the other strand on the four-strand 
structures of the molecular hinge contains the GlyArg mutation at the residue of 52. However, 
the individual determinants for viral infection and dissemination in Ae. aegypti remain to be 
identified. 
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 E. YFV in Ae. aegypti 
Although the proposed concept of the transmission of YFV through the arthropod vectors 
by Dr. Carlos Finlay preceded the experiments by Walter Reed, the critical factors such as the 
extrinsic incubation period and the presence of viruses in mosquitoes were not determined or 
demonstrated until later (Bauer and Hudson 1928, Whitman 1937). The report that the Asibi 
strain was able to replicate, disseminate and be transmitted by Ae. aegypti was first established 
by  oral infection with the Asibi strain propagated in mouse brains and further repeated with the 
cloned Asibi strain generated by the reverse genetics system (Whitman 1937, Miller and Adkins 
1988, McElroy, Tsetsarkin et al. 2006). The infection ultimately led to the dissemination of virus 
into the salivary glands, which is required for the inoculation of infectious virions into the next 
immunological naïve host (Miller and Adkins 1988, McElroy, Tsetsarkin et al. 2005). In 
contrast, the infection of 17D strains and other attenuated strains showed the non-disseminating 
patterns that were primarily restricted to the midguts (Miller and Adkins 1988, McElroy, 
Tsetsarkin et al. 2005, McElroy, Girard et al. 2008).  
Similar to the vector competence for other arboviruses, the infection and dissemination of 
YFV in Ae. aegypti are subjected to interactions between the genetics and the physiological 
conditions of mosquitoes.  The variations observed in the susceptibility among Ae. aegypti 
populations collected from different geographic locations were first shown through the infection 
experiments of French viscerotropic virus (Aitken, Downs et al. 1977). The susceptibility of Ae. 
aegypti was further attributed to the differences in the genetic backgrounds of different strains 
(Tabachnick, Wallis et al. 1985). The selection and crossing of the inbred Ae. aegypti colonies 
with different susceptibilities suggested the genetic loci in individual mosquitoes can potentially 
govern the vector competence  for YFV and other viruses (Wallis, Aitken et al. 1985, Miller and 
Mitchell 1991). Additionally, the laboratory colonization has also been taken into account as the 
susceptibility of Ae. aegypti to YFV varies between different generations (Lorenz, Beaty et al. 
1984).  
Significant advancements in the knowledge in identifying the viral determinants of 
infection and dissemination were achieved with the laboratory Ae. aegypti RexD strain and 
infectious clones of YFV by McElroy et al. The observations from the chimerized YFV genomes 
between the Asibi and 17D-204 strains suggested multiple genetic loci are related to the non-
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disseminating phenotype of 17D strains (McElroy, Tsetsarkin et al. 2005, McElroy, Tsetsarkin et 
al. 2006, McElroy, Tsetsarkin et al. 2006).  
 1.5 Justification of the research 
 A.  Infection and dissemination of virulent and attenuated YFV strains in Ae. aegypti  
Although the phenotype of YFV 17D strains in Ae. aegypti has been repeatedly 
demonstrated to be non-disseminating in the infected mosquitoes, the mechanisms responsible 
for the attenuation remain largely unknown (Miller and Adkins 1988, McElroy, Girard et al. 
2008). The purpose of the studies described in this dissertation was to perform functional 
characterization using molecular viriological approaches to provide the critical knowledge for 
the viral attenuation of YFV. The central hypothesis of the study is: “the amino acid substitutions 
in the E protein of YFV result in the change in the biochemical properties of the functionally 
important residues and the attenuated phenotype of YFV 17D strains in Ae. aegypti.” The genetic 
characterization has identified 68 nucleotide substitutions between the virulent Asibi strain and 
the attenuated 17D-204 strain, which was used as the model for the study of viral attenuation 
(Hahn, Dalrymple et al. 1987). Among the 68 nucleotide substitutions, 15 point mutations are 
located in the E gene, resulting in 12 amino acid changes. The specific amino acid mutations of 
other flavivirus E proteins that led to different phenotypes will be reviewed in the sections of 
individual specific aims. The 15 nucleotide substitutions led to a total 12 amino acid mutations in 
the E protein of 17D-204 strain as summarized in table 1.4. The attenuating amino acid 
mutations of the E proteins of 17D-204 strain and 17DD strain differ only at the ThrAla/Thr 
mutations located at the residue 416 in EDIII, which is not exposed at the surface of virion based 
on the available structure (Volk, May et al. 2009). The following paragraph and table 1.5 
provide the summary of results that are specifically related to YFV Asibi and 17D-204 strains in 
Ae. aegypti as the justification for the targets for mutagenesis (McElroy, Tsetsarkin et al. 2006).  
Virus  Infection rates Dissemination Rates 
Asibi 42/58   (72.4%) 35/42   (83.3%) 
Asibi+17D M-E 16/60   (26.6%) 5/16   (31.3%) 
Asibi M L36F 16/49 (32.7%) 8/16   (50.0%) 
Asibi+17D EDI-EDII 9/58   (15.5%) 6/9   (66.7%) 
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Asibi+17D EDIII 22/58   (37.9%) 7/22   (31.8%) 
17D+Asibi EDIII 28/85   (32.9%) 4/28   (14.3%) 
17D+Asibi M-E 16/76   (21.1%) 11/16   (68.8%) 
17D 17/56   (30.4%) 0/17   (0.0%) 
 
Table 1.5 The infection and dissemination reported in YFV chimeras at 14 d.p.i. modified 
from McElroy et al. (2006) 
The Asibi strain infected a higher percentage of mosquitoes and disseminated in the 
infected mosquitoes; whereas the 17D strain was only able to infected a lower percentage of 
mosquitoes with no or limited dissemination observed (McElroy, Tsetsarkin et al. 2005, McElroy, 
Tsetsarkin et al. 2006, McElroy, Girard et al. 2008). The chimerization of the structural genes of 
the 17D strain with the Asibi nonstructural genes led to the low viral infectivity and limited the 
dissemination into the secondary tissues. Due to the conserved sequences of the capsid genes 
between the Asibi and 17D strains, the attenuation determinants are located in the prM and E 
genes. The L36F mutation in the M protein resulted in the significant reduction in the infection 
rate of Ae. aegypti. However, the dissemination was still observed in 50% of the infected 
mosquitoes. The substitution of the E protein in the Asibi strain with the corresponding region of 
the 17D strain reduced both the infection and dissemination rates of the Asibi strain. 
Chimerization of the different domains of the E protein led to different consequences of viral 
infection and dissemination suggesting that the attenuation determinants are encoded in both EDI 
and EDII. The Asibi strain substituted with EDI and EDII of 17D strain was only able to infect a 
lower percentage of mosquitoes but disseminated at a comparable level as the Asibi strain at 14 
days post infection (d.p.i.). The substitution of EDIII of the Asibi strain with EDIII of 17D strain 
led to a lower infection and dissemination rates. In contrast to the attenuation caused by the 
chimerization of the genetic materials from the 17D strain, the substitution of the prM and E 
structural proteins in the 17D strain with the corresponding regions of the Asibi strain only 
reproduced the disseminating phenotype of the wildtype virus without significantly increased the 
infection rates.  Substituting the region of EDIII in the 17D strain with that of the Asibi strain 
failed to increase the infection and dissemination rates to the equivalent level of the Asibi strain. 
Together, the results demonstrated that a partially attenuated phenotype can be produced by 
introducing the mutations in the E protein. However, the presence of attenuating mutations in the 
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nonstructural regions can be confirmed as the reversions to the sequences of the Asibi strain in 
the E protein of 17D strain was unable to restore the viral infection and dissemination. The 
research described in the dissertation is based on two cDNA infectious clones- the Asibi strain 
and the 17D/Asibi M-E chimera. Mutations were introduced to both infectious clones for the 
assessment of attenuation. The mutations tested in the Asibi strain were devised to evaluate the 
consequence of mutations in the E protein; whereas, the mutants based on the 17D/Asibi M-E 
chimera were generated to evaluate the attenuation caused by the mutations coupled with other 
attenuating mutations in the nonstructural genes. 
The research is expected to characterize the mechanisms that attenuate YFV in Ae. aegypti. 
Such knowledge is critical for the design and optimization of the live-attenuated flavivirus 
vaccines and vaccine candidates by increasing the safety through the reduction of transmissibility. 
The identification of attenuating mutations will lead to the better understanding in the viral 
determinants that are critical for the vector competence of arboviruses. 
 B. Specific aims of the research 
Four amino acid residues were selected for testing based on the locations, biochemical 
properties and functions in three different sets of infectious clones. 
Specific aim 1 focuses on the assessment of mutants leading to the change in the positive 
charges on the lateral surface in YFV EDIII in Ae. aegypti. The positive charges introduced by 
the T380R mutation on the lateral surface of YFV EDIII were demonstrated to be critical for the 
binding between the negatively charged heparin sulfate in vitro and the viral dissemination in 
mice (Lee and Lobigs 2008, Nickells, Cannella et al. 2008). The increase of the heparin binding 
capacity in vitro has frequently been identified in RNA viruses passaged in naturally 
nonsusceptible hosts. The increase in the binding with heparin sulfate led to the higher binding 
affinity with other negatively charged cellular glycosaminoglycan molecules and this caused the 
subsequent retention and readsorption of the progeny virions, which assisted the withdraw of 
virions from the blood circulation and thereby limit systematic infection and viral dissemination. 
As the ubiquitously expressed cellular molecules, the presence of glycosaminoglycans in the 
midgut of mosquitoes also suggests the possibility of the retention of the virus through similar 
electrostatic interactions.  Therefore, the hypothesis that the biochemically non-conservative 
T380R mutation in the RGD motif is responsible for the binding of cellular negatively charged 
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molecules was tested to evaluate the contribution for the mutation in viral attenuation in 
mosquitoes.  
Specific Aim #1: Determine the impact of amino substitution in the RGD motif of YFV 
envelope protein domain III (EDIII) in changing the efficiencies of viral infection and 
dissemination in Ae. aegypti. 
Specific aim #1a: develop and characterize the YFV cDNA infectious clones containing 
T380R mutation.  
Specific aim #1b: evaluate the infection and dissemination of recovered mutants containing 
T380R mutations in orally infected Ae. aegypti. 
Specific aim 2 was devised to analyze two mutations in EDI and EDII, which are 
independent from the receptor binding process. By incorporating the G52R and T173I mutations 
simultaneously and separately, the mutants were assessed for the viral infection and 
dissemination. The significance of the G52R mutation is based on its location IN the EDI-EDII 
molecular hinge region. Similarly, the non-disseminating FNV also contains A54V mutation in 
the neighboring region (Wang, Ryman et al. 1995). The T173I mutation was found to be a 
neurovirulence determinant as a vaccine specific B-cell epitope (Ryman, Xie et al. 1997). Its 
impact in the phenotype in mosquitoes remains unclear. 
Specific Aim #2: Determine the minimal requirement of mutants responsible for the reduced 
infection rates in Ae. aegypti caused by the mutations in the YFV envelope protein domain I 
(EDI) and domain II (EDII) 
Specific aim #2a: develop and characterize YFV cDNA infectious clones containing G52R 
and T173I mutations.  
Specific aim #2b: evaluate the infection and dissemination of recovered mutants containing 
G52R and T173I mutations simultaneously and respectively in orally infected Ae. aegypti. 
 
In specific aim 3, three infectious clones were generated to evaluate the M299I mutation in 
the molecular linker region between EDI and EDIII. The linker region was recently proved to 
change the dissemination of DENV-2 in vitro (de Wispelaere and Yang 2012).  
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Specific Aim #3: Determine the minimal requirement of mutants responsible for the reduced 
infection rates in Ae. aegypti caused by the mutations in the YFV envelope protein domain I 
(EDI) and domain III (EDIII) 
Specific aim #3a: develop and characterize YFV cDNA infectious clones containing M299I 
mutations;  
Specific aim #3b: evaluate the infection and dissemination of recovered mutants containing 
M299I mutation in orally infected Ae aegypti.  
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Chapter 2 - Materials and Methods 
The research described in the dissertation requires the manipulation of YFV genomes, the 
propagation of YFV mutants, the per os infection and dissection of Ae. aegypti, the detection and 
quantification of viral antigens in mosquito tissues in vitro. Section 2.1 contains the information 
of the eukaryptic cell lines used for the propagation and titration of YFV and the bacterial 
competent cells for the manipulation of cDNA derived from the viral genomes. Section 2.2 is 
devised to provide the information of the molecular cloning strategies and procedures to generate 
viral mutants. The details of the rearing, per os infection and dissection of Ae. aegypti are 
described in section 2.3 The procedures of the detection and titration of infectious viruses from 
the mosquito tissues are listed in section 2.4. The statistical methods for the analysis are 
described in section 2.5. 
 2.1 Cell lines and competent cells 
 A. Mammalian cells 
The cell line BHK-21 was derived from baby hamster (Mesocrecitus auratus) kidney. 
(MACPHERSON & STOKER, 1962) For this research project, it was maintained in minimum 
essential media (MEM) α media (Life Technologies) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS) (Life technologies), antibiotics (penicillin at 100 units/ml and 
streptomycin at 100 μg/ml) (Life Technologies), L-glutamine at 2 mM (Life technologies) and 
MEM vitamins (Life technologies). The cells were maintained at 37℃ with 5% CO2 and used for 
the recovery of YFV by electroporation. 
African green monkey (Cercopithecus aethiops) kidney Vero cells were maintained in 
Leibovitz-15 (L-15) media (Life Technologies) with 10% FBS, 10% tryptose phosphate broth 
(TPB) (Sigma Aldrich), penicillin, streptomycin and L-glutamine (Simizu 1988). The cells were 
maintained at 37℃ without CO2 and used for the titration of viremic blood meals and the 
homogenized mosquito tissues. The media for the titration of mosquito tissues were modified by 
the addition of Fungizone® antimycotic (Life Technologies) containing amphotericin B at 
1μg/ml and sodium deoxycholate at 0.82μg/ml. 
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 B. Bacterial Competent Cells 
E. coli strain MC1061 was obtained from Dr. Ilya Frolov’s laboratory. The MC1061 strain 
of E. coli was the original competent cells used for the construction of the YFV 17D cDNA 
infectious clone (pANCR-FLYF17Dx) and allows the stable maintenance of the cDNA of the 
full-length YFV genome (Bredenbeek, Kooi et al. 2003). Stocks were made from 16-hour 
overnight culture and preserved in 10% glycerol at -80℃. Cells for chemical transformation at 
the log phase of propagation were made in 2X YT both (1.6% peptone, 1% yeast extract and 
0.5% NaCl) at 37℃ and 300 r.p.m. Competent cells transformed with plasmids were propagated 
in terrific broth supplemented with ampicillin at appropriate conditions. Details of the 
transformation and cloning procedures are listed in the section 2.2. 
 2.2 Plasmids and molecular cloning procedures 
 A. Plasmids for cDNA infectious clones of YFV mutants 
The cDNA infectious clones of YFV 17D-204 strain, Asibi strain, and 17D/Asibi M-E 
chimera were established in previously published studies by Bredenbeek et al. (2003) and our 
laboratory (Bredenbeek, Kooi et al. 2003, McElroy, Tsetsarkin et al. 2005). The plasmids of the 
Asibi E M299I mutant and the 17D E I299M mutant were provided by Dr. Alan Barrett 
(University of Texas Medical Branch (UTMB) , Galveston Texas). All plasmids were selected 
based on the ampicillin resistance. The subcloned plasmids based on the pGEM® T Easy system 
were propagated in 2X YT broth supplemented by ampicillin at 100 μg/ml. The full-length 
cDNA infectious clones based on the low-copy number pANCR system were propagated in 
terrific broth (1.2% peptone, 2.4% yeast extract, 72 mM K2HPO4, 17 mM KH2PO4 and 0.4% 
glycerol) supplemented by ampicillin at 40 μg/ml. 
The comprehensive list of YFV mutants characterized in this study is shown in Figure 
2.1 based on the locations of the mutations in the E protein. The mutants were designed based on 
the previously published results by McElroy et al. and described in section 1.5.B.(McElroy et al., 
2006b) In specific aim #1, the T380R mutation in YFV EDIII was characterized in the two 
mutants, the Asibi E T380R mutant and the 17D+Asibi M-E E T380R mutant. The 
characterization of the G52R mutation in the molecular hinge region between EDI and EDII and 
the T173I mutation in EDI were performed in specific aim #2. The G52R and T173I mutations 
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were evaluated by introducing single mutations in the Asibi strain and the 17D+Asibi M-E 
chimera in specific aim #2a. The assessment of the attenuation caused by the simultaneous 
presence of the G52R and T173I mutations was performed in specific aim #2b by the oral 
challenge with the Asibi E G52R-T173I double mutant and the 17D+Asibi M-E E G52R-T173I 
double mutant. The phenotypic change associated with the M299I mutation in the EDI-EDIII 
linker region was determined in specific aim #3 by orally infecting Ae. aegypti with the Asibi E 
M299I mutant, the 17D+Asibi M-E E M299I mutant and the 17D E I299M revertant. The M299I 
mutation was introduced to the Asibi strain and the Asibi M-E chimera, respectively. The I299M 
reversion was inserted to the 17D strain in order to generate the 17D E I299M revertant. 
 
Figure 2.1 cDNA infectious clones of YFV characterized in this study 
Four point mutations, T380R, G52R, T173I and M299I, in the E protein were 
characterized in three specific aims and are highlighted in green. The genes derived from 
the Asibi strain and the 17D strain are colored in red and yellow, respectively. The genetic 
materials in the 5’ NCR region and the C gene contain the consensus amino acid sequences 
colored in orange. 
The details of the molecular cloning strategies are listed in figure 2.2. The structural 
regions between the nucleotide position 474 and 2970 of the genome of Asibi strain were 
amplified by Pfu turbo polymerase (Stratagene) from the cDNA infectious clone of the Asibi 
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strain with the primer set, 17D-F2 and 17D-R3. The amplicons were generated by 25 cycles of 
denaturation at 95℃for 30 seconds, annealing at 55℃ for 30 seconds and extension at 72℃ for 3 
minutes, separated on 1% agarose gel and extracted with the Qiaquik PCR Purification kit 
(Qiagen) and modified by the addition of deoxyadenosine triphosphate (dATP) with Taq 
polymerase (Life Technologies) at 72℃ for 30 minutes in order to provide the complementary A 
overhang sequence to the linearized vector. The modified amplicon was purified by the Qiaquik 
PCR purification kit (Qiagen) and subcloned to the linearized pGEM®T Easy vector (Promega) 
by T4 DNA ligase (Promega) at 4℃ overnight. The ligation reaction was transformed into 
MC1061 cells and the positive clone, pGEM® T Easy-Asibi-st, was selected after propagation 
and purification by the Qiaprep Spin Miniprep kit (Qiagen) followed by the confirmation of 
nucleotide sequences. 
 
Figure 2.2 Cloning strategies for generating Asibi or 17D/Asibi M-E mutants 
The mutations were made by PCR site-directed mutagenesis on the subcloned M and E 
genes of the Asibi strain to exclude the possibility of additional spontaneous mutations. The 
full-length mutants of YFV were generated by the ligations between the subcloned 
fragments and the full-length cDNA infectious clone digested by restriction endonucleases. 
The mutations were introduced to the pGEM® T Easy-Asibi-st plasmid by polymerase 
chain reaction (PCR) site-directed mutagenesis with the Quikchange® II XL kit (Agilent). The 
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primer sets for each point mutation are summarized in table 2.1. Four subcloned mutants contain 
the single mutations in the E gene of Asibi strain. The G1127A mutation led to the G52R 
mutation in the E protein. The C1491T mutation led to the T173I mutation in the E protein. The 
G1870A mutation generated the M299I mutation in the E protein. The C2112G mutation resulted 
in the T380R mutation in the E protein.  The pGEM® T Easy-Asibi-st-G1127A mutant was 
subjected to a second round of PCR site-directed mutagenesis with the primer set introducing the 
C1491T mutation to generate the pGEM® T Easy-Asibi-st-G1127-C1491T mutant. The reaction 
products were digested with the DpnI restriction endonucleasae at 37℃ for 60 minutes to remove 
the template with the wildtype sequence. The amplicons were transformed to MC1061 cells and 
propagated in 10 ml 2X YT broth supplemented with ampicillin followed by the miniprep 
purification method. The mutations were confirmed by nucleotide sequencing. 
 
Primer name Sequence (5’-3’) 
17D-F2 ACGGGTGGAGTGACCTTGGTCCGGAAAAACAGATGGTTGC
17D-R3 AAGACTGCGTCCATGTACAC 
G1127A-sense ACTAGAGACAGTAGCCATTGATAGACCTGCTGAGG 
G1127A-antisense CCTCAGCAGGTCTATCAATGGCTACTGTCTCTAGT 
C1491T-sense CTCCCAGGAAGCCGAGTTCATTGGGTATGGAAAAG 
C1491T-antisense CTTTTCCATACCCAATGAACTCGGCTTCCTGGGAG 
G1870A-sense CACTCAAGGGGACATCCTACAAAATATGCACTGACAAAA 
G1870A-antisense TTTTGTCAGTGCATATTTTGTAGGATGTCCCCTTGAGTG 
C2112G-sense ACAGCTACATTATCGTTGGGAGAGGAGATTCACG 
C2112G-antisense CGTGAATCTCCTCTCCCAACGATAATGTAGCTGT 
Table 2.1 Primers used for the subcloning of the structural genes of the Asibi strain and 
PCR site-directed mutagenesis 
The subcloned structural genes from the mutants on the pGEM® T Easy-Asibi-st plasmid 
were released by digestion with the BspEI (New England Biolabs) and MluI (New England 
Biolabs) to generate the insert for cloning into the reciprocal fragments derived from the cDNA 
infectious clones of the Asibi strain and the 17D/Asibi M-E chimera that were digested with 
BspEI and MluI. Prior to the ligation reaction, the digested subcloned plasmids were separated by 
the electrophoresis with 0.8% agarose gels. The DNA fragments were excised from the argarose 
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gels and purified with the Qiaquik purification kit (Qiagen). The plasmids of the cDNA 
infectious clones were digested with BspEI and MluI at 37℃ for 60 minutes to remove the 
fragments corresponding to the inserts containing the mutations. The digested vectors were 
separated by electrophoresis with 0.5% agarose gels, removed by the excision of the products 
with the correct molecular weight and then purified by the Qiaquik purification kit (Qiagen). The 
inserts and vectors were quantified by O.D.260 and ligated together at the molar ratio of 9:1 at 4
℃ overnight with T4 DNA ligase to generate the full-length cDNA infectious clones of YFV 
mutants and transformed to MC1061 cells. The mutants were selected by propagating individual 
colonies in 10ml 2X YT broth, purified by the miniprep purification method and confirmed by 
nucleotide sequencing. 
The full-length mutants were transformed to MC1061 cells and propagated in 250 ml 
terrific broth containing ampicillin at 40 μg/ml. The plasmids were purified by alkaline 
purification method followed by the cesium chloride (CsCl) gradient purification at UTMB or 
the QIAfilter Plasmid midi kit (Qiagen) at the Kansas State University. 
The detail methods for transformation, plasmid purification and PCR site-directed 
mutagenesis are listed in the section 2.2.B, 2.2.C, and 2.2.D, respectively.  
 B. Transformation and propagation of E. coli MC1061 strain 
The transformation of the cDNA infectious clones and the subcloned plasmids was 
performed by the permeabilization of the bacterial cells treated by calcium chloride (CaCl2) and 
heatshock transformation. 
The starting culture of cells were made by inoculating ~5 μl of the glycerol stock into 5 
ml of 2X YT broth propagated at 37℃ for 16 hours at 300 r.p.m. The log phase culture was 
prepared by transferring 1 ml of the overnight culture to 50 ml of 2X YT broth which was 
subjected to the shaking culture at 37℃ for 50~60 minutes at 300 r.p.m. Cells were chilled on ice 
for 10 minutes and pelleted by centrifugation at 4,000 r.p.m. for 10 minutes at 4℃. The cells 
were suspended in 10 ml ice-cold BF1 buffer and pelleted at 4,000 r.p.m. for 10 minutes at 4℃. 
The pellet was gently suspended in 10 ml ice-cold BF2 buffer and chilled on ice for at least 20 
minutes. The cells were pelleted by centrifugation at 4,000 r.p.m. for 10 minutes at 4℃ and 
resuspended in 220 μl of BF2 buffer per transformation reaction for up to 10 reactions. Cells for 
each transformation were aliquoted into a pre-chilled 15 ml conical tubes (BD Biosciences), 
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mixed with 3 μl of dimethylsulfoxide and 5 μl of plasmid DNA and chilled on ice for 30 
minutes. The cell-plasmid DNA mixtures were heatshocked at 43.5℃ for 45 seconds, recovered 
on ice for 10 minutes, gently suspended in 5 ml of pre-warmed 2X YT broth and incubated at 37
℃ for 60 minutes at 300 r.p.m. Transformed bacteria were pelleted at 4,000 r.p.m. for 10 
minutes and plated on 2X YT agar supplemented with ampicillin. 
The plates were incubated at 37℃ overnight until the individual colonies appeared. The 
individual colonies were transferred to 10 ml of 2X YT broth for the subcloned vectors or terrific 
broth for the full-length cDNA infectious clones containing appropriate concentrations of 
ampicillin for overnight 16-hr cultures. The large-scale 250 ml cultures of the cDNA infectious 
clones were made by inoculating 1 ml of overnight 10 ml cultures to 250 ml terrific broth with 
ampicillin and culturing at 37℃ for 16 hours at 300 r.p.m.  
 C. Purification of plasmids 
Three methods of alkaline lysis plasmid purification methods were used in the project 
based on the quantities of plasmid DNA propagated and the availability of equipment. The mini-
scale preparation was performed in 10 ml of broth to isolate individual clones from transformed 
E. coli for nucleotide sequencing. The stocks of cDNA infectious clones were made from the 
purification of 250 ml cultures. 
The overnight miniprep cultures were pelleted by centrifugation at 4,000 r.p.m. for 10 
minutes. The bacterial pellet was resuspended in 250 μl buffer P1 (50 mM Tris-HCl, 10 mM 
ethylenediaminetetracetic acid (EDTA) pH 8.0 with 100 μg/ml RNase A) and lysed with 250 μl 
buffer P2 (200 mM NaOH and 1% sodium dodecylsulfate (SDS)) by gently inverting the tubes 
for 4-6 times. The bacterial debris was precipitated by adding 350 μl buffer N3 (3 M sodium 
acetate pH 5.5) and pelleting at 13,500 r.p.m. for 10 minutes. The clear lysate was flown through 
the spin column at 13,500 r.p.m. for one minute and subsequently washed with 500 μl buffer PB 
and 750 μl buffer PE at 13,500 r.p.m. for one minute. The plasmid DNA was eluted with 50 μl 
nuclease-free H2O at 13,500 r.p.m. for one minute and stored at -20℃. 
The supercoiled form of the plasmid DNA was isolated by alkaline lysis followed by 
CsCl gradient centrifugation. The pellets of the 250 ml cultures of cDNA infectious clones were 
collected by centrifugation at 6,500 r.p.m. for 10 minutes at 4℃ . The bacterial pellet was 
resuspended in 8 ml BF1 buffer (25 mM Tris-HCl, 100 mM NaCl, and 10 mM EDTA pH 7.5) 
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and subsequently lysed with 16 ml BF2 buffer (200 mM NaOH and 1% SDS). The plasmids 
were released into clear lysate by adding 12 ml of BF3 buffer (3 M potassium acetate in 20% 
acetic acid aqueous solution) and centrifugation at 4,000 r.p.m. for 15 minutes.  The debris was 
removed by filtering the supernatant with sterilized gauzed and the nucleic acids were 
precipitated with isopropanol in a 50 ml reaction at -20℃ for at least 40 minutes. The pellet of 
nucleic acids was isolated by centrifugation at 4,000 r.p.m. for 10 minutes at 4℃, dissolved in 2 
ml of TE buffer (10 mM Tris-HCl and 1 mM EDTA pH 8.0) and precipitated with 2 ml of 5M 
LiCl solution on ice for at least 20 minutes. The ribosomal RNA was removed by pelleting the 
mixture at 4,000 r.p.m. for 10 minutes at 4℃ and the dissolved plasmid DNA was precipitated 
with 8 ml of ethanol at -20℃ for at least 60 minutes. The plasmid DNA was pelleted at 4000 
r.p.m. for 10 minutes at 4℃ and dissolved in 3.3 ml TE buffer containing 4.8 g of CsCl2 and 40 
μl of 1% ethidium bromide aqueous solution and subjected the gradient centrifugation in NVP90 
rotors (Beckman Coulter) at 65,000 r.pm. for 16 hours. The supercoiled form of plasmid DNA is 
concentrated in the lower band based on its compact structure and extracted by the aspiration 
with 1 ml tuberculin syringe needles. The extracted solution was mixed with 1 ml TE buffer and 
3.5 ml ethanol, precipitated at -20℃ for 40 minutes, and pelleted at 4,000 r.p.m. for 10 minutes 
at 4℃ . The pellet was dissolved with 400 μl TE buffer and mixed with 400 μl 25:24:1 
phenol:chloroform:isoamylalcohol mixture by vortexing at 3,000 r.p.m. for 15 seconds. The 
aqueous layer was separated by centrifugation at 13,500 r.pm. for 5 minutes at room temperature 
and mixed with 400 μl 24:1 chloroform:isoamylalcohol mixture by vortexing at 3,000 r.p.m. for 
15 seconds. The aqueous layer was collected after centrifugation at 13,500 r.p.m., mixed with 
1000 μl ethanol and 100 μl  5M NaCl and precipitated at -20℃ for at least 15 minutes. The 
purified plasmid was pelleted at 13,500 r.p.m. for 30 minutes at room temperature. The pellet 
was washed with 500 μl 70% ethanol, centrifuged at 13,500 r.p.m. for 5 minutes, dissolved with 
50~100 μl nuclease-free H2O and stored at -20℃. 
The QIAFilter Plasmid Midi kit was used for the purification of plasmids with modified 
procedures. The bacteria were pelleted at 4,000 r.p.m. for 25 minutes at 4℃ and resuspended in 
8 ml BF1 buffer (25 mM Tris-HCl, 100 mM NaCl, and 10 mM EDTA pH 7.5 supplemented with 
RNase A at a concentration of 100 μg/ml). The lysis reaction was performed with 16 ml BF2 
buffer (200 mM NaOH and 1% SDS) and neutralized with 12 ml of BF3 buffer (3 M potassium 
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acetate in 20% acetic acid aqueous solution). The lysate were obtained by centrifugation at 4,000 
r.p.m. for 15 minutes at 4℃ and filtered through the QIAfilter Cartridge. The plasmid DNA was 
purified by flowing the lysates through the Qiagen-tip 100 resin columns, which were previously 
activated by applying 4 ml buffer QBT (750 mM NaCl, 50 mM MOPS, 15% isopropanol, and 
0.15% Triton X-100 pH 7.0). The columns were washed with 10 ml buffer QC twice and eluted 
with 4 ml buffer QF. The eluted DNA was precipitated with 3.5 ml at 15,000 g for 30 minutes at 
4℃. The pellet was rinsed with 70% ethanol, centrifuged at 15,000 g for 10 minutes, dried for 10 
minutes at room temperature, dissolved in 50~100 μl nuclease-free H2O and stored at -20℃.  
 D. PCR site-directed mutagenesis 
The PCR site-directed mutagenesis was performed with the Quikchange® XL II site-
directed mutagenesis kit (Agilent). The template DNA molecules are produced in bacterial 
competent cells that are competent in methylation enzymatic mechanisms. The reaction required 
the mutations to be incorporated into the oligonucleotide primer sets, which could tolerate the 
mismatch between the nucleotides of the wildtype templates and the desired mutations designed 
in the primers between the primers and the template double-stranded plasmid DNA. The sense 
and anti-sense primers are complementary to each other and the unmethylated cDNA products 
are increased in the linear fashion with the high-fidelity DNA polymerases. The unmethylated 
DNA molecules are protected from the digestion of DpnI restriction endonuclease that reduces 
the transformation efficiency by digesting the circular plasmid DNA templates to produce linear 
fragments. The mutants are/were subsequently isolated by the transformation of bacterial 
competent cells. 
  In the research described in this dissertation, the subcloned pGEM® T Easy-Asibi-st 
plasmid was used as the template for PCR site-directed mutagenesis. The reactions were 
assembled with 500 ng of plasmid DNA as the template, 5 μl of 10X reaction buffer, 125 ng of 
sense and anti-sense primers, 1 μl of dNTP mix, 3 μl of QuikSolution reagent and 1 μl of 
PfuUltra HF DNA polymerase in the 50 μl reactions. The mutants were produced by 
denaturation at 95℃ for 120 seconds, 18 cycles of denaturation at 95℃ for 30 seconds, primer 
annealing at 60℃ for 30 seconds and amplification at 68℃ for 7 minutes, and final incubation at 
68℃ for 20 minutes. The reactions were chilled on ice briefly and 1 μl of DpnI was added for the 
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removal of methylated template DNA at 37℃ for 60 minutes. Mutants were transformed to 
MC1061 and individual clones were isolated for nucleotide sequencing. 
 E. Linearization of plasmids 
The linearization of the cDNA infectious clones was performed to generate the linear 
form of plasmids which provided the termination site for the transcription of the SP6 DNA-
dependent RNA polymerase. The cDNA infectious clones of the 17D-204 strain, 17D/Asibi 
chimera and its mutants were digested by the XhoI restriction endonuclease (New England 
Biolabs). The cDNA infectious clones of the Asibi strain and its mutants were digested by the 
NruI restriction endonuclease (New England Biolabs). The digested plasmids were purified by 
the phenol-chloroform purification and ethanol precipitation methods. 
The digestion of plasmids was performed with 2-3 μg of plasmids in 40 μl reactions 
supplemented with 4 μl  of 10X reaction buffer, 4 μl of 10X bovine serum albumin (BSA) and 1 
μl of restriction endonuclease at 37℃. The reactions were diluted with 60 μl of nuclease-free 
H2O (Life Technologies) and mixed with 100 μl of phenol:chloroform:isoamylalcohol 25:24:1 
solution (Life Technologies) by vortexing at 3,000 r.p.m. for 15 seconds and centrifugation at 
13,500 r.p.m. for 5 minutes. The aqueous layer was collected and the phenol was removed by 
mixing with 100 μl of chloroform:isoamylalcohol 24:1 (Amresco) at 3,000 r.p.m. for 15 seconds 
and centrifugation at 13,500 r.p.m. for 3 minutes. The aqueous layer was collected and mixed 
with 220 μl of ethanol and 10 μl of 3M sodium acetate pH 4.2. Plasmid DNA was precipitated at 
-80℃ for at least 20 minutes followed by centrifugation at 13,500 r.p.m. for 20 minutes at 
ambient temperature. The pellet was collected and washed with 400 μl of 70% ethanol solution 
by centrifugation at 13,500 r.p.m. for 5 minutes. The pellet was resuspended in 12 μl nuclease-
free H2O and subjected to in vitro transcription. 
 F. In vitro transcription 
The in vitro transcription of YFV cDNA infectious clones described in the study is 
regulated by the SP6 promoter sequence prior to the sequences of viral genomes and used to 
generate the positive-sense viral RNA for the recovery of viruses. All the reactions were 
performed and modified from the procedures of the mMESSAGE mMACHINE® SP6 
Transcription kit (Life Technologies).   
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The reactions were assembled by combining 12 μl of linearized plasmid DNA, 4 μl of 
10X reaction buffer, 4 μl of 20 mM GTP, 20 μl of 2X NTP/CAP mixture and 2.8 μl of SP6 
enzyme mix and incubated at 37℃ for 60 minutes. The integrity and the yield of RNA products 
were examined by separating 1 μl of the reaction collected at 20 minutes after the start of the 
incubation on 1% agarose gel at 125 volt for 20 minutes. Each reaction was divided into four 
aliquots and stored at -80℃ for electroporation. 
 G. Electroporation 
The infectious viral RNA was electroporated into BHK-21 cells and incubated at 37 ℃ 
supplemented with 5% CO2 for the production and recovery of viruses as detailed below.  
BHK-21 cells were seeded in tissue culture-treated T150 flaks (BD Biosciences) and 
maintained until the cells reach 80-90% confluence. The cells were rinsed with 20 ml of 
Dulbecco’s phosphate buffer saline (DPBS) without Ca2+ or Mg2+ (Cellgro) and treated with 3 
ml of 0.25% trypsin-EDTA (Life technologies) briefly at 37℃ to detach the cells from the 
surface. The reaction of trypsin was terminated by adding 7 ml of MEM-α supplemented with 
10% FBS. The cells were pelleted by centrifugation at 1,200 r.p.m. for 5 minutes at 4℃. The 
cells were resuspended in 10 ml of ice-cold DPBS and pelleted by centrifugation at 1,200 r.p.m. 
for 5 minutes at 4℃ for three times to remove the excessive nucleases on the cellular surface. 
The cells were suspended in ice-cold DPBS and adjusted to the total volume 400 μl. The 
cells were chilled on ice and mixed with 10 μl of viral RNA transcripts. The mixtures were 
immediately transferred to pre-chilled 2 mm electroporation cuvettes (Fisher Scientific) for 
electroporation on the GenePulser Xcell electroporation system (BioRad). The electroporation 
was performed at 140V for 25 msec with the preset BHK-21 electroporation protocol. The 
electroporated cells were placed on ice briefly for recovery and the cuvettes were rinsed with 
600μl pre-warmed media for three times. The fluid containing the cells was mixed with 8-10 ml 
of media and maintained in T75 flasks (Corning). For the Asibi strain and its mutants, the 
electroporated cells were incubated for five days; whereas, the cells electroporated with the viral 
RNA of the 17D-204 strain, 17D/Asibi M-E chimera and its mutants were incubated for four 
days.  
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 2.3 Mosquitoes and per os infection 
 A. Rearing of Ae. aegypti 
Ae. aegypti, the urban vector of YFV, was used in the study. The Ae. aegypti Red D 
white-eye laboratory colony was used based on its high susceptibility to YFV and other 
mosquito-borne viruses (McElroy, Tsetsarkin et al. 2005). The mosquito colony was reared at the 
rearing facility at the University of Texas Medical Branch and the Arthropod-borne Animal 
Disease Research Unit of the United States Department of Agriculture. 
The eggs of Ae. aegypti were maintained on moist paper towels and hatched in tap water 
at room temperature. The larvae were maintained at the density of ~300 larvae per liter of water 
and supplied with the mixture of 1:1 fish food and rodent food mixture. At 28℃, the process of 
the development from the first to forth instar larvae generally requires six to eight days and the 
pupae stage lasts approximately two days prior to the adult eclosion. The adults were maintained 
with unlimited amount of 10% sucrose solution in 12”-by-12” collapsible cages (Bioquip) at 28
℃. For the production of egg-liners, 8-10-day-old adults acquired mammalian blood through 
anesthetized rodents proved by IACUC at UTMB or artificial glasses feeders and laid eggs on 
moist paper towels 3~5 days after the blood meals.   
For per os infections, 6-8-day-old adults were collected from the rearing cages by 
mechanically aspirators, cold anesthetized and females were sorted from each pool of 
mosquitoes. Each pint-size carton was used to house 100 female mosquitoes. Mosquitoes were 
fed with 10% sucrose solution through saturated cotton pellets above the mesh secured on the top 
of cartons. The sucrose solution was replaced with cotton pellets saturated with water 24 hours 
prior to the per os infection. 
 B. Procedures of per os infection 
All the per os infection experiments were performed in the arthropod containment level 3 
(ACL-3) laboratories at UTMB’s  Department of Pathology and at the Biosecurity Research 
Institute  at Kansas State University. 
The mosquitoes were transferred from the rearing facilities and the cotton pellets were 
removed 2~3 hours prior to the per os infection. The Hemotek membrane blood feeding 
apparatus (Discovery Workshop, Lancastershire, England, United Kingdom) was used to orally 
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administer the blood meals. The freshly harvested YFV was mixed with prewarmed defibrinated 
sheep blood (Colorado Serum Company) at 1:1 volume ratio. The negative control group 
received defibrinated sheep blood mixed with tissue culture media. Each blood meal reservoir 
was covered with rodent skin, secured with O-rings and filled with 3 ml of artificial viremic 
blood. The reservoirs were fastened to the pre-warmed feeding cones with the rodent skin facing 
the cartons. The acquisition of blood meals was achieved by probing through the skin and the 
mosquitoes were allowed to engorge during the 60-minute oral feeding period. The blood meals 
were collected immediately after the feeding and stored at -80℃ for titration. 
Cartons were briefly chilled to cold anesthetize the mosquitoes and the engorged 
mosquitoes were counted and separated from the pools. For each clone of YFV, three engorged 
mosquitoes were immediately collected to confirm the intake of virus. The mosquitoes were 
placed in the cartoons and maintained in the secondary containers. The cotton pellets were 
saturated with 10% sucrose solution, placed on the mesh of each carton and replaced every two 
days. The mosquitoes were maintained at 28℃ under the 16hr:8hr light-dark photoperiod for up 
to 14 days. 
 C. Viruses used in per  os infection 
Two cDNA infectious clones, the Asibi strain and the 17D/Asibi M-E chimera, were used 
in the study to generate mutants for oral infection of Ae. aegypti as described in section 2.2. The 
infectious clones were  generated in the previous studies described by McElroy et al (McElroy, 
Tsetsarkin et al. 2005, McElroy, Tsetsarkin et al. 2006). The viruses used in the oral infection 
studies are listed below. The rationale of the experimental design with the viruses is summarized 
in figure 2.3. 
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Figure 2.3 The rationale of experimental design with the viruses.  
The mutations were introduced to the cDNA infectious clone of the Asibi strain and the 
17D/Asibi M-E chimera. The 17D/Asibi M-E chimera was included due to the presence of 
the attenuation determinants present in the nonstructural proteins. The Asibi mutants 
were generated to evaluate the attenuation caused by the mutations in the E protein. The 
17D/Asibi M-E chimeric mutants were devised to assess the attenuation caused by the 
mutations in the E protein and the attenuation determinants in the nonstructural proteins. 
The Asibi and 17D strains were used as the disseminating and non-disseminating controls 
respectively. 
The attenuated YFV 17D strain was use in the study as the control of virus which is 
defective in viral dissemination in Ae. aegypti. The sites of viral replication of YFV 17D strains 
has been repeatedly found restricted to the midgut of infected mosquitoes (Miller and Adkins 
1988, McElroy, Girard et al. 2008).  
The YFV Asibi wildtype strain was included as the control for the infectious and 
disseminating phenotype of virus. The virus was first proved to be disseminating into the heads, 
wings and legs of infected mosquitoes and transmissible to immunologically naïve primates 
(Whitman 1937). The characterization of the infection process was further  investigated to 
determine dissemination rates into the secondary tissues such as the fat body, ganglia tissues and 
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the salivary glands (McElroy, Girard et al. 2008). The viruses containing the mutations in the E 
protein of Asibi strain were tested to evaluate the phenotypical change due to the mutations. 
The 17D/Asibi M-E chimera, which carried the 3’ end of capsid gene, the full-length prM 
and E genes and the 5’ portion of NS1 gene, showed a significantly lower infection rate and a 
insignificantly lower dissemination rates in Ae. aegypti (McElroy, Tsetsarkin et al. 2006). The 
attenuated phenotype was proposed to be attributed to the mutations present in the non-structural 
genes of 17D strain and the chimerization-induced attenuation. The virus was used as a control 
group representing the virus with the lowest infectivity and dissemination. The mutants were 
generated by introducing the mutations to the E protein of 17D/Asibi M-E chimera in the same 
locations as the Asibi E protein mutants. 
D. Collection and dissection of mosquitoes 
  At 7, 10 and 14 d.p.i., mosquitoes were mechanically aspirated from the cartons and cold 
anesthetized. All the samples were submerged in 1 ml of L-15 media supplemented with 
amphotericin B at 1μg/ml and sodium deoxycholate at 0.82μg/ml and stored at -80℃ until tested. 
Whole mosquitoes were collected for the assessment of the growth kinetics of individual 
clones of viruses. The dissection of mosquitoes was performed with electron microscopy forceps 
and double-edged dissecting needles (Electron Microscopy Sciences, Hatfield, PA) and 10-mm 
petri dishes on ice. Paired mosquito samples were collected by removing the body containing the 
abdominal segments from the head, thorax, wings and legs. The body section contained the 
midgut, where viral infection is initiated. The head, thorax, wings and legs are considered as 
secondary tissues, which are subsequently infected after the virus disseminates from the infected 
midgut.  
2.4 Quantification and detection of viral antigens in vitro 
 A. Homogenization of mosquito samples 
Mosquito samples were disrupted by mechanical homogenization to release the infectious 
virions from the tissues prior to the viral titration as described by McElroy et al.(McElroy et al., 
2005) All the manipulations of infectious viruses were performed in the BSL-3 laboratories at 
the UTMB’s Department of Pathology or at K State’s Biosecurity Research Institute. 
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Samples were thawed in 37℃ water bath immediately after being removed from the 
freezers. The homogenization process was performed at 26.0 Hz for 4 minutes at room 
temperature on a Tissue Lyser II Homogenizer (Qiagen) placed in a Class IIA biosafety cabinets.  
The homogenates were cleared by centrifugation at 10,000 r.p.m. for 10 minutes at room 
temperature and immediately subjected to tissue culture infectious dose 50 (TCID50) titration. 
 B. Tissue culture infectious dose 50 titration 
TCID50 titrations were performed with homogenates of mosquito tissues on Vero cells 
seeded in 96-well microtiter plates (Nunc) as described by Higgs et al (Crampton, Beard et al. 
1997). The limit of detection of the assay was at 1.06 logTCID50/ml. The clear homogenates 
were titrated in two duplicated columns on each plate up to 10-6 dilutions. The negative control 
wells received media and the positive control wells were infected with YFV 17D strain. 
Each row from B to H was filled with 90 μl of L-15 media containing Fungizone® at 
4μl/ml. The wells in row A received 100 μl of homogenates in duplicate format and titrated by 
10-fold serial dilution from row B to G. Plates were temporarily stored on ice prior to the 
addition of cells. Each T150 flask was rinsed with 20 ml of Mg2+/Ca2+-free DPBS and cells were 
removed with 4 ml of 0.25% trypsin-EDTA at 37℃ briefly. The cells were resuspended with L-
15 media and the volume was adjusted to 65 ml. Each well received 100 μl culture fluid. 
The plates were sealed with plastic parafilm and incubated at 37℃ for 7 days. The tissue 
culture fluid was removed and each well was fixed with 150~200 μl ice-cold acetone:phosphate 
buffer saline 3:1 mixture for 20 minutes at room temperature. The fixatives were removed and 
the plates were allowed to dry at room temperature to remove residual fluid. The plates were 
stored at -20℃ until the staining of viral antigens. 
 C. Indirect immunofluorescence assay 
The lack of cytopathic effect in Vero cells caused by YFV infection necessitates 
detection of viral antigens by immunostaining methods on acetone-fixed cells. The indirect 
immunofluorescence assay (IFA) was performed with mouse anti-YFV hyperimmune serum 
MA93 (provided by S. Higgs) and goat anti-mouse IgG secondary antibodies. The viral antigens 
were detected from the emission of light provided by the excitation energy from ultraviolet (UV) 
light.  
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The microtiter plates were removed from -20℃ and allowed to dry at room temperature 
to remove the excessive moisture due to condensation. Anti-YFV MA93 hyperimmune serum 
used as the primary antibody was reconstituted from lyophilized antibodies and stored at -20℃.  
The primary antibody was thawed at 37℃ and diluted with PBS at 1:200 volume ratio. Each well 
received 40 μl of diluted MA93 and incubated at 37℃ for 40 minutes. Plates were washed with 
200 μl PBS twice and stained with 40 μl of 200-fold diluted Alexa Fluor® 488 goat anti-mouse 
IgG (H+L) polyclonal antibody (Life Technologies) at 37℃ for 40 minutes. The counter staining 
compound, tetrasodium (6E,6'E)-6,6-[(3,3'-dimethylbiphenyl-4,4'-diyl)di(1E)hydrazin-2-yl-1-
ylidene]bis(4-amino-5-oxo-5,6-dihydronaphthalene-1,3-disulfonate) (Evans Blue), was mixed 
with the secondary antibody at the concentration (w/v %) of 1%. Excessive antibodies were 
removed by washing with 200 μl PBS followed by a final wash with 200 μl of deionized water. 
Each well was stabilized with ~20 μl of stabilizer mixture, which contains 2.5% 1,4-
diazobicyclo-2,2,2-octane (DABCO) (Sigma Aldrich) in glycerol:PBS 9:1 mixture, pH 8.6, and 
stored at 4℃. The stabilizer was made by gently heating 450 ml of glycerol at 53℃ and adding 
12.5 g of DABCO and 50 ml of PBS and buffered with 3 ml of hydrochloric acid solution 
(Fisher Scientific). 
The excitation energy was provided by the UV light on the Olympus IX-71 inverted 
microscope and the green fluorescence was visualized with the filters from fluorescein 
isothiocyanate (FITC) or green fluorescent protein (GFP). The scoring of the plates was 
performed by the presence of the positive cytosolic immunofluorescence signal at the highest 
dilutions. 
 2.5 Statistical analysis 
 A. Fisher’s exact test 
The numbers of positive and negative mosquito samples were recorded at each time 
point. The infection rate was derived from the percentage of the positive staining from the whole 
mosquito homogenates and the positive staining from the samples of dissected mosquito bodies 
or mosquito secondary tissues divided by the total number of mosquitoes orally challenged by 
the same type of viremic blood meals. The comparison was made between the Asibi strain and 
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the Asibi mutants as well as the 17D/Asibi M-E chimera and the 17D/Asibi M-E mutants by 
Fisher’s exact test with the Sigmaplot version 12.0 (Systat Software Inc.). 
 B. Analysis of Variance 
The comparison of viral titers among the homogenized whole mosquitoes and mosquito 
tissue samples derived from the groups of mosquitoes orally infected by wild-type and mutant 
viruses was performed with one-way analysis of variance (ANOVA) on the Sigmaplot 
version12.0 (Systat Software Inc.). The post-hoc analysis between two groups was conducted to 
compare the Asibi strain and the Asibi mutants as well as the 17D/Asibi M-E chimera and the 
17D/Asibi M-E mutants with Tukey’s test. 
 C. Non-parametric test 
The comparison of viral growth kinetics from the tissue culture supernatants of 
electroporated BHK-21 cells was performed with non-parametric test on the Sigmaplot 
version12.0 (Systat Software Inc.).  Mann-Whitney U-test was used to compare the viral titers of 
the wildtype and mutant viruses as described by Wang et al. (Wang and Bushman 2006) 
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Chapter 3 - Characterization of T380R mutation in YFV E protein 
 3.1 Introduction 
 A. Location and putative function of T380R mutation 
Based on the available structure, the T380R mutation in YFV 17D strains is located in the 
FG loop of the lateral surface in YFV EDIII (Volk, May et al. 2009). The functions of flavivirus 
EDIIIs have been reported to include mediating receptor binding and stimulation of humoural 
immunity due to the presence of critical epitopes. It has been shown that several putative 
molecules  that are expressed on the surfaces of arthropod or vertebrate cells, interact with the 
FG loops of flavivirus EDIIIs prior to  clathrin-mediated endocytosis that results in  viral entry 
(Chen, Maguire et al. 1997, Lee and Lobigs 2008). The FG loop is a structure that contains up to 
six amino acids between the F and G β-strands and is exposed on the lateral surface of EDIII. 
The lateral surface of EDIII is located in the distal end of the envelope protein dimer and has 
been suggested for its potential roles in determining the tissue tropisms and antigenicity as the 
receptor-binding region on the surface of virions (Rey, Heinz et al. 1995). The earlier studies 
with other flaviviruses closely related to YFV suggested that the FG loop contains residues 
which interact with negatively charged cellular molecules that  are likely to serve as receptors for 
virus entry (Chen, Maguire et al. 1997, Germi, Crance et al. 2002). Additionally, the importance 
of the FG loop in determining the viral infectivity into mosquito cells was confirmed in 
completion assays using synthetic peptides corresponding to the sequence of the FG loop in the 
EDIII of DENV-2. These peptides prevented the viral entry in C6/36 cells by saturating the 
cellular receptors (Hung et al., 2004). The complexity of the roles of flavivirus FG loops was 
supported by the fact that the strong affinity of FG lop sequences for cellular molecules may alter 
the tropisms or virulence of the viruses. These observations were interpreted as suggesting the 
importance of FG loops in determining the efficiency of dissemination and pathogenesis (Lee 
and Lobigs 2000, Lee, Hall et al. 2004, Lee and Lobigs 2008). The putative receptors for YFV 
and mosquito-borne flaviviruses, the process of viral entry and the structures and functions of 
EDIIIs will be reviewed in the section 3.1.B, 3.1.C and 3.1.D, respectively.  
The T380R mutation in YFV 17D E protein was acquired during the in vitro passage of 
YFV Asibi strain and was first shown to facilitate the adaptation of YFV 17D strains to the in 
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vitro cell cultures. The underlying mechanism of this adaptation is primarily due to increased 
dissemination into neighboring uninfected cells (van der Most, Corver et al. 1999). The mutation 
led to the formation of  an arginine-glycine-aspartate (RGD) motif that has been characterized as 
the putative receptor-binding site of flaviviruses for negatively charged integrin molecules (Lee 
and Lobigs 2000). By utilizing the reverse genetics system of flaviviruses within the JEV 
serocomplex, it was further demonstrated that such electrostatic interactions also contributed to 
the interactions with the glycosaminoglycan (GAG) molecules and resulted in both the enhanced 
viral entry in vitro and the attenuation in vivo in the serially passaged MVEV, JEV, KUNV and 
WNV (Lee and Lobigs 2000, Lee and Lobigs 2002, Lee, Hall et al. 2004). GAG molecules 
ubiquitously exist as the post-translational modifications on the proteins and use the non-
template-driven synthesis mechanisms in eukaryotic cells. The synthetic mechanisms of GAG 
molecules lead to the structural variations that are tissue-specific and require the use of heparan 
or heparin sulfate as molecules for the assessment of the interactions between the virions and 
GAG molecules (Shriver, Capila et al. 2012). The further experiments demonstrated that the 
presence of the RGD motif led to a phenotype with increased binding to the negatively charged 
heparin sulfate in vitro and it was hypothesized to result in the more efficient interaction with the 
negatively charged molecules on the cell surface such as GAG as shown in Figure 3.1. Although 
the increased binding affinity to heparin sulfate may lead to the enhancement in viral entry, the 
consequence of such a phenotype may further complicate the mechanisms for disease 
pathogenesis in vivo by increasing the viral clearance through the higher binding affinity 
between the virions and cellular molecules. More efficient viral clearance reduces the likelihood 
of systemic infections in the viremic phase, and the progression to viscerotropic diseases during 
the intoxication phase of the infection.  In the experiments using the type-I/II interferon (IFN)-
deficient mice, the T380R mutation attenuated the recombinant 17D virus chimerized with the E 
gene of the Asibi strain by reducing the viral dissemination and viscerotropism. The progeny 
virions were likely to be retained in the extracellular matrix or readsorbed in the primary target 
cells prior to the spread to other susceptible organs (Lee and Lobigs 2008). However, the T380R 
mutation in the YFV 17D E protein had not been tested for the viral infection and dissemination 
in Ae. aegypti. The available genome sequence of Ae. aegypto suggested the presence post-
translational modification enzymes for the production of proteoglycans in the extracellular 
matrix and the potential of a  common attenuation mechanism of YFV for both  the vertebrate 
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hosts and mosquito vectors by the increased affinity between the 17D virions and the 
glycosaminoglycans in the extracellular matrix (Kato, Mueller et al. 2005).  
 
 
Figure 3.1 Invasion and disease pathogenesis of wildtype virulent strains and attenuated 
vaccine strains in vertebrate hosts 
(a) The infection of the wildtype virulent strains is initiated at the site of inoculation 
followed by the infection of susceptible cells and subsequent  dissemination into the blood 
stream. The viremia results in the systemic infection or severe clinical disease depending on  
the tissue tropisms of the viruses. (b) The inoculation of the attenuated vaccine strain lead 
to the infection of primary target cells and the limited dissemination due to the binding 
with GAG molecules. The binding with GAG molecules enhances the viral clearance from 
the blood stream. The resulting low viremia prevents the systemic infection and viral 
dissemination to target organs. The clearance of virus is followed by the development of the 
memory immune response. 
The alignment of YFV E protein sequences derived from the Asibi strain, the 17D-204 
substrain, the 17DD substrain, FVV and FNV indicated that the T380R mutation in the FG loop 
is only present in the attenuated YFV 17D strains derived from the Asibi strain. It is not found in 
the virulent and attenuated FVV and FNV strains. All other field isolates in Africa and Latin 
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America also showed the conserved threonine residue at the corresponding position. It was 
therefore, proposed that the attenuation was due to the RGD sequence is likely to be specific to 
17D strains (Lee and Lobigs 2008). The sequences of the FG loops of YFV strains are 
summarized in table 3.1. 
Strain FG loop sequence 
(Amino acid residues 379-384) 
Asibi GTGDSR 
17D-204 GRGDSR 
17DD GRGDSR 
FVV GTGDSR 
FNV GTGDSR  
Table 3.1 The FG loop amino acid sequences of wildtype and vaccine YFV strains 
The RGD motif was highlighted by underline. 
The comparison of the region of FG loop with other flaviviruses revealed different 
patterns between the mosquito-borne and tick-borne flaviviruses, and among different 
serocomplexes of mosquito-borne flaviviruses. Interestingly, in spite of the variation of vectoring 
species and tissue tropisms, all of the FG loops present in mosquito-borne flavivirus EDIIIs are 
invariantly longer than the corresponding region in tick-borne flaviviruses. This is due to the 
absence of four amino acid residues in the tick-borne flaviviruses (Gritsun, Holmes et al. 1995, 
Rey, Heinz et al. 1995, Volk, Chavez et al. 2006, Volk, May et al. 2009).  
 
Figure 3.2 NMR structures of flavivirus EDIIIs  
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The EDIIIs of six flaviviruses are displayed in the order of (a) YFV (PDB: 2JQM), (b) 
DENV-2 (PDB: 2JSF), (c) JEV (PDB:1PJW), (d) WNV (PDB:1S6N), (e) TBEV (PDB:1Z66) 
and (f) OHFV (PDB: 1Z3R) with the FG loops labeled in red. The mosquito-borne 
flaviviruses share the longer FG loops than the tick-borne flaviviruses with the insertion of 
integrin-binding RGD motif. 
The first glycine residue of FG loops is highly conserved among all the mosquito-borne 
flaviviruses; whereas, the last amino acid is only conserved in a serocomplex-specific manner. 
The sequences of the four amino acids are conserved in different serocomplexes which were 
classified based on serological antigenicity and are transmitted by different vector species. 
Members of JEV serocomplex, which are transmitted mainly by Culex mosquitoes, have highly 
conserved sequences containing the RGD motif in the region. For JEV and MVE within the JEV 
serocomplex, the RGD sequence is conserved and followed by a lysine residue (Ni, Burns et al. 
1994, Hurrelbrink, Nestorowicz et al. 1999). The first functional characterization of the RGD 
motif in the flaviviruses under the JEV serocomplex demonstrated that the number of the 
positive charges associated with the RGD motif is direcly correlated with the efficienct of virus 
entry in vitro. However,  the addition of the positive charge by substituting the aspartate residue 
with the histidine residue resulted in the attenuation in vivo (Lee and Lobigs 2000). In an NMR-
structure study with the JEV monoclonal antibody (mAb) E3.3, the RGD motif was confirmed to 
determine antigenicity (Wu, Wu et al. 2003). In the two JEV-serocomplex members found in 
North America, namely SLEV and WNV, the arginine and glycine residues are conserved with 
the variations in third residue utilizing glutamate in WNV or threonine in SLEV and the forth 
residue utilizing glutamate in WNV and threonine in SLEV (Jia, Briese et al. 1999, Baillie, 
Kolokotronis et al. 2008). Whilst the sequence variation exsits in the third residue of the RGD 
motif, the aspartate, glutamate and threonine share the biochemical property due to the presence 
of the negatively charged hydroxyl group on the sidechains.  The RGD sequence was less 
conserved under the DENV and YFV serocomplexes, which mainly consists of viruses that are 
transmitted by Ae. aegypti and Ae. albopictus. The FG loops of DENV-1, 3 and 4 use a 
hydrophobic amino acid as the first residue of the RGD motif followed by the conserved glycine 
and aspartate residues. DENV-2 has the most different sequences in the same region, which 
consists of the sequence of valine, glutamate, proline and glycine. In spite of the lack of 
sequence homology in the FG loop of DENV-2, it has been shown that the length of the FG loop 
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is critical for maintaining viral infectivity of DENV-2.  Deletion of the region significantly 
reduces the infection rate of DENV-2 (Erb, Butrapet et al. 2010). The other viruses that are 
genetically closely related to YFV also showed a limited degree of sequence homology, 
especially at the positions of glycine and aspartate residues, in the FG loops. Notably, these 
viruses including Yokose virus, Sepik virus and Entebbe bat virus were known to be in the no 
known vector group, being  viruses of bats and rodents and transmitted through the contact of 
excreta (Tajima, Takasaki et al. 2005, Kuno and Chang 2006). The sequences of the FG loops 
among the different serocomplexes of flaviviruses are summarized in table 3.2. 
Serocomplex Virus Strain Sequence of FG loop 
YFV YFV Asibi GTGDSR 
YFV 17D-204 GRGDSR 
ENTV UgIL-30 GNGEDR 
SEPV MK7148 GSGDDK 
YOKV Oita36 GNGEDR 
DENV DENV-1 Haiwaii GAGEKA 
DENV-2 New Guinea C GVEPGQ 
DENV-3 H87 GIGDKA 
DENV-4 H241 GVGDSA 
JEV JEV SA14 GRGDKQ 
JEV SA14-14-2 GRGDKQ 
WNV NY99 GRGEQQ 
KNV MRM61C GRGEQQ 
SLEV MSI-7 GRGTTQ 
MVEV MVE-1-151 GRGDKQ 
TBEV TBEV Neudoerfl G‒ ‒ ‒ ‒ E 
OHFV Bogoluvovska G‒ ‒ ‒ ‒ E 
KFDV W-377 G‒ ‒ ‒ ‒ E 
Table 3.2 Amino acid sequences of the FG loop region in different flaviviruses. 
The presence of the RGD motif is underlined. 
Based upon the available knowledge related to the FG loop, one would predict that it is 
likely to serve as the determinants for the viral entry of DENV-2 into the mosquito midgut and 
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the viral dissemination of YFV and other encephalitic flaviviruses in mice. The different virus-
vector relationships among the serocomplexes demonstrate that the viruses transmitted by Culex 
mosquitoes within the JEV serocomplex, contain the greatest degree of sequence homology for 
the RGD motif in the FG loop, whilst the DENV serocomplex and YFV serocomplex transmitted 
by Aedes mosquitoes show a higher diversity of amino acid sequences in the same region. The 
presence of the RGD motif is largely restricted to the flaviviruses, such as WNV and JEV, that 
are capable of utilizing a relatively broad number of different mosquito vectors species (Weng, 
Lien et al. 1997, Goddard, Roth et al. 2002, Capelli, Drago et al. 2011). Additionally, the 
attenuated JEV SA14-14-2 vaccine strain and KNV, which is an attenuated subtype of WNV, still 
contain the conserved RGD or RGE sequence in the FG loops (Coia, Parker et al. 1988, Ni, 
Burns et al. 1994). The JEV SA14-14-2 vaccine strain still retained the capacity of infecting 
multiple vertebrate hosts and vector species although it is attenuated and immunogenic as a 
human vaccine (Chen and Beaty 1982, Song, Yun et al. 2012, Calvert, Dixon et al. 2014).   
The per os infection experiments using YFV T380R mutants in Ae. aegypti were 
designed to characterize the two critical mechanisms related to viral infection and dissemination. 
Our studies of the mutants will lead to a better understanding of the impact of the introduction of 
the RGD motif in the FG loop with respect to viral infection in Ae.aegypti. Additionally, the 
dissemination of the mutants will deterimine if the increased binding affinity with cellular GAG 
molecules might contribute to the retention of progeny virions from the infected midgut.  
 B. Receptors for YFV and other mosquito-borne flaviviruses 
The biology of mosquito-borne flaviviruses requires the binding of infectious virions to 
cellular receptors of a diverse range of animal types, namely mammalian, avian and arthropod. 
The definition of viral receptors in the Fields Virology is as follows (Knipe and Howley 2013): 
Virus receptors can be defined as cell surface molecules that bind the incoming viruses to 
the cell, and, in addition, promote entry by (a) inducing conformational changes in the virus that 
lead to priming, association with other receptors, membrane fusion and penetration; (b) 
transmembrane signals through the plasma membrane that lead to virus uptake or penetration, 
and prepare the cell for invasion; or (c) guiding bound virus particles into a variety of endocytic 
pathways.  
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The available knowledge suggests that multiple cellular molecules can be used 
simultaneously or sequentially by flaviviruses during the process of viral entry. Although the 
alternative route of viral entry through the endocytosis of the partially neutralized viruses bound 
to the recycled Fcγ receptors has been described, the first cellular component for the binding of 
YFV identified was the GAG molecules as the post-translational modifications to host proteins 
(Schlesinger and Brandriss 1981, Germi, Crance et al. 2002). The major cellular targets 
hypothesized to be the receptors for other related flavivirus described in the available literature 
will also be discussed in this section. The conservation of amino acid sequences of the 
ectodomains in the E proteins among many different mosquito-borne flaviviruses suggests the 
use of the same or similar receptor molecules as viral receptors across a broad range of 
susceptible host cell types. The identification of receptor molecules is often based on 1) the pre-
treatment and competition of biochemically similar molecules with the endogenously expressed 
molecules in the susceptible cells, 2) the depletion or blockade of functional receptor molecules 
by the addition of chemical compounds and specific antibodies, and 3) the overlay assays of viral 
structural components with cell lysates separated electrophoretically. The major types of cellular 
receptors are summarized in table 3.3. 
Molecules  Viruses Cell type Experimental approaches 
Glycaosaminoglycans 
(GAG) 
YFV Vero Heparin sulfate inhibition (Germi et al., 
2002) 
DENV-1 Huh-7 Viral overlay binding (Hilgard & 
Stockert, 2000) (Hilgard et al. 2000) 
DENV-2 CHO 
Vero 
Heparin sulfate inhibition (Yaping Chen 
et al., 1997; Germi et al., 2002) 
Genetically deficient cells (Yaping Chen 
et al., 1997) 
DENV-4 HUVEC Heparinase III treatment (Dalrymple & 
Mackow, 2011) 
JEV CHO Heparin sulfate inhibition, sulfation 
inhibition, genetic deficient cells, 
immobilized heparin beads (Su, Liao, 
Lee, & Lin, 2001) 
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Integrins WNV Vero 
BHK 
CEF 
Neuro2a 
HeLa 
Anti-α5β3 integrin antibody (Chu and Ng 
2004) 
MVEV BHK-21 
SW13 
Vero 
Heparin sulfate treatment(E Lee & 
Lobigs, 2000a) 
Heatshock proteins DENV-2 HepG2 
U937 
Viral overlay protein binding assay and 
chromatography purification 
(Jindadamrongwech, Thepparit, & Smith, 
2004; J. R. Valle, Chávez-Salinas, 
Medina, & Angel, 2005) 
DENV-4 C6/36 
Ae. aegypti 
tissues 
Viral overlay protein binding assay 
(Mendoza, Salas-Benito, Lanz-Mendoza, 
Hernández-Martínez, & Angel, 2002; J. 
S. Salas-Benito & Angel, 1997, p. -) 
JEV Neuro2a 
Huh7 
Viral overlay protein binding assay, cell 
membrane fractionation, and 
computational prediction (Soma Das, 
Laxminarayana, Chandra, Ravi, & Desai, 
2009; Zhu et al., 2012) 
Laminin receptors DENV-1 HepG2 Anti-laminin receptor antibody and lamin 
inhibition (Thepparit & Smith, 2004) 
DENV-
1,2,3 
Porcine kidney 
cells 
Viral overlay protein binding assay (Tio, 
Jong, & Cardosa, 2005) 
WNV Vero Soluble lamin treatment(J. J. Chu & Ng, 
2004) 
C-type lectin WNV Ae. aegypti 
Cx. 
quinquefasciatus
RNAi in mosquitoes (Cheng et al., 2010) 
L-SIGN-expressing K562 cells (Davis et 
al., 2006) 
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K562 
DENV-2 3T3 Expression of DC-SIGN in 3T3 cells(J. 
L. Miller et al., 2008) 
TIM/TAM proteins DENV-2 293T Expression of TIM and TAM molecules 
in 293T cells (Meertens et al., 2012) 
YFV 293T Expression of TIM and TAM molecules 
in 293T cells (Meertens et al., 2012) 
WNV 293T Expression of TIM and TAM molecules 
in 293T cells (Meertens et al., 2012) 
Table 3.3 Summary of the cellular receptors utilized by mosquito-borne flaviviruses 
Similar to other mosquito-borne flaviviruses that are able to cause viremia and 
hemorrhagic fever, especially  DENV, the capacity of YFV in establishing infections in Fcγ-
receptor-bearing leukocytes of human peripheral blood has been demonstrated and the infection 
of the YFV 17D strain was augmented in vitro by the presence of IgG antibodies through the Fcγ 
receptors (Schlesinger and Brandriss 1981). However, in vivo experiments have demonstrated 
that the increase in viral entry of wild-type YFV strains through antibody-dependent 
enhancement only took place in specific combinations between virus strains and antibodies. The 
mechanisms of viral entry remained unidentified (Barrett and Gould 1986, Gould and Buckley 
1989).  
 Glycosaminoglycans 
By introducing mutations to the RGD motif in the envelope protein of the 17D strain, 
viral dissemination into neighboring uninfected cells was abolished in the human SW13 cells but 
the mutants remained infectious to other mammalian and insect cells (van der Most, Corver et al. 
1999). The results suggested that the binding to the integrins through the RGD motif may not be 
critical for virus entry, however, the use of integrin as receptors by YFV still cannot be excluded 
(Ruoslahti 1996). In Vero and BHK-21 cells, the YFV 17D strain was further shown to be 
sensitive to inhibition caused by the treatment with highly sulfated polysaccharides such as 
heparan sulfate or heparin sulfate. Such observation suggested that the receptor-binding motif of 
the E protein probably interacts with the heparan/heparin sulfate or other related GAG molecules 
as the initial receptors for viral entry (Germi, Crance et al. 2002, Lee and Lobigs 2008). The 
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disruption of RGD motif by the substitution of a TGD sequence in the wild-type YFV E protein 
led to a phenotype that was resistant to heparin sulfate treatment. As such, the  motif has also 
been mapped as the potential GAG binding region of mosquito-borne flaviviruses (Hung, Hsieh 
et al. 2004). It therefore follows, that the GAG molecules on the cell surface are likely to be the 
receptors favored by YFV vaccine 17D strains, but not by other natural isolates. The passage of 
the Asibi strain in naturally non-susceptible mouse and avian cells resulted in the adaptation of 
viruses by utilizing GAG molecules as receptors. The change in the choice of cellular receptors 
is the consequence of the removal of the negative charges on the receptor binding motif by the 
amino acid substutions with positively charged or neutral side chains. This has been reported not 
only in flaviviruses but also for other enveloped RNA viruses. The adaptation of MVEV, JEV 
and WNV in tissue culture showed the consensus removal of the negative charge at the aspartate 
residue of the RGD motif and the increase affinity to GAG molecules (Lee and Lobigs 2000, Lee 
and Lobigs 2002, Lee, Hall et al. 2004). The GAG-binding phenotype of passaged attenuated 
viruses may contribute to the viral attenuation by promoting the more rapid viral clearance and 
preventing the systematic infection in vivo. Data using the immunocompromised mouse 
challenge model suggested that the potential mechanisms for the attenuation can be potentially 
achieved by the more efficient readsorption of progeny virions onto the primary target cells prior 
to the release into the blood stream. Altentatively, attenuation may also be achieved by the 
retention of virions in the extracellular matrix (ECM) through the interactions between the RGD 
motif and GAG molecules, which are ubiquitously expressed on the cellular surface (Lee and 
Lobigs 2008). The details of the mechanisms leading to the attenuation due to the increase 
electrostatic interactions among the vaccine or attenuated strains will be discussed in section 
3.1.E.  Another class of newly identified molecules as YFV receptors is human T-cell 
immunoglobulin and mucin-domain containing proteins (TIM-1,3 and 4) which mediate the 
phosphatidylserine-dependent phagocytosis for the cellular materials. The expression of TIM-1 
in 293T cells was found to enhance the infectivity of YFV 17D strain and other mosquito-borne 
flaviviruses (Meertens, Carnec et al. 2012). However, this class of molecules is only encoded in 
the genomes of vertebrate hosts and the major viral receptors for YFV in the vectors remain 
unknown. 
With the similar structures and amino acid sequences in the FG loop of E proteins, the 
interactions between GAG and flavivirus E proteins have also been reported as potential receptor 
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binding mechanisms for viral entry in multiple combinations of viruses and target tissues. By 
utilizing heparan disaccharides that vary in the concentrations of the sulfate modification and 
Vero cells, DENV-2 was found to interact with disaccharide units that were modified with the 
sulfate moieties. The disaccharide units are the minimal structural units required for the 
interaction with the E protein. The mutant CHO cells that are deficient in the sulfation 
mechanisms, also exhibited reduced binding efficiency to the virions (Chen, Maguire et al. 1997, 
Germi, Crance et al. 2002). Further supportive evidence was also provided by experiments that 
were based on Huh7 human hepatocytes exposed to DENV-1, as well as endothelial cells 
challenged with DENV-4 (Hilgard and Stockert 2000, Dalrymple and Mackow 2011). Both cell 
types are regarded as susceptible tissues that support the productive infection of DENV in 
human. Although variations in the sensitivity of the antiviral effect have been reported in 
different sulfated disaccharides and serotypes of DENV, multiple sulfated saccharides have been 
evaluated as inhibitors for the entry of DENV for use as  antiviral treatments (Lin, Lei et al. 2002, 
Kato, Era et al. 2010, Vervaeke, Alen et al. 2013). Although the crystal structures and sequences 
of DENV E proteins suggested the presence of potential heparin binding motifs in EDI and 
EDIII, respectively, the in vitro experimental evidence demonstrated that the heparin sulfate 
binding motif is likely to be located in the FG loop region. For YFV, this is also where the RGD 
motif  in the EDIII is located (Chen, Maguire et al. 1997, Hung, Hsieh et al. 2004, Lee and 
Lobigs 2008). In contrast to the observations for YFV, for JEV it was demonstrated that both 
virulent and attenuated strains, which shared the conserved RGD motif of the EDIII FG loop, 
interact with GAGs during the early stage of infection in vitro (Su, Liao et al. 2001). However, 
the variants of JEV and other viruses within the JEV serocomplex showed that  multiple motifs 
in the E protein may be responsible for such interactions and that these motifs may differ  from 
those identified in YFV and DENV (Lee, Hall et al. 2004, Liu, Chiou et al. 2004, Chiou, Liu et al. 
2005).  Interestingly, experiments utilizing TBEV have demonstrated that an increase in the 
binding of heparan sulfate among the variant viruses can be frequently caused by the mutations 
that accumulated during the process of in vitro passage, and that led to a gain of positive charges 
in the E protein (Mandl, Kroschewski et al. 2001). The capacity of establishing productive 
infection by TBEV in heparan sulfate-deficient cell lines further suggested the involvement of 
other non-GAG molecules serving as the receptors for flaviviruses.  
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Together, the experimental evidence suggests that the GAG molecules are likely to 
function as viral receptors or as the docking molecules that create the concentrated distribution of 
virions prior to the binding other viral receptors. However, the conclusions should be made 
carefully based on the fact that the mutants with  the higher affinity to the GAG molecules can be 
artificially selected after the serial passage of viruses in vitro, especially in cell lines derived 
from naturally non-susceptible hosts (Kroschewski, Allison et al. 2003).  
 Integrins 
The other class of molecules abundantly expressed in both vertebrate hosts and arthropod 
vectors are integrin molecules. These are involved in the interactions between cells and the 
scaffold of the ECM,  and have been identified as receptors for arboviruses and other small 
enveloped RNA viruses (Gavrilovskaya, Shepley et al. 1998, La Linn, Eble et al. 2005). 
Interestingly, the viral protein regions proposed to interact with integrin molecules may overlap 
with the GAG-binding region in the flavivirus E proteins, primarily in the RGD motif in EDIII 
(van der Most, Corver et al. 1999, Chu and Ng 2004, Lee and Lobigs 2008). However,  the 
subsequent competition binding assays with the recombinant RGD peptide suggested that WNV 
may use a non-classical integrin-binding motif that does not contain the RGD sequence in these 
interactions (Chu and Ng 2004). For MVEV which was the first virus proposed to utilize 
integrins as cellular receptors, it was found that the virus was resistant to heparin sulfate 
treatment. This lack of the sensitivity to heparin sulfate treatment, supported the importance of 
molecules other than GAG molecules in the viral entry process because  the receptor-binding 
domain of the virions was able to interact with the viral receptors despite of the high 
concentration of heparin sulfate (Lee and Lobigs 2000, Hurrelbrink and McMinn 2001). In 
contrast to MVEV,  DENV-2 which requires the presence of GAGs on the cellular surface is 
resistant to the depletion of divalent cations such as Ca2+ and Mg2+, which disrupt the structure 
and function of cellular integrin molecules (Stuiver, Ruggeri et al. 1996, Bielefeldt-Ohmann, 
Meyer et al. 2001). The reverse genetics system for  MVEV allowed the evaluation of the 
integrin-interacting RGD sequences (that are conserved across the members of JEV 
serocomplex) and were proposed to interact with integrin molecules among flaviviruses by van 
der Most et al (van der Most, Corver et al. 1999).  By selectively mutating the aspartate residue 
in the RGD motif to glycine or histidine, the mouse neurovirulence of MVEV was significantly 
reduced, however, the mutant viruses remained resistant to heparin sulfate treatment. 
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Unfortunately, experiments to evaluate the physical interaction between the virions and the 
integrins or the effects of depletion of functional integrins were not performed (Lee and Lobigs 
2000). Further supporting a role of integrin as a receptor, are results with specific antibodies to 
block α5β3 integrin, which resulted in the inhibition of WNV and JEV infection.  The elevated  
expression of the α5β3 integrin in the variant CS-1β3 cells also led to the increase of virus entry of 
WNV in contrast to the lack of the permissiveness to WNV in the CS-1 cells (Chu and Ng 2004). 
Interestingly, discrepancies between the experiments based on the genotype I and genotype II of 
WNV suggested that α5β3 integrin-mediated viral entry may be genotype specific (Medigeshi, 
Hirsch et al. 2008). The β3 integrins exhibited the capacity of modulating the permissiveness of 
WNV infection in vitro (Schmidt, Keller et al. 2013).  A specific  β3 integrin molecule, CD61, 
has been  proposed to be associated with the DENV antigens in the platelets of patients 
(Noisakran, Onlamoon et al. 2012). Together, the evidence based on blocking and expression 
experiments has generally supported the possibility that integrin molecules play a role as the 
receptors for flaviviruses.   The actual/specific roles of integrins as receptors for flaviviruses 
remain obscure and can be complicated by the fact that integrins may be involved in various 
parts of virus infection. 
 Heatshock proteins 
Multiple types of data suggest that the family of heat shock proteins (HSP) encoded in 
genomes of both vertebrate hosts and mosquitoes may be receptors of mosquito-borne 
flaviviruses. These include: viral overlay protein binding assay (VOPBA) data from  DENV-2 
infection of HepG2 cells, mass spectrometry data and antibody inhibition results which identified 
the glucose regulated protein 78 GRP78 (Bip) under the family of HSP as a potential DENV-2 
receptor in humans (Jindadamrongwech, Thepparit et al. 2004). Purified cellular lysates 
interacting with DENV-2 E protein through chromatography also suggested that the other two 
other heat shock proteins HSP70 and HSP90 may be receptors in monocytic U937 cells (Reyes-
Del Valle, Chavez-Salinas et al. 2005). Similar VOPBA methods were also used to identify 
DENV-4 receptors in C6/36 cells leading to the discovery of two glycoproteins, gp40 and gp45, 
which were subsequently identified in other permissive tissues in Ae. aegypti for DENV-4 
(Salas-Benito and del Angel 1997, Yazi Mendoza, Salas-Benito et al. 2002). The gp45 protein 
was also identified in the experiments using DENV-2, together  with the other heat shock protein 
Hsp74 (Salas-Benito, Reyes-Del Valle et al. 2007). Subsequently, HSP70 was identified as a 
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receptor for JEV in Neuro2a and Huh7 cells through the potential interaction of the RGD motif 
in the E protein based on the bioinformatics analysis (Das, Laxminarayana et al. 2009, Zhu, Cao 
et al. 2012).  
 Laminin receptors 
The other class of molecules identified as the potential receptors for flaviviruses based on 
the VOPBA experiments was laminin receptors. Laminin receptors are molecules expressed on 
the cellular surface for the binding of the basement membrane and have been reported to mediate 
the entry of members under the Flaviviridae and Togaviridae (Nelson, McFerran et al. 2008). 
DENV-1 was also demonstrated to interact with the 37 kDa/67 kDa high-affinity laminin 
receptor in HepG2 cells. Antibodies targeting the laminin receptors and the soluble laminin 
treatments led to the reduced viral titer potentially by reducing the viral entry (Thepparit and 
Smith 2004). The same receptor derived from porcine kidney cells also interacted with DENV-1, 
2 and 3 (Tio, Jong et al. 2005). Laminin receptors reactive to anti-37 kDa/67 kDa antibodies 
were also found to interact with DENV-3 and DENV-4 in C6/36 cells (Sakoonwatanyoo, 
Boonsanay et al. 2006). The interactions between the laminin receptors and JEV were also 
observed with similar methods and the pretreatment of soluble laminin inhibited the virus entry 
(Boonsanay and Smith 2007). In the experiments devised to test the hypothesis that WNV 
utilizes receptors molecules other than α5β3 integrin, the physical interaction was observed 
between the laminin binding protein and the recombinant polypeptide of WNV E protein. The 
atomic force spectroscopy data further suggested EDIIs of flaviviruses are the conserved region 
which interact with the laminin receptors (Bogachek, Protopopova et al. 2008).  
 C-type lectins 
The studies on the three groups of C-type lectin receptors indicated such mechanisms are 
conserved in vertebrate hosts, especially among the myeloid cells which express other 
homologous proteins. The glycosylation sites conserved across flaviviruses have been shown to 
complex with the carbohydrate recognition domain (CRD) of the dendritic cell-specific 
intracellular adhesion molecule-3grabbing non-integrin (DC-SIGN) in the immature dendritic 
cells, which may act as the primary target cells for viral infections in humans (Pokidysheva, 
Zhang et al. 2006). As the primary susceptible cells at the locations for the initiation of arbovirus 
infection, the identification of DC-SIGN as the viral receptors supports the importance of 
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dendritic cells as the susceptible cells in human (Wu, Grouard-Vogel et al. 2000). The other 
similar molecule, liver/lymph node-specific ICAM-3 grabbing non-integrin (L-SIGN), has also 
been proposed to enhance the infection of WNV (Davis, Nguyen et al. 2006). Similarly,  the 
mannose receptor which also belongs to the family of C-type lectin receptor has also been 
demonstrated as a receptor of DENV-2 in various cell types that are involved in DENV disease 
pathogenesis (Taylor, Gordon et al. 2005, Miller, de Wet et al. 2008).  
Although it has only been found for WNV, the galactose-specific binding C-type lectin 
serves as the bridging factor which anchors the virions to the cellular receptor, mosPTP-1 
tyrosine phosphatase in mosquitoes (Cheng, Cox et al. 2010). The hemocytes of hematophagus 
arthropods, including Ae. aegypti, exhibit the lectin binding activity and have been found 
susceptible to the infection of arboviruses. This suggests  the possibility that the C-type lectin 
receptors may also function as virus receptors for mosquitoes (Sriurairatna and Bhamarapravati 
1977, Yamamoto, Kimura et al. 1987, Hillyer and Christensen 2002, Parikh, Oliver et al. 2009). 
Although the importance of C-type lectins to assist the binding between virions and hemocytes 
has been recognized, the receptors for flaviviruses on the midgut epithelial cells remains 
unknown. 
 T cell immunoglobulin domain and mucin domain 
In mammalian hosts of flaviviruses, the recycling machinery for the apoptotic cells 
through the T-cell immunoglobulin domain and mucin domain (TIM) proteins may directly 
facilitate viral entry through direct interactions between TIM-1,3 and 4 with the virion of 
flaviviruses. Similarly, the class of TAM receptors consist of the family of surface protein 
tyrosine TYRO3, AXL and MER kinases also increases the virus entry via the binding through 
their natural ligands as the bridging molecules (Meertens, Carnec et al. 2012). The recognition of 
virions by both classes of the receptors is achieved by the recognition of the phosphatidylserin 
derived from the cell membrane of the hosts. 
In conclusion, the research to identify receptors for YFV and other mosquito-borne 
flaviviruses has suggested the virus entry may be achieved by multiple molecules and pathways. 
Although the extensive research has identified several molecules in the vertebrate hosts and the 
arthropod vectors, there was no confirmative evidence showing YFV and other related 
flaviviruses rely on a specific class of molecules as receptors. Such information is critical for its 
application in the development of antiviral inhibitors targeting at the virus entry for humans and 
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other vertebrate hosts. On the other hand, the mapping of the viral determinants for receptor 
binding can contribute to the goal of rationale-based vaccine design that limits the infectivity of 
live-attenuated vaccines in both vertebrate hosts and arthropod vectors. 
 C. The process of viral entry 
It is generally accepted that members in the family of Flaviviridae and other arboviruses 
enter cells through endocytosis pathways. The specific knockdown and blockade of genes 
required for the different subsets of endocytosis mechanisms through molecular biological or 
pharmacological approaches have been used to determine the specific routes of viral entry, and 
the cellular compartments that are responsible for the trafficking of viral components prior to the 
formation of replication complex in the perinuclear space in the infected cells.  Lysosomotropic 
weak bases such as chloroquine were first demonstrated to suppress the infection by 10-fold of 
YFV in murine macrophage P388D1 cell line at early stage of infection, and suggested that the 
endocytosis pathways shared by other mosquito-borne flaviviruses can mediate virus entry of 
YFV (Brandriss and Schlesinger 1984). Subsequent experiments utilizing other weak bases such 
as ammonium chloride, or the depletion of the V-ATPase by RNA interference, showed that the 
gradual decrease of pH in the endocytosis pathway is critical for DENV-2 and WNV (Krishnan, 
Sukumaran et al. 2007). Although clathrin-mediated endocytosis is considered to be the 
predominant pathway for the entry of flaviviruses, additional pathways including 
macropinocytosis, caveolae-dependent endocytosis, and lipid-raft have also been reported in 
different combinations of flaviviruses and cell types. 
 Clathrin-mediated endocytosis 
In the clathrin-mediated endocytosis pathway, the virions of flaviviruses are transported 
by endosomes that are exposed to the gradient of acidic conditions prior to reaching the 
perinuclear space of the infected cells, where the viral replication complex is formed (Welsch, 
Miller et al. 2009, Mercer, Schelhaas et al. 2010).  Clathrin protein was first found in the coat of 
vesicles that contain KUNV (Ng and Lau 1988). Treatment of chlorpromazine inhibited the 
clathrin-mediated endocytosis and also resulted in reduced numbers of infected Vero and HeLa 
cells challenged with JEV and WNV respectively (Nawa, Takasaki et al. 2003, Krishnan, 
Sukumaran et al. 2007). The evidence suggesting that flaviviruses enter the host cells through 
clathrin-mediated endocytosis, followed by the transportation in the early endosomes, is based on 
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the reduced viral replication of DENV-2 and WNV in the HeLa cells with the depletion of Rab5 
GTPase and Eps15 adapter protein functions. Both the enzyme and the protein have been found 
as two critical components of clathrin-mediated endocytosis (Krishnan, Sukumaran et al. 2007). 
The silencing of clathrin genes also led to  a reduced number of DENV-2 infected cells and a 
reduced  extracellular viral load in Huh7 cells, HepG2 cells and primary monocyte cultures (Ang, 
Wong et al. 2010, Alhoot, Wang et al. 2011, Alhoot, Wang et al. 2012). The expression of anti-
clathrin antibodies and the dominant negative mutant of Eps15 also effectively suppressed the 
WNV and DENV-2 entry in C6/36 cells and supports the importance of the clathrin-mediated 
endocytosis in viral entry of flaviviruses (Lee, Chu et al. 2006, Mosso, Galvan-Mendoza et al. 
2008). The inhibitor treatment further demonstrated that clathrin-mediated endocytosis is 
required for the viral entry of DENV-1, DENV-3 and DENV-4 into C6/36 cells (Acosta, Castilla 
et al. 2011). Together, it is likely that the entry of flaviviruses may utilize the conserved clathrin-
mediated endocytosis pathways in both vertebrate hosts and arthropod vectors. Subsequently, the 
adapter protein such as AP2 and its homologous molecules interact with Eps15 will lead to the 
formation of clathrin-coated pits that contain the virions under the outside-in endocytosis 
signaling via the focal adhesion kinase (FAK) (Benmerah, Lamaze et al. 1998, Chu, Leong et al. 
2006). The switching of the Rab5 GTPase to the Rab7 GTPase in the late endosomes containing 
viral antigens was also observed in HeLa cells. The acidic environment of late endosomes 
triggers the fusion process mediated by the exposed fusion peptide in the EDII of flaviviruses 
(Miller, de Wet et al. 2008). In C6/36 cells, the colocalization of the early endsome marker 
EEA1 and the late endosome markers MRP-1 and the antigens indicated that the same 
endocytosis pathways and subset of endosomes may be conserved in infected vertebrates hosts 
(Chu, Leong et al. 2006). However, the sequestering of functional Rab7 GTPase by the 
overexpression of dominant negative Rab7 mutant did not affect the virus internalization of two 
serotypes of DENV and WNV in vitro (Krishnan, Sukumaran et al. 2007, Acosta, Castilla et al. 
2012). The Rab22 GTPase majorly localized in the recycling endosomes has also been 
implicated as an alternative route for viral endocytosis (Acosta, Castilla et al. 2012). There have 
been at least three types of cytoskeletal structures, microfilaments, microtubules and vimentin, 
reported for the post-entry trafficking processes (Chu, Leong et al. 2006, Acosta, Castilla et al. 
2008, Chen, Gao et al. 2008).  
 Macropinocytosis 
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 Although the blockade of clathrin-mediated endocytosis resulted in the significant 
reduction in viral infection, DENV-2 antigens were still detected in a subset of HepG2 cells 
suggesting that alternative pathways may contribute to viral entry. The growth-factor mediated 
macropinocytosis pathway has also been described as an additional endocytosis pathway used by 
microorganisms (Mercer, Schelhaas et al. 2010). Similar to other growth-factor-mediated signal 
transduction pathways, the macropinocytosis is subjected to the regulation of phosphoinositol 3-
kinase (PI 3-kinase) at the step of endocytosis vesicle formation (Murray, Wilson et al. 2000). 
Simultaneous inhibition of the clathrin-mediated endocytosis and macropinocytosis by RNA 
interference and the PI 3- kinase inhibitor wortmannin led to the more profound reduction in the 
quantities of viral antigens than the monovalent inhibition of both pathways. The observation is 
also consistent with the result that cytochalasin D led to a minor reduction of JEV infection in 
Vero cells (Nawa, Takasaki et al. 2003). Macropinocytosis may therefore act as an alternative 
mechanism for the entry of flaviviruses (Suksanpaisan, Susantad et al. 2009). Alternatively, the 
knockdown of caveolin-1 also led to the reduction of JEV infection in neuroblastoma cells and 
the same study also showed the dynamin GTPase that is required for the scission of endocytosis 
vesicles is also required for viral entry. However, whether the macropincytosis or the caveolae-
dependent endocytosis of flaviviruses acts as alternative viral entry mechanisms for other 
flaviviruses in other tissues in either vertebrate hosts or in arthropod vectors has not been 
determined. 
 Lipid Raft-dependent entry 
Another critical structure that has been reported to be involved in the viral entry on the 
cell surface is the cholesterol-dependent lipid raft. The significance of the local lipid raft for 
flavivirus entry was established by the experimental observation that the withdrawal of 
cholesterol is often assicuated with the inhibition of viral entry. The lipid raft-mediated the viral 
entry requires the early and late endosomes with ER as an alternative destination of the 
uncoating of viral genetic material.The process is less well characterized because the removal of 
cholesterol can also subsequently impair the clathrin-mediated endocytosis pathway (Mercer, 
Schelhaas et al. 2010). The importance of lipid raft for virus entry was first demonstrated by 
treatment of U937 cells with methyl-β-cyclodextrin (MβCD) which suppressed DENV-2 
infection. The lipid raft structures were co-purified with the putative receptors Hsp70 and Hsp90 
suggesting that lipid rafts act as a platform for the enrichment of viral receptors on the cell 
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membrane (Salas-Benito, Reyes-Del Valle et al. 2007). The cholesterol-rich membranous 
structures were demonstrated to be required for the entry of WNV but were  independent from 
α5β3 integrin (Medigeshi, Hirsch et al. 2008).  Depletion of cholesterol by MβCD also disrupted 
the lipid raft structure and simultaneously suppressed JEV infection in the porcine kidney 
epithelial PK15 cell line (Yang, He et al. 2013). The lipid raft, which may act as the platform for 
various viral receptors, was first found to be associated with the JEV infection in the neural 
stem/progenitor cells by the colocalization of the lipid-raft marker Cholera toxin B (Das, 
Chakraborty et al. 2010). Although it was not tested in the cells derived from its naturally 
susceptible tissues, the observation was further expanded to an association between the putative 
JEV receptor Hsp70 and the lipid raft of HepG2 cells s. The infection with JEV led to the 
migration of Hsp70 into the lipid raft and triggered the signaling of the PI3K/Akt signaling 
pathway (Zhu, Cao et al. 2012).  
Although the various endocytosis mechanisms identified for the viral entry of flaviviruses 
suggested that multiple pathways may be used by individual viruses, the virions are ultimately 
transported to the late endosome, where the acidic environment triggers the conformational 
change of the E proteins. All the flaviviruses share similar mechanisms triggering the 
conformational changes, which lead to the exposure of the fusion peptides in the E proteins and 
its insertion into the cellular membranes. The details of membrane fusion process and 
mechanisms will be described in section 4.1. 
 D. Structures and functions of YFV and flavivirus EDIIIs 
The available structure information of flavivirus EDIIIs including YFV has been 
determined by the nuclear magnetic resonance (NMR) spectroscopy. The structure of YFV EDIII 
was obtained by the recombinant EDIII of YFV Asibi strain and NMR spectroscopy (Volk, May 
et al. 2009). Although the mature infectious form of YFV particles has not been characterized in 
cryoelectron microscopy (cryoEM), the immature virus particles of YFV resemble those of 
DENV-2 suggesting high homology of the mature particles of YFV and DENV-2 and also  high 
similarity after the removal of the pr peptide from the prM protein prior to the release into 
extracellular space (Zhang, Corver et al. 2003). The EDIIIs project away from the surface of the 
virion to enable binding of cellular receptors, and form the pore-like structure under the 5-fold 
axes of symmetry (Kuhn, Zhang et al. 2002). Each monomeric unit of EDIII is anchored to the 
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lipid membrane by the transmembrane region in the C terminus of E protein. The transmembrane 
region consists of three perimembrane helical structures at its N-terminal region and two helical 
structures spanning the viral membrane at its C-terminal region connected by the loop structures. 
The perimembrane helices are the transition amphipathic regions with hydrophilic amino acids 
arranged outwards and hydrophobic amino acids located at the bottom within the close proximity 
of viral membrane. The two transmembrane helical structures are stabilized by the formation of 
the coiled-coil structural unit with the hydrophobic residues exposed outwards and the 
hydrophilic amino acids facing inward (Zhang, Chipman et al. 2003, Zhang, Ge et al. 2013). The 
structures and arrangement of EDIIIs on the virion surface among other flaviviruses are also 
highly similar (Zhang, Kaufmann et al. 2013, Kostyuchenko, Chew et al. 2014).  
The overall structure of YFV EDIII resembles the IgG-like β-barrel structure consisting 
of nine β-strands arranged in three β-sheets. The permembrane and transmembrane helices were 
not included in the available NMR structure derived from the soluble portion of EDIII (Volk, 
May et al. 2009). The detailed annotated structure of YFV EDIII is displayed as Figure 3.1.The 
first β-sheet is composed of four β-strands, β-strand A from Ser305 to Asp312, β-strand B from 
Val318 to Lys323, β-strand D from Ile348 to Leu349, and β-strand E Glu362 to Asn368. (Figure 
3.1 (a)) The ABED β-sheet faces EDI via the linker region between EDI and EDIII. Two short β-
strands, β-strand Cx from Cys330 to Lys331 and β-strand Dx from Ile355 to Ala356, form the 
second β-sheet. The third β-sheet consists of three β-strands, β-strand C from Val334 to Ala337, 
β-strand F from Gly372 to Val378 and β-strand G from Leu385 to Lys391. The CFG β-sheet is 
exposed in the outer lateral surface of the dimeric structure of E protein. (Figure 3.1 (b)) The 
conservide disulfide bond is formed between Cys300 in the N-terminal loop structure and 
Cys330 in the β-strand Cx. There are four surface exposed loop structures connecting the β-
strands between different β-sheets or within the same β-sheet. DE loop exists between β-strand D 
and β-strand E within the first β-sheet. The BC loop is comprised of the amino acids between β-
strand B in the first β-sheet and β-strand C in the third β-sheet. Similarly, the CD loop structure 
connects the β-strand C in the third β-sheet and the β-strand D of the first β-strand. The FG loop 
is located between the β-strand F and β-strand G within the third β-sheet. 
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Figure 3.3 NMR 3D structure of recombinant YFV EDIII is displayed and annotated.  
(a)The inner ABED β-sheet is colored in yellow. Cys300 and Cys330 that contribute to the 
formation of the disulfide bond are colored in green. (b) The lateral surface portion formed 
by the third CFG β-sheet is colored in magenta. The second β-sheet formed by the two 
short Cx and Dx β-strands is colored in orange. 
 
With respect to YFV, there have been four amino acid substitutions identified in the 
ectodomain of EDIII between the Asibi and 17D strains. The M299I mutation is located in the 
N-terminal loop, which is part of the linker region between EDI and EDIII. The region 
accommodates the mechanical force generated due to the pH-dependent conformational changes 
during the virus entry and the exocytosis of progeny virions (Modis, Ogata et al. 2004, de 
Wispelaere and Yang 2012). The details of the conformational changes and the phenotypes 
associated with the mutations in the N-terminal loop will be discussed in section 5.1. The S305F 
mutation in the A β-strand is located in the inner face of EDIII formed by the ABED β-sheet. 
(b) 
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The ABED β-sheet faces the region between the C β-strand and the D β-strand of EDI and 
interacts with the cd loop structure of EDII from the other subunit. The P325F mutation is part of 
the BC loop structure in the upper portion of EDIII that has been found variable among different 
serocomplexes of flaviviruses. The conservative K331R mutation exists in the small Cx β-strand 
as part of the second β-sheet structure of the two-layer sandwich IgG-like structure. The T380R 
mutation is located in the FG loop between the F and G β-strands of the third β-sheet. The 
sequence diversity and the phenotypes associated with the mutations within the FG loop are 
listed in the section 3.1.a. 
The detail functions and antigenicities of YFV and flavivirus EDIIIs were characterized 
with the mutant viruses or recombinant proteins carrying specific mutations. The mutations that 
present in YFV 17D strain EDIIIs have been found related to the protective humoral immune 
responses or the changes in the electrostatic interactions with the host cellular proteins. The 
S305F mutation on the A β-strand and the P325S mutation in the BC loop of YFV are the B-cell 
epitopes for the 17D strains identified by the neutralization escapes of the monoclonal antibody 
(MAb) Mab864 (Despres, Ruiz-Linares et al. 1990, Ryman, Ledger et al. 1998). The substitution  
of Phe305 with valine was found associated with the increase of neurovirulence and 
neuroinvasiveness in the escape mutants and the mouse-neuroadapted strains of YFV, 
respectively (Ryman, Ledger et al. 1998, Nickells and Chambers 2003). The immunogenic 
properties of the A β-strand region neighboring to the S305 mutation in YFV EDIII were also 
supported by the mapping of B-cell epitopes in other flaviviruses. The regions in the A β-strand 
of DENV-2 and WNV EDIIIs have also been demonstrated to contain the epitopes for the 
subcomplex-specific neutralizing MAbs and the neutralizing MAbs, respectively (Beasley and 
Barrett 2002, Sukupolvi-Petty, Austin et al. 2010).  
The wildtype YFV Asibi and attenuated 17DD strains showed the Pro325 residue forcing 
the BC loop turning towards the C β-strand and created the unique structure of the N-terminus of 
BC loop by substituting the conserved tyrosine or phenylalanine residues among all flaviviruses 
with the valine for YFV BC loop (Volk, May et al. 2009, Zhang, Bovshik et al. 2010). The use of 
proline residue forces the turn of BC loop towards the C β-strand. Interesting, the Pro325 residue 
was mutated to serine in YFV 17D-204 strains and identified as the substrain-specific epitope for 
YFV 17D-204 strains (Ryman, Ledger et al. 1998, Stock, Boschetti et al. 2012). Interestingly, 
the P325S mutation of the 17D-204 strand led to the smaller BC loop structure than the other 
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strains of YFV and all other mosquito-borne flaviviruses without altering the valine residue 
present in the first residue of the BC loop. In addition to the alteration of the conserved tyrosine 
or phenylalanine to valine in the N-terminus of BC loop, the unique structure of YFV BC loop 
also led to the amino acid substitution of the conserved phenylalanine to methionine at the last 
residue of the N-terminal loop due to the molecular interactions with the first residue of the BC 
loop (Volk, May et al. 2009).  
As the exposed structure in the upper portion of YFV EDIII, the BC loop is associated 
with a change of GAG-binding affinity due to the amino acid substitutions at the Lys326 residue 
in a mouse neuroadapted 17D strain. The K326E mutation led to the higher neuroinvasiveness 
resembling the mouse-neuroadapted 17D strain (Nickells, Cannella et al. 2008). Although the 
T380R and K326E mutations are located in distinct locations in the upper portion of YFV EDIII, 
the experimental results suggested that an accumulation of the positive charges on the exposed 
surface of EDIII is likely to determine viral dissemination in mammals. The E327G mutation in 
the BC loop of DENV-4 also led to the predicted gain of net positive charges on the virion 
surface through the structural rearrangement and reduced the infectivity and immunogenicity in 
rhesus monkeys (Anez, Men et al. 2009). The other additional region that has been extensively 
reported to confer the determinants for GAG binding affinity, exists in the N-terminal loop 
region (Chen, Her et al. 2010, Watterson, Kobe et al. 2012, Roehrig, Butrapet et al. 2013). 
However, the results were obtained from the binding of recombinant proteins of EDIII or the 
rescued mutants that contain the secondary compensatory mutations. Althought the G304K 
mutation in the N-terminal loop of DENV-2 E protein was characterized as an additional GAG-
binding determinant, the G304K mutant also contains the G330D compensatory mutation located 
in the BC loop, which was reported to change the GAG binding affinity in YFV and DENV-
4.(Añez et al., 2009; J. Nickells et al., 2008; Roehrig et al., 2013). 
The K331R mutation in the short Cx β-strand was also found in both the lethal and non-
lethal viscerotropic strain of hasmster-passaged YFV Asibi strain (McArthur, Xiao et al. 2005). 
The tolerance between the lysine and arginine residues may be explained by the similar chemical 
and physical properties, and suggested a lack of the short Cx β-strand involvement in either 
attenuation or virulence. 
97 
 
 E. Viral attenuation due to the increased electrostatic interactions through negatively 
charged cellular molecules 
The attenuation of virulent viruses has often been achieved by the serial passages in vitro 
in order to increase the interactions between the virions and the negatively charged molecules on 
the cellular surface. The gain of positive charges on such locations has been hypothesized to be 
the consequence of the adaptation made by the various viruses to the environment of non-natural 
hosts or tissue cultures. Although the post-translation modification of GAG has been considered 
as the potential underlying mechanism that mediates viral entry in vitro through the electrostatic 
interactions, the GAG molecules are also likely to cause the attenuation of virulent strains in the 
experimental models of vertebrate hosts predominantly through the retention of progeny virions 
after the processes of morphogenesis and virion secretion are completed. The attenuated GAG-
binding variant viruses exhibit a higher affinity to heparin or heparan molecules that may be  
used as the approach for phenotype characterization (Klimstra, Ryman et al. 1998, Perera-Lecoin, 
Meertens et al. 2014).  
The attenuation of YFV being attributed to the positive charges on the E protein has been 
reported in two experimental models. The first involves the T380R mutation that was described 
in the section 3.1.A and which shares a  similar phenotype with the GAG-binding variants of 
flaviviruses (Lee and Lobigs 2008). The second involves the characterization of the K326E 
mutation in the neuroadapted 17D strain which  implicated  the BC loop as a potential locus for 
the binding with negatively charged cellular molecules and the neurovirulence of the virus 
(Nickells, Cannella et al. 2008).  
The attenuation caused by the mutations in the GAG-binding region of EDIII was first 
observed in MVEV. The RGD motif in MVEV EDIII was found to be critical for the growth 
kinetics in vitro and the virulence in vivo. The conservative mutation from aspartate to glutamate 
resulted in the minor reduction in the viral titers and the virulence; whereas, the non-conservative 
glycine, histidine, and tyrosine mutations attenuated the virus and led to the lower mortality rates 
among the outbred Swiss mice. Interestingly, the gain of positive charge by the histidine 
mutation not only was responsible for the most significant attenuation by causing no or 
negligible mortality among intraperitoneally challenged mice,  but it also increased the inhibition 
of viral entry caused by heparin sulfate treatment (Lee and Lobigs 2000). In the other 
independent study characterizing the hinge region and the RGD motif of MVEV E protein, the 
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non-conservative mutation of the aspartate residue to asparagine or tyrosine significantly reduced 
both the neurovirulence and neuroinvasiveness in intracranially or intraperitoneally inoculated 
outbred Swiss mice. Whilst the growth kinetics showed that the non-conservative mutations 
impaired the viral replication, the pH-dependent conformational change was not altered as the 
optimal pH of hemagglutination activity remained the same. The lower viral titers in the brains 
of intracranially challenged mice further supported the attenuation caused by the mutations 
(Hurrelbrink and McMinn 2001). The RGD motif is therefore likely to harbor the determinant 
for viral attenuation by enhancing the interactions with negatively charged cellular materials. 
The serial passage experiments of other flaviviruses within the JEV serocomplex in 
naturally nonsusceptibile tissues further identified additional locations in the E protein associated 
with viral attenuation. The additional three amino acid substitutions were identified as the lysine 
substitutions in the glutamate 49, 138, and 306 of the envelope proteins of viral variants which 
were shown to have higher GAG binding affinity (Lee, Hall et al. 2004). However, the results 
still support the importance of mutations in RGD motif of EDIII which was previously tested in 
the mutants generated by the reverse genetics systems for viral attenuation. The mutations still 
appeared in the regions corresponding to the RGD motif in the EDIIIs of KUNV MRM61C 
strain and JEV SA14 strain after the wildtype viruses were serially passaged in human 
adenocarcinoma SW13 cells. The mutation of Glu390, which shares the biochemical properties 
of the aspartate in the RGD motif, to glycine in KUNV EDIII has been identified in three plaque-
purified variants. Experimentally, the Asp389 in the EDIII of JEV SA14 strain was substituted 
with glycine in one of the five JEV variants. Both of the mutations in KUNV and JEV were 
considered as the non-conservative mutations with the replacement of the acidic electrically 
charged side chains of glutamate and aspartate with the small side chain of glycine. Both variants 
favored the binding of GAG molecules in vitro and significantly reduced the neuroinvassiveness 
in the intraperitoneally challenged Swiss mice. In addition to the mutations in the FG loops of 
EDIII, the glutamatelysine mutation at the residue 38 of WNV E protein and JEV E protein 
was detected after the five serial passages in SW13 cells. Both of the mutations are located in the 
E0 β-strand in EDI of WNV and JEV as part of the external sheet structure of EDI exposed on 
the surface of flavivirus virions (Rey, Heinz et al. 1995).  The increase of the binding to the 
heparin was observed among the mutants in vitro and the LD50 for intracerebral and 
intraperitoneal inoculation was higher by 50 and 200 fold in Swiss mice  when the mutation was 
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tested with the WNV cDNA infectious clone (Lee, Hall et al. 2004). The glutamate  lysine 
mutation at the residue 49 in the EDI of JEV also increased the affinity of heparin binding but 
only led to the partial attenuation by the reduction of mortality by 80%. The mutants of KUNV 
and WNV that caused the increase of heparin binding and the attenuation in mice were removed 
more efficiently from the blood circulation. Together, the amino acid substitutions with basic 
amino acid residues among encephalitic mosquito-borne flaviviruses are the consequences of the 
viral adaptation after the serially passage in vitro. The mutants favored the binding to the 
negatively charged molecules in the vertebrate hosts and led to the viral attenuation through the 
higher efficiency of viral clearance in the blood stream. The available one-plasmid reverse 
genetics system of JEV further supported the role of the lysine substitution at the residue 138 and 
revealed the retention of progeny virions in the infected cells, which was consistent with the 
proposed model of the attenuation of the GAG-binding variant of recombinant YFV described by 
Lee et al (Zhao, Date et al. 2005, Lee and Lobigs 2008). On the other hand, the lysine 
substitution at the residue 306 also occurred in variants of the T1P1 strain isolated from 
Armigeres subalatus and purified based on the difference in plaque morphologies and led to the 
delay in the peak viral titer in the brain of intracranially inoculated ICR mice confirming its 
potential contribution to the attenuation (Chiou and Chen 2007).  
The dependence of utilizing GAG molecules for the retention of variant viruses was 
further tested in different strains of DENV-2, which have a different history of passage in vitro. 
The mouse neurovirulent New Guinea C strain acquired the lysine substitution at the residue 126 
of the envelope protein and this led to the higher affinity of GAG binding, which differs from 
other natural isolates of DENV-2. The gain of positive charges due to the lysine substitutions at 
the residue 120 and the arginine substitutions at the residue 227 led to the attenuation in AG129 
mice; whereas the lysine substitution at the residue 202 resulted in the phenotypic instability 
without the attenuation. Also, the compensatory mutation at asparagine 124 is required for the 
stabilization of the structure (Lee, Wright et al. 2006). Although the gain of positive charges in 
DENV-2 E proteins also led to the attenuation, the locations of the mutations were found in the 
surface of EDII and differ from the flaviviruses in the JEV serocomplex. 
Although TBEV is listed under the other distinct category of tick-borne flaviviruses and 
predominantly utilizes ticks as its vectors, its attenuation in vivo was associated with the 
phenotype of increased GAG binding after the serial passage in vitro (Mandl, Kroschewski et al. 
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2001, Kroschewski, Allison et al. 2003). The adaptation of TBEV by serial passage in BHK-21 
cells resulted in the substitutions with predominantly positively charged basic amino acids on the 
upper and lateral surface of virions across the three domains of the E protein. Three mutants, 
E201K, E122G and S158R-G159R, exhibited the higher sensitivity of soluble heparin inhibition 
and shared the phenotype of the reduced infectivity and neuroinvasiveness in Swiss mice model. 
The evidence has suggested that the tropism and disease pathogenesis characteristic of 
different flaviviruses are likely altered due to the mutations causing the different GAG-binding 
properties. In addition to the phenotypic changes in the binding affinity with the GAG molecules 
and virulence associated with the mutations in the FG loop of the flavivirus EDIII, the structural 
and sequence homology between the E2 glycoprotein of alphaviruses and the E protein of 
flaviviruses suggested the presence of a secondary structure similar to the FG loop of flaviviruses 
in the domain A of the E2 glycoprotein of alphaviruses. Such structure consists of the linear 
polypeptide between the E and F β-stands of alphavirus E2 glycoprotein (Pierro, Powers et al. 
2008, Voss, Vaney et al. 2010). The same region has been found to harbor the glutamatelysine 
substitution in the epizootic strains of VEEV IE subtype and associated with the GAG-binding 
affinity (Brault, Powers et al. 2002, Wang, Brault et al. 2003). However, there has not been any 
clear association identified between the enzootic and epizootic types of VEEV that utilize 
different vector species. 
Together, the gain of positive charges on the E protein of flaviviruses has led to the 
attenuation in mice. Although the mutations are found in various locations clustered in the 
serocomplex-specific manner, the consequences of serial passage in vitro is likely to lead to the 
lysine or arginine substitutions that increase the GAG- binding affinity, which in turn results in 
the rapid viral clearance from the blood circulation. Similar negatively charged homologs are 
also synthesized by the mosquitoes as the post-translational modifications of cellular proteins 
(Kato, Dasgupta et al. 2002, Kato, Mueller et al. 2005). The evaluation of the GAG-binding 
variants of flaviviruses in its infectivity and disseminability in the vector mosquitoes will provide 
the mechanistic understanding in the role of such a conserved class of molecules in the vertebrate 
hosts and insect vectors in determining the vector competence for arboviruses. 
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 3.2 Results 
 A. Infection and dissemination of YFV E T380R mutants in Ae. aegypti 
The titers of viremic blood meals and the infection rates of wildtype and mutant YFV are 
summarized in Table 3.4. The infection rates of the Asibi strain, the 17D strain and the 
17D+Asibi M-E chimera followed the pattern described previously by McElroy et al suggesting 
the Asibi strain is the most infectious strain among the three viruses orally administered. 
Although the Asibi strain was administered at the lower titer, the infection rates of Ae. aegypti 
exposed to the Asibi strain were consistently higher than those exposed to the 17D strain at 7 
(p=0.01) and 14 d.p.i. (p=0.01) but similar at 10 d.p.i. (p=0.47). The infection rates of 17D+Asibi 
M-E chimera were comparable to the Asibi strain at 7 (p=0.20), 10 (p=1.00) and 14 (p=1.00) 
d.p.i. The exposure of 17D+Asibi M-E chimera also led to the higher infection rates than the 
17D strain at 7 (p=0.78) and 14 (p=0.01) d.p.i. except for 10 d.p.i., where both viruses led to the 
similar infection rates (p=0.72).  
 Viremic blood meal 
(logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
Defibrinated sheep blood (N.A.) 0/30 (0.0%) 0/24 (0.0%) 0/35 (0.0%) 
17D (6.24) 9/25 (36.0%) 8/12 (66.7%) 8/32 (25.0%) 
17D+Asibi M-E (5.77) 12/29 (41.4%) 13/24 (54.2%) 21/39 (53.8%) 
17D+Asibi M-E E T380R (5.85) 21/23 (91.3%)† 10/12 (83.3%) 14/16 (87.5%)† 
Asibi (3.99) 20/33 (60.6%) 9/18 (50.0%) 21/38 (52.6%) 
Asibi E T380R (4.21) 32/48 (66.7%) 21/36 (58.3%) 21/39 (53.8%) 
Table 3.4 Infection rates of YFV  mutants and control strains in Ae. aegypti at 7, 10 and 14 
d.p.i. 
† indicates the statistical significance between the 17D/Asibi M-E E T380R mutant and the 
17D/Asibi M-E chimera by Fisher’s exact test. 
The introduction of the T380R mutation caused the increase in the infection rates of the 
Asibi strain at 7 (60.6% vs. 66.7%, p= 0.64), 10 (50.0% vs. 58.3%, p=0.58) and 14 (52.6% vs. 
53.8%, p=1.00) d.p.i. without reaching the statistical significance. Interestingly, the infection 
rates of 17D+Asibi M-E E T380R mutant was significantly higher than those of 17D+Asibi M-E 
chimera at 7 (41.4% vs 91.3%, p=0.0003) and 14 (54.2% vs. 87.5%, p=0.03) d.p.i. although the 
higher infection rate of the 17D+Asibi M-E E T380R mutant at 10 d.p.i. was not significant from 
the 17D+Asibi M-E chimera (54.2% vs. 83.3%, p=0.14). 
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The dissemination rates of wildtype and mutant YFV are summarized in Table 3.5. 
Although the 17D strain was orally challenged with the highest average titer, the control virus 
failed to disseminate from the infected midguts to the secondary tissues among the infected 
mosquitoes except for one disseminated infection detected at 10 d.p.i. The dissemination was 
observed among mosquitoes that were infected by the control Asibi strain and the 17D+Asibi M-
E chimera at 7 (47.1% vs. 33.3%, p=0.66), 10 (80.0% vs. 37.5%, p=0.27) and 14 (60.0% vs. 
50.0%, p=0.72) d.p.i. Although the dissemination rates remain higher in the dissected 
mosquitoes infected by the Asibi strain, the dissemination rates were not significantly different 
between the Asibi strain and the 17D+Asibi M-E chimera. 
The Asibi E T380R mutant was equally disseminating as the Asibi strain at 7 (47.1% vs. 
79.0%, p=0.08), 10 (80.0% VS. 64.3%, p=1.00) and 14 (60.05 VS. 66.7%, p=1.00) d.p.i. 
Similarly, the dissemination of 17D+Asibi M-E E T380R mutant was comparable to the 
17D+Asibi M-E chimera (7 d.p.i.:33.3% vs. 21.4% , p=0.61; 10 d.p.i.: 37.5% vs. 16.7, p=0.58; 
14 d.p.i. 50.0% vs. 62.5%, p=0.67) 
  7 d.p.i. 10 d.p.i. 14 d.p.i. 
17D 0/3 (0.0%) 1/5 (20.0%) 0/12 (0.0%) 
17D+Asibi M-E 2/6 (33.3%) 3/8 (37.5%) 7/14 (50.0%) 
17D+Asibi M-E E T380R 3/14 (21.4%) 1/6 (16.7%) 5/8 (62.5%) 
Asibi 8/17 (47.1%) 4/5 (80.0%) 9/15 (60.0%) 
Asibi E T380R 15/19 (79.0%) 9/14 (64.3%) 10/15 (66.7%) 
Table 3.5 Dissemination rates of YFV   mutants and control strains in Ae. aegypti at 7, 10 
and 14 d.p.i. 
 B. Viral titers of whole mosquitoes, bodies and secondary tissues 
The growth kinetics of YFV mutants were assessed in the homogenates of whole-
mosquitoes to the wildtype YFV. The whole-mosquito titers of the Asibi strain and the Asibi E 
T380R mutant and the 17D+Asibi M-E chimera and the 17D+Asibi M-E E T380R mutant are 
compared in Figure 3.4. 
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Figure 3.4 Titers of the whole mosquitoes infected by YFV at 7, 10 and 14 d.p.i.  
(a) The Asibi strain and the Asibi E T380R strain are labeld in red and green, respectively. 
(b) The 17D+Asibi M-E chimera and the 17D+Asibi M-E E T380R mutant are labeled in 
red and green, respectively. 
Although the infection of the Asibi E T380R mutant did not lead to the significant higher 
infection and dissemination rates, the titers of whole mosquitoes infected by the Asibi E T380R 
mutant were consistently higher than the Asibi strain at 7 (1.55 logTCID50/ml, n=14 vs. 2.14 
logTCID50/ml, n=3, p>0.05) and 10 (2.32 logTCID50/ml, n=4 vs. 2.43 logTCID50/ml, n=7, 
p>0.05) d.p.i. At 14 d.p.i., the infection of the Asibi strain resulted in the higher titer among 
whole mosquitoes than the Asibi E T380R mutant (2.46 logTCID50/ml, n=5 vs. 2.41 
logTCID50/ml, n=6, p>0.05). The 17D+Asibi M-E E T380R mutant replicated to the higher viral 
titers in whole mosquitoes at 7 (2.20 logTCID50/ml, n=5, vs. 2.51 logTCID50/ml, n=9) and 14 
(2.31 logTCID50/ml, n=6 vs. 2.46 logTCID50/ml, n=10) d.p.i. but not at 10 (2.18 logTCID50/ml, 
n=3 vs. 2.08 logTCID50/ml, n=10) d.p.i. However, the titers between the wildtype and mutant 
viruses did not differ significantly throughout the timecourse of the experiments. 
 
(a) (b) 
(a) (b) 
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 Figure 3.5 Titers of dissected mosquito bodies infected by YFV at 7, 10 and 14 d.p.i  
(a) The Asibi strain and the Asibi E T380R strain are labeled in red and green, 
respectively. (b) The 17D+Asibi M-E chimera and the 17D+Asibi M-E E T380R mutant are 
labeled in red and green, respectively. 
Although the titers of the dissected bodies containing the abdomen section of mosquitoes 
did not differ significantly based on the ANOVA test, the T380R mutation led to the constantly 
higher titer in the mosquito bodies than the wildtype sequence. (Figure 3.5) The body titers of 
mosquitoes infected by the 17D+Asibi M-E E T380R mutant were higher at 7 (2.43 
logTCID50/ml, n=6 vs. 2.57 logTCID50/ml, n=11, p>0.05), 10 (1.94 logTCID50/ml, n=7 vs. 2.99 
logTCID50/ml, n=7, p>0.05) and 14 (1.91 logTCID50/ml, n=14 vs. 2.43 logTCID50/ml, n=10, 
p>0.05 ) d.p.i. than those infected by the 17D+Asibi M-E chimera. The Asibi E T380R mutant 
also led to the higher body titers than the Asibi strain at 7 (1.98 logTCID50/ml, n=11 vs. 2.02 
logTCID50/ml, n=13), 10 (1.18 logTCID50/ml ,n=4 vs. 1.96 logTCID50/ml, n=8) and 14 (1.57 
logTCID50/ml, n=12 vs. 2.11 logTCID50/ml, n=14) d.p.i. 
  
Figure 3.6 Titers of dissected mosquito secondary tissues infected by YFV at 7, 10 and 14 
d.p.i. 
(a) The Asibi strain and the Asibi E T380R strain are labeld in red and green, respectively. 
(b) The 17D/Asibi M-E chimera and the 17D/Asibi M-E E T380R mutant are labeled in red 
and green, respectively. 
The titers of the homogenized secondary tissues did not show the consistent patterns 
between the wildtype and mutant YFV or identify any statistically significant difference in viral 
titers. The Asibi E T380R mutant disseminated into the secondary tissues and resulted in the 
(a) (b) 
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higher viral titers at 10 (1.51 logTCID50/ml, n=4 vs. 1.87 logTCID50/ml, n=9) d.p.i. than the 
Asibi strain, which led to the higher average viral titers in the infected secondary tissues at 7 
(1.67 logTCID50/ml, n=8 vs. 1.55 logTCID50/ml, n=15) and 14 (2.58 logTCID50/ml, n=9 vs. 2.35 
logTCID50/ml, n=9) d.p.i. The dissemination of 17D+Asibi M-E E T380R mutant resulted in the 
higher average titers at 7 (1.79 logTCID50/ml, n=2 vs. 2.59 logTCID50/ml, n=4) and 14 (2.26 
logTCID50/ml. n=7 vs. 3.57 logTCID50/ml, n=5) d.p.i. than the 17D+Asibi M-E chimera. At 10 
d.p.i., the 17D+Asibi M-E chimera replicated to the higher viral titer in the secondary tissues 
than the 17D+Asibi M-E E T380R mutant (3.00 logTCID50/ml, n=3 vs. 2.10 logTCID50/ml, n=5) 
 3.3 Conclusions 
Our results in Ae. aegypti demonstrated that the YFV E T380R mutants still maintain the 
viral infectivity and disseminability in vivo. The presence of the T380R mutation may further 
enhance the viral infectivity of the 17D+Asibi M-E chimera as the 17D+Asibi M-E E T380R 
mutant resulted in significantly higher infection rates at 7 and 14 d.p.i. and the marginal increase 
of the infection rate at 10 d.p.i. The insignificant gain of viral infectivity was also observed in 
Ae. aegypti which were orally challenged with the Asibi E T380R mutant and showed higher 
infection rates throughout the time course.  
The gain of viral infectivity could also potentially result in the higher average titers of the 
homogenates of bodies infected with the Asibi E T380R mutant and the 17D+Asibi M-E E 
T380R mutant with no demonstrable difference. However, the  insignificantly higher average 
viral titers in the bodies did not lead to the higher average titers of whole mosquitoes in both the 
Asibi E T380R mutant and the 17D+Asibi M-E E T380R mutant. Similarly, the propagation of 
viruses in the secondary tissues did not show the demonstrable difference in  viral titers in the 
secondary tissues between the wildtype controls and the E T380R mutants. 
The T380R mutation in the E protein of the Asibi strain and the 17D+Asibi M-E chimera 
failed to prevent the viruses from disseminating into the secondary tissues. The similar 
dissemination rates and the average titers of the secondary tissues suggested that the mutants 
based on the Asibi strain and the 17D+Asibi chimera are equally capable of disseminating as the 
wildtype virus controls.  Neither the single amino acid substitution in the E protein nor the 
combination of the mutation in the E protein and the other additional attenuation determinants in 
the nonstructural genes did not lead to the non-disseminating phenotype of the 17D strains. 
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In conclusion, the results suggested that the gain of the positive charge in the FG loop of 
the wildtype Asibi E protein enhanced  viral infectivity and maintained the capacity of viral 
dissemination. The infectivity of the 17D+Asibi M-E T380R mutant was significantly higher 
than the 17D+Asibi M-E chimera. The Asibi E T380R mutant showed a  marginal increase in the 
viral infectivity compared to the Asibi strain. The T380R mutation in YFV E protein is not an 
attenuation determinant between the virulent Asibi strain and the attenuated 17D strains. 
 3.4 Discussion 
 A. The increase of viral infectivity by the T380R mutation 
In spite of the same amino acid sequences present in the E protein of both the Asibi strain 
and the 17D+Asibi M-E chimera, the significant enhancement in the viral infectivity was only 
observed in the 17D+Asibi M-E E T380R mutant but not for the Asibi E T380R mutant. The 
previously published characterization on the 17D+Asibi M-E chimera suggested that the virus 
only retained the partial infectivity of the Asibi strain even though the envelope protein of the 
Asibi strain was present (McElroy, Tsetsarkin et al. 2006). Therefore, it is likely that the T380R 
mutation only resulted in the observed marginal increase of the infectivity in the Asibi strain 
since this strain is already highly infectious in Ae. aegypti.  
Additionally, the Asibi strain and the Asibi E T380R mutant, which were only able to 
propagate to the relatively lower viral titer in vitro, were administered at the concentration of 
3.99 and 4.21 logTCID50/ml; whereas, the 17D+Asibi M-E chimera and its mutant, which shared 
the high capacity of growth in vitro, were administered at titers of at 5.77 and 5.85 
logTCID50/ml, respectively. The different titers in the viremic blood meals may also result in the 
differences in the results of the experiments. 
The observations suggested the attenuation caused by the T380R mutation in the 
envelope protein in IFN-α/γ-R-/- mice model through the retention of virions due to the increase 
in the GAG-binding capacity at the step of viral dissemination into the secondary tissues was not 
conserved in the mosquitoes (Lee and Lobigs 2008). Although the experimental evidence 
suggested that the gain of positive charges in the structural proteins is likely to lead to the 
attenuation in vivo, there have been at least two reports for arboviruses to show higher infectivity 
among the mutants carrying the amino acid substitutions with positively charged amino acids in 
the structure genes. Both the flaviviruses and the alphaviruses utilize class II fusion proteins as 
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the mechanisms of the viral entry (Harrison 2008).(Harrison, 2008) The structural and sequence 
homologies have also been reported between the structural genes of both classes of viruses 
(Pierro, Powers et al. 2008). The positively charged mutations in the E2 protein acquired in the 
process of the in vitro adaptation of SINV resulted in  higher morbidity and mortality in 
intracranially challenged CD-1 mice (Ryman, Gardner et al. 2007). The positive charges on the 
E2 protein of naturally isolated strains of EEEV were also found to associate with the heparan 
sulfate binding and the neurovirulence in CD-1 mice. The neurovirulent strains of EEEV also 
caused higher numbers of the infected cells among the intracranially challenged mice (Gardner, 
Ebel et al. 2011). The general gain of positive charges has also been reported to associate with a 
gain of infectivity in other unrelated virus, adeno-associated viruses (Lerch and Chapman 2012). 
In addition to the attenuation effects that are frequently reported among viruses, the gain of the 
positive charges on the structural proteins can also potentially serve as the mechanism for the 
gain of infectivity.  
 B. GAG molecules in mosquitoes 
In contrast to the extensive characterization of the interactions between various viruses 
and the GAG molecules in vertebrate hosts (Samreen, Khaliq et al. 2012, Tiwari, Maus et al. 
2012), the knowledge in the interactions between the viruses and GAG molecules in arthropod 
vectors remains limited (Smith 2012). The presence  of the GAG molecules in arthropod vectors 
originated from the characterization of Anopheles mosquitoes, which are vectors for malarial 
parasites (Sinnis, Coppi et al. 2007). The available genomic sequences further suggested that the 
enzymes required for the synthesis of GAG molecules are also present in the genome of Ae. 
aegypti (Altschul, Madden et al. 1997). To the best of our knowledge, the results described in 
this dissertation are the first available evidence that the increase of the GAG-binding affinity 
would likely favor the establishment of viral infection in arthropod vectors. The higher 
infectivity of YFV E T380R mutants is consistent with the characterization of the GAG-binding 
variant of MVEV in mammalian cells, which showed that the addition of positive charges in the 
FG loop of EDIII favors the virus intake (Lee and Lobigs 2008).  A knowledge gap  remains 
with respect to the identity of  which types of GAG molecules are responsible for the higher viral 
infectivity in Ae. aegypti.  Mosquito GAG molecules differ in chemical and structural properties 
in a  tissue-specific manner. It is noteworthy that a  relatively minor structural difference can 
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cause the difference in the binding between flavivirus virions and the GAG molecules. For 
example, the different sulphation patterns of chondroitin sulfate are  associated with the different 
inhibitory effect on JEV infection (Kim, Okumura et al. 2011). Additionally, as with  the 
argument proposed by Perera-Lecoin et al., the conclusive mechanistic evidence to demonstrate 
that  GAG molecules function in mosquitoes as viral receptors or as  attachment factors that 
enrich the local virion concentrations prior to the binding of viral receptors is still missing 
(Perera-Lecoin, Meertens et al. 2014).  
The establishment of arbovirus infection in mosquitoes takes place in the midgut. 
Therefore, the higher viral infectivity of YFV E T380R mutants might  be achieved by the higher 
binding affinity with the GAG molecules present on the apical surface of mosquito midgut 
epithelial cells, which is exposed to the viremic blood after the ingestion of the blood meal. The 
GAG molecules in the apical surface of midgut cells mainly consists of chondroitin sulfate, 
which is synthesized by the pathway with peptide-O-Xylosyltransferase in An. gambiae and Ae. 
aegypti (Altschul, Madden et al. 1997, Dinglasan, Alaganan et al. 2007). The interaction between 
flaviviruses and chondroitin sulfate has been found in DENV and JEV (Kato, Era et al. 2010, 
Kim, Okumura et al. 2011). It is highly likely that the higher  binding affinity of YFV E T380R 
mutant can arise from electrostatic interactions between the positively charged arginine in the FG 
loop and the negatively charge chondroitin sulfate.  One approach that could be employed to 
identify the specific GAG molecules responsible for viral entry into the midgut of Ae. aegypti 
would be  to use RNAi targeting to selectively knockdown specific genes that encode for  
expression of enzymes  involved in  GAG synthesis. Another significant gap in our knowledge is 
our understanding  of  how the differences in the quantities of YFV E T380R mutants and the 
wildtype viruses which entered the midgut epithelial cells, may influence infection   Since the 
efficiency of infection of arboviruses in mosquitoes is dose-dependent, the quantity of viruses 
that enters  susceptible midgut epithelial cells may  be a  critical factor to determine the infection 
rate of arboviruses (Gubler and Rosen 1976). It remains unclear as to whether or not the higher 
viral infectivity of the YFV E T380R mutants is mediated by the increase in the affinity with 
GAG molecules and subsequently the viral entry into the primary target cells in the midgut of Ae. 
aegypti. Alternatively, the higher-binding affinity between the GAG molecules and the YFV E 
T380R mutants could potentially result in a more efficient attachment to the epithelial cells and 
subsequently a higher number of infected cells than the wildtype controls.  
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 The other source of GAG molecules in the mosquito midgut lumen is the peritrophic 
matrix. The peritrophic matrix has been known to be secreted after the blood meal and abundant 
in the chintin proteins modified with GAG molecules. The chitins of the type I peritrophic matrix 
have previously been shown to be sequentially modified to the negatively charged β-(1,4)-N-
acetyl-D-glucosamine structure polymers (Hegedus, Erlandson et al. 2009). Unlike the malarial 
parasites, which secret chitnases to distrupt the physical barrier created by peritrophic matrix, the 
formation of the peritrophic matrix takes place after the arboviruses encounters the susceptible 
cells in the midgut. Therefore, the timing limits the likelihood of the GAG molecules in 
peritrophic matrix retaining the infectious virions in viremic blood.  The lack of the retention of 
YFV T380R mutants and 17D strains regardless of the increase electrostatic interactions with 
GAG molecules agreed with the earlier observation that the manipulation of the thickness of 
peritrophic matrix with RNAi mechanisms did not change the infectivity and dissemination of 
DENV-2 in Ae. aegypti (Kato, Mueller et al. 2008).  
The proteins on the basal surface of the mosquito midgut epithelial cells have been 
known to be frequently modified by the heparan sulfate molecules in Ae. aegypti and An. 
gambiae (Sinnis, Coppi et al. 2007). Under the hypothesis that viral escape and dissemination 
from the basal surface of the midgut epithelial cells takes place in the basal lamina followed by 
the subsequent infection of cells and tissues in the hemocoels, for example fat bodies, muscles 
and nerve tissues, the heparin sulfate on the basal surface of the midgut epithelial cells is unable 
to retain the progeny virions of YFV E T380R mutants in the vicinity of midgut. Subsequently, 
the YFV E T380R mutants disseminate into the secondary tissues. The similar dissemination 
rates between the wildtype and mutant viruses suggested the T380R mutation did not serve as a 
attenuation determinant that contribute to the lack of dissemination in Ae. aegypti infected by 
YFV 17D strains.  The observation for  Ae. aegypti is strikingly different from the observation in 
immunocompromised mice. In the study described by Lee et al., the progeny virions that were 
released into the vertebrate’s blood stream were efficiently removed by the binding with the 
GAG molecules in the extracellular matrix.  This process is conserved as the critical mechanism 
for viral attenuation as the progeny virions are readsorbed in the extraceullar matrix (Lee and 
Lobigs 2008). Clearly, the mechanism, which the increased affinity with the GAG molecules 
attenuates YFV, only contributes to the viral attenuation in vertebrate hosts but not in the 
mosquito vectors.  
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 C. Public health significance and potential application 
The results of the increased infectivity due to the T380R mutation can potentially create a  
concern that  the increase of the positive charge in the FG loop of YFV E protein may result in 
the viral transmission. However, the advantage created by the higher infectivity of the YFV E 
T380R mutants should not be considered as representing an attempt to increase the potential for 
the transmission of YFV 17D vaccine strains used in the field. The characterization of the 
mutation was performed in the context of the E protein encoding the sequence of the Asibi strain.  
The other mutations present in the structural genes of YFV 17D strains have also been 
characterized as the attenuation determinants and together ensure the significant reduction in the 
viral infection and dissemination (McElroy, Tsetsarkin et al. 2006). The chance of the 
simultaneous amino acid substitutions at multiple genetic loci for the reversion back to the 
virulent and infectious phenotypes is highly unlikely. In such an extremely unlikely scenario, the 
single T380R mutation have only been found to the increase in the viral infectivity without 
significantly enhance the disseminability, which is essential for the viral transmission in nature. 
Other evidence also indicates that vaccine viruses remain attenuated in the non-human primates 
in the presence of other amino acid substitutions in the nonstructural genes of YFV. The 
attenuated viruses have been known to cause the reduced viremia by greater than 1,00 fold 
compared to the virulent Asibi strain when 104 TCID50 of viruses were used in the challenge 
experiments (McGee, Lewis et al. 2008). Additionally, the viremic phase of YFV 17D strains has 
been characterized to be low in the quantities of virions and transient after the vaccination. The 
vaccination with YFV 17D vaccines only resulted in the transient and low-titer viremia below 
103 viral RNA copies per ml in humans (Miller, van der Most et al. 2008). The oral challenge of 
YFV 17D-204 strain in our experiments demonstrated low infectivity of the vaccine strains in 
spite of the high viral titers between 106 and 107 TCID50/ml. In such an unlikely event where the 
amino acid substitutions in the E protein undergo the significant reversions, the attenuated 
phenotype and the low viremic titers limit the chance of initiating further transmissions. 
Together, the other attenuation determinants may synergistically contribute to the attenuated 
phenotype in both vertebrate hosts and mosquitoes. 
The use of a threonine residue in the E protein FG loop of the 17D strains to limit the 
viral infectivity in mosquitoes is not a practical approach because the T380R mutation is likely to 
be the determinant for viral dissemination in vertebrate hosts. Our observation on YFV in Ae. 
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aegypti can potentially be applied towards the attenuation of JEV-serocomplex members. In 
comparison to other mosquito-borne flaviviruses, which share the elongated structure of the FG 
loops, the T380R mutation resulted in the formation of the RGD motif, which is present in the 
genomes of flaviviruses within the JEV serocomplex. The available sequences suggest the RGD 
motif is conserved between the virulent SA14 strain and other attenuated vaccine strains. The 
JEV 2-8 vaccine strain showed the lower infectivity and caused the lower percentage of 
dissemination in orally infected Cx. tritaeniorhynchus mosquitoes than the wildtype SA14 strain 
(Chen and Beaty 1982). Together with our observations, it is clear that the presence of the RGD 
motif, which has been previously characterize to increase the binding between the viruses and 
the GAG molecules of the hosts, has a limited impact for the infection and dissemination of 
flaviviruses in mosquitoes. This may also explain why the RGD motif and its similar sequences 
have been detected among the naturally isolated strains of other flaviviruses under the JEV 
serocomplex without compromising the transmission by mosquito vectors. It is also consistent 
with the observation that the length of the FG loop is more critical for the vector competence of 
Ae. aegypti in DENV-2 than the actual sequences. This may also be the plausible explanation 
that the sequences of the FG loops among all four serotypes of DENV are not strictly conserved 
(Erb, Butrapet et al. 2010). The sequences of the FG loops of the mosquito-only flaviviruses also 
suggested that the RGD motif is likely to be dispensable for the infection and the dissemination 
in mosquitoes. The alignment of at least six known mosquito-only flaviviruses that infect either 
Aedes or Culex mosquitoes did not identify strictly conserved or any similar sequences of the 
RGD motif (Cammisa-Parks, Cisar et al. 1992, Crabtree, Sang et al. 2003, Cook, Moureau et al. 
2009, Crabtree, Nga et al. 2009, Farfan-Ale, Lorono-Pino et al. 2009, Haddow, Guzman et al. 
2013).  Together, the dispensable role of the FG loop for the attenuation in mosquitoes allows the 
variations in the sequences and also agrees with the previously published study on SINV, which 
selectively mutated the region resembling the RGD motif  downstream of the PPFGDS sequence 
but did not result in the significant reduction in the infection of Ae. aegypti (Pierro, Powers et al. 
2008).  
However, by comparing the vector and host species in nature, the members of JEV 
serocomplex has been described to have a broader spectrum of competent vectors and 
susceptible vertebrate hosts. It is unclear if the RGD motif increases the host range of YFV. As 
demonstrated using the model of YFV 17D+/Asibi M-E chimera in Ae. aegypti, the RGD motif 
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increased the viral infectivity of YFV. It will be interesting to evaluate whether or not the 
mutation would result in the successfully infection of, and transmission by   less competent 
vectors or incompetent mosquito species in the laboratory. Future experiments that are designed 
to delineate the mechanisms should also focus on mutating the conserved RGD motif of EDIII 
among the flaviviruses under the JEV serocomplex to the sequences of the corresponding regions 
of other flaviviruses under the DENV and YFV serocomplexes. The experimental results will 
provide the knowledge in understanding the mechanisms that JEV-serocomplex members are 
able to infect multiple species of mosquitoes.  
Previous experimental evidence with the peptides with the RGD sequence has excluded 
the possibility that the RGD motif of the WNV mediates the integrin-dependent viral entry (Chu 
and Ng 2004). However, such observations did not exclude the potential increase of viral 
infectivity in the vertebrate hosts due to the presence of the RGD motif in EDIII. The members 
of the JEV serocomplex have been shown to infect multiple types of vertebrate hosts. This is 
especially true for JEV and WNV, which contain the conserved RGD or RGE sequences (Gould 
and Solomon 2008). Both viruses are able to establish the CNS infection after the intradermal 
challenge in immunocompetent rodent model such as the C57BL/6 and C3H/NeH mice, which 
are not considered as natural hosts of flaviviruses. Other flaviviruses under the DENV and YFV 
serocomplex, which do not contain the conserved RGD motif, are unable to establish the 
infection and cause comparable morbidity and mortality with the same route of challenge at the 
comparable concentration of inoculated viruses in the same model (Kimura, Sasaki et al. 2010). 
Furthermore, the mosquito-only flaviviruses, which are unable to infect any known vertebrate 
hosts, also showed the lack of the RGD motif in the corresponding region. With the history of 
passages in the non-natural chicken embryo host system, the T380R mutation may be the 
consequence of tissue adaptation due to the relative advantage in viral uptake in the non-natural 
vertebrate hosts of YFV. The mutation further caused the attenuation by the stronger affinity to 
the GAG molecules that ultimately led to the ideal phenotype of a live-attenuated vaccine. 
However, the mutation alone also unexpectedly favors the establishment of infection in Ae. 
aegypti by mehcanisms that still require further characterization. Therefore, it will be critical to 
identify other genetic mutations in the genome of YFV 17D strains which suppress the gain of 
the infectivity in mosquitoes due to the T380R mutation. 
113 
 
Chapter 4 - Characterization of Two Point Mutations in YFV EDI 
and EDII 
 4.1 Introduction 
McElroy et al. (2006a) demonstrated that the substitution of YFV 17D EDI and EDII into 
the full-length YFV Asibi genome resulted in a significant reduction of infection rates in Ae. 
aegypti at 14 d.p.i. The results therefore suggested that the presence of the determinants for the 
infectivity of YFV in Ae. aegypti in these domains (McElroy, Tsetsarkin et al. 2006).  A 
comparison of the amino acid sequences identified five mutations between the parental Asibi 
strain and the passaged 17D strains. (Table 4.1) For the current studies, two point mutations, 
G52R and T173I, were selected for the characterization. They were chosen due to the predicted 
locations in the three-dimensional structure, and their  association  with neurovirulent and 
attenuated phenotypes in mice (Hahn, Dalrymple et al. 1987, Gould and Buckley 1989, Rey, 
Heinz et al. 1995, Schlesinger, Chapman et al. 1996, Ryman, Xie et al. 1997, Kuhn, Zhang et al. 
2002). The details regarding the predicted locations of these mutations in the three-dimensional 
structures and the sequences in the corresponding regions of the other strains of YFV and other 
flaviviruses will be provided in section 4.1.A. The functional and the structural importance of 
flavivirus EDI and EDII have been shown to be related to structural rearrangement due the pH-
dependent conformational change that occurs during viral envelope fusion with the host cell 
membrane. The details of the structural rearrangement of flavivirus E proteins during fusion will 
be described in section 4.1.B. The information of the phenotypes associated with the G52R and 
T173I mutations in YFV E protein or the corresponding regions in the E proteins of other 
flaviviruses will be discussed in section 4.1.C and 4.1.D. 
Mutation (Asibi/17D) Location 
G52R EDI-EDII molecular hinge 
A56V A β-strand of EDII 
A170V G0 β-strand of EDI 
T173I G0H0 loop of EDI 
K200T FG loop of EDII 
Table 4.1 Amino acid mutations in EDI and EDII of 17D strains 
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There is evidence supporting the functional importance of the G52R and T173I mutations 
in determining the virulence of YFV and other flaviviruses in mice. However, the 
characterization of the two mutations in the Ae. aegypti mosquito vector has not yet been 
performed.(Schlesinger, Chapman et al. 1996, Ryman, Xie et al. 1997)  Characterization studies 
described in this chapter represent the first attempt to investigate the relationship between the 
G52R and T173I mutations in YFVE protein and viral phenotype in Ae. aegypti. The purpose of 
the studies was to provide mechanistic understanding that could assist in the rationale  
attenuation of arboviruses in mosquito vectors, based on the homology of the amino acid 
sequences and the conserved secondary structures among the E proteins of flaviviruses.   
A. Location and putative function 
The  two point mutations, G52R and T173I, are located in two separate positions in the  
YFV E protein. Although the crystal structure of YFV E protein has not been described, based on 
the homology of the amino acid sequences among flaviviruses, the G52R mutation is considered 
to be part of the molecular hinge structures between EDI and EDII. (Table 4.2) There are four 
molecular hinge peptides (designated as H1-H4) which exist as loosely packed structures in the 
junctions between EDI and EDII of flavivirus E proteins (Rey, Heinz et al. 1995, Modis, Ogata 
et al. 2004). The sequences of the four amino acids in the H1 region which harbors the G52R 
mutation of YFV 17D strain show a  high degree of variation in the first and second amino acid 
residues among flaviviruses.  Regardless of the virus serocomplex and vector type,   the last two 
amino acids of the hinge region, are characterized by having high hydrophobic sidechains. The 
third amino acid residue is predominantly composed of proline and leucine, although DENV-4 
utilizes valine. The fourth amino acid residue typically is the small hydrophobic alanine except 
for the use of proline or threonine in three flaviviruses (ENTV, SEPV, YOKV) that have not 
been isolated from arthropod vectors but are classified under the YFV serocomplex based on the 
genetic homology. 
 
Serocomplex Virus  strain Sequence of H1 peptide (E 51-54) 
YFV YFV Asibi DGPA 
YFV 17D DRPA 
ENTV UgIL-30 NGPP
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SEPV MK7148 DTPT
YOKV Oita36 NNPP
DENV DENV-1 Hawaii TNPA 
DENV-2 New Guinea C KQPA 
DENV-3 H87 TQLA 
DENV-4 H241 KEVA 
JEV JEV SA14 SQLA 
JEV SA14-14-2 SQLA 
WNV NY99 ANLA 
KNV MRM61C ANLA 
SLEV MS1-7 TELA 
MVEV MVE1-151 TNLA 
TBEV TBEV Neudoerfl ENPA 
OHFV Bogluvovska ENPA 
Table 4.2 Sequences of the molecular hinge H1 peptide between flavivirus EDI and EDII  
The hydrophobic amino acids are labeled by underline. 
Although the four molecular hinge peptides are often displayed as four distinct regions in 
the alignment of full-length E proteins, due to the discontinuous nature of the numbering of the 
residues of EDI and EDII, the peptides are consistently located in close proximity to the three-
dimensional structure of flavivirus E proteins. The location and overall structure of the molecular 
hinge region is displayed in the crystal structure of the DENV-2 E protein dimer as shown in 
Figure 4.1. The G52R mutation exists in the H1 molecular hinge between the β-strand D0 of EDI 
and β-strand a of EDII. The region has been hypothesized to accommodate the conformational 
change between EDI and EDII during viral membrane fusion. The detail mechanisms of viral 
membrane fusion and the crystal structure and functional characterization of four peptides in the 
molecular hinge will be discussed in section 4.1.B and 4.1.C. 
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Figure 4.1 The location of the molecular hinge region in the crystal structure of DENV-2 E 
protein dimer (PDB ID: 1OAN) 
The individual domains of DENV-2 E protein are coded in red for EDI, yellow for EDII 
and blue for EDIII. The four short peptides consist of the molecular hinge region are 
labeled in cyan. 
The G52R mutation is a conserved between the 17D-204 and 17DD substrains used for 
vaccine production. The H1 molecular hinge of the FNV strain showed conservatation of the 
mutation at the forth amino acid residue compared to the parental FVV. The sequence alignment 
of the YFV E proteins is summarized in table 4.3. 
Strain Sequence of H1 molecular hinge 
Asibi DGPA 
17D-204 DRPA 
17DD DRPA 
FVV DGPA 
FNV DGPV 
Table 4.3 Sequences of H1 molecular hinge region in YFV E proteins of the wildtype 
virulent strains and the attenuated vaccine strains 
The T173I mutation is located in the G0H0 loop structure between the G0 and H0 β-
strands of YFV EDI. The G0H0 loop structure is composed of the conserved “glycine-tyrosine-
glycine” tripeptidic sequences facilitating the turn of the polypeptide chain that contributes to the 
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formation of G0 and H0 β-strands observed in all flavivirus E proteins. The relative location of 
the G0H0 loop structure of flavivirus EDI is displayed in the crystal structure of DENV-2 E 
protein dimer in Figure 4.2.  
 
Figure 4.2 The relative location of the G0H0 loop in the crystal structure of DENV-2 E 
protein dimer (PDB ID: 1OAN) 
The three domains are labeled in red for EDI, yellow for EDII and blue for EDIII. The 
G0H0 loop structure is labeled in cyan. 
The flavivirus EDI serves as a structurally central domain which connects EDII and 
EDIII.  EDI contains two β-sheets that contributes to the formation of the overall β-barrel 
structure. The G0H0 loop is located between the neighboring antiparallel G0 and H0 β-strands as 
displayed in Figure4.3. With the additional B0 and I0 β-strands, the inner B0I0G0H0 β-sheet faces 
the viral membrane underneath the outer A0C0D0E0F0 β-sheet. The two β-sheet structures are 
stabilized by the interactions of the tightly packed hydrophobic interactions. 
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Figure 4.3 The relative location of the G0H0 loop structure in the crystal structure of 
DENV-2 E protein monomer (PDB ID: 1TG8) 
EDI is labeled in red with two neighboring domains, EDII in yellow and EDIII in blue. The 
β-barrel structure of DENV-2 EDI consists of two β-sheets structures. The B0I0G0H0 β-
sheet faces the viral membrane and contains the G0H0 loop labeled in cyan. Five β-strands 
form the A0C0D0E0F0 β-sheet forms as the external surface. 
The structurally central domain, EDI does not undergo extensive structure rearrangement 
during the fusion process. In addition to the presence of several B-cell epitopes that have been 
reported on the G0H0 loop in EDI of wildtype YFV and DENV, the YFV EDI is different from 
the DENV EDI due to the absence of the Asn67 glycosylation site  that has been characterized as 
the binding site of DC-SIGN (Gould, Buckley et al. 1989, Pokidysheva, Zhang et al. 2006, Lai, 
Goncalvez et al. 2007, Fibriansah, Tan et al. 2014). The details of the B-cell epitopes in the G0H0 
loop of EDI will be discussed in section 4.4. The sequences of the G0H0 loop in flavivirus EDI, 
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suggested that YFV uses amino acid residues that are largely conserved among other flaviviruses 
as summarized in table 4.4.  
Serocomplex Virus  Strain Sequence of G0H0 loop  
YFV YFV Asibi EAEFTGYGK 
YFV 17D EVEFIGYGK 
ENTV UgIL-30 VVVFTGYGT 
SEPV MK7148 TVTFTGYGN 
YOKV Oita36 VIGFAGYGT 
DENV DENV-1 Hawaii EIQLTDYGA 
DENV-2 New Guinea C EAELTGYGT 
DENV-3 H87 EAILPEYGT 
DENV-4 H241 EVKLPDYGE 
JEV JEV SA14 TLKLGDYGE 
JEV SA14-14-2 ALKLGDYGE 
WNV NY99 TLKLGEYGE 
KNV MRM61C TLKLGEYGE 
SLEV MS1-7 TANMGEYGT 
MVEV MVE1-151 TAKMGDYGE 
TBEV TBEV Neudoerfl ILTMGEYGD 
OHFV Bogluvovska ILTMGEYGD 
Table 4.4 Sequences of the G0H0 loops in EDI of flaviviruses 
The amino acid residues in the G0H0 loops are underlined based on the available three-
dimensional structures and the sequence homologies. 
The consistent use of glycine or proline as the amino acid residues in the flavivirus  G0H0 
loop structure follows the biochemical properties of the secondary turn structures (Lodish 2013). 
However, minor structural difference remains in flaviviruses in YFV serocomplex, DENV-1 and 
DENV-2. The G0H0 loops of YFV-serocomplex flaviviruses, DENV-1, DENV-2 and DENV-3 
are consistently shorter than the loops of members of the JEV and TBEV serocomplexes. The 
elongated structure of JEV- and TBEV-serocomplex flaviviruses is due to the insertion of an 
aspartate or glutamate residue following the first turn made by the glycine residue, and an 
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aspartate or glutamate residue prior to the H0 β-strand. The comparison was made utilizing the 
available crystal structures of DENV-2, DENV-3, JEV and TBEV E proteins. (Fig. 4.4) 
 
Figure 4.4 The G0H0 loop structure in flavivirus EDI 
EDI of four different flaviviruses are displayed in (a) DENV-2 (PDB ID: 1TG8), (b) DENV-
3 (PDB ID: 1UZG), (c) JEV (PDB ID: 3P54), and (d) TBEV (PDB ID: 1SVB). The G0H0 
loop structure is labeled in cyan with residues from EDI in red, EDII in yellow and EDIII 
in blue. 
The T173I mutation is a conserved mutation between the 17D-204 and 17DD vaccine 
substrains. As the wildtype YFV-specific B-cell epitope, the threonine residue is conserved 
among natural isolates of YFV. The plaque purification of the 17D-204 substrain demonstrated 
maintenance of a minor viral population  that use  a threonine residue in the G0H0 loop structure. 
This  was recognized by the wildtype-specific mAb 117 (Gould, Buckley et al. 1989). The details 
regarding to the phenotype of the mAb 117-reactive variants in vivo will be discussed in section 
4.1.D.  
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 B. Viral membrane fusion mediated by flavivirus E proteins 
The pH-dependent energy-driven fusion between the viral envelope and host membranes 
allows the release of the genetic materials of enveloped viruses into the host cellular 
compartment (Helenius, Kartenbeck et al. 1980). Based on  structural characteristics, there  are 
three distinct mechanisms of pH-dependent viral membrane fusion (Knipe and Howley 2013). 
The conformational changes in each class of the fusion proteins are listed in figure 4.5 and 
reviewed by Harrison et al (Harrison 2008). The E proteins of flaviviruses and the E1 
glycoproteins of alphaviruses are considered as class II fusion proteins which undergo dimer-to-
trimer structural rearrangement during the process of viral membrane fusion. The details of the 
conformational change will be described in the following paragraph. The family of class I fusion 
proteins is exemplified by the hemagglutinin (HA) protein of influenza virus and the gp41 
protein of human immunodeficiency virus type 1 (HIV-1). Class I fusion proteins consist of 
mostly α-helical structures and they maintain the trimeric conformation before and after t fusion. 
The protonation-initiated structure rearrangement is followed by the insertion of the fusion 
peptide into the host membrane and then the refolding of the trimeric structure to produce a 
stable rod-like conformation. The only available structural information is derived from the 
crystal structures of the pre- and post-fusion conformations of vesicular stomatitis virus (VSV) G 
protein. Class III fusion proteins retain the trimeric conformation throughout the fusion process. 
The acidic environment results in the extended intermediate structure and the insertion of the 
fusion peptide. Finally, the carboxy-terminal segment folds back towards the fusion peptide to 
create the post-fusion conformation. 
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Figure 4.5 Viral membrane fusion process (modified from Harrison et al. 2008) 
The pre-fusion and post-fusion conformational changes are displayed at the left and right 
of each figure with the extended intermediate structure in the middle. (a) The influenza 
virus HA protein is used as an example of class I fusion protein. Each color represent a 
monomer of the HA protein. The receptor binding region is located at the tip of the 
individual monomer. The protonation leads to the dissociation of the HA1 subunit and the 
insertion of the fusion peptide into the host membrane. The carboxyl terminus folds back 
on the outside of the trimer. (b) The class II fusion protein is arranged in the dimeric 
conformation on the surface of virion as the flavivirus displayed in the figure. The acidic 
environment triggers the outward movement of EDI (red) and EDII (yellow) followed by 
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the insertion of the fusion peptide into the host membrane. The trimmers were formed by 
the physical association among three monomers and stabilized by the fold back of EDIII 
(blue) to form the post-fusion conformation. (c) VSV G protein is used as an example for 
class III fusion proteins. The fusion peptide is packed to face viral membrane in the pre-
fusion conformation. Each color is used to label each monomer of the trimeric structure. 
The insertion of the fusion peptide is induced by the exposure to the acidic environment. 
The carboxyl terminus folds back towards the fusion peptide to form the post-fusion 
conformation. 
The release of the positive-sense genomes of flaviviruses requires fusion between viral 
envelope and host membranes.  All flavivirus E proteins are classified as class II fusion protein 
and share the β-strand structures  that are characteristic  of other class II fusion proteins (Modis, 
Ogata et al. 2004, Zhang, Zhang et al. 2004, Roussel, Lescar et al. 2006). The E protein dimers 
are stabilized by the interactions between two neighboring EDIIs and converted to the trimeric 
structure in the fusion.  (Figure 4.5) The conformational change from the dimeric structure to the 
trimeric structure has been  confirmed by the observation that soluble monomers of DENV-2 E 
protein were associated into the trimeric structures and inserted into the membrane of liposomes 
with an  acidic environment (Modis, Ogata et al. 2004). The insertion of the fusion peptide was 
achieved by the extended intermediate structure, followed by molecular interactions between the 
EDII of each of the monomers. The E protein trimer is stabilized by molecular interactions at the 
tip and the base of EDII, and the foldback of EDIII. At the base of the post-fusion trimer, the 
interaction between EDI and EDIII further stabilizes its structure (Modis, Ogata et al. 2004). The 
fused viral and host membranes form the fusion pore which is the channel for release of viral 
genetic material. As shown in the Figure 4.6, using the available DENV-2 E protein crystal 
structure as a model, the acidic environment in the endosomes triggers the destabilization of the 
structure and the conformational changes by the protonation of conserved four histidine residues, 
which are His144, His244, His282, and His317, among all the known flaviviruses. The His244 and 
His282 are located in the junction between EDI and EDII. The His144 and His317 are located 
between EDI and EDIII (Stiasny, Fritz et al. 2011). It is still unclear if the protonation process is 
completed simultaneously or initiated at specific residues in a sequential order. 
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Figure 4.6 The conserved histidine residues subjected to protonation in the DENV-2 E 
protein (PDB: 10AN) 
The four conserved histidine residues are showed in the green sphere structure. The His244 
and His282 residues are located in the interface between EDI (red) and EDII (yellow). The 
His144 and His317 residues are located in the junction between EDI (red) and EDIII (blue). 
The destabilized structure results in the relative rotations of EDII and EDIII towards the 
structurally central domain. The available crystal structures of the pre- and post-fusion 
monomers of DENV-2 E protein are used as examples to illustrate the conformational change of 
the flavivirus E protein in Figure 4.7. The first step of the conformational change is a 30˚ 
rotation of EDII with respect to EDI (Modis, Ogata et al. 2004, Zhang, Zhang et al. 2004). The 
movement is tolerated because of the stability created by the hydrophobic properties of the 
amino acids in the molecular hinge region at the interface between EDI and EDII (Modis, Ogata 
et al. 2004, Luca, Nelson et al. 2013). The relative location between EDI and EDII at the post-
fusion state is further stabilized by the hydrogen bonds created between the D0 β-strand of EDI 
and the l β-strand of EDII (Modis, Ogata et al. 2004). The refolding of the EDIII is the 
consequence of the displacement created by the 70˚ degree rotation with respect to EDII and its 
original location. The displacement reduces the distance between the center of mass of EDIII and 
EDII to 36Å by the distortion of the linear structure between EDI and EDIII (Modis, Ogata et al. 
2004).  
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Figure 4.7 Pre- and post-fusion conformation of DENV-2 E protein monomer (PDB ID: (a) 
1TG8 and (b) 10K8) 
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EDI, EDII and EDIII are labeled in red, yellow, and blue, respectively. The molecular 
hinge region and the fusion peptide are highlighted in the ovals. (a) the pre-fusion 
conformation of DENV-2 E protein monomer at physiological pH (b) the post-fusion 
conformation of DENV-2 E protein monomer The relative locations of EDII and EDIII are 
altered with respect to EDI. The EDII undergoes the 30˚ rotation which disrupted the kl 
hairpin structure to form the hydrogen bonds between the neighboring D0 β-strand of EDI 
and l β-strand in EDII. The refolding of EDIII results in the shorter distance between EDII 
and EDIII and the elongated structure of the linear structure between EDI and EDIII. 
The conformational change of flavivirus E proteins during viral membrane fusion has 
implicated that, because of their location in the three-dimensional structure,   at least two point 
mutations in YFV 17D strains may result in a phenotypic change. The G52R mutation in the 
molecular hinge region between EDI and EDII is considered as a non-conservative mutation due 
to the modification of the sidechain by the increase of the positive charge. The phenotypes of 
YFV and flavivirus mutants related to the amino acid substitutions in the molecular hinge region 
will be discussed in section 4.1.C. The characterization of the M299I mutation in the linear 
structure between EDI and EDIII will be described in chapter 5.  
 C. Molecular hinge region of flavivirus E protein 
The molecular hinge region (H1-H4) of flavivirus E proteins is composed of four 
peptides at the interface between EDI and EDII. Although the four peptides are located in the 
distinct locations in the full-length sequences, due to the discontinuous nature of EDI and EDII, 
the H1-H4 peptides are located in close proximity to the interface between EDI and EDII. The 
G52R mutation in the H1 peptide has been described in section 4.1.A and the sequence 
homology of H1 peptides among flaviviruses has been summarized in table 4.2. The sequences 
of H2, H3 and H4 of flaviviruses are listed in table 4.5, 4.6 and 4.7, respectively. 
The second peptide, H2, exists between the E0 β-strand of EDI and e β-strand of EDII. 
The sequences of H2 peptide among flaviviruses show conserved hydrophobicity at both ends of 
the peptides because hydrophobic amino acids present at the amino-terminus and carboxy-
terminus. The amino-terminus of the H2 peptide of different mosquito-borne flaviviruses shares 
the use of hydrophobic amino acids. YFV and DENV use valine as the first residue. The 
flaviviruses under the JEV serocomplex and other flaviviruses under the YFV serocomplex with 
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no known vectors utilize isoleucine as the first residue. The last residue of the H2 peptide is also 
composed of the hydrophobic isoleucine or leucine. For WNV, KUNV, MVEV and SLEV, the 
third residue still remain hydrophobic due to the consistent presence of leucine.  
Serocomplex Virus  Strain Sequence of H2 peptide (E 130-135) 
YFV YFV Asibi VDQTKI 
YFV 17D VDQTKI 
ENTV UgIL-30 IGQDKV
SEPV MK7148 IDSTKI
YOKV Oita36 IDQNKI
DENV DENV-1 Hawaii VQYENL 
DENV-2 New Guinea C VQPENL 
DENV-3 H87 VQHENL 
DENV-4 H241 VQIENL 
JEV JEV SA14 IQPENI 
JEV SA14-14-2 IQPENI 
WNV NY99 ILKENI 
KNV MRM61C ILKENI 
SLEV MS1-7 ILRENI 
MVEV MVE1-151 ILPEDI 
TBEV TBEV Neudoerfl YDANKI 
OHFV Bogluvovska YDANKI 
Table 4.5 Sequences of the molecular hinge H2 peptide between flavivirus EDI and EDII 
The hydrophobic amino acids are labeled by underline. 
For  the H3 peptide of YFV E protein,  hydrophobic amino acids are present in the Val184, 
Ala187, Val188 and Phe190. In the corresponding region of the YFV E Val184 residue, the use of 
hydrophobic amino acids is conserved by the presence of proline in other mosquito-borne 
flaviviruses and valine in tick-borne flaviviruses. The biochemical property of the Val188 residue 
in YFV E protein is also maintained in tick-borne flaviviruses or in other flaviviruses by the use 
of leucine or isoleucine in other mosquito-borne flaviviruses. The hydrophobicity of the E Phe190 
residue in YFV is also conserved in the DENV or TBEV serocomplex by the conserved 
sequence of phenylalanine or the substitution with leucine, respectively. The carboxy terminus of 
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the H3 peptide in the E proteins of DENV- and JEV-serocomplex flaviviruses also contains the 
hydrophobic amino acids. 
Serocomplex Virus  Strain Sequence of H3 peptide (E 183-193) 
YFV YFV Asibi QVQTAVDFGNS 
YFV 17D QVQTAVDFGNS 
ENTV UgIL-30 NLKTTMDLGNY
SEPV MK7148 HVQMMVDLGNS
YOKV Oita36 NLKTSMDLNNY
DENV DENV-1 Hawaii SPRTGLDFNEM 
DENV-2 New Guinea C SPRTGLDFNEM 
DENV-3 H87 SPRTGLDFNEM 
DENV-4 H241 EPRSGIDFNEM 
JEV JEV SA14 EPRSGLNTEAF 
JEV SA14-14-2 EPRSGLNTEAF 
WNV NY99 EPRSGIDTNAY 
KNV MRM61C EPRSGIDTSAY 
SLEV MS1-7 EARSGINTEDY 
MVEV MVE1-151 EPRSGLNTEAY 
TBEV TBEV Neudoerfl RVASGVDLAQT 
OHFV Bogluvovska RVASGVDLAQT 
Table 4.6 Sequences of the molecular hinge H3 peptide between flavivirus EDI and EDII 
The hydrophobic amino acids are labeled by underline. 
The fourth hydrophobic H4 peptide in the molecular hinge region shows the greatest 
sequence and structure diversity. The H4 molecular hinge of YFV E protein is invariantly longer 
than other flaviviruses due to the presence of four amino acids between Asn268 and Asn271. 
However, the distribution of the hydrophobic amino acids shows clustering at both amino and 
carboxy termini of the H4 peptide. The first cluster consists of Ala261, Met262, and Val264 in YFV. 
The corresponding region of Ala261 is conserved among all flaviviruses except for TBEV, which 
contains a valine substitution. The Met262 also shows the conserved biochemical properties in the 
flaviviruses within the JEV- and TBEV-serocomplex by the use of isoleucine and proline 
respectively. The hydrophobic Val264 in YFV is conserved in JEV serocomplex and shares the 
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similar biochemical properties with the isoleucine and alanine in DENV- and TBEV 
serocomplex respectively. The second cluster of the hydrophobic amino acids shows the greater 
diversity by the use of two or three hydrophobic amino acids in different serocomplexes. YFV E 
protein contains three hydrophobic residues Leu273, Tyr274 and Leu276 with the positively charged 
Lys275. The Leu273 is conserved by the use of leucine or valine in JEV serocomplex and tyrosine 
in TBEV serocomplex. The Leu276 is identified as the conserved residue in the corresponding 
region of JEV- and TBEV-serocomplex flaviviruses. In the DENV serocomplex, three 
hydrophobic amino acids are located together at the corresponding region between the Leu277 
and Phe279 in DENV-2. At the carboxy terminus, all the flaviviruses share the use of hydrophobic 
valine or leucine at the corresponding position of Val281 in YFV E protein. 
Serocomplex Virus  Strain Sequence of H3 peptide (E 259-281) 
YFV YFV Asibi TGAMRVTKDTNDNNLYKLHGGHV 
YFV 17D TGAMRVTKDTNDNNLYKLHGGHV 
ENTV UgIL-30 SGATRLQLSSGK---NVLKGGHA
SEPV MK7148 SGAMVVEVSSNR---YTLKGGHV
YOKV Oita36 VGATKISYSENK---YHIKGGHA
DENV DENV-1 Hawaii TGATEIQTSG----TTKIFAGHL 
DENV-2 New Guinea C TGATEIQMSS----GNLLFTGHL 
DENV-3 H87 TGATEIQTSG----GTSIFAGHL 
DENV-4 H241 TGATEVDSGD----GNHMFAGHL 
JEV JEV SA14 AGAIVVEYSS----SVKLTSGHL 
JEV SA14-14-2 AGAIVVEYSS----SVMLTSGHL 
WNV NY99 AGAIPVEFSSN---TVKLTSGHL  
KNV MRM61C AGAIPVEFSSN---TVKLTSGHL  
SLEV MS1-7 AGAIPATVSSS---TLTLQSGHL  
MVEV MVE1-151 AGAIPVEFSSS---TLKLTSGHL  
TBEV TBEV Neudoerfl AGVPVAHIEG---TKYHLKSGHV 
OHFV Bogluvovska AGAPLAHIEG---TKYHLKSGHV 
Table 4.7 Sequences of the molecular hinge H4 peptide between flavivirus EDI and EDII 
The hydrophobic amino acids are labeled by underline. 
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In conclusion, the molecular hinge region of different viruses displays sequence 
variations but contains conserved hydrophobic amino acids at specific locations in four different 
peptides. The  biochemical properties and sequence homologies contributes to the loosely packed 
structure of the peptides, which not only accommodates the pH-dependent conformational 
change but also the sequence variation (Modis, Ogata et al. 2004).  Mutations reported in the 
molecular regions of various flaviviruses are primarily associated with changes in the threshold 
of optimal fusion pH (Lee, Weir et al. 1997, Modis, Ogata et al. 2003). The importance of such 
regions in disease pathogenesis in mice and the replication of virus in mosquitoes has been 
demonstrated in YFV, JEV, DENV-2 and MVEV (Schlesinger, Chapman et al. 1996, 
Hurrelbrink and McMinn 2001, Monath, Arroyo et al. 2002, Butrapet, Childers et al. 2011).  
The G52R mutation is a conserved substitution in both of the attenuated 17D-204 and 
17DD vaccine substrains (Stock, Boschetti et al. 2012). The R52G reversion was discovered in 
the neurovirulent YFV Porterfield strain variant. This neurovirulent Porterfield strain was 
derived from the serial passage of YFV 17D in the brain of sucking mice. The genetic and 
phenotypic characterization demonstrated that the YFV Porterfield strain, replicated to consistent 
higher viral titers in the central nervous system. It contained two mutations that resulted in the 
R52G and T173I reversions resembling the E protein sequence of the virulent Asibi strain 
(Schlesinger, Chapman et al. 1996). The chimerization of the genetic materials by introducing 
the R52R, I173T, F305V, and I462M mutations in the E protein, the L228Q and S239G 
mutations in the NS1 protein and the M17L and F79L mutations in the NS2A protein to the 
genome of the genome of YFV 17D strain increased the neurovirulence of YFV 17D strain in 
CD1 mice (Schlesinger, Chapman et al. 1996). The results suggested that the mutations at 
multiple genetic loci in the E, NS1 and NS2A protein were able to increase the virulence of YFV 
17D strain.  However, whether the R52G reversion in the H1 region of YFV E protein alone is 
able to increase the virulence remains unclear. 
  The functional characterization of the molecular hinge region of MVEV E protein was 
performed by introducing the mutations into the H4 peptide by the selection of neutralization 
escape mutants and  mutants generated by the reverse genetics system (McMinn, Lee et al. 1995, 
Hurrelbrink and McMinn 2001). The MVEV neutralization escape mutants of mAb 4B6C-2 
demonstrated that the H4 peptide within the molecular hinge region in the E protein contains the 
MVEV-specific neutralization epitope for mAb 4B6C-2. The two selected neutralization escape 
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mutants, BHv1 and BHv2, contain the S277I and S277N mutations, respectively. Whilst both 
mutants were only neutralized in the presence of concentrated mAb 4B6C-2 and showed the high 
neurovirulence in outbred Swiss mice, the significant reduction of neuroinvasiveness only 
occurred in the non-conservative S277I mutant (Hurrelbrink and McMinn 2001).  
Characterization of the escape mutants was further performed using the reverse genetics system 
of MVEV. The neutral Ser277 residue was substituted with the hydrophobic amino acids, 
isoleucine and valine, or the hydrophilic amino acid, proline. The other mutant was generated by 
conservative substitution with asparagine. The S277I mutation was able to reproduce the 
phenotype associated with the low neuroinvasiveness observed in the neutralization escape 
S277I mutant. The conclusion of the studies provided the first evidence that the molecular hinge 
region can simultaneously serve as both a component of the conformational B-cell epitope and a 
determinant of neurovirulence. Unfortunately, the mutant was not further characterized for the 
infection and dissemination in mosquitoes. 
For JEV, the H4 molecular hinge contains the virulence determinant that was identified in 
the passaged chimeric YFV/JEV vaccine candidate (ChimeriVax-JE) in fetal rhesus lung cells 
(Monath, Arroyo et al. 2002). The single M279K reversion in the H4 peptide to the sequence of 
the wildtype E protein was associated with an increase of neurovirulence in mice. In contrast to 
the increase in neurovirulence, the viscerotropism of the virus was further reduced resembling 
the serially passaged YFV in vitro (Theiler and Smith 1937, Barrett, Monath et al. 1990).  
The serial passage of DENV-3 in mouse brain led to A54E and F277S mutations in the 
H1 and H4 peptide, respectively. By performing the fusion-from-within (FFW) assay in C6/36 
cells, the mutants with the amino acids substitutions in the H1 and H4 peptides showed a 
requirement for higher activation energy. This is explained  by the decrease of the optimal pH for 
fusion because  the viral membrane fusion process is driven by the energy provided by the 
acidification of the late endosome (Chernomordik and Kozlov 2003, Harrison 2008). The 
optimal pH for fusion of the A54E mutant decreased by 0.2. The F277S mutation further resulted 
in the decrease of the optimal pH for fusion by 0.7 (Lee, Weir et al. 1997).  
The H1-H4 peptides of the molecular hinge region in DENV-2 E protein have also  been 
tested using a  the reverse genetics system (Butrapet, Childers et al. 2011).  Mutations were 
introduced to all four peptides. The recovery of mutants was first performed on Vero cells and  
mutants that were lethal in Vero cells were recovered by passage in C6/36 cells. The non-
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conservative substitutions in the H1 and H3 peptides led to the production of mutants in Vero 
cells except for the introduction of the F193R mutation which resulted in mixed population of 
the F193L and F193R mutants. Two non-conservative mutations, G52R and A54E identified in 
YFV 17D strain and the serially passaged DENV-3, respectively, in the H1 peptide led to a 
minor reduction in the peak viral titer in C6/36 cells. The higher optimal pH for the FFW assay 
suggested that the energy required for the viral membrane fusion is lower in both mutants. The 
G190F, G190W and F193A mutations in the H3 peptide showed comparable peaked viral titers 
in C6/36 cells; whereas the non-conservative F193R mutation rescued from C6/36 cells had a 
lower peaked titer in C6/36 cells. The non-conservative mutations in the H2 and H4 peptides 
were lethal and precluded recovery of the mutants in Vero cells, although electroporation into 
C6/36 cells enabled recovery of the F279A and T280Y mutants. The L135W, L135G and L135K 
mutations in the H2 peptide led to the lower peaked viral titer in C6/36 cells and the significantly 
lower infection rates in intrathoracically inoculated Ae. aegypti mosquitoes. Furthermore, the 
L135G mutation abolished the viral fusogenic capacity. The F279A and T280Y mutations 
resulted in a minor reduction of peak viral titer in C6/36 cells and the comparable optimal pH for 
the fusogenic activity. With respect to vector infectivity, the results obtained for DENV-2 
provide a partial understanding of the importance of the molecular hinge region of the flavivirus 
E proteins.  Viral infectivity can potentially be impaired by the single non-conservative mutation 
in the molecular hinge region. However, the evidence was derived from the L135G mutation in 
the DENV-2 H2 peptide, and this mutation does not exist in the YFV 17D strain.  The DENV-2 
G52R mutation that resembles  the mutation in the envelope protein of YFV 17D strains showed 
no demonstrable difference in the peaked viral titers and the activation energy required for viral 
membrane fusion. Whether the G52R mutation of DENV-2 impairs the viral infectivity in Ae. 
aegypti remains unclear. 
In summary, the molecular hinge has been repeatedly demonstrated to control the 
neurovirulence or neuroinvasiveness of flaviviruses in mice.  Mutations in the molecular hinge 
region generated by the serial passage of YFV and JEV were identified as attenuation 
determinants for neurovirulence although the mutations are located in the H1 and H4 peptides, 
respectively (Schlesinger, Chapman et al. 1996, Monath, Arroyo et al. 2002). It has been shown 
that the fusogenic capacity can be altered due to the mutations in the molecular hinge region in 
DENV-2 and DENV-3. These observations support  the structural evidence that the molecular 
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hinge region accommodates a  conformational change required for viral membrane fusion of 
flaviviruses (Lee, Weir et al. 1997, Butrapet, Childers et al. 2011). It is still unclear whether or 
not the mutations in the molecular hinge region can lead to the attenuation of flaviviruses in 
orally infected arthropod vectors. We propose that  the characterization of the G52R mutation in 
the E  protein of YFV 17D strains by the oral infection of the mutant viruses may  provide the 
mechanistic knowledge for the viral attenuation created by the mutations in the molecular hinge 
region. 
 D. The T173I mutation as the YFV wildtype-specific epitope 
Monoclonal antibodies were originally used to detect and characterize  the variants of 
vaccine seed viruses among the 17D strains and the FNV strain (Buckley and Gould 1985, Gould, 
Buckley et al. 1985).  The mAb117 was first found reactive to wildtype YFV and subsequently 
mapped to recognize the epitope containing the Thr173 residue (Gould, Buckley et al. 1989, 
Ryman, Ledger et al. 1998). This  epitope is conserved across all genotypes of naturally isolated 
YFV, and the reported acquisition of the wildtype-specific epitope by the 17D(+wt) variant was 
associated with the loss of the antigenic structure specifically recognized by vaccine-specific 
mAbs (Gould, Buckley et al. 1989). Indirect immunofluorescence staining with the wildtype 
YFV-specific mAb 117 on the Vero cells infected by the 17D-204 strain demonstrated the 
presence of a minor viral population that contains the wildtype-specific epitope. The plaque 
purification of the 17D-204 strain resulted in the isolation of  at least eight variants and 
demonstrated that a variant virus, later designated as 17D(+wt), contained the epitope recognized 
by mAb117, and had lost the epitope recognized by the vaccine-specific mAb411 (Gould, 
Buckley et al. 1989). The characterization of the eight YFV variants by the intracerebral 
challenge of newborn and weanling mice further identified the 17D(-wt) variant, which was 
found to be avirulent despite  producing  the highest viral yield in the brain homogenates up to 
10 d.p.i. (Gould, Buckley et al. 1989).  
 Intracerebral challenge by  17D(+wt) in various outbred and inbred mouse models as 
summarized in table 4.8, demonstrated  that the attenuated phenotype of the 17D(+wt) variant 
was maintained despite  the presence of the wildtype-specific epitope (Ryman, Xie et al. 1997, 
Ryman, Ledger et al. 1998). Intracerebral challenge of the outbred or inbred mice with the 17D-
204 strain resulted in a nearly 100% mortality rate in six mouse model systems tested. The 
134 
 
plaque-purified variant 17D(+wt) showed  attenuation resulting in 85.0% mortality rate in the 
outbred TO mice, and 0% mortality in the inbred Balb/C mice although there was 100.0% 
mortality in four other mouse strain models. In contrast, the 17D(-wt) variant was demonstrated 
to have the significant attenuation and led to  17.7% and 0% mortality rate in the TO and Balb/C 
mice, respectively. 
 17D-204-UK 17D(+wt) 17D(-wt) 
T0 10/10 (100.0%) 17/20 (85.0%) 8/45 (17.7%) 
NIH Swiss 20/20 (100.0%) 10/10 (100.0%) 2/45 (4.4%) 
C3H 8/8 (100.0%) 8/8 (100.0%) 12/18 (66.7%) 
DBA/2 18/18 (100.0%) Not tested 8/17 (17.0%) 
C57BL/6 10/10 (100.0%) 10/10 (100.0%) 9/10 (90.0%) 
Balb/C 26/27 (96.3%) 0/7 (0.0%) 0/16 (0.0%) 
 
Table 4.8 Mortality of mice intracerebrally challenged with the 17D-204 strain and its 
variants derived from Ryman et al. (1997) 
The nucleotide sequencing of the prM and E gene identified two genetic mutations 
among the 17D-204 substrains and two variants listed in table 4.9. The 17D(+wt) and 17D(-wt) 
share the A240V mutation from the 17D-204 substrains, 17D-204-UK and 17D-204-WHO. This 
mutation attenuated the 17D(+wt) and 17D(-wt) and did not caused the 100% mortality as seen 
with the two 17D-204 substrains that have the consensus sequence of the Ala240 residue in the E 
protein. The Thr173 and Ile173 residues in the E protein of the 17D(+wt) and 17D(-wt) variants 
distinguished by the binding of mAb 117 in two different subpopulations in the 17D-204 strain. 
The presence of the wild-type YFV-specific epitope by the reversion of the isoleucine residue to 
threonine in the E protein of 17D(+wt) led to increased neurovirulence in intracerebrally 
challenged adult mice (Ryman, Ledger et al. 1998).  
Strains Mortality rate in intracerebrally challenged mice E-153 E-173 E240 
17D-204-UK 10/10 (100.0%) N I A 
17D-204-WHO 8/8 (100.0%) T I A 
17D(+wt) 17/20 (85.0%) N T V 
17D(-wt) 8/45 (17.7%) N I V 
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Table 4.9 The neurovirulence and the genetic mutations distinguish YFV17D-204 
substrains and the variants modified from Ryman et al. (1998) 
The intracerebral challenge was performed in adult outbred mice intracerebrally 
challenged with 104 plaque forming unit. (P.F.U.) The amino acid substitutions were 
observes at the residues 153, 173 and 240 in the E protein of the 17D-204 substrains and 
variants. 
In summary, the binding of mAb117 is specific to the E proteins of wildtype YFV and 
the variant of the 17D-204 substrain with the I173T reversion in the E protein. The I173T 
reversion enhanced the neurovirulence, suggesting that the T173I mutation is likely to be an 
attenuation determinant. The mechanism distinguishing the neurovirulence in mice between the 
17D(+wt) and 17D(-wt) remains unclear. 
The antigenicity of the corresponding G0H0 loop structure of EDI containing the T173I 
mutation has also been observed in at least three other flaviviruses, TBEV, DENV-1 and DENV-
4. By selecting the variant of TBEV in the presence of mAb i2, the K171E mutation was 
identified in the variant Vi2 and confirmed as a B-cell epitope for TBEV in mice (Heinz, Berger 
et al. 1983, Mandl, Guirakhoo et al. 1989). The fusion-from-without assay performed with mAb 
i2 (50μg/ml) and TBEV Neudoerfl strain in C6/36 cells demonstrated that the binding of the 
mAb i2 completely abolished the fusion activity at the step of viral entry. The optimal pH for the 
fusogenic activity of the  TBEV Vi2 variant was significantly lower than that for the wildtype 
TBEV Neudoerfl strain, thereby indicating that the K173E mutation results  in the requirement 
for higher energy for viral membrane fusion (Guirakhoo, Heinz et al. 1991). The epitope 
mapping of  a chimpanzee anti-DENV-4 mAb also suggested that the G0H0 loop of EDI is part of 
the interdomain conformational epitope (Lai, Goncalvez et al. 2007). Recently, the G0H0 loop of 
EDI was also demonstrated to be recognized by a DENV-1-specific human mAb 1F4. The Thr176 
residue in the G0H0 loop region was recognized by the complementarity-determining regions of 
the heavy chain in mAb (Fibriansah, Tan et al. 2014).  
In conclusion, the current understanding in the G0H0 loop structure is derived from 
studies with variants of flaviviruses that demonstrate the different binding affinities with mAb.  
B-cell epitopes have been repeatedly identified within the G0H0 loop structure of the E proteins 
among YFV, TBEV, DENV-1 and DENV-4. For YFV 17D strain,  the T173I mutation was 
identified as an attenuation determinant leading to the low neurovirulence phenotype in mice 
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(Ryman, Ledger et al. 1998). The putative function of the region may be related to the fusogenic 
activity of the flavivirus E proteins in the process of viral membrane fusion during viral entry. 
The fusion-from-without experiments in C6/36 cells with a TBEV E K171E mutation provided 
an understanding of the function of the G0H0 loop in flavivirus E proteins (Guirakhoo, Heinz et 
al. 1991). The actual functional importance of the T173I mutation in the E protein of YFV 17D 
strain for the viral infection and dissemination in Ae. aegypti still remains unknown. 
 4.2 Results 
Clearly, the G52R mutation in the molecular hinge between EDI-EDII and the T173I 
mutation in EDI have been extensively tested in vitro and in mice. In spite of the experimental 
evidence that suggests the functional importance of both regions in the E protein of YFV and 
other flaviviruses, it is still unclear how the G52R and T173I mutations might lead to the 
phenotypic changes of YFV in orally infected Ae. aegypti. The characterization of the mutations 
was first performed by introducing single G52R or T173I mutations into the Asibi strain and the 
17D+Asibi M-E chimera. This approach was used to assess the attenuation associated with the 
single mutations in the E protein alone, and the attenuation caused by the single mutations in the 
E protein and the attenuation determinants in the nonstructural proteins, respectively. The YFV E 
G52R-T173I double mutants were also characterized.  
 A. Infection and dissemination of YFV E G52R mutants 
The YFV 17D E protein G52R mutation was introduced into the cDNA infectious clone 
of the Asibi strain and the 17D/Asibi M-E chimera to evaluate the role of the G52R mutation   as 
an attenuation determinant. The infection and dissemination rates of the YFV wildtype controls 
and E G52R mutants at 7, 10 and 14 d.p.i. are summarized in Table 4.10 and 4.11, respectively. 
Viremic blood meal  
(titer in logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
Mock (N.A.) 0/24 (0.0%) 0/18 (0.0%) 0/24 (0.0%) 
17D (4.24) 9/24 (37.5%) 3/6 (50.0%) 4/16 (25.0%) 
17D+Asibi M-E (7.02) 16/20 (80.0%) 4/7 (57.1%) 11/24 (45.8%) 
17D+Asibi M-E G52R (7.14) 5/24 (20.8%)* 3/15 (20.0%) 4/24 (16.7%) 
Asibi (6.11) 17/24 (70.8%) 12/15 (80.0%) 15/24 (62.5%) 
Asibi E G52R (5.52) 7/24 (29.2%)† 3/9 (33.3%)‡ 5/16 (31.3%) 
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Table 4.10 Infection rate of YFV wildtype controls and E G52R mutants in Ae. aegypti at 7, 
10 and 14 d.p.i. 
† and ‡ indicate the statistically significant difference by Fisher’s exact test compared to the 
infection rates of the Asibi strain at 7 and 10 d.p.i., respectively. (p<0.05) 
* indicates the statistically significant difference by Fisher’s exact test compared to the 
infection rate of the 17D+Asbi M-E chimera at 7 d.p.i., respectively. (p<0.05) 
The average titer of the viremic blood meals containing the Asibi strain and the Asibi E 
G52R mutant were 6.11 and 5.52 logTCID50/ml, respectively. The infection rate of the Asibi E 
G52R mutant was consistently lower than that observed for the Asibi strain at 7 (70.8% vs. 
29.2%, p=0.0087) and 10 (80.0% vs. 33.3%, p=0.0361) d.p.i. At 14 d.p.i., the infection rate of 
the Asibi E G52R mutant remained lower than the Asibi strain without significant difference 
(62.5% vs. 31.3%, p=0.10). 
The 17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R mutant were orally 
administered at 7.02 and 7.14 logTCID50/ml, respectively. The infection rate of the 17D+Asibi 
M-E E G52R mutant was significantly lower than the 17D+Asibi M-E chimera (80.0% vs. 
20.8%, p=0.0001) at 7 d.p.i. There was no demonstrable difference in the infection rates of the 
17D+Asibi M-E chimera and 17D+Asibi M-E E G52R mutant at 10 (57.1% vs. 20.0%) and 14 
(45.8% vs. 16.7%) d.p.i. 
 Viremic blood meal  
(titer in logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
17D (4.24) 0/5 (0.0%) 0/1 (0.0%) 0/3 (0.0%) 
17D+Asibi M-E (7.02) 1/10 (10.0%) 1/2 (50.0%) 3/8 (37.5%) 
17D+Asibi M-E G52R (7.14) 1/6 (16.7%) 0/1 (0.0%) 0/3 (0.0%) 
Asibi (6.11) 3/10 (30.0%) 6/9 (66.7%) 8/10 (80.0%) 
Asibi E G52R (5.52) 1/3 (33.3%) 0/2 (0.0%) 1/1 (100.0%) 
Table 4.11 Dissemination rate of YFV wildtype controls and E G52R mutants in Ae. aegypti 
at 7, 10 and 14 d.p.i. 
There was no significant difference in viral dissemination observed between the YFV 
wildtype strains and the E G52R mutants. The dissemination rate of the Asibi E G52R mutant 
was comparable but not significantly higher than the Asibi strain at 7 (30.0% vs. 33.3%, p=1.00) 
and 14 (100.0% vs. 80.0%, p=1.00) d.p.i. At 10 d.p.i., there was no dissemination observed in 
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the dissected Ae. aegypti infected by the Asibi E G52R mutant, whilst the infection of the Asibi 
strain led to the dissemination rate at 66.7% (6/9, p=0.18). The dissemination rate of the 
17D+Asibi M-E E G52R mutant was lower with no demonstrable difference at 7 (10.0% vs. 
16.7%, p=1.00) , 10 (50.0% vs. 0.0%, p=1.00) and 14 (37.5% vs. 0.0%, p=0.49) d.p.i. 
In summary, the infection rate of the Asibi E G52R and 17D+Asibi M-E E G52R mutants 
was significantly lower at 7 d.p.i. The infection rate of the Asibi E G52R mutant remained 
significantly lower than the Asibi strain at 10 d.p.i. At, 14 d.p.i., the infection rate of the wildtype 
and mutant viruses showed no significant difference. The infection of the Asibi E G52R and 
17D+Asibi M-E E G52R mutants led to the comparable dissemination rates at 7, 10 and 14 d.p.i. 
compared to YFV wildtype controls. The results suggested that the infectivity of the Asibi strain 
and the 17D+Asibi M-E chimera is significantly impaired at 7 d.p.i. The reduced infectivity was 
further observed in the Asibi E G52R mutant at 10 d.p.i., when the 17D+Asibi M-E E G52R 
mutant did not show a demonstrable difference in the infection rate from the 17D+Asibi M-E 
chimera. The dissemination of the Asibi E G52R mutant was still observed at 14 d.p.i. 
implicating the G52R mutation in the E protein did not impair viral dissemination in Ae. aegypti. 
In conclusion, the G52R mutation should be considered as a determinant for the infectivity of 
YFV in Ae. aegypti.  
 B. Viral titers of whole mosquitoes, bodies and secondary tissues infected by YFV E 
G52R mutants 
The titers of the whole mosquitoes infected by the Asibi E G52R and the 17D/Asibi M-E 
E G52R are summarized in Figure 4.8. The titers between the Asibi E G52R mutant and the 
Asibi strain or between the 17D/Asibi M-E chimera and the 17D/Asibi M-E E G52R mutant did 
not show any significant difference (p>0.05). The engorgement of viremic blood containing the 
Asibi E G52R mutant and the Asibi strain resulted in the average titer of 1.92 and 2.83 
logTCID50/ml at 0 d.p.i. The whole-mosquito titers of the Asibi E G52R mutant and the Asibi 
strain remain similar at 7 (2.25 logTCID50/ml, n=7 vs. 2.23 logTCID50/ml, n=4) and 10 (2.16 
logTCID50/ml, n=3 vs. 2.52 logTCID50/ml, n=1) d.p.i. At 14 d.p.i., the Asibi E G52R mutant and 
the Asibi strain replicated to 2.56 (n=4) logTCID50/ml and 3.89 logTCID50/ml (n=5), 
respectively. The whole-mosquito titers of the 17D+Asibi M-E chimera and the 17D+Asibi M-E 
E G52R mutant were comparable at 7 (2.99 logTCID50/ml, n=5 vs. 1.51 logTCID50/ml, n=2), 10 
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(3.52 logTCID50/ml, n=2 vs. 2.51 logTCID50/ml, n=2) and 14 (2.58 logTCID50/ml, n=3 vs. 2.95 
logTCID50/ml, n=1) d.p.i. 
   
Figure 4.8 Average titers of whole mosquitoes infected by YFV wildtype controls and E 
G52R mutants 
(a) Titers of whole mosquitoes infected by the Asibi strain (red) and the Asibi E G52R 
mutant (green) (b) Titers of whole mosquitoes infected by the 17D+Asibi M-E chimera 
(red) and the 17D+Asibi M-E E G52R mutant (green) 
The Asibi E G52R mutant and the 17D+Asibi M-E E G52R mutant was able to replicate 
to the similar level as the Asibi strain and the 17D+Asibi M-E chimera (p>0.05). The results are 
shown in Figure 4.9. The average body titer of Ae. aegypti infected by the Asibi E G52R mutant 
was insignificantly lower than the Asibi strain at 7 (2.44 logTCID50/ml, n=10 vs. logTCID50/ml, 
n=2) and 10 (2.17 logTCID50/ml, n=8 vs. 1.77 logTCID50/ml, n=2) d.p.i. There was no positive 
body sample among the Ae. aegypti dissected at 14 d.p.i. as the average body titer of Ae. aegypti 
infected by the Asibi E G52R mutant. The average body titer of the Asibi strain increased to 2.68 
logTCID50/ml (n=8). The infection of the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
G52R mutant resulted in the similar average body titer at 7 d.p.i. (2.41 logTCID50/ml, n=10 vs. 
2.51 logTCID50/ml, n=5) The average body titer of the 17D+Asibi M-E E G52R mutant was 
lower with no significant difference from the 17D+Asibi M-E chimera at 10 (3.52 logTCID50/ml, 
n=1 vs. 1.95 logTCID50/ml, n=1) and 14 (2.32 logTCID50/ml, n=8 vs. 1.83 logTCID50/ml, n=3) 
d.p.i. 
(a) (b) 
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Figure 4.9 Average body titers of Ae. aegypti infected by YFV wildtype controls and E 
G52R mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E G52R mutant (green) (b) 
Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-E E G52R 
mutant (green) 
The average titers of the secondary tissues are summarized in Figure 4.10. There was no 
statistically significance in the difference of viral titers between the Asibi strain and the Asibi E 
G52R mutant or between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R mutant. 
The titers of the secondary tissues in Ae. aegypti infected by the Asibi E G52R mutant were 
lower without demonstrable difference at 7 (3.00 logTCID50/ml, n=3 vs. 2.52 logTCID50/ml, 
n=1) and 14 (2.50 logTCID50/ml, n=8 vs. 1.06 logTCID50/ml, n=1) d.p.i. The disseminated 
17D+Asibi M-E E G52R mutant resulted in the lower titer (2.95 logTCID50/ml, n=1 vs. 1.95 
logTCID50/ml, n=1) than the 17D+Asibi M-E chimera at 7 d.p.i. 
 
Figure 4.10 Average secondary tissue titers of Ae. aegypti infected by YFV wildtype 
controls and E G52R mutants 
(a) (b) 
(a) (b) 
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(a) Average secondary tissue titers of the Asibi strain (red) and the Asibi E G52R mutant 
(green) The green dash line was used to represent the average secondary tissue titers of the 
Asibi E G52R mutant between 7 and 14 d.p.i. due to the lack of positive secondary tissues 
derived from the dissected mosquitoes, which were previously exposed to the blood meal 
containing the Asibi E G52R mutant. (b) Average body titers of the 17D+Asibi M-E 
chimera (red) and the 17D+Asibi M-E E G52R mutant (open circle) 
In summary, the average titers of samples derived from the whole mosquitoes, the bodies 
and the secondary tissues showed no statistical significance between the Asibi strain and the 
Asibi E G52R mutant or between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R 
mutant. Although the significantly lower infection rates caused by the G52R mutation have been 
observed and described in section 4.2.B, the dissemination and the average titers of 
homogenized mosquito samples did not show the significant difference between the YFV E 
G52R mutants and the wildtype controls. Presumably, the G52R mutation contributes to the 
attenuated phenotype of the 17D strains by lowering the infection rate but not preventing the 
viral dissemination into the secondary tissues. 
C. Infection and dissemination of YFV E T173I mutants 
The Asibi E T173I mutant and the 17D+Asibi M-E E T173I mutant were produced to 
characterize the potential phenotypic effects of the T173I mutation in the E protein. The 
infection and dissemination rates of the YFV wildtype controls and E T173I mutants are 
summarized in Table 4.12 and 4.13. 
Viremic blood meal 
(titer in logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
Mock (N.A.) 0/24 (0.0%) 0/18 (0.0%) 0/24 (0.0%) 
17D (4.24) 9/24 (37.5%) 3/6 (50.0%) 4/16 (25.0%) 
17D+Asibi M-E (7.02) 16/20 (80.0%) 4/7 (57.1%) 11/24 (45.8%) 
17D+Asibi M-E T173I (7.14) 14/24 (58.3%) 10/16 (62.5%) 10/24 (41.7%) 
Asibi (6.11) 17/24 (70.8%) 12/15 (80.0%) 15/24 (62.5%) 
Asibi E T173I (6.24) 10/24 (41.7%) 14/24 (58.3%) 8/24 (33.3%) 
Table 4.12 Infection rate of YFV wildtype controls and E T173I mutants in Ae. aegypti at 7, 
10 and 14 d.p.i 
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The infection rate of the Asibi E T173I mutant was not significantly different to the Asibi 
strain at 7 (41.7% vs. 70.8%, p=0.08), 10 (58.3% vs. 80.0%, p=0.43) and 14 (33.3% vs, 62.5%, 
p=0.08) d.p.i. Similarly, there was no significant difference in the infection rate of the 
17D+Asibi M-E E T173I mutant from the 17D+Asibi M-E chimera at 7 (80.0% vs. 58.3%, 
p=0.19), 10 (57.1% vs. 62.5%, p=1.00) and 14 (45.8% vs. 41.7%, p=1.00) d.p.i.  
 Viremic blood meal 
(titer in logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
17D (4.24) 0/5 0.0% 0/1 0.0% 0/3 0.0% 
17D+Asibi M-E (7.02) 1/10 10.0% 1/2 50.0% 3/8 37.5% 
17D+Asibi M-E T173I (7.14) 2/10 20.0% 1/7 14.3% 4/6 66.7% 
Asibi (6.11) 3/10 30.0% 6/9 66.7% 8/10 80.0% 
Asibi E T173I (6.24) 4/8 50.0% 3/11 27.3% 3/4 75.0% 
Table 4.13 Dissemination rate of YFV wildtype controls and E T173I mutants in Ae. aegypti 
at 7, 10 and 14 d.p.i 
The dissemination rate showed no significant difference between the Asibi strain and the 
Asibi E T173I mutant at 7 (30.0% vs. 50.0%, p=0.63), 10 (66.7% vs. 27.3%, p=0.17) and 14 
(80.0% vs. 75.0%, p=1.00) d.p.i. The infection of the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E T173I mutant resulted in the similar infection rate at 7 (10.0% vs. 20.0%, 
p=1.00), 10 (50.0% vs. 14.3%, p=1.00) and 14 (37.5% vs. 66.7%, p=0.59) d.p.i. 
In summary, the T173I mutation in the E protein of YFV 17D strains caused no 
demonstrable attenuation. The infection rate and the dissemination rate of the Asibi E T173I and 
17D+Asibi M-E E T173I mutants were comparable to the Asibi strain and the 17D+Asibi M-E 
chimera.  
 D. Viral titers of whole mosquitoes, bodies and secondary tissues infected by YFV E 
T173I mutants 
The average titers of the whole mosquitoes infected by the YFV wildtype controls and E 
T173 mutants are shown in Figure 4.11. The titers between the Asibi strain and the Asibi E 
T173I mutant remain comparable (p>0.05) at 7 (2.25 logTCID50/ml, n=7 vs. 1.06 logTCID50/ml, 
n=1), 10 (2.16 logTCID50/ml, n=3 vs. 2.25 logTCID50/ml, n=3) and 14 (3.89 logTCID50/ml, n=5 
vs. 2.62 logTCID50/ml, n=4) d.p.i. There was no significant difference in the average titers of 
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whole mosquitoes infected by the 17D+Asibi M-E chimera and the 17D+Asibi M-E E T173I 
mutant at 7 (2.99 logTCID50/ml, n=5 vs. 1.89 logTCID50/ml, n=4), 10 (3.52 logTCID50/ml, n=2 
vs. 2.51 logTCID50/ml, n=3) and 14 (2.58 logTCID50/ml, n=3 vs. 3.42 logTCID50/ml, n=4) d.p.i. 
   
Figure 4.11 Average titers of whole mosquitoes infected by YFV wildtype controls and E 
T173I mutants 
(a) Titers of whole mosquitoes infected by the Asibi strain (red) and the Asibi E T173I 
mutant (green) (b) Titers of whole mosquitoes infected by the 17D+Asibi M-E chimera 
(red) and the 17D+Asibi M-E E T173I mutant (green) 
The comparison of the average body titers did not identify any significant difference 
between the Asibi strain and the Asibi E T173I mutant or the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E T173I mutant as summarized in Figure 4.12. The average titers of the bodies 
infected by the Asibi E T173I mutant were comparable to those infected by the Asibi strain at 7 
(2.44 logTCID50/ml, n=10 vs. 2.60 logTCID50/ml, n=7), 10 (2.17 logTCID50/ml, n=8  vs. 2.49 
logTCID50/ml, n=11) and 14 (2.68 logTCID50/ml, n=8 vs. 2.38 logTCID50/ml, n=4) d.p.i. There 
was no significant difference in the average titers of the bodies infected by the 17D+Asibi M-E 
chimera and the 17D+Asibi M-E E T173I mutant at 7 (2.41 logTCID50/ml, n=10 vs. 2.50 
logTCID50/ml, n=9), 10 (3.52 logTCID50/ml,n=1 vs. 2.71 logTCID50/ml, n=1) and 14 (2.32 
logTCID50/ml, n=8 vs. 2.46 logTCID50/ml, n=6) d.p.i. 
(a) (b) 
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Figure 4.12 Average body titers of Ae. aegypti infected by YFV wildtype controls and E 
T173I mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E T173I mutant (green) (b) 
Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-E E T173I 
mutant (green) 
The average titers of secondary tissues among the disseminated form of infection showed 
no significant difference between the Asibi strain and the Asibi E T173I mutant or between the 
17D+Asibi M-E chimera and the 17D+Asibi M-E E T173I mutant (p>0.05) in Figure 4.13. The 
dissemination of the Asibi E T173I mutant resulted in  similar average titers of homogenized 
secondary tissues to the Asibi strain at 7 (3.00 logTCID50/ml, n=3 vs. 3.49 logTCID50/ml, n=4), 
10 (3.31 logTCID50/ml, n=6 vs. 4.00 logTCID50/ml, n=3) and 14 (2.50 logTCID50/ml, n=8 vs. 
3.66 logTCID50/ml, n=2) d.p.i. The average titers of the secondary tissues infected by the 
17D+Asibi M-E chimera and the 17D+Asibi M-E T173I mutant remained similar at 7 (2.95 
logTCID50/ml, n=1 vs. 2.29 logTCID50/ml, n=2), 10 (3.95 logTCID50/ml, n=1 vs. 1.52 
logTCID50/ml, n=1) and 14 (2.00 logTCID50/ml, n=3 vs. 3.09 logTCID50/ml, n=4) d.p.i. 
  
(a) (b) 
(a) (b) 
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Figure 4.13 Average secondary tissue titers of Ae. aegypti infected by YFV wildtype 
controls and E T173I mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E T173I mutant (green) (b) 
Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-E E T173I 
mutant (green) 
Similar to the no demonstrable difference in the infection and dissemination rates 
observed in the Asibi E T173I and the 17D+Asibi M-E E T173I mutants. The replication of both 
mutants resulted in the comparable average titers to the wildtype controls in the homogenized 
whole mosquitoes, bodies and secondary tissues. 
 E. Infection and dissemination of YFV E G52R-T173I double Mutants 
It is clear that the attenuation of the Asibi strain requires multiple genetic mutations in the 
structural genes. The significant impairment in viral infectivity for mosquitoes was achieved by 
the substitution of 17D EDI and EDII into the Asibi strain. (McElroy et al., 2006b) Based on the 
significant attenuation caused by the single G52R mutation, the YFV E G52R-T173I double 
mutants were generated in order to determine the the potential synergistic effect of two point 
mutations. The infection rate and dissemination rate of the YFV E G52R-T173I double mutants 
and wildtype controls are summarized in Table 4.14 and 4.15, respectively. 
Ae. aegypti exposed to the Asibi strain and the Asibi E G52R-T173I mutant at 3.66 and 
2.52 logTCID50/ml showed comparable infection rates at 7 (72.7% vs. 67.7%) d.p.i. The 
infection rate of the Asibi E G52R-T173I mutant was consistently lower than the Asibi strain at 
10 (100.0% vs. 61.1%, p=0.0076) and 14 (76.3% vs. 32.3%, p=0.0005) d.p.i. The infectivity of 
the 17D+Asibi M-E E G52R-T173I mutant was significantly lower than that of the 17D+Asibi 
M-E chimera at 7 (62.1% vs. 30.8%, p=0.0139) and 14 (65.6% vs. 25.6%, p=0.0009) d.p.i.; 
whereas, the infection rate of the 17D+Asibi M-E E G52R-T173I mutant was similar to the 
17D+Asibi M-E chimera at 10 d.p.i. (45.5% vs. 64.4%, p>0.05). 
 Viremic blood meal 
(titer in logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
Mock (N.A.) 0/30 (0.0%) 0/24 (0.0%) 0/35 (0.0%) 
17D (6.19) 15/25 (60.0%) 11/12 (91.7%) 12/32 (37.5%) 
17D+Asibi M-E (5.77) 18/29 (62.1%) 5/11 (45.5%) 21/32 (65.6%) 
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17D+Asibi M-E E G52R-T173I (4.69) 12/39 (30.8%)† 29/45 (64.4%) 10/39 (25.6%)‡ 
Asibi (3.66) 24/33 (72.7%) 18/18 (100.0%) 29/38 (76.3%) 
Asibi E G52R-T173I (2.52) 23/34 (67.7%) 11/18 (61.1%)* 10/31 (32.3%)**
Table 4.14 Infection rate of YFV wildtype controls and E G52R-T173I mutants in Ae. 
aegypti at 7, 10 and 14 d.p.i 
* and ** indicate the significant difference by Fisher’s exact test between the Asibi strain the 
Asibi E G52R-T173I mutant at 10 (p=0.0076) and 14 (p=0.00035)d.p.i., respectively. 
† and ‡ indicate the significant difference by Fisher’s exact test between the 17D+Asibi M-E 
chimera and the 17D+Asibi M-E E G52R-T173I mutant at 7 (p=0.0139) and 14 
(p=0.0009)d.p.i., respectively. 
Although  a  significant reduction in the infection rate was observed in the group orally 
challenged by the Asibi E G52R-T173I mutant at 10 and 14 d.p.i., the dissemination rate of the 
Asibi E G52R-T173I mutant remained similar (p>0.05) to that of the Asibi strain at 7 (82.4 vs. 
87.5%), 10 (83.3% vs. 85.7%) and 14 (70.0% vs. 16.7%) d.p.i. Similarly, there was no 
significant difference in the dissemination rate between the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E G52R-T173I mutant at 7 (50.0% vs. 80.0%), 10 (25.0% vs. 63.16%) and 14 
(50.0% vs. 20.0%) d.p.i. 
 Viremic blood meal 
(titer in logTCID50/ml) 
7 d.p.i. 10 d.p.i. 14 d.p.i. 
17D (6.19) 0/12 (0.0%) 0/8 (0.0%) 1/9 (11.1%) 
17D+Asibi M-E (5.77) 6/12 (50.0%) 1/4 (25.0%) 6/12 (50.0%) 
17D+Asibi M-E G52R-T173I (4.69) 8/10 (80.0%) 12/19 (63.16%) 1/5 (20.00%) 
Asibi (3.66) 14/17 (82.4%) 10/12 (83.3%) 14/20 (70.0%) 
Asibi E G52R-T173I (2.52) 14/16 (87.5%) 6/7 (85.7%) 1/6 (16.7%) 
Table 4.15 Dissemination rate of YFV wildtype controls and E G52R-T173I mutants in Ae. 
aegypti at 7, 10 and 14 d.p.i 
The YFV E G52R-T173I double mutants showed consistently lower infection rates at 14 
d.p.i. between the Asibi strain and the Asibi E G52R-T173I mutant and between the 17D+Asibi 
M-E chimera and the 17D+Asibi M-E E G52R-T173I mutant. The Asibi E G52R-T173I mutant 
and the 17D+Asibi M-E E G52R-T173I mutant also showed the significantly lower infection rate 
at 10 and 7 d.p.i., respectively. The lower infection rates observed in the YFV E G52R-T173I 
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double mutants suggest the mutations together caused the impairment of viral infectivity that 
were observed in the YFV E G52R mutants. 
 F. Viral titers of whole mosquitoes, bodies and secondary tissues infected by YFV E 
G52R-T173I double mutants 
The viral replication in whole mosquitoes resulted in no demonstrable difference 
(p>0.05) between the Asibi strain and the Asibi E G52R-T173I mutant or between the 
17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R-T173I mutant. The average titers are 
summarized in Figure 4.14.The average titers of homogenized whole mosquitoes infected by the 
Asibi E G52R-T173I mutant were lower than the Asibi strain without any statistical significance 
at 7 (1.87 logTCID50/ml, n=7 vs. 1.66 logTCID50/ml, n=7), 10 (2.53 logTCID50/ml, n=6 vs. 1.06 
logTCID50/ml, n=1) and 14 (3.09 logTCID50/ml, n=8 vs. 2.37 logTCID50/ml, n=4) d.p.i. The 
whole-mosquito homogenates derived from Ae. aegypti infected by the 17D+Asibi M-E E 
G52R-T173I mutant had the comparable titers with Ae. aegypti infected by the 17D+Asibi M-E 
chimera at 7 (2.46 logTCID50/ml, n=6 vs. 1.79 logTCID50/ml, n=2), 10 (1.06 logTCID50/ml, n=1 
vs. 1.71 logTCID50/ml, n=10) and 14 (2.47 logTCID50/ml, n=8 vs. 1.51 logTCID50/ml, n=5) 
d.p.i. 
 
Figure 4.14 Average titers of whole mosquitoes infected by YFV wildtype controls and E 
G52R-T173I mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E G52R-T173I mutant 
(green) (b) Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-
E E G52R-T173I mutant (green) 
(a) (b) 
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The comparison in the body titers did not identify any significant difference in the 
average body titers between the Asibi strain and the Asibi E G52R-T173I mutant or between the 
17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R-T173I mutant (p>0.05) as 
summarized in Figure 4.15. The average body titers of Ae. aegypti infected by the Asibi E 
G52R-T173I mutant were similar to those infected by the Asibi strain at 7 (2.91 logTCID50/ml, 
n=12 vs. 2.03 logTCID50/ml, n=14), 10 (2.31 logTCID50/ml, n=11 vs. 1.56 logTCID50/ml, n=4) 
and 14 (1.70 logTCID50/ml, n=16 vs. 1.83 logTCID50/ml, n=5) d.p.i. The comparable average 
body titers were also observed between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
G52R-T173I mutant at 7 (3.24 logTCID50/ml, n=10 vs. 1.49 logTCID50/ml, n=7) , 10 (2.48 
logTCID50/ml, n=4 vs. 1.43 logTCID50/ml, n=10) and 14 (2.28 logTCID50/ml, n=11 vs. 2.12 
logTCID50/ml, n=4) d.p.i.  
  
Figure 4.15 Average body titers of Ae. aegypti infected by YFV wildtype controls and E 
G52R-T173I mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E G52R-T173I mutant 
(green) (b) Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-
E E G52R-T173I mutant (green) 
Among the disseminated form of infection, the average titers of the secondary tissues did 
not show any significant difference between the Asibi strain and the Asibi E G52R-T173I mutant 
or between the 17D+Asibi M-E chimera and the 17D+Asibi M-E G52R-T173I mutant (p>0.05). 
The results are shown in Figure 4.16. The average titers of the secondary tissues infected by the 
Asibi E G52R-T173I mutant were similar to those infected by the Asibi strain at 7 (1.75 
logTCID50/ml, n=15 vs. 2.19 logTCID50/ml, n=11), 10 (2.19 logTCID50/ml, n=10 vs. 1.36 
logTCID50/ml, n=6) and 14 (2.69 logTCID50/ml, n=14 vs. 2.95 logTCID50/ml, n=1) d.p.i.  The 
(a) (b) 
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dissemination of the 17D+Asibi M-E E G52R-T173I mutant resulted in the comparable average 
titers in the secondary tissues as the 17D+Asibi M-E chimera at 7 (1.60 logTCID50/ml, n=6 vs. 
2.37 logTCID50/ml, n=8), 10 (2.95 logTCID50/ml, n=1  vs. 1.49, n=13 logTCID50/ml) and 14 
(2.33 logTCID50/ml, n=6 vs. 2.52 logTCID50/ml, n=1) d.p.i. 
  
Figure 4.16 Average secondary tissue titers of Ae. aegypti infected by YFV wildtype 
controls and E G52R-T173I mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E G52R-T173I mutant 
(green) (b) Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-
E E G52-T173I mutant (green) 
In conclusion, the YFV E G52R-T173I double mutants did not show reduced replication 
in comparison to the YFV wildtype controls. Although the infection rates of the YFV E G52R-
T173I mutants showed the consistently lower infection rate at 14 d.p.i., there was no 
demonstrable difference in the average titers of homogenized whole mosquitoes, bodies and 
secondary tissues between the YFV wildtype controls and the E G52R-T173I mutants. 
 4.3 Conclusions 
 A. Attenuation caused by the G52R single mutation and the G52R-T173I double 
mutations 
Our results demonstrated that the single G52R mutation in YFV E protein was sufficient 
to cause a significant reduction in the infection rate, especially between 7 and 10 d.p.i. The Asibi 
E G52R mutant was associated with consistently lower infection rates at 7 and 10 d.p.i. Although 
there was no demonstrable difference at 14 d.p.i., a low infection rate of the Asibi E G52R 
mutant was consistently observed. The exposure of the 17D+Asibi M-E E G52R mutant resulted 
(a) (b) 
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in a significantly lower infection rate at 7 d.p.i. At 10 and 14 d.p.i., the infection rate remained 
lower but did not show any statistical significance in Ae. aegypti challenged by the 17D+Asibi 
M-E E G52R mutant. The dissemination of the Asibi E G52R mutant at 7 and 14 d.p.i. and the 
17D+Asibi M-E G52R mutant at 7 d.p.i. suggested that the single YFV 17D G52R mutation 
when introduced into YFV Asisbi was unable to achieve the complete blockade of viral 
dissemination. The attenuation caused by the 17D G52R mutation in the E protein 
correspondingly caused a substantial reduction of the viral infectivity when cloned into the 
wildtype Asibi control. Therefore, the G52R mutation should be considered as a potential target 
to incorporate when designing biologically non-transmissible live-attenuated flavivirus vaccine 
candidates.  
The single T173I mutation in the E protein did not lead to significant attenuation of the 
Asibi strain and the 17D+Asibi M-E chimera. The infection rate between the Asibi strain and the 
Asibi E T173I mutant or between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E T173I 
mutant remained comparable at 7, 10 and 14 d.p.i. The dissemination of the YFV E T173I 
mutants also support the minor effect contributed by the T173I mutation in the E protein. 
The infection with the YFV Asibi E 17D G52R-T173I mutant resulted in the similar 
attenuated phenotype associated with the single G52R mutation. The E G52R-T173I double 
mutants did not lead to the more attenuated phenotype by causing the consistently lower 
infection rate than wildtype controls. The infection rate of the YFV E G52-T173I mutants 
remained significantly lower for at least two of the three time points of collection. The infection 
rate of the Asibi E G52R-T173I mutant at 10 and 14 d.p.i. and the 17D+Asibi M-E E T173I 
mutant at 7 and 14 d.p.i was significantly lower than the wildtype controls. The non-
dissemination phenotype was also not achieved by the simultaneous presence of the G52R and 
T173I mutations. 
In summary, the YFV E G52R mutants and the YFV E G52R-T173I double mutants 
showed an attenuated phenotype with respect to significantly lower infection rates of 
mosquitoes. However, the mutations were unable to cause the non-disseminating phenotype of 
the YFV 17D strains. The results are consistent with the observation described by McElroy et al. 
(2006) that the genetic determinants for the viral infectivity of YFV in Ae. aegypti are likely to 
exist in EDI and EDII (McElroy, Tsetsarkin et al. 2006). The single and double mutants 
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characterized in the study also reproduced the disseminating phenotype that was observed in the 
Asibi+17D EDI-EDII chimera. 
 B. Viral titers of homogenized mosquito tissues 
In spite of the significant loss of the infectivity in the YFV E G52R mutants and the YFV 
E G52R-T173I double mutants, the comparison of the average titers did not show any significant 
reduction between the wildtype controls and the mutants. The results are similar to the earlier 
observation that the Asibi strain and the Asibi+17D EDI-EDII chimera did not show any 
significant difference in the average titers of homogenized whole mosquitoes (McElroy, 
Tsetsarkin et al. 2006).  
 4.4 Discussion and future directions 
To the best of our knowledge, the characterization of the YFV E G52R mutants is the 
first report that the single point mutation located in the molecular hinge region of the structure 
gene is sufficient to cause a significant viral attenuation of arboviruses in orally infected 
mosquito vectors. The presence of the T173I mutation caused a minor but non-statistically 
significant decrease in the infection rate. There was no additive effect by the simultaneous 
presence of the G52R and T173I mutations in the E protein of the Asibi strain. Therefore, it is 
likely the G52R mutation contributes to the attenuation independently. The observation does not 
exclude the possibility that three other additional mutations, A56V, A170V and K200T, in EDI 
and EDII of YFV can also result in significant attenuation. 
The capacity of efficient viral dissemination that is characteristic of YFV Asibi was not 
impaired due to the introduction of the single YFV 17D G52R mutation. The disseminated form 
of infection was observed in Ae. aegypti infected by the Asibi E G52R mutants at 7 and 14 d.p.i. 
Although there was no disseminated form of infection observed in Ae. aegypti infected by the 
17D+Asibi M-E E G52R mutant at 10 and 14 d.p.i., it is likely to be the consequence of the 
further attenuated phenotype when the G52R mutation in the E protein is coupled with known  
attenuation determinants in the nonstructural proteins. The mutations in the NS2A and NS4B 
genes of YFV 17D strains have been described to contribute to the significant reduction of 
dissemination in comparison to the highly disseminating phenotype of the Asibi strain (McElroy, 
Tsetsarkin et al. 2006). The 17D+Asibi M-E E G52R mutant contains the I95M mutation in the 
YF 17D NS4A protein, which has been described as the attenuation determinant which 
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significantly impairs the viral dissemination by McElroy et al (McElroy, Tsetsarkin et al. 2006). 
Therefore, the lack of dissemination of the 17D+Asibi M-E E G52R mutant is likely to be the 
results of the combined effect of attenuation among the G52R mutation in the E protein and the 
other additional attenuation determinants in the nonstructural proteins. 
The average titers of the whole-mosquitoes, bodies and secondary tissues infected by the 
YFV E G52R or the YFV E G52R-T173I mutant did not show a significant difference from 
those infected by the YFV wildtype controls. The result was similar to the observation made by 
McElroy et al. that the chimerization of the 17D EDI and EDII with the Asibi strain did not lead 
to the significant reduction of average titers of homogenized whole mosquitoes (McElroy, 
Tsetsarkin et al. 2006).  
A. Attenuation of YFV and flaviviruses by the mutations in the molecular hinge region 
Our results not only have identified at least one attenuation determinant in the region of 
YFV EDI and EDII but also confirmed that the introduction of point mutations in the molecular 
hinge region is a feasible approach to reduce the infectivity of mosquito-borne flaviviruses. As 
the only mutation which exists in the molecular hinge region between EDI and EDII of YFV 
17D strains, the characterization of the G52R mutation was only able to lead to the conclusion 
that the mutations in the H1 peptide can be a potential target for mutagenesis in order to generate 
biologically nontransmissible live-attenuated vaccine candidates for mosquito-borne flaviviruses. 
The attenuation of flaviviruses due to the mutations in the molecular hinge region has also been 
described in the H2 peptide of DENV-2 E protein and the H4 peptide of MVEV (Hurrelbrink and 
McMinn 2001, Butrapet, Childers et al. 2011).  More complete characterization can be achieved 
by orally administering the mutants described by Butrapet et al. and McMinn et al. to competent 
vector species, or selectively mutatating the corresponding residues in the E protein of the Asibi 
strain. Although it has been shown that the mutations in all four peptides of the molecular hinge 
region in DENV-2 E protein can be associated with the viral attenuation in vitro in the study 
published by Butrapet et al., the evaluation of the viral infectivity was only performed with the 
mutants derived from the mutations which substitute the Leu135 residue of the H2 peptide. The 
experimental approach of intrathoracic inoculation of mosquitoes in their  study to assess the 
infection rate has been used to characterize a challenge method that promotes the infection and 
dissemination of flaviviruses in mosquitoes but is of course unnatural since it does not include 
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the important process of midgut infection. Therefore, the attenuation caused by the mutations 
evaluated in the study can potentially be underestimated by artificially forcing the establishment 
of infection among the attenuated mutant viruses. The per os challenge of DENV-2 mutants 
generated in the same study should be conducted to provide the information generated by the 
experimental approach which resembles the natural route of infection (McElroy, Tsetsarkin et al. 
2006, Butrapet, Childers et al. 2011).   
 It is still unclear how the single G52R mutation was able to result in the significant viral 
attenuation. The G52R mutation is structurally isolated from the known receptor-binding region 
of the flavivirus E protein as shown in Figure 4.1. The plausible mechanism for the viral 
attenuation may be the impairment of the viral membrane fusion process (Chen, Maguire et al. 
1997, Modis, Ogata et al. 2004). The earlier experimental evidence derived from the analysis of 
virus-mediated fusion in C6/36 cells suggested that the mutations in the molecular hinge regions 
of flavivirus E proteins may result in the change of the optimal pH required for the fusogenic 
activity (Lee, Weir et al. 1997, Butrapet, Childers et al. 2011). Such observations are  consistent 
with the knowledge derived from the comparison of the crystal structures of pre- and post-fusion 
flavivirus E proteins, which require the molecular hinge region to accommodate the structure 
rearrangement between EDI and EDII during the viral membrane fusion (Modis, Ogata et al. 
2003). The process of the viral membrane fusion is driven by the energy generated during the 
acidification of the endosomes. Although, the assay provides the functional characterization on 
the fusogenic capacity, the biochemical nature of the membrane fusion process renders the assay 
on the virus-mediated cell fusion in insects  highly specific to the osmotic pressures of culture 
media in the experimental system (Higgs and Gould 1991). The fusion process can also be 
spontaneously initiated due to the confluence in some insect cell culture (Maramorosch and 
McIntosh 1994). Therefore, the development of a more standardized method to analyze the 
fusogenic activity of arboviruses in insect culture or cell-free system is needed in order to fully 
characterize the phenotypic changes associated with the mutations in the molecular hinge region 
at the cellular level. It is less likely to adopt the full-length DENV-2 E protein and liposome 
platform described by Modis et al. although the study successfully reproduced the dimer-to-
trimer conformational change. The observation of the process requires electron microscopy 
studies which requires specific techniques and knowledge for operation (Modis, Ogata et al. 
2004).(Modis et al., 2004) The use of the DENV replicon system described by Ansarah-Sobrino 
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et al. may be a feasible approach since the platform has been successfully coupled with the 
reporter gene. The amino acid substitutions in the molecular hinge region can be introduced and 
the quantification of viral entry by the expression of the reporter genes in the cellular 
compartment should provide the quantitative analysis to mechanistically characterize the viral 
attenuation at the molecular level.(Ansarah-Sobrinho, Nelson, Jost, Whitehead, & Pierson, 2008) 
B. Characterization of the T173I mutations 
The characterization of the YFV E T173I mutants in Ae. aegypti showed that there was 
no demonstrable difference in the infection and dissemination from the wildtype controls. 
Although the insignificant reduction in the infection rate occurred, the conclusion of the 
statistical analysis suggest the significant attenuation did not occur. 
  The plaque purification of the 17D-204 substrain suggested the presence of the viral 
population 17D(+wt) which contains the reversion from the isoleucine to threonine in the E 
protein and exists at the minor quantity in the viral population of the vaccine pool.(E A Gould et 
al., 1989) The comparison  of the neurovirulence between the 17D(+wt) and (17D(-wt) 
suggested that the I173T reversion can be a neurovirulence determinant in mice.(K D Ryman et 
al., 1997a) It is still unknown if the single YFV Asibi I173T reversion introduced into YFV 17D 
would increase the viral infection and dissemination in Ae. aegypti. The better understanding can 
be gained by characterize the 17D(+wt) variant or the YFV E I173T mutants by the per os 
infection of Ae. aegypti. 
It was also reported that the acquisition of the wildtype epitope in the 17D(+wt) variant is 
also associated with the change of the antigenic structure by the A240V mutation in the E 
protein.(E A Gould et al., 1989; K D Ryman et al., 1998) Therefore, in addition to the 
assessment in the phenotype of the naturally occurring 17D(+wt) variant in Ae. aegypti, the 
complete understanding will be achieved by characterizing the additional A240V mutation, 
which has previously been shown as a known cause of  the attenuation in mice.(K D Ryman et 
al., 1998) The result is expected to provide the knowledge for the unlikely, but worst case 
scenario, that whether the simultaneous presence of the I173T reversion and the A240V 
mutations will maintain the attenuated phenotype when the I173T reversion becomes the major 
genetic component in the 17D strains.   
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The importance  of characterizing the phenotypes of viruses associated with the 
mutations in the G0H0 loop of EDI, where the T173I mutation is located, can also further 
contribute to the evaluation of the safety of utilizing the type-specific anti-flavivirus mAb as 
potential therapies or the rationale-based design of the vaccine candidates eliciting the antibody 
responses targeting the G0H0 loop.(Cockburn et al., 2012) Similar to the B-cell epitope present in 
the G0H0 region of YFV E protein, two potent primate anti-DENV type-specific mAb that are the 
chimpanzee anti-DENV-4 5H2 and the human anti-DENV-1 4F1 both recognize the G0H0 region 
of the EDI as part of the epitope based on the inter-domain quaternary structures.(Fibriansah et 
al., 2014; C.-J. Lai et al., 2007) The characterization of the neutralization escape mutants of the 
5H2 mAb suggested that potential mutations can potentially accumulate in the G0H0 region. It is 
still unknown if the selective pressure created by the application of antibodies targeting the G0H0 
loop of EDI will result in the change of phenotypes of flaviviruses in vector mosquitoes.  
 C. Locations of YFV 17D mutations in EDI and EDII   
The observation is consistent with the currently available structures of flavivirus E 
proteins. Based on the available knowledge in the structures of flavivirus E proteins, it is likely 
that the two point mutations located in the two distinct regions of YFV E protein as shown 
Figure 4.1 and 4.2. Therefore, the interactions between the two point mutations are likely to be 
limited and the G52R-T173I double mutants were not able to substantiate the attenuation caused 
by the G52R single mutation. 
The results suggested that the more significant role of the G52R mutation in molecular 
hinge region of YFV E protein for the viral attenuation, can potentially provide critical 
information for future characterization on other mutations in the YFV E protein. As shown in the 
available crystal structure of the structurally similar DENV-2 E protein, the K200T mutation is 
located in the close proximity of the molecular hinge region at the interface between EDI and 
EDII as shown in Figure 4.17. 
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Figure 4.17 Relative locations of the molecular hinge region and the YFV 17D K200T 
mutation in the corresponding region of structurally similar DENV-2 E protein (PID ID: 
1TG8) 
EDI and EDII are labeled in red and yellow, respectively. The four peptides (H1-H4) are 
color in cyan and the G52R mutation is displayed in spheres. The K200T mutation is 
displayed in spheres and colored in green. 
It is still unclear whether or not  the K200T mutation in YFV E protein contributes to any 
attenuation in vertebrate hosts and vector mosquitoes. The K200T mutation is part of the fg loop 
region between the f and g β-strands of EDII. Structurally, the fg loop of EDII among mosquito-
borne flaviviruses is consistently shorter than the corresponding region of the tick-borne 
flavivirus E proteins due to the presence of additional six amino acids in the carboxy 
terminus.(Rey et al., 1995) The region is in the neighboring region of the H4 peptide of the 
molecular hinge region, which consists of the k and l β-strand of EDII. The k and l β-strand 
forms the hairpin structure which are stabilized by hydrophobic interactions among amino acids 
in the pre-fusion and dissociated in the post-fusion conformation as shown in Figure 4.6.(Modis 
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et al., 2004) The characterization of  the YFV E K200T mutant and the YFV E G52R-K200T 
double mutant might be able to provide a  more comprehensive understanding in not only the 
attenuation caused by mutations in the molecular hinge and its neighboring region but also the 
potential difference in the structures and functions of the mosquito-borne and tick-borne 
flavivirus E proteins. 
In summary, the YFV E G52R mutants have been determined as an attenuation 
determinant for infection in mosquitoes whilst the T173I mutation did not contribute to the 
significant attenuation. The knowledge derived from the YFV mutants and other attenuated 
phenotypes associated with the mutations in the molecular hinge region of the E proteins 
highlights the possibility that the attenuation in both the vertebrate hosts and the arthropod 
vectors. The understanding of the mechanisms for viral attenuation can provide the critical 
knowledge for the design of the biologically non-transmissible live-attenuated flavivirus 
vaccines. 
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Chapter 5 - Characterization of the M299I Mutation in the EDI-
EDIII Linker 
 5.1 Introduction 
The importance of mutations in EDIII of the YFV 17D strains has been demonstrated by 
the significantly lower infection and dissemination rate among Ae. aegypti when orally 
challenged by the Asibi+17D EDIII chimera. In the ectodomain of EDIII, there are five amino 
acid mutations identified between the Asibi strain and the 17D-204 substrain as summarized in 
Table 5.1 (Hahn, Dalrymple et al. 1987). The comparison between the 17D-204 substrain and 
the 17DD substrain demonstrated that the P325S mutation is only present in the E protein of the 
17D-204 substrain (dos Santos, Post et al. 1995). Therefore, the potential attenuation 
determinants that resulted in the attenuated phenotype of YFV 17D strains are likely to exist in 
the other four amino acid mutations. 
Mutation (Asibi/17D) Location 
M299I EDI-EDIII linker 
S305F A β-strand 
P325S* BC loop 
K331R Cx β-strand 
T380R FG loop of EDIII 
Table 5.1 Amino acid mutations in EDIII between the YFV Asibi strain and 17D strains 
* indicates the P325S as the 17D-204 substrain-specific mutation. 
The characterization of the T380R mutation has been performed and described in Capter 
3 indicating that the T380R mutation probably promotes the propagation of the virus in vitro, and 
has a limited contribution to the attenuated phenotype in Ae. aegypti (Huang, Nuckols et al. 
2014). The K331R mutation is likely to be tolerated by YFV due to the minor biological change 
associated with what is regarded as a relatively conservative amino acid substitution. The 
conserved presence of the K331R in the two hamster-passage variants of the YFV Asibi strain 
that caused distinct pathological characteristics in the livers of intraperitoneally challenged 
hamsters, suggested that the mutation is less likely to result in the significant phenotypic change 
(McArthur, Xiao et al. 2005). The characterization of the M299I mutation was performed and 
described in this chapter based on its critical location in the linker region at the interface of EDI 
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and EDIII, and the conserved sequences of the corresponding region in the E proteins of the 
flaviviruses. 
 A. Conserved sequences and biochemical properties of EDI-EDIII linker region 
The M299I mutation is located in the carboxy-terminus of the EDI-EDIII linker region of 
YFV 17D E protein. The EDI-EDIII linker region in flavivirus E proteins is a polypeptide which 
consists of 12 amino acid residues between the I0 β-strand of EDI and the N-terminal loop of 
EDIII. An alignment of the sequences shows that the conserved sequences or biochemically 
similar amino acids are present in either the pan-flavivirus manner or the serocomplex-specific 
manner as shown in Table 5.2. The region consists of at least four highly hydrophobic leucine or 
methionine amino acids with other additional residues conserved among flaviviruses or within 
specific serocomplexes. 
Serocomplex Virus  strain Sequence of EDI-EDIII linker region (290-300) 
YFV YFV Asibi LTLKGTSYKMC 
YFV 17D LTLKGTSYKIC 
ENTV UgIL-30 LTLKGKTYAMC
SEPV MK7148 LTLKGSTYPMC
YOKV Oita36 LTMKGSTYTMC
DENV DENV-1 Hawaii LTLKGMSYVMC 
DENV-2 New Guinea C LQLKGMSYSMC 
DENV-3 H87 LKLKGMSYAMC 
DENV-4 H241 LRIKGMSYTMC 
JEV JEV SA14 LALKGTTYGMC 
JEV SA14-14-2 LALKGTTYGMC 
WNV NY99 LQLKGTTYGVC 
KNV MRM61C LQLKGTTYGVC 
SLEV MS1-7 VKIKGTTYGMC 
MVEV MVE1-151 LKLKGTTYGMC 
TBEV TBEV Neudoerfl LKMKGLTYTMC 
OHFV Bogluvovska LKMKGLTYTMC 
 Table 5.2 Sequences of the EDI-EDIII linker region in the flavivirus E proteins 
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There are at least five amino acids, Met299, Lys293, Gly294, Tyr297 and Cys300, which are 
conserved among flaviviruses, or only allow minor variation. The Ile299 residue in the EDI-EDIII 
linker region of YFV 17D strains, which was characterized in our study, is unique.  Other 
flaviviruses, largely use the Met299 residue with the exception of  a V299 residue in the E proteins 
of WNV and KUNV. The other four amino acid residues that are universally conserved across all 
the known flaviviruses are Lys293, Gly294, Tyr297, and Cys300.  
Although the corresponding positions in all other flaviviruses at the Leu290, Leu292 and 
Ser296 residues of YFV E protein vary, the biochemical properties of these positions are generally 
conserved by conservative amino acid substitutions. The Leu290 residue is conserved across 
flaviviruses except that the biochemically conserved valine was observed in the corresponding 
position by SLEV. The hydrophobic nature of the Leu292 residue in YFV E protein is universally 
conserved in the mosquito-borne flaviviruses and is biochemically similar to the methionine 
residue in the corresponding region of the TBEV-serocomplex flaviviruses. The Ser296 is shared 
by YFV and all four serotypes of DENV and shows the conservative biochemical property 
associated with the presence of threonine in other flaviviruses in the corresponding positions. 
The Thr295 residue in the YFV E protein is conserved in the serocomplex-specific manner. YFV 
and the members of the JEV serocomplex show the consensus use of threonine. The DENV-
serocomplex and TBEV-serocomplex flaviviruses utilize the hydrophobic methionine and 
leucine, respectively.  
In addition to the pan-flavivirus and serocomplex-specific conserved residues described 
above, the residue 291 in the EDI-EDIII linker region allows for variation of sequences among 
different flaviviruses. The neutral polar Thr291 residue is specific to YFV-serocomplex and 
DENV-1 and shows the highest diversity in sequences and biochemical properties. The neutral 
polar glutamine residue is present in the corresponding position of DENV-2, WNV, and KUNV. 
The positively charged lysine and arginine residues, which contain polar sidechains, are shared 
in the corresponding region of DENV-3, DENV-4, SLEV, MVEV and the tick-borne 
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r alanine residue in contrast to the other flaviviruses, which use largely polar residues. 
There has been no known function assigned to the YFV EDI-EDIII linker region. The 
EDI-EDIII linker region of flavivirus E proteins initially has been proposed as a potential 
binding site for GAG molecules in DENV-2 due to the high density of  positively charged lysine 
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and arginine (Chen, Maguire et al. 1997). The evaluation of the GAG-binding capacity was 
further  investigated using  recombinant EDIII of DENV-2 and it was reported to act as a viral 
entry mechanism into mammalian cells (Watterson, Kobe et al. 2012). Furthermore, the residues 
responsible for the GAG binding in the EDI-EDIII linker region have recently been identified 
observing that  removal of the positively charged residues abolished viral entry of DENV-2 
mutants (Roehrig, Butrapet et al. 2013). With the availability of flavivirus EDIIIs NMR 
structures, it was clearly demonstrated that the two proposed and characterized GAG-binding 
motifs, (i.e. the EDI-EDIII linker region and the FG loop of EDIII), are located in the same 
region of EDIII (Huang, Lee et al. 2008, Volk, May et al. 2009). (Figure 5.1) 
 
Figure 5.1 Locations of the two GAG-binding, the EDI-EDIII linker region and the FG 
loop, motifs in YFV EDIII and DENV-2 EDIII (PDB ID: 2JQM; 2JSF) 
(a) YFV EDIII is labeled based on the secondary structure. The EDI-EDIII linker and the 
FG loop are shown in spheres and labeled in cyan and green, respectively. The ABDE β-
sheet is labeled in yellow. The CxDx β-sheet is labeled in orange. The CFG β-sheet is 
labeled in magenta.  (b) DENV-2 EDIII is labeled based on the secondary structure. The 
EDI-EDIII linker and the FG loop are shown in spheres and labeled in cyan and green, 
respectively. The ABDE β-sheet is labeled in yellow. The CxDx β-sheet is labeled in orange. 
The CFG β-sheet is labeled in magenta. 
The crystal structures of the pre- and post-fusion DENV-2 E protein soluble monomer 
suggests that the structure of EDI-EDIII is critical for the displacement of the EDIII, which 
results in the stabilized structure with a  lower free energy state in the fused viral and cell lipid 
bilayers (Harrison 2008). The pre-fusion conformation of DENV-2 E protein contains the 
disordered linear structure in the EDI-EDIII linker region. The displacement of the EDIII is 
achieved by the refolding of the EDIII with respect to EDI which leads to the elongated structure 
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of the EDI-EDIII linker region. Therefore, the EDI-EDIII linker region has  long been 
hypothesized to be  the critical region for the viral membrane fusion (Modis, Ogata et al. 2004). 
The pre-fusion and post-fusion structure of the EDI-EDIII linker region is displayed in DENV-2 
E protein and shown in Figure 5.2. Similar sequences and structures have also been reported to 
exist in the other two class II fusion proteins; namely the E1 protein of alphaviruses and the E2 
protein of hepatitis C virus (HCV) (Albecka, Montserret et al. 2011, Zheng, Sanchez-San Martin 
et al. 2011). The details of the conformational change that occurs during viral membrane fusion 
has been discussed in section 4.1.B. The structure of the similar linker region in the available 
crystal structures of alphavirus E1 protein will be discussed in section 5.1.B. 
 
Figure 5.2 EDI-EDIII linker region in the pre-fusion (a) and post-fusion (b) conformation 
of DENV-2 E protein. (PDB ID: 1OAN; 1OK8) 
The three distinct domains of DENV-2 E protein are labeled in red (EDI), yellow (EDII) 
and blue (EDIII). The EDI-EDIII linker region is highlighted in cyan. 
In contrast to the proposed importance based on the currently available crystal structures 
of flavivirus E protein, the characterization of the EDI-EDIII linker region in DENV-2 suggested 
that the mutations in such regions did not show the anticipated impairment of viral entry but 
rather led to a defective phenotype in  for virion assembly (de Wispelaere and Yang 2012). The 
details of the virion particle assembly and the structural change of the E protein during the 
maturation of virions will be reviewed in section 5.1.C. The phenotypic changes associated with 
the mutations in the DENV-2 EDI-EDIII linker region will be discussed in section 5.1.D. 
B. The linker region in alphavirus E1 protein 
Although the surface of alphavirus (Togaviridae) virions are coated with the trimeric 
units composed of the E1, E2 and E3 proteins, they utilize similar entry mechanisms to those of 
flaviviruses that have E proteins (Mancini, Clarke et al. 2000, Kielian 2006, Zhang, Hryc et al. 
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2011). For alphaviruses, the key initiation step for viral entry requires the binding of cellular 
receptors mediated by the E2 protein. The E1 protein of alphaviruses mediates the membrane 
fusion and is categorized under the class II fusion proteins. Both the alphavirus E1 proteins and 
the flavivirus E proteins undergo an extended intermediate structure in order to insert the fusion 
peptides into the host membranes. The acidification in the endosomes provides the energy that 
leads to the extended structure of the trimers of E1 protein, and the subsequent insertion of the 
fusion peptides into the host cell membrane (Fuller, Berriman et al. 1995, Harrison 2008). By 
encoding the receptor-binding domain separately in the E2 gene, the E1 protein of alphaviruses 
functionally resembles the flavivirus EDII because of the presence of the hydrophobic region in 
the domain II of the E1 proteins (Smith, Cheng et al. 1995, Lescar, Roussel et al. 2001). The 
domain I and domain III of the E1 proteins are responsible for the central restructure and the 
tethering of the entire E1 protein to the viral membrane through the transmembrane domain, 
respectively (Lescar, Roussel et al. 2001). At the interface between the structurally central DI 
and the transmembrane DIII, the DI-DIII linker region was found to tolerate the displacement of 
DIII in the membrane fusion process and resembles the structure and function of the flavivirus 
EDI-EDIII linker region (Zheng, Sanchez-San Martin et al. 2011).  
Using the pre-fusion soluble monomer of the SFV E1 protein and the post-fusion 
homotrimer of the SFV E1 protein as a model, the relatively movement of DII and the 
displacement of DIII were described.  The different conformations of the DI-DIII linker region 
are highlighted in Figure 5.3.  At  physiological pH, the three copies of the E1 monomer form 
the trimeric structure in each spike on the surface of the virion and share the more extended 
conformation displayed in Figure 5.3(a) (Lescar, Roussel et al. 2001, Gibbons, Vaney et al. 
2004). The DI-DIII exists as the disordered structure between the I0 β-strand of EDI and the A β-
strand of EDIII (Gibbons, Vaney et al. 2004). The movement of DIII relative to the location of 
DI is the most significant overall change of the architecture of E1 in the post-fusion 
conformation. After the insertion of the fusion loop into the host membrane, the extended 
intermediate structure of EDI is pulled down due to the stacking of the α-helical structure. 
Similar to the displacement of the flavivirus EDIII relative to EDI, the DIII of alphavirus E1 
protein approaches the tip of DII by 37Å and creates the extended structure of the DI-DIII linker. 
In addition to the conserved mechanisms of structural displacement, the sequences of the DI-DIII 
linker region of E1 protein show a high degree of sequence homology among alphaviruses 
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similar to the sequence homology in the EDI-EDIII linker region observed among the 
flaviviruses. 
 
 
Figure 5.3 The relative locations of three distinct domains, DI, DII, and DIII of SFV E1 
protein and the conformational change of the DI-DIII linker region during viral membrane 
fusion (PDB ID: 2ALA; 1RER) 
(a) The pre-fusion conformation of the SFV E1 glycoprotein is displayed in the monomeric 
form. The DI, DII, and DIII are labeled in red, yellow and blue, respectively. The disorder 
structure of DI-DIII linker region at the pre-fusion stage is highlighted in cyan. (b) The 
post-fusion conformation of SFV E1 glycoprotein is displayed in the homotrimeric form. 
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The DI, DII, and DIII are labeled, in red, yellow and blue, respectively. The DI-DIII linker 
region is elongated due to the displacement of DIII and highlighted in cyan. 
In contrast to the frequent use of the hydrophobic leucine and methionine by the EDI-
EDIII linker region of flaviviruses, the hydrophobic nature of DI-DIII reflects the frequent 
presence of alanine and valine, which have small hydrophobic sidechains, and also phenylalanine 
which contains a sidechain with an aromatic ring structure. Based on the numbering of SFV E1 
protein, the considered sequences of alphavirus D1-DIII linker region are summarized on Table 
5.3. 
Serocomplex Clade Virus Sequence of EDI DI-DIII linker (283-294) 
SFV Old world SFV PDSAFTRIVEAP
RRV PDSAFTRVVDAP
CHIKV PEAAFTRVVDAP
ONNV PDAAFTRVTDAP
New world MAYV ADSAFTRLTDAP
BFV Old world BFV PDSAFTRVVDAP
WEEV Old world SINV PNAAFIRTSDAP
 New world WEEV PDAAFVRSSESP
EEEV New world EEEV PDAAFTRISETP
VEEV New world VEEV PDALFTRVSETP
WEEV-like Old world ELV PDASFTRSFDAP
Table 5.3 Sequences of the EDI-EDIII linker region in the alphavirus E1 proteins 
The hydrophobic amino acids Ala286 and Phe287 are highly conserved in various 
serocomplexes under the Alphavirus genus, with the exception of VEEV and the mosquito-only 
Eilat virus (ELV). VEEV and ELV utilize leucine and serine at the corresponding region of 
Ala286. The hydrophobic Ile290 in the SFV E1 protein is conserved by the presence of 
hydrophobic valine or leucine in SFV and BFV serocomplex members in the old world clade, 
and isoleucine or valine in EEEV and VEEV serocomplex in the new world clade. The 
neighboring Val291 residue allows the variation of the sequence due to the presence of threonine 
in ONNV and MAYV and serine in WEEV, EEEV and VEEV. However, the hydrophobic 
nature is still maintained by the conserved valine in the corresponding region of RRV, CHIKV 
and BFV, and phenylalanine in the corresponding region of ELV. Notable, the new world 
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WEEV complex members, and SINV from the old world clade do not contain amino acids that 
share the comparable hydrophobicity in the same region of DI-DIII linker as other alphaviruses. 
Finally, the Ala293 is largely conserved among alphaviruses except for the new world WEEV, 
EEEV and VEEV. 
Similar to the positively charged basic nature of Lys293 in the flavivirus EDI-EDIII linker, 
the Arg289 residue is conserved in all known alphaviruses. The consistent presence of charged 
amino acids is also observed in the corresponding positions of Asp284 and Glu292. The Asp284 is 
largely conserved in all known alphaviruses except for CHIKV which contains the biochemically 
conserved glutamate, and SINV which uses asparagine in the corresponding region. The 
biochemical property of the Glu292 residue is conserved by the presence of aspartate or glutamate 
in the corresponding positions among all known flaviviruses. Both the amino- and carboxy 
termini of the DI-DIII linker contain the conserved proline residue except for the amino-terminus 
of MAYV in which the DI-DIII linker contains the hydrophobic alanine. 
In summary, the flavivirus E protein EDI-EDIII linker region, and the alphavirus E1 
protein DI-DIII linker region, both display high similarity in the structure of the polypeptide 
during the rearrangement of the overall architecture of the flavivirus E protein and the alphavirus 
E1 protein. The structures of both regions switch from the disordered conformation in the pre-
fusion state to the elongated structures in the post-fusion conformation. The flavivirus EDI-EDIII 
linker region and the alphavirus DI-DIII linker region have been characterized using reverse 
genetics systems of DENV-2 and SFV, respectively. The details of the characterization will be 
discussed in Section 5.1.C. 
 C. Characterization of the linker regions in flavivirus E protein and alphavirus E1 
protein 
The characterization of the linker regions in flavivirus E protein and alphavirus E1 
protein has been performed for DENV-2 and SFV, respectively (Zheng, Sanchez-San Martin et 
al. 2011, de Wispelaere and Yang 2012). Based on the sequence homologies and the conserved 
mechanisms for the structure rearrangement of both proteins during viral membrane fusion, it 
was first hypothesized that the mutations in the linker regions would  likely impair  viral entry 
(Gibbons, Vaney et al. 2004, Modis, Ogata et al. 2004).  
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In the study published by de Wispelaere et al.,  mutations in the EDI-EDIII linker region 
were introduced by  alanine screening performed on the cDNA infectious clone and replicon of 
DENV-2 (de Wispelaere and Yang 2012). The mutants were designed to carry the alanine 
mutations at the corresponding position of Gly294and Ser296 in the EDI-EDIII linker region of 
YFV, as well as the phenylalanine substitution at the corresponding position of Tyr297 in the 
EDI-EDIII linker region of YFV.  Gly294 and Tyr297 represent the amino acids that are conserved 
in the pan-flavivirus manner; whereas, Ser296 is uniquely conserved between YFV and DENV. 
Regardless of the locations of the alanine or phenylalanine substitution, the mutants exhibited a 
similar phenotype in vitro. The importance of the conserved sequences of the EDI-EDIII linker 
region was supported by the lack of viable mutants being recovered after the electroporation of 
infectious viral RNA in Huh-7 cells. The presence of individual antigen positive cells was 
observed in all three mutants and suggested that the mutants were capable of replicating in vitro 
and may share the impairment of viral dissemination that requires the production of infectious 
progeny virions. The characterization of the mutations in the replicon system, coupled with the 
luciferase reporter gene, further excluded the possibility that the mutations in the EDI-EDIII 
linker region of DENV-2 may interfere with the viral entry mechanism, while the mutant 
replicons were infectious and able to enter the cells and produce the luminance in vitro. The 
characterization based on the separation of the intracellular membrane organelles derived from 
the electroporated Huh-7 cells suggested a dysfunctional assembly and secretion process that 
prevents production and release of progeny virions. The mutants showed a high degree of 
retention of E protein in the ER without advancement to the Golgi apparatus, which is required 
to accomplish the final steps of morphogenesis of infectious virion by removing the pr peptide 
from the prM protein. These observations emphasize the complexity in the roles of the flavivirus 
EDI-EDIII linker regions. In addition to the anticipated impairment of viral membrane fusion, 
the assembly and maturation of flaviviruses may also require a functional EDI-EDIII linker 
region. The flavivirus E proteins also undergo an extensive conformational change since the 
different cellular compartments in the exocytosis pathway exhibit different pH. The details of the 
mechanisms and conformations of flavivirus E proteins will be discussed in Section 5.1.C. 
In contrast to the phenotypic change solely associated with viral assembly due to the 
mutations in the DENV-2 EDI-EDIII linker region,  mutations in the DI-DIII linker region of 
SFV E1 protein have been  reported to result in altered  fusogenic capacity and the efficiency of 
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viral particle assembly (Zheng, Sanchez-San Martin et al. 2011). It was first demonstrated that 
mutations in the DI-DIII linker region of alphavirus E1 proteins exist as the compensatory 
mutations in the presence the mutations in the B0 β-strand of DI. The post-fusion conformation 
of SFV E1 protein suggested that the interactions between the DI-DIII linker and the B0 β-strand 
of DI are likely to exist in a network format among the Glu2, His3 and Tyr15 in the B0 β-strand of 
DI and the Phe287 and Arg289 of the DI-DIII linker region. Similarly to the DENV-2 mutants 
reported by de Wispelaere et al., the SFV F287A mutant had  significantly lower viral titers 
when compared with  the wildtype parental virus and a correspondingly  lower efficiency in viral 
particle assembly and secretion into the culture media (de Wispelaere and Yang 2012). The SFV 
R289A mutant showed an expected phenotype which had a lower optimal pH for fusion as 
reported for the DI-DIII linker of DI that undergoes the pH-dependent conformational change. 
The lower pH implicates the higher energy required for the mutant to accomplish the viral 
membrane fusion. Both the F287A and R289A SFV mutants showed the lower fusogenic 
capacity as the optimal pH for both mutants resulted in the lower fusion index than the wildtype 
virus. 
In addition to the flavivirus E proteins and the alphavirus E1 proteins, the presence of the 
structurally similar linker region has also been suggested for the E2 glycoprotein of hepatitis C 
virus (HCV), which is also classified under the family of Flaviviridae and is widely recognized 
as being of high public health importance. Following the conserved translation strategy to 
produce the polyprotein which contains the structural and nonstructural proteins in the family of 
Flaviviridae, the envelope structure of the HCV virion consists of two structural proteins E1 and 
E2, which are both tethered to the viral membrane through the transmembrane regions in the 
carboxy-terminus (Reed and Rice 2000). The research on, and characterization of HCV were 
largely limited due to the lack of an efficient in vitro propagation platform (Kolykhalov, Agapov 
et al. 1997). With the newly available molecular virology tools including development of cDNA 
infectious clones, use of  pseudoviral particles based on  retroviral vectors, and a  recombinant 
expression system in Drosophila cells has led to the characterization of the E2 glycoprotein and 
the subsequent prediction of its secondary structure based on the sequence homologies with 
alphavirus E1 proteins (Kolykhalov, Agapov et al. 1997, Bartosch, Dubuisson et al. 2003, Krey, 
d'Alayer et al. 2010). Although the crystal structure of HCV E2 glycoprotein is not yet  available, 
the predicted structure of recombinant HCV E2 protein has suggested that the protein is rich in 
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the β-sheet structure and resembles the alphavirus E1 protein (Krey, d'Alayer et al. 2010). The 
HCV E2 glycoprotein is predicted to consist of three discontinuous domains similar to those of 
the flavivirus E proteins and the alphavirus E1 proteins. The proposed tertiary organization 
suggested that the domain I (DI) of HCV E2 protein is composed of eight β-strands similar to the 
structurally central flavivirus EDI and that it connects to the domain II (DII) containing the 
fusion loop and the transmembrane domain III (DIII). The domain II of HCV E2 protein is 
located between discontinuous sequences of two β-sheets in DI and contains the proposed fusion 
loop, which is rich in the hydrophobic amino acids. Finally, the carboxy-terminus of DI and the 
transmembrane DIII are connected by the linker region specifically named as the intergenotypic 
variable region (IgVR). The proposed three-dimensional structure of HCV E2 protein is shown 
in Figure 5.4. 
 
Figure 5.4 The proposed tertiary organization of HCV E2 protein modified from Krey et al. 
(2011) 
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The DI, DII and DIII are labeled in red, yellow and blue, respectively. The organization of 
the three domains resembles the other class II fusion proteins. The predicted eight β-
strands are labeled according to the standard nomenclature of class II fusion proteins.  
Similar to the conserved sequences observed within the serocomplexes of flaviviruses 
and alphaviruses, the IgVR region of HCV E2 glycoprotein contains high sequence homology 
within seven different genotypes of HCV, i.e. the intergenotypic sequence diversity (Hijikata, 
Kato et al. 1991). Subsequently, the IgVR region of HCV E2 glycoprotein, which resembles the 
structure of the linker region of flavivirus E proteins and alphavirus E1 glycoproteins, was 
shown to confer intergenotypic incompatibility among different genotypes.  Experiments 
performed with chimeric HCV genotypes 1a and 2a demonstrated that the substitution of the 
amino acid residues in the IgVR region of the genotype-2a HCV with the residues derived from 
the IgVR region of the genotype-1a HCV abolished the viral infectivity of the resulting 
pseudoviral particle that was produced by presentation of HCV E1 and E2 glycoproteins with a 
retroviral vector system.  By the chimerization of the IgVR region from the HCV genotype-1a 
variant with the HCV genotype-2a variant in the infectious clones of HCV, it was demonstrated 
that the lack of infectivity observed in the pseudoviral particle system was a consequence of 
impaired viral particle assembly (Albecka, Montserret et al. 2011).  
In conclusion, the structure of the flavivirus EDI-EDIII linker region is conserved in two 
other categories of enveloped small RNA viruses. The sequences of the linker regions showed 
high sequence homology among flaviviruses and alphaviruses.  Although the IgVR region of the 
HCV E2 protein shows the diversity in the sequences of different genotypes, the phenotypic 
change associated with the mutations in the IgVR region is also similar to the phenotypic 
changes associated with the mutations in the flavivirus EDI-EDIII linker region and the 
alphavirus DI-DIII linker region. The mutations in the DENV-2 EDI-EDIII linker region resulted 
in the defects in viral particle assembly, which was also observed in SFV E1 F287A mutant and 
the genotype-2a HCV chimera containing the IgVR sequence of the genotype-1a HCV variant 
(Albecka, Montserret et al. 2011, Zheng, Sanchez-San Martin et al. 2011, de Wispelaere and 
Yang 2012). Therefore, the M299I mutation in YFV EDI-EDIII linker region is likely to result in 
the consensus impairment in viral particle assembly and subsequently cause the attenuation in 
vivo. 
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 D. Viral particle assembly and virion maturation of flaviviruses 
Based on the homologous genomic structures and the conserved translational strategies 
among flaviviruses, YFV and other flaviviruses apparently share common  mechanisms for viral 
particle assembly and virion maturation prior to the secretion into the extracellular space 
(Chambers, Hahn et al. 1990). The matured virions of flaviviruses consist of the three structural 
proteins assembled upon the lipid bilayers derived from the host cells and the encapsidated viral 
RNA. Using immunogold labeling and the thin-section transmission electron microscopy, the 
assembly of the structural proteins and the encapsidation of viral RNA have been demonstrated 
to take place in the rough ER near the nuclear envelope membrane (Welsch, Miller et al. 2009).  
The conformation of mature flaviviruses virions share the smooth surface structure which 
is formed by the dimerized E protein monomers. Prior to the completion of the pH-dependent 
maturation process, 180 copies of the E protein monomers are arranged in the trimeric 
conformation leading to the presence of 60 spike structures that consists of three E protein 
monomers. Maturation requires the extensive quaternary structure rearrangement of the 
ectodomain of the E protein (Kuhn, Zhang et al. 2002, Zhang, Chipman et al. 2003). The original 
trimeric conformation of each spike upon the assembly of the immature virions of YFV and 
DENV-2 is shown in Figure 5.5.  
 
Figure 5.5 The trimeric conformation of E protein monomers in the immature virion of 
flaviviruses (PDB ID: 1NA4;1TGE) 
(a) The spike structure consists of three YFV E protein monomers in the immature virion. 
(b) The spike structure consists of three DENV-2 E protein monomers in the immature 
virion. The EDI, EDII and EDIII are labeled in red, yellow and blue, respectively. The 
EDI-EDIII linker region is highlighted in cyan. 
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Due to the nature of the pH-dependent maturation process, the immature virions of 
flaviviruses can be obtained by the treatment of infected cells with NH4Cl (Heinz, Stiasny et al. 
1994). The transition from the trimeric conformation of E proteins in the immature virions to the 
dimeric conformation of E proteins in the mature virions occurs by the decrease of pH between 
ER and the Golgi network as shown in Figure 5.6. The presence of spike structures on the 
immature virions were was confirmed  by cryo-EM reconstructed virion structures that appear as  
a spiky image with a  larger diameter than seen with the matured virions of flaviviruses (Zhang, 
Corver et al. 2003). During  the process of virion maturation in infected cells, the trimeric spike 
structure of immature virions undergoes a structural rearrangement to form the dimer which 
results in the smooth surface of mature virions in the acidic compartment of the trans Golgi 
network. In contrast to the relative rotation between EDI and EDII in each monomer of the E 
protein during the viral membrane fusion by 37˚ in the cryo-EM fitted structures, the structural 
rearrangement that occurs during virion maturation has been reported to lead to the swing of the 
EDI-EDII molecular hinge region by 27˚ based on the comparison of the fitted pre-mature E 
monomer in the cryo-EM reconstituted structure and the available structure of the soluble E 
monomer (Zhang, Zhang et al. 2004). According to the models from both the cryo-EM fitted 
structures and the soluble recombinant monomers, the maturation of virions does not  involve 
reorientation between EDI and EDIII (Modis, Ogata et al. 2004, Zhang, Zhang et al. 2004).  
 
Figure 5.6 The conformational changes of flavivirus E protein during the process of virion 
maturation (PDB ID: 3C6D;3C6R) 
(a) The trimeric conformation of DENV-2 E protein monomers in the immature virion 
assembled in the rough ER. The residues of the cryo-EM-fitted structure is displayed in 
spheres. Three monomers are arranged in the trimeric conformation with EDI, EDII and 
EDIII labeled in red, yellow and blue, respectively. The pr peptide of the prM protein is 
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colored in green and docks on the fusion loop in EDII colored in cyan. (b) The dimeric 
conformation of DENV-2 E protein monomers in the immature virion from the trans Golgi 
network prior to the furin cleavage. The residues of the cryo-EM-fitted structure is 
displayed in spheres. The envelope protein domain I, II and III are labeled in red, yellow 
and blue, respectively.  The pr peptide colored in green remains docked on the fusion loop 
to prevent the premature membrane fusion in the acidic compartment of the trans Golgi 
network. 
Prior to the formation of the fully matured dimeric structure which is capable of 
mediating viral membrane fusion via the exposed fusion loop structure, the fusion loop is 
protected in the immature dimers due to the continued docking of the pr peptide above the fusion 
loop (Yu, Zhang et al. 2008). The relative locations of the pr peptide and the envelope protein are 
shown in Figure 5.7. The removal of the pr peptide of the flavivirus prM proteins from the E 
protein is achieved by the host furin protease after the release of the immature virions from the 
trans Golgi network in order to obtain the full fusogenic capacity which is essential for the viral 
infectivity (Stadler, Allison et al. 1997).  
 
Figure 5.7 The removal of the pr peptide prior to the exocytosis of matured flavivirus 
virions 
(a) The immature dimer of DENV-2 E protein exist in the immature virions released from 
the trans Golgi network with EDI, EDII and EDIII labeled in red, yellow and blue, 
respectively. The pr peptide remains attached to the E protein by docking above the fusion 
loop and is labeled in green. (b) The cleavage of furin protease removes the pr peptide and 
leads to the exposed fusion loop (cyan) at the tip of two neighboring EDII labeled (yellow). 
The efficiency of the removal of the pr peptide from the prM protein is determined by the 
sequence at the junction between the pr peptide and the M protein (Keelapang, Sriburi et al. 
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2004). It was clearly demonstrated that the inefficient removal of DENV pr peptide results in the 
retention of the pr peptide on a subset of 180 copies of envelope protein monomers (Keelapang, 
Sriburi et al. 2004, Plevka, Battisti et al. 2011). For DENV, the incomplete removal of the pr 
peptide resulted in the production of immature-like non-infectious virions. The presence of anti-
pr peptide antibodies in response to a primary infection of DENV may lead to more efficient 
viral entry in a subsequent infection due to an antibody-dependent enhancement mechanism. The 
anti-pr peptide antibodies fail to neutralize the virions in the secondary infection by another 
heterologous serotype of DENV and the severity of the disease is augmented by the increase 
uptake of virus through the internalization of Fcγ receptors, which are associated with the anti-pr 
antibodies and non-neutralized virions (Dejnirattisai, Jumnainsong et al. 2010).  
In summary, the process of viral particle assembly and virion maturation contain multiple 
steps, about which we still lack complete understanding. Although the ultrastructural studies 
suggested that the site of virion assembly resides in close proximity to the rough ER, the details 
of the encapsidation mechanism for viral RNA are still unknown (Welsch, Miller et al. 2009). It 
is clear that the maturation of flavivirus virions occurs within the pH gradient from ER to the 
Golgi complex, and is characterized by the conformational transition of the E proteins from the 
trimeric to the dimeric form. Observation based on the reconstituted structures from cryo-EM 
images suggested that the quaternary organization of the flavivirus E protein monomers is 
rearranged from the trimeric spikes to the anti-parallel dimers, although  the actual process is 
unknown (Kuhn, Zhang et al. 2002, Zhang, Corver et al. 2003, Zhang, Zhang et al. 2004). The 
comparison between the available crystal structures of flavivirus E proteins resembling the 
conformations on the mature virions and the cryo-EM-fitted structures of immature virions 
suggested that the majority of the structural rearrangement take place at the molecular hinge 
region between EDI and EDII and the relative movement in the EDI-EDIII linker region is 
limited (Kuhn, Zhang et al. 2002). Therefore, the observations derived from the structural 
biology studies are contradictory to the characterization of the class II fusion proteins based on 
the molecular virological tools, which suggest the phenotypes associated with the EDI-EDIII 
linker region are associated with the deficiency in viral particle assembly or virion maturation 
(Albecka, Montserret et al. 2011, Zheng, Sanchez-San Martin et al. 2011, de Wispelaere and 
Yang 2012).  
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The characterization of the M299I mutation in the YFV EDI-EDIII linker region based 
upon approaches and experiments described in chapter 2 was expected to provide the 
information for the further understanding in the function of flavivirus EDI-EDIII linker region. 
 5.2 Results 
In spite of the experimental evidence suggesting the importance of the EDI-EDIII linker 
region in the flavivirus E proteins and its homology with the linker regions in the alphavirus E1 
glycoproteins, the conclusions have largely been derived from in vitro experimental models 
based on Huh7 and BHK-21 cells (Zheng, Sanchez-San Martin et al. 2011, de Wispelaere and 
Yang 2012). The lack of the characterization of mutants in vivo creates a gap in our knowledge 
on how mutations in the EDI-EDIII linker or other regions which resemble the EDI-EDIII linker 
impair the lifecycle of arboviruses in susceptible hosts and arboviruses. To assess the phenotypic 
changes associated with the M299I mutation in the YFV E protein, three mutants were evaluated 
by orally infecting Ae. aegypti mosquitoes. The single M299I mutation was introduced into both 
the Asibi strain and the 17D+Asibi M-E chimera in order to produce the Asibi E M299I mutant 
and the 17D+Asibi M-E E M299I mutant, respectively. The I299M reversion was introduced 
into the 17D strain. The 17D E I299M revertant was evaluated for the infection and 
dissemination in Ae. aegypti.  
 A. Infection and dissemination of YFV E M299I mutantsin mosquitoes 
The characterization of the M299I mutation in the YFV EDI-EDIII linker region is 
characterized by the Asibi E M299I mutant and the17D+Asibi M-E E M299I mutant. The 
infection and dissemination rates of the YFV wildtype controls and the E M299I mutants as 
determined at 7, 10 and 14 d.p.i. are summarized in Table 5.4 and Table 5.5, respectively. The 
Asibi strain and the Asibi E M299I mutant were administered at 4.44 and 4.07 logTCID50/ml, 
respectively. The challenge with the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I 
mutant was performed with average titers of 5.91 and 6.77 logTCID50/ml, respectively. 
Viremic blood meal  
(titer in logTCID50/ml) 7 d.p.i. 10 d.p.i. 14 d.p.i. 
DSB (N.A.) 0/29 (0.0%) 0/22 (0.0%) 0/37 (0.0%) 
17D (5.47) 20/37 (54.1%) 16/34 (47.1%) 13/26 (50.0%) 
17D+Asibi M-E (5.91) 36/44 (81.8%) 25/28 (89.3%) 28/34 (82.4%) 
17D+Asibi M-E E M299I (6.77) 31/33 (93.9%) 49/53 (92.5%) 19/23 (82.6%) 
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Asibi (4.44) 31/38 (81.6%) 26/39 (66.7%) 31/42 (73.8%) 
Asibi E M299I (4.07) 18/38 (47.4%)* 19/24 (79.2%) 32/43 (74.4%) 
Table 5.4 Infection rate of YFV wildtype controls and E M299I mutants in Ae. aegypti at 7, 
10 and 14 d.p.i. 
* indicates the statistically significant difference by Fisher’s exact test compared to the 
infection rate of the Asibi strain at 7 d.p.i., respectively. (p<0.05) 
The infection rate of the Asibi E M299I mutant (47.4%) was significantly lower than the 
parental Asibi strain (81.6%) at 7 d.p.i. (p=0.0036) However,  the infection rate of the Asibi 
strain and the Asibi E M299I mutant became indistinguishable at 10 (66.7% vs. 79.2%, p=0.39) 
and 14 (73.8% vs. 74.4%, p=1.00) d.p.i. The infection rates of the 17D+Asibi M-E chimera and 
the 17D+Asibi M-E E M299I mutant were not significantly different  at 7 (81.8% vs. 93.9%, 
p=0.17), 10 (89.3% vs. 92.5%, p=0.69) and 14 (82.4% vs. 82.6%, p=1.00) d.p.i. 
 Viremic blood meal  
(titer in logTCID50/ml) 7 d.p.i. 10 d.p.i. 14 d.p.i. 
17D (5.47) 0/13 (0.0%) 0/11 (0.0%) 1/9 (11.1%) 
17D+Asibi M-E (5.91) 10/24 (41.7%) 7/16 (43.8%) 9/19 (47.4%) 
17D+Asibi M-E E M299I (6.77) 5/22 (22.7%) 9/35 (25.7%) 7/13 (53.9%) 
Asibi (4.44) 12/21 (57.1%) 11/18 (61.1%) 12/24 (50.0%) 
Asibi E M299I (4.07) 10/21 (47.6%) 6/11 (54.6%) 14/24 (58.3%) 
Table 5.5 Dissemination rate of YFV wildtype controls and E M299I mutants in Ae. aegypti 
at 7, 10 and 14 d.p.i. 
 Similar dissemination rates were observed for the Asibi strain and the Asibi E M299I 
mutant at 7 (57.1% vs. 47.6%, p=0.76), 10 (61.1% vs. 54.6%, p=1.00) and 14 (50.0% vs. 58.3%, 
p=0.77) d.p.i. The 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant showed a  
lower but not significantly different  dissemination rate at 7 (41.7% vs. 22.7%, p=0.29) and 10 
(43.8% vs. 25.7%, p=0.24) d.p.i. At 14 d.p.i., there was no significant difference in the 
dissemination rate of the 17D+Asibi M-E chimera (47.4%) and the 17D+Asibi M-E E M299I 
mutant (53.9%) (p=1.00). 
In summary, the infection rate of the Asibi E M299I mutant was significantly lower than 
that of the Asibi strain only at 7 d.p.i. The infection rate of the Asibi strain and the Asibi E 
M299I mutant were similar at 10 and 14 d.p.i. Similarly, there was no significant difference in 
the infection rate of the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant at 7 
and 14 d.p.i. The M299I mutation in the E protein of the Asibi strain and the 17D+Asibi M-E 
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chimera did not result in to the demonstrable difference in the dissemination rate between 7 and 
14 d.p.i.  
 B. Viral titers of whole mosquitoes, bodies and secondary tissues infected by YFV 
M299I mutants 
The average titers of whole mosquitoes infected by the YFV wildtype controls and the E 
M299I mutants showed no significant difference at 7, 10 and 14 d.p.i. and the results are 
summarized in Figure 5.8. 
 
Figure 5.8 Average titers of whole mosquitoes infected by YFV wildtype controls and E 
M299I mutants 
(a) Average whole-mosquito titers of the Asibi strain (red) and the Asibi E M299I mutant 
(green) (b) Average whole-mosquito titers of the 17D+Asibi M-E chimera (red) and the 
17D+Asibi M-E E M299I mutant (green) 
The engorgement of the viremic blood meals containing the Asibi E M299I mutant (2.80 
logTCID50/ml) led to the relatively higher titers in the whole-mosquito homogenates than the 
Asibi strain (2.27 logTCID50/ml) collected at 0 d.p.i. Similarly, the engorgement of the 
17D+Asibi M-E E M299I mutant (5.19 logTCID50/ml) resulted in the relatively higher titers of 
the whole-mosquito homogenates than the 17D+Asibi M-E chimera (4.40 logTCID50/ml). 
The average titers in the whole mosquitoes infected by the Asibi strain and by the Asibi E 
M299I mutant did not show a significant difference at 7 (2.42 logTCID50/ml, n=10 vs. 1.77 
logTCID50/ml, n=5, p>0.05), at 10 (2.52 logTCID50/ml, n=8 vs. 2.22 logTCID50/ml, n=8, 
p>0.05) and at 14 (3.60 logTCID50/ml, n=7 vs. 2.59 logTCID50/ml, n=8, p>0.05) d.p.i. There was 
no demonstrable difference in the average titers in the whole mosquito homogenates between the 
(a) (b) 
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17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant at 7 (2.66 logTCID50/ml, 
n=11 vs. 2.97 logTCID50/ml, n=9, p>0.05), 10 (2.70 logTCID50/ml, n=8 vs. 3.20 logTCID50/ml, 
n=14, p>0.05) and 14 (2.81 logTCID50/ml, n=9 vs. 2.87 logTCID50/ml, n=8, p>0.05) d.p.i. 
The average titers of the bodies derived from Ae. aegypti showed no demonstrable 
difference between the Asibi strain and the Asibi E M299I mutant or between the 17D+Asibi M-
E chimera and the 17D+Asibi M-E E M299I mutant. The results are summarized in Figure 5.9. 
  
Figure 5.9 Average body titers of mosquitoes infected by YFV wildtype controls and E 
M299I mutants 
(a) Average body titers of the Asibi strain (red) and the Asibi E M299I mutant (green) (b) 
Average body titers of the 17D+Asibi M-E chimera (red) and the 17D+Asibi M-E E M299I 
mutant (green) 
At 7 d.p.i., the infection of Asibi strain (2.79 logTCID50/ml, n=20) resulted in a similar  
average body titer to that recorded for the Asibi E M299I mutant (2.35 logTCID50/ml, n=18) 
(p>0.05). The Asibi strain and the Asibi E M299I mutant had comparable average body titers at 
10 (2.36 logTCID50/ml, n=17 vs. 2.81 logTCID50/ml, n=9, p>0.05) and 14 (2.31 logTCID50/ml, 
n=24 vs. 2.54 logTCID50/ml, n=22, p>0.05) d.p.i. Similarly, the 17D+Asibi M-E chimera (2.61 
logTCID50/ml, n=23) resulted in the insignificantly higher average body titer than the 17D+Asibi 
M-E E M299I mutant (2.43 logTCID50/ml, n=22) at 7 d.p.i. (p>0.05) The average body titers of 
Ae. aegypti infected by the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant 
were comparable at 10 (2.48 logTCID50/ml, n=15  vs. 2.75 logTCID50/ml, n=33, p>0.05) and 14 
(2.55 logTCID50/ml, n=17 vs. 3.21 logTCID50/ml, n=33, p>0.05) d.p.i. 
The dissemination of YFV E M299I mutants did not lead to any significant difference in 
the average titers of homogenized secondary tissues between the Asibi strain and the Asibi E 
(a) (b) 
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M299I mutant or between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant. 
The average titers of the secondary tissues are shown in Figure 5.10. 
  
Figure 5.10 Average secondary-tissue titers of mosquitoes infected by YFV wildtype 
controls and E M299I mutants 
(a) Average secondary-tissue titers of the Asibi strain (red) and the Asibi E M299I mutant 
(green) (b) Average secondary-tissue titers of the 17D+Asibi M-E chimera (red) and the 
17D+Asibi M-E E M299I mutant (green) 
The average titers of the secondary tissues containing the Asibi E M299I mutant was 
insignificantly higher than those containing the Asibi strain at 7 (2.10 logTCID50/ml, n=12 vs. 
2.58 logTCID50/ml, n=10, p>0.05) and 14 (3.03 logTCID50/ml, n=12 vs. 3.34 logTCID50/ml, 
n=16, p>0.05) d.p.i.; whereas, the average secondary-tissue titer of the Asibi strain was not 
significantly different to  that of the Asibi E M299I mutant at 10 (2.88 logTCID50/ml, n=11 vs. 
2.25 logTCID50/ml, n=6, p>0.05) d.p.i. The dissemination of the 17D+Asibi M-E E M299I 
mutant also led to the insignificantly higher average secondary-tissue titer than the 17D+Asibi 
M-E chimera at 7 (1.66 logTCID50/ml, n=10 vs. 2.67 logTCID50/ml, n=5, p>0.05) and 14 (2.54 
logTCID50/ml, n=9 vs. 3.05 logTCID50/ml, n=7, p>0.05) d.p.i. At 10 d.p.i., the insignificantly 
higher average secondary-tissue titer was observed in the mosquitoes infected by the 17D+Asibi 
M-E chimera (3.02 logTCID50/ml, n=7 vs. 2.68 logTCID50/ml, n=9, p>0.05) 
In conclusion, the comparison of the average titers of the whole mosquitoes, bodies and 
secondary tissues did not show the significant difference in the corresponding type of samples 
collected at the same time points between the Asibi strain and the Asibi E M299I mutant or 
between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant. Based upon our 
data, the M299I mutation in the E protein led to the change of phenotype in the Asibi strain at 7 
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d.p.i. The amino acid at position E 299 can potentially be a determinant at the early stage of YFV 
infection in Ae. aegypti.  
 C. Infection and dissemination of YFV E I299M revertant 
The I299M reversion in the E protein of the YFV 17D strain was tested for infection and 
dissemination. The infection and dissemination rates of the YFV wildtype controls and the 17D 
E I299M revertant are summarized in Table 5.6 and Table 5.7, respectively.  The average titers 
of the viremic blood meals of the 17D strain, the 17D E I299M revertant and the 17D+Asibi M-E 
chimera are 5.47, 5.78 and 5.91 logTCID50/ml, respectively. The Asibi strain as the 
disseminating control was administered at the relatively lower titer at 4.44 logTCID50/ml. 
 Viremic blood meal  
(titer in logTCID50/ml) 7 d.p.i. 10 d.p.i. 14 d.p.i. 
DSB (N.A.) 0/29 (0.0%) 0/22 (0.0%) 0/37 (0.0%) 
17D (5.47) 20/37 (54.1%) 16/34 (47.1%) 13/26 (50.0%) 
17D E I299M (5.78) 21/33 (63.6%) 15/31 (48.4%)† 13/24 (54.2%)‡ 
17D+Asibi M-E (5.91) 36/44 (81.8%) 25/28 (89.3%) 28/34 (82.4%) 
Asibi (4.44) 31/38 (81.6%) 26/39 (66.7%) 31/42 (73.8%) 
Table 5.6 Infection rate of YFV wildtype controls and E M299I mutants in Ae. aegypti at 7, 
10 and 14 d.p.i. 
† and ‡ indicate the statistically significant difference by Fisher’s exact test compared to the 
infection rates of the Asibi strain at 7 and 10 d.p.i., respectively. (p<0.05) 
The I299M reversion in the E protein of the 17D strain failed to significantly increase the 
infection rate of the live-attenuated 17D vaccine strain. There was no demonstrable difference in 
the infection of the 17D strain and 17D E I299M revertant at 7(54.1% vs. 63.6%, p=0.47), 10 
(47.1% vs. 48.4%, p=1.00) and 14 (50.0% vs. 54.2%, p=0.79) d.p.i. The blood meal of the 17D E 
I299M revertant resulted in the lower but comparable infection rate that was not significantly 
different from the 17D+Asibi M-E chimera at 7 d.p.i. (81.8% vs. 63.6%, p=0.11) The infection 
rate of the 17D E I299M revertant was consistently lower than the 17D+Asibi M-E chimera at 10 
(89.3% vs. 48.4%, p=0.0009) and 14 (82.4% vs. 54.2%, p=0.04) d.p.i. 
 Viremic blood meal  
(titer in logTCID50/ml) 7 d.p.i. 10 d.p.i. 14 d.p.i. 
17D (5.47) 0/13 (0.0%) 0/11 (0.0%) 1/9 (11.1%) 
17D E I299M (5.78) 5/11 (45.5%) 0/10 (0.0%)† 4/9 (44.4%) 
17D/Asibi M-E (5.91) 10/24 (41.7%) 7/16 (43.8%) 9/19 (47.4%) 
Asibi (4.44) 12/21 (57.1%) 11/18 (61.1%) 12/24 (50.0%) 
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Table 5.7 Dissemination rate of YFV wildtype controls and E I299M mutants in Ae. aegypti 
at 7, 10 and 14 d.p.i. 
† indicates the significant difference by Fisher’s exact test from 17D/Asibi M-E chimera 
(p=0.02) and Asibi strain (p=0.0016) at 10 d.p.i. 
The I299M mutation resulted in the dissemination into the secondary tissues at 7 and 14 
d.p.i.; whereas no dissemination was observed at 10 d.p.i. The dissemination rate of the 17D E 
I299M revertant was significantly higher than the 17D strain at 7 d.p.i. (0.00% vs. 45.5%, 
p=0.01) but showed no statistically significant difference at 10 (0.0% vs. 0.0%, p=1.00) and at 14 
d.p.i. (11.1% vs. 44.4%, p=0.29) The comparison in the dissemination rate between the 
17D+Asibi M-E chimera and the 17D E I299M revertant showed that the infection of the 
17D+Asibi M-E chimera led to the comparable dissemination rate with the 17D E I299M 
revertant at 7 (41.7% and vs. 45.5%, p=0.24) and 14 (47.4% vs. 44.4%, p=1.00) d.p.i. The 
17D+Asibi M-E chimera had  a  significantly higher dissemination rate than the 17D E I299M 
mutant at 10 d.p.i. (43.8% vs. 0.0%, p=0.02) Although the Asibi strain was administered at the 
relatively lower titer, the comparable dissemination rate was observed at 7 (57.1% vs. 45.5%, 
p=0.72) and 14 (50.0% vs. 44.4%, p=1.00) d.p.i. At 10 d.p.i., the dissemination rate of the Asibi 
strain was significantly higher than the 17D E I299M mutant (61.1% vs. 0.0%, p=0.0016).  
In conclusion, the I299M mutantation in the E protein of the 17D strain failed to 
significantly increase the infectivity of the 17D strain. The infection of the 17D E I299M 
revertant did not show the significant higher infection rate than the 17D strain between 7 and 14 
d.p.i. Additionally, the 17D E I299M revertant showed the significantly lower infection rate than 
the 17D+Asibi M-E chimera at 10 and 14 d.p.i. Although the dissemination of the 17D E I299M 
revertant was observed at 7 and 14 d.p.i., the dissemination rate of the 17D E I299M revertant 
remained lower than the Asibi strain and the 17D+Asibi M-E chimera. The dissemination rate of 
the 17D E I299M revertant was insignificantly lower than that of the Asibi strain and the 
17D+Asibi M-E chimera at 7 and 14 d.p.i. and significantly lower than that of the Asibi strain 
and the 17D+Asibi M-E chimera at 10 d.p.i. 
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 D. Viral titers of whole mosquitoes, bodies and secondary tissues infected by YFV 
I299M revertant 
The evaluation of the viral replication based upon titration of the whole mosquitoes 
infected by the YFV wildtype controls and the 17D E I299M revertant did not identify the 
significant difference in the average titers of whole mosquitoes. These average whole-mosquito 
titers are summarized in Figure. 5.11.  
 
Figure 5.11 Average titers of whole mosquitoes infected by the Asibi strain, the 17D+Asibi 
M-E chimera, the 17D strain, and the 17D E I299M revertant 
The curves representing the average titers of the whole-mosquito homogenates infected by 
the 17D strain, the 17D E I299M mutant, the 17D+Asibi M-E chimera and the Asibi strain 
are labeled in blue, green, orange and red, respectively. 
Although the initial engorgement of the viremic blood meal containing the Asibi strain 
resulted from a  relatively lower input of virus than the 17D E I299M revertant (2.27 
logTCID50/ml vs. 3.33 logTCID50/ml), the average whole-mosquito titers of the Asibi strain  
were insignificantly higher than the 17D E I299M revertant at 7 (2.42 logTCID50/ml, n=10 vs. 
2.32 logTCID50/ml, p>0.05, n=10),10 (2.52 logTCID50/ml, n=8 vs. 2.46 logTCID50/ml, n=6, 
p>0.05) ,14 (3.60 logTCID50/ml, n=7 vs. 2.58 logTCID50/ml, n=5, p>0.05) d.p.i. Similarly, the 
infection of the 17D+Asibi M-E chimera resulted in  an insignificantly higher whole-mosquito 
titers at 7 (2.66 logTCID50/ml, n=11 vs. 2.32 logTCID50/ml, n=10, p>0.05), 10 (2.70 
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logTCID50/ml, n=8 vs. 2.46 logTCID50/ml, n=6, p>0.05) and 14 (2.81 logTCID50/ml, n=9 vs. 
2.58 logTCID50/ml, n=5, p>0.05) d.p.i. The average whole-mosquito titers between the 17D 
strain and the 17D E I299M revertant remained indistinguishable at 7 (2.79 logTCID50/ml, n=7 
vs. 3.30 logTCID50/ml, n=10, p>0.05), 10 (1.63 logTCID50/ml, n=5 vs. 2.32 logTCID50/ml, n=6, 
p>0.05) and 14 (2.09 logTCID50/ml, n=4  vs. 2.58 logTCID50/ml, n=5, p>0.05) d.p.i. 
 
Figure 5.12 Average body titers of mosquitoes infected by the Asibi strain, the 17D+Asibi 
M-E chimera, the 17D strain and the 17D E I299M revertantThe curves representing the 
average body titers of Ae. aegypti infected by the 17D strain, the 17D E I299M revertant, the 
17D+Asibi M-E chimera and the Asibi strain are labeled in blue, green, orange and red, 
respectively. 
The comparison of the average body titers is summarized in Figure. 5.12. There was no 
demonstrable difference in the average body titers between the 17D I299M revertant and any of 
the control infectious clones. The average body titers of Ae. aegypti infected by the Asibi strain 
were indistinguishable from those infected by the 17D E I299M mutant at 7 (2.79 logTCID50/ml, 
n=20 vs. 2.21 logTCID50/ml, n=10, p>0.05), 10 (2.36 logTCID50/ml, n=17 vs. 2.74 
logTCID50/ml, n=9, p>0.05) and 14 (2.31 logTCID50/ml, n=24 vs. 2.12 logTCID50/ml,n=8 , 
p>0.05) d.p.i. Similarly, there was no significant difference in the average body titers of Ae. 
aegypti infected by the 17D+Asibi M-E chimera and the 17D I299M revertant at 7 (2.61 
logTCID50/ml, n=23 vs. 2.21, n=10 logTCID50/ml, p>0.05), 10 (2.48 logTCID50/ml, n=15 vs. 
2.74 logTCID50/ml, n=9 p>0.05) and 14 (2.55 logTCID50/ml, n=17, vs. 2.12, n=8, logTCID50/ml, 
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p>0.05) d.p.i. The average body titers of Ae. aegypti infected by the 17D strain did not show any  
significant difference from those infected by the 17D E I299M revertant at 7 (2.11 logTCID50/ml, 
n=13 vs. 2.21 logTCID50/ml, n=10, p>0.05), 10 (2.35 logTCID50/ml, n=11 vs. 2.74 
logTCID50/ml, n=9, p>0.05) and 14 (2.45 logTCID50/ml, n=9, vs. 2.12 logTCID50/ml, n=8, 
p>0.05) d.p.i. 
 
Figure 5.13 Average secondary-tissue titers of mosquitoes infected by the Asibi strain, the 
17D+Asibi M-E chimera, the 17D strain and –the 17D E I299M mutant 
The curves representing the average secondary-tissue titers of Ae. aegypti infected by the 
17D strain, the 17D E I299M mutant, the 17D+Asibi M-E chimera and the Asibi strain are 
labeled in blue, green, orange and red, respectively. 
The average titers of secondary tissues infected by the 17D E I299M revertant and the 
wildtype controls did not show any significant difference at 7 and 14 d.p.i. The average 
secondary-tissue titers of the 17D E I299M revertant remained insignificantly lower than the 
Asibi strain at 7 (2.10 logTCID50/ml, n=12 vs. 1.93 logTCID50/ml, n=5) and 14 (3.30 
logTCID50/ml, n=12 vs. 1.43, n=3 logTCID50/ml) d.p.i. The average titers of secondary tissues 
infected by the 17D+Asibi M-E chimera and the 17D E I299M revertant were indistinguishable 
at 7 (1.66 logTCID50/ml, n=10  vs. 1.93 logTCID50/ml, n=5) and 14 (2.54 logTCID50/ml, n=9 vs. 
1.43 logTCID50/ml, n=3) d.p.i. 
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In summary, when compared with the control infectious clones, the cloning of the Asibi 
E I299M reversion into the YFV 17D strain did not result in an elevation in the average titers of 
the homogenized whole mosquitoes, bodies and secondary tissues. . 
 5.3 Conclusions 
 A. Attenuation caused by the M299I mutation 
The incorporation of the single YFV 17D E M299I mutation into the E protein of the 
Asibi strain resulted in a  significantly lower infection than in the wild type Asibi strain at 7 d.p.i. 
However, the infection rate of the Asibi strain and the Asibi E M299I mutant became 
comparable at 10 and 14 d.p.i. The similar attenuation was not observed in the comparison 
between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant. The infection 
rate remained indistinguishable between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
M299I mutant between 7 and 14 d.p.i. I It is plausible that the observed  attenuation caused by 
the M299I mutation characteristic of the YFV 17D E protein may contribute to the restriction of 
the infection through  delayed or reduced establishment during the early stage of viral infection. 
Importantly, the dissemination of the Asibi strain failed to be impaired by the substitution 
of the 17D M299I mutation.  The Asibi E M299I mutant still possessed the disseminating 
phenotype between 7 and 14 d.p.i. Although the insignificantly reduction of the dissemination 
rate was observed in Ae. aegypti challenged by the 17D+Asibi M-E E M299I mutant at 7 and 10 
d.p.i., the statistical analysis suggested the significant attenuation was not achieved. 
There was no demonstrable increase of viral infectivity due to the Asibi wild type I299M  
sequence into the E protein of the 17D strain. There was no significant difference in the infection 
rate between the 17D+Asibi M-E chimera and the 17D E I299M revertion. Additionally, the 
infection rate of the 17D E I299M revertant remained significantly lower than the 17D+Asibi M-
E chimera, which was challenged at the comparable viral titer, at 10 and 14 d.p.i. 
The 17D E I299M revertant showed the restoration of the disseminating capacity whilst 
the positive secondary tissues infected by the 17D E I299M revertant were identified at 7 and 14 
d.p.i. The dissemination rate of the 17D E I299M mutant remained insignificantly lower with a 
restricted phenotype at 7 and 14 d.p.i. in comparison to the 17D+Asibi M-E chimera and the 
Asibi strain.  
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In summary, the YFV 17D M299I mutation was able to cause the viral attenuation at the 
early stage of infection but did not show a significant contribution to the non-disseminating 
phenotype that is characteristic of the 17D strain. The genetic reversion by the single Asibi 
I299M introduction into 17D did not result in the highly infectious and disseminating phenotype 
of the Asibi strain. The I299M mutation insignificantly increased the infectivity of the 17D strain 
without reaching the comparable infectivity of the 17D+Asibi M-E chimera. Additionally, the 
viral dissemination that is only present in the virulent strains of YFV is likely to be partially 
restored by the I299M mutation. Although the dissemination was observed at 7 and 14 d.p.i., the 
dissemination rate still remained insignificantly different to that of the Asibi strain and the 
17D+Asibi M-E chimera. 
 B. Viral titers of homogenized mosquito tissues 
 There was no demonstrable difference in the average titers of the homogenized whole-
mosquitoes, bodies and secondary tissues infected by the wildtype controls and the E M299I 
mutants. Similarly, no significant difference in the average titers of the homogenized whole-
mosquitoes, bodies and secondary tissues infected by the wildtype controls and the E I299M 
mutants was identified. The comparable titers of all three types of samples between the wildtype 
controls and the mutants are consistent with the observation reported by McElroy et al. (McElroy, 
Tsetsarkin et al. 2006).  
 5.4 Discussion and future directions 
Our observation suggests the phenotypic change, i.e. non-disseminating 17D in the 
mosquito, caused by the E M299I mutation when introduced into the Asibi strain is at best, only 
limited to the early stage of the infection. In our experimental model using the reverse genetics 
system of YFV and Ae. aegypti, the significant attenuation was only observed at 7 d.p.i. It is the 
first available evidence to suggest that the mutations in the EDI-EDIII linker region may 
contribute to the attenuation in vivo. In contrast to the lethality to DENV-2 caused by the alanine 
substitutions in the EDI-EDIII linker region, the comparable average titers of the viremic blood 
meals and the similar infection and dissemination rates among Ae. aegypti between the YFV 
wildtype controls and E M299I mutants, YFV E M299I mutants were found viable in vitro and 
infectious to Ae. aegypti (de Wispelaere and Yang 2012).  
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It remains unclear as to how the intitial attenuation observed in our experiments during  
the early phase of viral infection is achieved by the M299I mutation in the YFV EDI-EDIII 
linker region. The most plausible explanation based on the in vitro experiments of DENV-2, SFV 
and HCV is that the M299I mutation in YFV E protein also impairs the viral particle assembly 
(Albecka, Montserret et al. 2011, Zheng, Sanchez-San Martin et al. 2011, de Wispelaere and 
Yang 2012). According to the available evidence that the binding of the receptors is mediated 
predominantly by the lateral surface of EDIII, which was not subjected to the mutagenesis in this 
study, the viral entry is less likely to be inhibited (Chen, Maguire et al. 1997, Hung, Hsieh et al. 
2004). Additionally, the replicon experiment described by de Wispelaere et al. demonstrated the 
mutations in the DENV-2 EDI-EDIII linker region did not significantly abolish the viral entry in 
vitro (de Wispelaere and Yang 2012). Although the deficiency in the viral particle assembly is 
not known to impair the viral entry, the process of the establishment of the infection by the 
arboviruses can still be potentially interfered. The establishment of the infection by YFV and 
other arboviruses in the midgut of mosquitoes has been repeatedly demonstrated to be initiated in 
individual infected epithelial cells followed by the replication and spread to the neighboring cells 
(Salazar, Richardson et al. 2007, McElroy, Girard et al. 2008, Smith, Adams et al. 2008). The 
observations suggest the successful establishment of arbovirus infection in mosquitoes 
potentially requires multiple steps, which are the viral entry in the primary target cells and the 
spread of infectious progeny virions to neighboring susceptible cells and ultimately other 
additional susceptible tissues in other body parts of the infected mosquitoes. The limited number 
of cells which are initially infected by the arboviruses often results in the so-called eclipse phase, 
when the viral titers of whole mosquitoes or infected tissues may decrease to the level which is 
below the input titer of the originally engorged virus or the limit of detection of specific assays, 
in the early stage of infection. The eclipse phase eventually is terminated by the propagation of 
the virus and the increase in the numbers of infected cells. Such kinetics in viral titer was 
described by the quantitative analysis of Ae. aegypti infected by YFV and DENV-2 (McElroy, 
Tsetsarkin et al. 2006, Richardson, Molina-Cruz et al. 2006). The examination of infected tissues 
also supported the observation based on the quantitative analysis. The earliest detection of YFV 
antigens by the immunohistochemistry staining in the mosquito midguts was reported to occur at 
3 d.p.i. and was predominantly localized in the posterior midgut followed by the spread to the 
anterior midgut between 3 and 7 d.p.i (McElroy, Girard et al. 2008). Similarly, among Ae. 
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aegypti that ingested a viremic blood containing DENV-2, the quantity of viral antigen in the 
infected midguts did not reach the detectable level of the immunofluorescence staining by anti-
DENV human pAb and anti-DENV-2 mouse 3H5 mAb until 3 d.p.i followed by the subsequent 
spread to the susceptible tissues in the legs, wings and head of the infected mosquitoes (Salazar, 
Richardson et al. 2007). In this study, the infection rates were calculated by the percentage of 
mosquitoes, which showed the detection of infectious virions in the homogenized tissues by 
TCID50 assay, among all the mosquitoes assayed. The lowest detectable titer of the assay was 
1.06 logTCID50/ml. Therefore, it is likely that the potentially impaired progeny viral particle 
assembly by the M299I mutation significantly delayed the spread of the virions to the 
neighboring cells in order to achieve the higher titers above the limit of detection. As a 
consequence of the delay in reaching the level above the limit of detection, the infection rate of 
the Asibi E M299I mutant was significantly lower than the wildtype control at 7 d.p.i. The 
continuous propagation and spread of the virus resulted in the similar infection rate between the 
Asibi strain and the Asibi E M299I mutant at the later time points, 10 and 14 d.p.i. In contrast to 
the Asibi strain which showed a transient and short eclipse phase between 0 and 3 d.p.i. in the 
study described by McElroy et al., it is likely that a subset of Ae. aegypti infected by the Asibi E 
M299I mutant experienced a significant longer eclipse phase prior to reaching the level of 
detection (McElroy, Tsetsarkin et al. 2006).  
Because the average titers of the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
M299I mutant in the viremic blood meals are relatively higher than the average titer of the Asibi 
strain and the Asibi E M299I mutant, the potential dose effect may result in the higher infection 
rate among Ae. aegypti exposed to the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
M299I mutant. Therefore, the comparison should only be made between the Asibi strain and the 
Asibi E M299I mutant or between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
M299I mutant. Additionally, the high-titer viremic blood meals may also lead to the similar 
infection rate between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I mutant. 
As the infection rates of arboviruses are proportionate to the concentration of viremic blood 
meals, the viremic blood meals containing the 17D+Asibi M-E M299I mutant could potentially 
infect a larger number of susceptible cells or result in the higher quantity of viral entry into the 
susceptible cells in the mosquito midguts (Hurlbut 1956, Gubler and Rosen 1976, Tsetsarkin, 
Vanlandingham et al. 2007, Oviedo, Romoser et al. 2011). Therefore, the eclipse phase required 
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for the viral titers of the homogenized tissues to exceed the limit of detection may be shorter and 
resulted in the comparable infection rate at 7 d.p.i. between the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E M299I mutant. 
Although the reversion of the sequence of the EDI-EDIII linker region in YFV 17D strain 
to the Asibi strain by the M299I mutation restored some capacity of viral dissemination, the 
infectivity of the 17D E M299I mutant remained similarly to that of the 17D strain and 
significantly lower than the 17D+Asibi M-E chimera. Therefore, the occurrence of the genetic 
reversion at the Ile299 residue of the EDI-EDIII linker should not be considered as a potential 
mechanism for the increase spread of the YFV vaccine strain and the phenotypic reversion to the 
virulent wildtype virus. In the presence of other attenuation determinants in the nonstructural 
genes, the complete reversion of the mutations in the structural genes of the 17D strain to the 
amino acid sequences of the Asibi strain by chimerizing the structural genes of the Asibi strain 
and the nonstructural genes of the 17D strain did not lead to the increase in the viremic titers and 
the incidence of viscerotropic diseases in the non-human primates (McGee, Lewis et al. 2008).  
In summary, the assessment of the attenuation caused by the M299I mutant in the E 
protein demonstrated its potential role as an attenuation determinant particularly by significantly 
reducing the infection rate of Ae. aegypti at the early stage of the study. The experimental design 
used in our study defined the disseminated form of infection by the presence of the infectious 
virion in the homogenized secondary tissues, which contain the head, wings and legs of the 
infected mosquitoes. As described by Miller et al., the disseminated form of infection in Ae. 
aegypti may necessarily not lead to the transmission of YFV to suckling mice (Miller and Adkins 
1988). Additionally, the presence of the virions of the YFV Asibi strain in the salivary glands 
took place after the viral dissemination into the thorax and head of the infected mosquitoes 
(McElroy, Girard et al. 2008). Therefore, prior to the viral dissemination into the salivary glands, 
it is likely that the virus undergoes multiple cycles of propagation and dissemination among the 
susceptible tissues in the midgut, thorax and head of the infected mosquitoes. Although there was 
no demonstrable difference in the dissemination rate between the Asibi strain and the Asibi E 
M299I mutant and between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E M299I 
mutant, it is unclear if the M299I mutation will prolong the extrinsic incubation period of the 
wildtype virus. The identification of the key mutations governing the period required for the 
extrinsic incubation period will provide the strategy for the design of biologically non-
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transmissible live-attenuated vaccines as the definition of incubation period is defined as the 
interval between the acquisition of the microorganisms and the ability of transmission in 
arthropod vectors. 
 A. Mutations and sequence variations in the EDI-EDIII linker region 
Our study contributes towards the more comprehensive functional analysis of the EDI-
EDIII linker region of flaviviruses. To the best of our knowledge, the Asibi E M299I mutant 
contains the first non-lethal single point mutation reported in the flavivirus EDI-EDIII linker 
region. In contrast to the lethality to the virus caused by the alanine and phenylalanine 
substitutions in the DENV-2 EDI-EDIII linker region, the M299I mutation in YFV EDI-EDIII 
linker region resulted in the minor attenuation in the early stage of viral infection (de Wispelaere 
and Yang 2012).  
  For vertebrate hosts, the largely prevailing theory is that the highly conserved amino 
acid sequences of protein products are the products of selection during the process of evolution 
(Boffelli, Nobrega et al. 2004, Gross 2007). The highly conserved amino acid sequences also 
present in the indispensable enzymatic components of flaviviruses (Valle and Falgout 1998, Zou, 
Chen et al. 2011). Therefore, the conserved sequences of the flavivirus EDI-EDIII linker region 
suggests that the region may potentially provide the critical function for the envelope proteins, 
although the region has only been known to exist in the disordered or linear structure in all the 
known available crystal structures of flavivirus E proteins in the pre- and post-fusion 
conformations (de Wispelaere and Yang 2012).  
With the available information from the DENV-2 and YFV mutants, the Gly294, Ser296 
and Tyr297 residues in the YFV EDI-EDIII linker region are likely to be the critical residues for 
the viability of the viruses. The conservative mutations in the corresponding regions in DENV-2 
EDI-EDIII linker region were still unable to allow the recovery of mutant viruses. Hence, the 
lack of the naturally occurring mutations or mutations associated with the attenuated strains of 
the virus will diminish the actual need for characterization of the mutations in the corresponding 
residues in other flaviviruses. The Met299 residue allows the presence of the conservative 
mutation utilizing isoleucine or valine in the YFV 17D strains and WNV. Currently, whether the 
M299I mutation causes any demonstrable attenuation in mammalian hosts of YFV still remains 
unknown. The complete understanding in the potential attenuation mechanisms of the M299I 
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mutation can potentially be achieved by the challenge of the Asibi E M299I mutant to the 
immunocompromised A129 or STAT1 mice model (Meier, Gardner et al. 2009).   
The future characterization of the EDI-EDIII linker region may focus on the assessment 
of phenotypic change associated with the mutations at the Lys293 and Cys300 residues, which are 
the other two conserved amino acids among all the flaviviruses. The other potential target for 
mutagenesis analysis can potentially be the Leu292 residue, which is highly conserved among 
mosquito-borne flaviviruses but is substituted with methionine in the tick-borne flaviviruses. 
Whilst the structurally similar IgVR segment in the HCV E2 protein suggested the 
intergenotypic incompatibility, which abolished the viral particle assembly, the screening of 
mutations in the flavivirus EDI-EDIII linker region to partially or significantly abolish the viral 
particle assembly will offer another potential mechanism to produce candidates for live-
attenuated flavivirus vaccines (Albecka, Montserret et al. 2011).  
 B. FG loop of EDIII located in the close proximity of the EDI-EDIII linker region 
Although the EDI-EDIII linker region and the FG loop are located at the carboxy- and 
amino-terminus of flavivirus E proteins. The folding of the protein leads to the neighboring 
locations of two fragments in EDIII. Using the crystal structure of the soluble monomer of 
DENV-2 and JEV E proteins, the relative locations of the EDI-EDIII linker region and the FG 
loop are shown in Figure 5.14. 
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Figure 5.14 The relative locations of the EDI-EDIII linker region and the FG loop in the 
crystal structures of DENV-2 and JEV E protein pre-fusion monomers (PDB ID: 
1TG8;3P54) 
(a) DENV-2 E protein structure is displayed in cartoon representation with EDI, EDII, and 
EDIII labeled in red, yellow, and blue, respectively. The EDI-EDIII linker region is shown 
in green spheres and the FG loop is shown in pink spheres. (b) JEV E protein structure is 
displayed in cartoon representation with EDI, EDII, and EDIII labeled in red, yellow, and 
blue, respectively. The EDI-EDIII linker region is shown in green spheres and the FG loop 
is shown in pink spheres. (c) DENV-2 E protein structure is displayed in surface 
representation with EDI, EDII, and EDIII labeled in red, yellow and blue, respectively. The 
EDI-EDIII linker region and the FG loop is colored in green and pink, respectively. (d) 
JEV E protein structure is displayed in surface representation with EDI, EDII, and EDIII 
labeled in red, yellow and blue, respectively. The EDI-EDIII linker region and the FG loop 
is colored in green and pink, respectively. 
The close proximity between the EDI-EDIII linker region and the FG loop suggests the 
M299I mutation and the T380R mutation are located in the neighboring region of YFV E 
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protein. Although the crystal structure of the YFV E protein has not yet been available, the 
available NMR structure of the recombinant YFV EDIII shown in Figure 5.1 demonstrated the 
relatively locations of two independent segments of the E protein (Volk, May et al. 2009). 
Therefore, the further characterization of the mutations in the EDIII region should be expanded 
to the assessment of the phenotypic change associated the YFV E M299I-T380R double mutants. 
 C. Potential interactions with the mutations in the H1 helice of E protein 
In the study described by de Wispelaere et al., the lethal T299F mutation, which is at the 
corresponding region of the Tyr297 in the YFV EDI-EDIII linker region, was compensated by 
the Q400H mutation which is located at the H1 helice of the transmembrane region in the 
DENV-2 E protein (de Wispelaere and Yang 2012). The viable mutant was recovered with the 
presence of both mutations and the further characterization of the single Q400H mutation 
suggested its potential role of enhancing the efficiency of viral particle assembly and virion 
secretion. 
In the available sequences of YFV Asibi strain and 17D substrains, the A416T mutation 
located at the H1 helice of the transmembrane region in the E protein was found in all 17D-204 
substrains and the 17DD Brazil substrain (Hahn, Dalrymple et al. 1987, dos Santos, Post et al. 
1995, Stokes, Bauer et al. 2001). It is still unknown if the A416T mutation will provide the 
similar compensatory mechanism as the compensatory Q400H mutation in DENV-2 E protein. 
We have successfully defined the M299I mutation in the YFV E protein is likely to be an 
attenuation determinant for the early stage of viral infection in Ae. aegypti. The mutation is likely 
to cause the delayed establishment of YFV infection in the mosquitoes. Its potential interaction 
with the additional neighboring T380R mutation, in other region of the E protein remains to be 
characterized. With the conserved sequences in the EDI-EDIII linker region, it is likely to 
provide the additional mechanisms for viral attenuation. 
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Chapter 6 - Major Findings, Conclusions, and Discussion 
The research described in the dissertation has provided further knowledge contributing to 
an understanding of the phenotypic changes associated with the four amino acid substitutions in 
the E protein that occurred during the attenuation process to produce YFV 17D vaccine virus 
from its wild type Asibi parental virus. The chapter provides the summary of the major findings 
and the potential application of the knowledge generated in the study as well as the future 
directions in characterizing the potential attenuation mechanisms for YFV and other flaviviruses.  
 6.1 The T380R mutation in YFV EDIII 
 A. Major finding 
The characterization of the Asibi T380R mutant and the 17D+Asibi M-E E T380R 
mutant demonstrated that the T380R mutation can slightly increase the viral infectivity in Ae. 
aegypti. The Asibi T380R mutant showed a insignificantly higher infection rate than the Asibi 
strain at 7, 10 and 14 d.p.i. The infection rate of the 17D+Asibi M-E E T380R mutant was 
significantly higher than the 17D+Asibi M-E chimera at 7 and 14 d.p.i. Although there was no 
demonstrable difference, the 17D+Asibi M-E E T380R mutant still resulted in the higher 
infection rate at 10 d.p.i. than the 17D+Asibi M-E chimera. 
In contrast to the increase in the viral infectivity, the dissemination rate of the Asibi 
T380R mutant and the 17D+Asibi M-E E T380R mutant showed no significant difference from 
the infection rate of the wild type Asibi strain and the 17D+Asibi M-E chimera. Additionally, 
there was no significant increase in the average titers of homogenates derived from whole 
mosquitoes, bodies and secondary tissues infected by the Asibi E T380R mutant and the 
17D+Asibi M-E E T380R mutant. The overall conclusion is therefore that the T380R mutation in 
the EDIII of YFV 17D strain does not on its own, contribute to the attenuated phenotype of this 
vaccine strain based on the higher infection rate, the comparable dissemination rate, and the 
similar average titers of homogenized tissues. 
 B. Comparison with the YFV structural-gene chimeras 
The phenotypes of the YFV chimeras containing the structural genes of the Asibi and 
17D strains provided the fundamental knowledge for the characterization of the individual 
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mutations in the three different domains of the E protein (McElroy, Tsetsarkin et al. 2006). The 
comparison of the infection and dissemination rate between the YFV chimeras and the E T380R 
mutants is summarized in Figure 6.1 and Figure 6.2, respectively. 
In the study described by McElroy et al., the chimerization of the EDIII from the 17D 
strain to the corresponding region of the Asibi strain significantly decreased the infection rate of 
Asibi strain from 72% to 38% (McElroy, Tsetsarkin et al. 2006). The T380R mutation is one of 
the five mutations present in EDIII of the 17D-204 strain. In contrast to the Asibi+17D+EDIII 
chimera which was shown to be significantly less infectious, the T380R mutation in the Asibi 
strain and the 17D+Asibi M-E chimera led to the increase of viral infectivity instead of the 
significant reduction in the infection rate. However, it must be remembered that in these 
experiments this T380R mutation was manipulated as part of a sequence substitution that 
included other mutations. 
 
 
Figure 6.1 The infection rate of the YFV structural-gene chimeras reported by McElroy et 
al. (2006) and the YFV E T380R mutants 
Similar to the significant reduction in the infection rate observed between the Asibi strain 
and the Asibi+17D EDIII chimera, the dissemination was significantly impaired by the 
chimerization of EDIII in the 17D strain to the corresponding region of the Asibi strain (83% vs. 
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32%). The Asibi E T380R mutant and the 17D+Asibi M-E E T380R mutant showed the 
comparable dissemination rate with the Asibi strain and the 17D+Asibi M-E chimera. 
 
Figure 6.2 The dissemination rate of the YFV structural-gene chimeras reported by 
McElroy et al. (2006) and the YFV E T380R mutants 
In conclusion, the Asibi E T380R mutant and the 17D+Asibi M-E E T380R mutant did 
not cause the significant viral attenuation in Ae. aegypti implicating that the attenuation observed 
in the Asibi+17D EDIII chimera is the consequence of attenuation caused by the other additional 
mutations in EDIII.  
 6.2 The G52R mutation in YFV EDI-EDII molecular hinge 
 A. Major finding 
The most prominent phenotypic change associated with the G52R mutation at the 
interface of YFV EDI and EDII is the loss of viral infectivity. The infection rate of the Asibi E 
G52R mutant was significantly lower than that of the Asibi strain at 7 and 10 d.p.i.; whereas, the 
infection rate of the 17D+Asibi M-E E G52R mutant showed the significant lower infectivity 
than the 17D+Asibi M-E E G52R mutant at 7 d.p.i. 
The single G52R mutation in the E protein was unable to completely prevent viral 
dissemination of the Asibi strain and the 17D+Asibi M-E chimera. The Asibi E G52R mutant 
and the 17D+Asibi M-E E G52R mutant were able to disseminate into the secondary tissues. 
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There was no significant reduction in the average titers of homogenized tissues from the 
mosquitoes infected by the YFV E G52R mutants in comparison to the wildtype controls. 
Therefore, based on the observation, the G52R mutation is likely to be a genetic determinant for 
viral infectivity. 
 B. Comparison with the YFV structural-gene chimeras 
Experiments using the Asibi+17D EDI-EDII chimera demonstrated that the infection rate 
of Ae. aegypti was significantly lower than that of the Asibi strain at 14 d.p.i (McElroy, 
Tsetsarkin et al. 2006). The result suggests one or more of the five amino acid mutations in EDI 
and EDII of the 17D strain are likely to be the determinant of viral infectivity. The comparison of 
the infection rate and the dissemination rate in the experiment utilizing the YFV structural-gene 
chimeras and the YFV E G52R mutants is shown in Figure 6.3 and Figure 6.4, respectively. 
  
 
Figure 6.3 The infection rate of the YFV structural-gene chimeras reported by McElroy et 
al. (2006) and the YFV E G52R mutants 
The introduction of the YFV 17D G52R mutation into the Asibi strain resulted in a lower 
infection rate (62.5% vs. 31.3%) similar to the decrease of viral infectivity observed by McElroy 
in Ae. aegypti orally challenged with the Asibi+17D EDI-II chimera. Although there was no 
demonstrable difference in the infection rate at 14 d.p.i. between the Asibi strain and the Asibi E 
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G52R mutant, the Asibi E G52R mutant had consistently and significantly lower infection rates 
when compared with the wild type Asibi strain at 10 and 14 d.p.i. The G52R mutation in the E 
protein also reduced the infectivity of the partially attenuated 17D+Asibi M-E chimera at 14 d.p.i. 
Similarly, in spite of the fact that there was no demonstrable difference in the infection rate 
observed at 10 and 14 d.p.i., the infection rate of the 17D+Asibi M-E E G52R mutant remained 
lower between 7 and 14 d.p.i. and there was a significant difference in the infection rate between 
the 17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R mutant at 7 d.p.i. Therefore, the 
YFV E G52R mutants reproduced the phenotype with the lower viral infectivity similar to the 
Asibi+17D EDI-II chimera. 
  
 
Figure 6.4 The dissemination rate of the YFV structural-gene chimeras reported by 
McElroy et al. (2006) and the YFV E G52R mutants 
The comparable dissemination rate between the Asibi strain and the Asibi+17D EDI-II 
chimera at 14 d.p.i. suggested the five mutations in EDI and EDII of the 17D strain do not 
prevent the viral dissemination (McElroy, Tsetsarkin et al. 2006). The dissemination rate of the 
Asibi E G52R mutant was similar to that of the Asibi strain at 14 d.p.i. The disseminated form of 
infection was not observed in Ae. aegypti infected by the 17D+Asibi M-E E G52R mutant at 14 
d.p.i.  The low infection rate of the 17D+Asibi M-E G52R mutant may originate from not only 
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the attenuation caused by the G52R mutation in the E protein but also the presence of the 
additional attenuation determinants in the nonstructural proteins. 
In summary, the comparison with the YFV wildtype controls and the results derived from 
the experiment of YFV structural-gene chimeras implicated that the G52R mutation in the E 
protein is responsible for the viral attenuation. The observation does not exclude the presence of 
additional attenuation determinants in the region of EDI and EDII.  
 6.3 The T173I mutation in YFV EDI G0H0 loop 
 A. Major finding 
The T173I mutation in the E protein was shown to have the limited contribution to the 
attenuation of YFV. The infection rate of the Asibi E T173I mutant and the 17D+Asibi M-E E 
T173I mutant remained was similar to that of the Asibi strain and the 17D+Asibi M-E chimera 
between 7 and 14 d.p.i. The dissemination of the Asibi E T173I mutant and the 17D+Asibi M-E 
E T173I mutant was equally efficient to the Asibi strain and the 17D+Asibi M-E chimera. The 
average titers from the homogenized tissues suggested the YFV E T173I mutants did not show 
the difference in the capacity of viral replication from the wildtype controls. 
 B. Comparison with the YFV structural-gene chimeras 
 The infection rate and dissemination rate of YFV E T173I mutants are compared to the 
YFV structural-gene chimeras and shown in Figure 6.5 and Figure 6.6., respectively. 
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Figure 6.5 The infection rate of the YFV structural-gene chimeras reported by McElroy et 
al. (2006) and the YFV E T173I mutants 
In contrast to the significantly lower infection rate of the Asibi+17D EDI-II chimera, the 
infection rate of the Asibi E T173I mutant (33.3%) was not significantly different to  that of the 
Asibi strain (62.5%) at 14 d.p.i. Similarly, the infection rate of the 17D+Asibi M-E chimera 
(45.8%) did not show a significant difference from that of the 17D+Asibi M-E E T173I mutant 
(41.7%) at 14 d.p.i.  
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Figure 6.6 The dissemination rate of the YFV structural-gene chimeras reported by 
McElroy et al. (2006) and the YFV E T173I mutants 
The dissemination rate of YFV E T173I mutants showed no significant difference from 
the wildtype controls. It is consistent with the comparable dissemination rate between the Asibi 
strain and the Asibi+17D-EDI-II chimera. The results are consistent with the observation that the 
Asibi+17D-EDI-II chimera disseminated in 69% of the infected Ae. aegypti at 14 d.p.i., which is 
comparable to the dissemination rate of the Asibi strain (83%). The Asibi E T173I mutant 
(75.0%) had the insignificantly lower dissemination rate than the Asibi strain (80.0%). The 
17D+Asibi M-E E T173I mutant (66.7%) also had the similar transmission rate as the 17D+Asibi 
M-E chimera (37.5%) at 14 d.p.i. 
In summary, the T173I mutation in the E protein of the Asibi strain did not lead to 
significant viral attenuation. The Asibi E T173I mutant did not resemble the phenotype of the 
Asibi+17D EDI-II chimera, which had the significantly lower infectivity than the Asibi strain. 
Therefore, we conclude that the T173I mutation is not an attenuation determinant of YFV in Ae. 
aegypti. 
202 
 
 6.4 The combined G52R and T173I mutations in YFV EDI-EDII 
 A. Major finding 
Both the Asibi E G52R-T173I double mutant and the 17D+Asibi M-E E G52R-T173I 
double mutant showed the significantly lower infectivity than the Asibi strain and the 17D+Asibi 
M-E chimera, respectively. The infection rate of the Asibi E G52R-T173I double mutant was 
significantly lower than the Asibi strain at 10 and 14 d.p.i. The infection rate of the 17D+Asibi 
M-E E G52R-T173I double mutant was significant lower than the 17D+Asibi M-E chimera at 7 
and 14 d.p.i. The YFV E G52R-T173I double mutants maintained the attenuated phenotype of 
the lower infectivity observed in the YFV E G52R mutants. 
The dissemination of the Asibi strain and the 17D+Asibi M-E chimera in infected Ae. 
agypti was not impaired by the G52R and T173I mutations. The infection of the Asibi E G52R-
T173I double mutant and the 17D+Asibi M-E E G52R-T173I mutant resulted in the 
disseminated form of infection at a similar level of the Asibi strain and the 17D+Asibi M-E 
chimera. The average titers of whole mosquitoes, bodies and secondary bodies did not show a 
significant difference between the Asibi strain and the Asibi E G52R-T173I mutant or between 
the 17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R-T173I double mutant. 
 B. Comparison with the YFV structural-gene chimeras 
The infection and dissemination rate of the Asibi E G52R-T173I double mutant and the 
17D+Asibi M-E E G52R-T173I double mutant is compared to the YFV structural-gene chimeras 
and shown in Figure 6.7 and Figure 6.8, respectively. 
The infection rate of the Asibi strain was significantly reduced by the 17D E G52R 
mutation in the EDI-EDII molecular hinge region and the 17D E T173I mutation in the H0G0 
loop of EDI. The reduction in the infection by the Asibi E G52R-T173I double mutant resembled 
the reduction of the infection rate by the chimerization of the 17D EDI and EDII with the Asibi 
strain. The significant loss of viral infectivity was also found significant between the 17D+Asibi 
M-E chimera and the 17D+Asibi M-E E G52R-T173I double mutant. 
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Figure 6.7 The infection rate of the YFV structural-gene chimeras reported by McElroy et 
al. (2006) and the YFV E G52R-T173I double mutants 
Although both the Asibi E G52R-T173I double mutant and the 17D+Asibi M-E E G52R-
T173I double mutant caused a decrease in the dissemination rate, there was no statistical 
significance identified in comparison to the Asibi strain and the 17D+Asibi M-E chimera, 
respectively. The results are consistent with the observation that the Asbi+17D EDI-II chimera, 
which contain all five mutations in EDI and EDII of 17D strain, did not show a  significant 
reduction in the dissemination rate. 
In conclusion, the Asibi E G52R-T173I double mutant and the 17D+Asibi M-E E G52R-
T173I double mutant showed the significantly attenuated lower infectivity in comparison to the 
Asibi strain and the 17D+Asibi M-E chimera. The non-disseminating 17D phenotype was not 
achieved by inclusion of the G52R and T173I mutations in EDI and EDII of the Asibi strain or 
the 17D+Asibi M-E chimera. Therefore, neither the simultaneous presence of the G52R and 
T173I mutations nor the simultaneous presence of the G52R and T173I mutations with other 
attenuation determinants in the nonstructural genes resulted in the non-disseminating phenotype 
in the 17D strain. 
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Figure 6.8 The dissemination rate of the YFV structural-gene chimeras reported by 
McElroy et al. (2006) and the YFV E G52R-T173I double mutants 
 6.5 The M299I mutation in YFV EDI-EDIII linker region 
 A. Major finding 
The characterization of the M299I mutation in the Asibi strain suggested that the M299I 
mutation is likely to result in the attenuation at the early stage of viral infection in Ae. aegypti. 
The Asibi E M299I mutant showed a significantly lower infection rate than the Asibi strain at 7 
d.p.i. However, the attenuation was not observed in the Asibi E M299I mutant at 10 and 14 d.p.i. 
In contrast to the attenuation observed between the Asibi strain and the Asibi E M299I mutant, 
the 17D+Asibi M-E E M299I mutant did not show any significant reduction of the infection rate 
between 7 and 14 d.p.i.  
The dissemination of the Asibi E M299I mutant into the secondary tissues implicated that 
the single M299I mutation in the EDI-EDIII linker region is not sufficient to restrict the 
replication of the virus in the midgut of infected mosquitoes. There was no demonstrable 
difference in the dissemination rate between the Asibi strain and the Asibi E M299I mutant 
between 7 and 14 d.p.i. Although the dissemination rate of the 17D+Asibi M-E E M299I mutant 
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was lower than that of the 17D+Asibi M-E chimera at 7 and 10 d.p.i., there was no significant 
difference identified. At 14 d.p.i., the dissemination rate between the 17D+Asibi M-E chimera 
and the 17D+Asibi M-E E M299I mutant was indistinguishable. The average titers of 
homogenized whole mosquitoes, bodies and secondary tissues showed no significant difference 
between the Asibi strain and the Asibi E M299I mutant or between the 17D+Asibi M-E chimera 
and the 17D+Asibi M-E E M299I mutant. 
The Asibi I299M reversion in the E protein of the 17D strain did not fully restore the 
virulent phenotype of the Asibi strain. The infection rate of the 17D strain and the 17D E I299M 
revertant showed no distinguishable difference between 7 and 14 d.p.i. Although the 
dissemination of the 17D E I299M revertant was observed at 7 and 14 d.p.i.,  The challenge of 
the 17D E I299M revertant resulted in a significantly lower infection rate than the 17D+Asibi M-
E chimera at 10 and 14 d.p.i.  
 B. Comparison with the YFV structural-gene chimeras 
 The infection and dissemination rate of the Asibi E M299I mutant and the 17D+Asibi 
M-E E M299I mutant at 14 d.p.i. are compared with the YFV structural-gene chimeras as shown 
in Figure 6.9 and Figure 6.10, respectively. 
  
 
Figure 6.9 The infection rate of the YFV structural-gene chimeras reported by McElroy et 
al. (2006) and the YFV E M299I mutants 
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The infection rate of the Asibi+17D EDIII chimera at 14 d.p.i. was lower than the Asibi 
strain. The observation suggested that one or more of the five mutations in EDIII of the 17D 
strain are likely to be the genetic determinants for the restricted viral replication of the 17D strain 
in Ae. aegypti. Although the Asibi E M299I mutant showed a significantly lower infection rate at 
7 d.p.i. than the Asibi strain, the evaluation of the potential viral attenuation caused by the M299I 
mutation, which is one of the five mutations, in the Asibi E M299I mutant and the 17D+Asibi 
M-E E M299I mutant demonstrated that the infection rate of both YFV E mutants had no 
significant difference in comparison to the wildtype controls at 14 d.p.i. Therefore, the 
observation suggested the continuous identification and characterization for other genetic 
determinants contributing to the low viral infectivity should further assess other mutations in 
YFV EDIII. 
  
 
Figure 6.10 The dissemination rate of the YFV structural-gene chimeras reported by 
McElroy et al. (2006) and the YFV 17D E M299I mutants 
In contrast to the significantly lower dissemination rate caused by the five mutations in 
the EDIII of the Asibi+17D EDIII at 14 d.p.i., the single 17D M299I mutation did prevent the 
viral dissemination from the midgut of the infected mosquitoes. The Asibi E M299I mutant 
showed only an insignificant change in the dissemination rate compared to the Asibi strain, 
207 
 
which was shown to have the most disseminating phenotype in the study of YFV structural-gene 
chimeras. Similarly, the dissemination of the 17D+Asibi M-E chimera was not impaired by the 
M299I mutation. 
The assessment of the increase in viral infection and dissemination caused by the I299M 
genetic reversion is summarized in Figure 6.11 and Figure 6.12, respectively. 
 
 
Figure 6.11 The infection rate of the YFV structural-gene chimeras reported by McElroy et 
al. (2006) and the YFV E I299M mutant 
The I299M reversion caused a insignificant increase of the infectivity in the 17D strain at 
14 d.p.i. The infectivity of the 17D+Asibi M-E chimera, which was comparable to the 17D strain 
in the study performed with the YFV structural-gene chimeras, remained significantly higher 
than the 17D E I299M revertant. The higher infection rate of the 17D+Asibi M-E chimera in this 
study than the 17D I299M revert  is likely to arise from the higher viral titer in the viremic blood 
meals in this study (McElroy, Tsetsarkin et al. 2006). Although the viremic titer of the Asibi 
strain was relatively lower than that of the 17D E I299M mutant, the Asibi strain was still able to 
cause the insignificantly higher infection rate than the 17D E I299M mutant. The dissemination 
rate of the 17D E I299M mutant remained insignificantly lower than the Asibi strain and the 
17D+Asibi M-E chimera at 14 d.p.i.  
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Figure 6.12 The dissemination rate of the YFV structural-gene chimeras reported by 
McElroy et al. (2006) and the YFV E I299M mutant 
In summary, we have demonstrated that the 17D M299I mutation is likely to be a genetic 
determinant for viral attenuation in the mosquito, which occurs at the early stage of viral 
infection. However, the presence of additional attenuation determinants in YFV EDIII is required 
in order to significantly limit the viral infection and dissemination in Ae. aegypti. In the event of 
a I299M reversion in a 17D backbone, we would predict that it is unlikely to fully revert the 
phenotype to that of the infectious and disseminating form characteristic of wild type virulent 
strains of YFV. The 17D E I299M revertant was significantly less infectious than the 17D+Asibi 
M-E chimera, which was orally administered at a comparable titer, and insignificantly less 
infectious than the Asibi strain, which was challenged at a relatively lower titer. Therefore, the 
lower infection rate of the 17D E I299M revertant should significantly reduce the number of 
infected mosquitoes, which ultimately would still lead to a lower number of disseminated 
infections. 
 6.6 General conclusions and discussion  
The study described in this dissertation provided the critical knowledge for the 
attenuation of YFV in Ae. aegypti by further defining the genetic determinants to single amino 
acid substitutions in the E protein. The mapping of the genetic determinants for the infection and 
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dissemination of YFV has become more specific to the level of single mutations in specific 
domains of YFV E protein. 
The 17D E T380R mutation has been found to increase the viral infectivity of YFV in Ae. 
aegypti. The mutation has previously been demonstrated to be the genetic determinant for the 
higher binding affinity between the virions and GAG molecules on the cell surface (Lee and 
Lobigs 2008). The propagation of the YFV E T380R mutants in BHK-21 cells suggested that the 
T380R mutation is likely to enhance the propagation of YFV in vitro. It is still unknown if the 
increased propagation of the YFV E T380R mutants in vitro is the consequence of the increase in 
the viral entry resulted from the higher binding affinity of the putative receptors, GAG 
molecules. The higher infectivity of the YFV E T380R mutants in Ae. aegypti suggests the 
T380R mutation is a contributory genetic determinant for viral attenuation specifically in 
mammalian hosts. The increase of the viral infectivity by the T380R mutation in the E protein 
may be diminished whilst the multiple attenuation determinants in the structural and 
nonstructural proteins of the 17D strains collaboratively attenuate the virus (McElroy, Tsetsarkin 
et al. 2006, McElroy, Tsetsarkin et al. 2006).  
The 17D E G52R mutation significantly attenuated the Asibi strain and the 17D+Asibi 
M-E chimera and resulted in the significantly lower infection rate in Ae. aegypti orally 
challenged by the Asibi  E G52R mutant and the 17D+Asibi M-E E G52R mutant. The results 
suggested that the selective mutagenesis in the hydrophobic residues in the interface of EDI and 
EDII is potentially the effective approach to attenuation of YFV and other flaviviruses 
(Hurrelbrink and McMinn 2001, Butrapet, Childers et al. 2011). The dissemination of the YFV E 
G52R mutants was not impaired because the dissemination of the Asibi E G52R mutant and the 
17D+Asibi M-E E G52R mutant was still observed and resulted in the comparable dissemination 
rate to the Asibi strain and the 17D+Asibi M-E chimera. It is likely that the attenuated phenotype 
of the 17D+Asibi M-E chimera further limited the incidence of the dissemination. Therefore, the 
dissemination of the 17D+Asibi M-E E G52R mutant only occurred at 7 d.p.i. in this study. 
The 17D T173I mutation in the YFV E protein, which was previously demonstrated to be 
the attenuation determinant of mouse neurovirulence, did not result in the significant reduction of 
viral infection and dissemination in Ae. aegypti. The lack of the demonstrable difference in the 
infection and dissemination rate between the Asibi strain and the Asibi E G52R mutant and 
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between the 17D+Asibi M-E chimera and the 17D+Asibi M-E E G52R mutant suggests the 
T173I mutation is not a genetic determinant for the attenuation of YFV in Ae. aegypti. 
The YFV 17D E G52R-T173I double mutants showed the similar phenotype observed in 
Ae. aegypti orally challenged by the single YFV E G52R mutants. The YFV E G52R-T173I 
double mutants were less infectious than the parental controls, the Asibi strain and the 
17D+Asibi M-E chimera. The dissemination of the YFV E G52R-T173I mutants was also 
observed in infected Ae. aegypti. Therefore, the most plausible explanation for the attenuated 
phenotype which was associated with the G52R and T173I mutations and led to significantly 
lower infection rate and the comparable dissemination rate can be attributed to the attenuation 
caused by the G52R mutation, which also led to the significantly lower viral infectivity and the 
similar capacity of viral dissemination.  
In contrast to the significantly lower infection and dissemination rate among Ae. aegypti 
orally infected by the Asibi+17D EDIII chimera, which contains five amino acid mutations in the 
EDIII of the 17D strains, at 14 d.p.i., the characterization of the single 17D M299I mutation in 
the YFV EDI-EDIII linker region suggested that the potential attenuation caused by the M299I 
mutation is limited at the early stage of viral infection. The infection rate of the Asibi E M299I 
mutant was significantly lower than that of the Asibi strain only at 7 d.p.i. The continuous 
propagation of the Asibi E M299I mutant in infected Ae. aegypti resulted in no demonstrable 
difference in the infection rate and the dissemination rate at 10 and 14 d.p.i. Additionally, the 
M299I mutation did not cause the significant difference in viral infection and dissemination by 
further attenuating the attenuated 17D+Asibi M-E chimera. The potential to increase the 
infection and dissemination by introducing the Asibi wild type I299M genetic reversion in the E 
protein of the 17D strain did not significantly increase the infection rate of the 17D strain but 
shows the capacity of viral dissemination was likely to be restored by the I299M mutation. 
In conclusion, the study described in this dissertation has characterized four genetic 
mutations in the YFV E protein and identified two attenuation determinants, the G52R mutation 
in the EDI-EDII molecular hinge region and the M299I mutation in the EDI-EDIII linker region.  
The G52R mutation and the M299I mutation contributed to the viral attenuation predominantly 
by reducing the viral infectivity of YFV in Ae. aegypti and resembled the phenotype of the 
Asibi+17D EDI-II chimera and the Asibi+17D EDIII chimera, respectively. The identification of 
the G52R mutation as an attenuation determinant has provided the knowledge towards the more 
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definitive mapping of the attenuation caused by the mutations in EDI and EDII of the 17D strains 
without excluding the possibility of other mutations in EDI and EDII causing the attenuation. 
Although the M299I mutation was only able to cause the significantly lower infection rate at 7 
d.p.i., the observation implicated that the lower infection rate among Ae. aegypti orally 
challenged by the Asibi+17D EDIII chimera at 14 d.p.i. may only be achieved in the presence of 
additional genetic mutations.  Similarly, the reduced dissemination rate of the Asibi+17D EDIII 
chimera is likely to be the consequence of the attenuation caused by multiple genetic loci. With 
the two point mutations in the YFV E protein causing the significantly lower infection rate, we 
are able to conclude that the multiple genetic loci in the E protein are likely to contribute to the 
reduction of viral infectivity but the genetic loci in the E protein which govern the capacity of 
viral dissemination into the secondary tissues remain to be identified. 
The results describe in this dissertation highlighted the possibility of the G52R mutation 
and the M299I mutation as candidates for the attenuation determinants of YFV. Furthermore, 
both mutations are located in the regions of the E protein, where the amino acid sequences are 
moderately- or highly-conserved in flaviviruses (Butrapet, Childers et al. 2011, de Wispelaere 
and Yang 2012). Currently, it is still unknown if the G52R mutation is able to cause the 
significant attenuation of YFV in the vertebrate host. The evidence from the 17D-variant 
Porterfield strain and the mutations in the homologous region in MVEV suggested its potential 
role of virulence determinant (Schlesinger, Chapman et al. 1996, Hurrelbrink and McMinn 
2001). Therefore, the challenge of the YFV E G52R mutants performed in the available animal 
models will be helpful for determining the potential contribution of the G52R mutation to viral 
attenuation. Similarly, the challenge of the YFV E M299I mutants has not yet been performed to 
determine the phenotypic changes associated with the M299I mutation. The lack of naturally 
occurring mutants of YFV and other flaviviruses also limited the accessible tools to further 
characterize the M299I mutation in YFV EDI-EDIII linker region or other mutations in the 
corresponding region of other flaviviruses. With the significantly lower infection rate observed 
in the YFV E M299I mutants in this study and the impairment of viral particle assembly by the 
mutations in the DENV-2 EDI-EDIII linker region in mammalian cell lines, it is highly likely the 
M299I mutation will result in the viral attenuation of YFV in vertebrate hosts (de Wispelaere and 
Yang 2012).  
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Although the characterization of the T173I mutation in EDI did not identify it being 
responsible for the phenotypic change of YFV in Ae. aegypti, the importance of the T173I 
mutation for viral attenuation should not be underestimated because of its role as the 
neurovirulence marker of YFV in mice (Carey, Kemp et al. 1972, Ryman, Xie et al. 1997, 
Ryman, Ledger et al. 1998). With the available mouse model leading to the viscerotropic 
diseases, the characterization of the T173I mutation by testing its importance in contributing to 
the viscerotropism of YFV will lead to the more comprehensive understanding of the disease 
pathogenesis in the vertebrate host (Meier, Gardner et al. 2009).  
Although the T380R mutation in YFV EDIII does not lead to the complete attenuation of 
YFV in Ae. aegypti, the importance of the T380R mutation should not be ignored since,  it 
contributes to  the attenuated phenotype of the 17D strain via  its capacity to  assist in  the 
removal of virions from the blood stream (Lee and Lobigs 2008).. The phylogenetic analyses of 
YFV 17D vaccine strains suggested there are five conserved mutations, which are M299I, 
S305F, K331R, T380R and A416T in the EDIII between the 17D-204 substrain and the 17DD 
substrain. Our results have demonstrated the M299I mutation contributes to the attenuation 
during the early stage of YFV infection and the T380R mutation does not alter the phenotype of 
YFV in Ae. aegypti. The serial passage of YFV Asibi strain in the hamster model suggested the 
K331R mutation was unable to cause the significant phenotypic change (McArthur, Xiao et al. 
2005). The future mapping of the genetic determinants in EDIII for the dissemination of YFV in 
Ae. aegypti should focus on the S305F mutation in the ectodomain of EDIII, where the physical 
interactions with the host cells and other domains of YFV E protein take place. Additionally, the 
mechanisms responsible for the increased viral infectivity of the YFV E T380R mutants remain 
unclear. The T380R mutation is located in the FG loop of YFV EDIII, where the mosquito-borne 
flaviviruses share the invariantly longer structure than the tick-borne flaviviruses (Rey, Heinz et 
al. 1995, Modis, Ogata et al. 2004). The presence of the T380R mutation in YFV EDIII resulted 
in not only the increase of the overall positive charge of the FG loop but also the formation of the 
RGD motif, which is also largely conserved in the mosquito-borne flaviviruses under the JEV 
serocomplex, which have been known to infect a wide variety of mosquito species.(Erb et al., 
2010) Whether the increase of the positive charge by the substitutions with positively charged 
amino acids such as arginine in the FG loop or the presence of the RGD motif promotes the 
infection of the mosquito-borne flaviviruses in the vectors remains to be determined. Such 
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knowledge is critical for the understanding of the choice of vector species by arboviruses in 
nature and has the ultimately value in generating the biological non-transmissible live-attenuated 
vaccines by specifically knocking out or manipulating the genetic composition which promotes 
the infection in arthropod vectors or inserting the sequences that restricts the infectivity of 
specific mosquito-borne flaviviruses. 
It is clear that the viral genetic sequences controlling the capacity of infection and 
dissemination of YFV in Ae. aegypti are likely to exist in multiple genetic loci of the E protein as 
the chimerization of the prM, E, NS2A, NS4B and 3’ untranslated regions between the Asibi 
strain and the 17D strain led to the attenuation (Bredenbeek, Kooi et al. 2003, McElroy, 
Tsetsarkin et al. 2006, McElroy, Tsetsarkin et al. 2006). In this study focusing on the 
characterization of the mutations in the E protein, we have demonstrated the significant loss of 
viral infectivity can be achieved by at least two point mutations with the potential genetic 
determinants which limit the viral dissemination remained to be identified. It is likely that the 
completely attenuated phenotype resembling the 17D strain requires the assembly of multiple 
mutations reported in this study and the previously published studies (McElroy, Tsetsarkin et al. 
2006, McElroy, Tsetsarkin et al. 2006).  
In contrast to the significantly lower infection and dissemination rate at 14 d.p.i. observed 
in the Asibi+17D EDI-II and the Asibi+17D EDIII chimera, which contain multiple genetic 
mutations in specific domains of YFV E protein, reported by McElroy et al, the single point 
mutations in the E protein were found to cause the transiently but significantly lower infection 
rate at 7 and 10 d.p.i. according to the comparison between the wildtype controls and the mutants 
(McElroy, Tsetsarkin et al. 2006). Therefore, it is likely the presence of multiple genetic 
mutations is required to produce the attenuated phenotype at 14 d.p.i. after the continuous 
propagation of YFV in the permissive cells. 
The histological examination reported by McElroy et al. has demonstrated the infection 
of the attenuated 17D+Asibi M-E chimera resulted in the distinct patterns in the distribution of 
antigens from the virulent Asibi strain in the epithelium of infected midguts. The infection of the 
17D+Asibi M-E chimera and the 17D strain in the midgut of orally infected Ae. aegypti was 
described to be initially focal at 7 d.p.i. followed by the widespread of antigens at 10 and 14 
d.p.i. in comparison with the homogeneous, widespread and dense distribution of viral antigens 
in the midgut of Ae. aegypti infected by the Asibi strain as early as 3 d.p.i. Additionally, the 
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dissemination of the attenuated 17D+Asibi M-E chimera into the secondary tissues was delayed 
compared to the Asibi strain although the 17D+Asibi M-E chimera maintained the capacity to 
disseminate into the same tissues as the Asibi strain (McElroy, Girard et al. 2008). Therefore, the 
attenuated phenotype of YFV might cause the lower number of the infected cells characterized 
by the focal distribution of viral antigens in the midgut or the prolonged period for viral 
replication prior to the dissemination into the other tissues. The similar histological examination 
will be helpful to determine the phenotypic changes caused by the G52R and M299I mutations in 
the infection and dissemination of YFV in Ae. aegypti. The quantity and distribution of the 
antigens among the epithelium in the midgut of infected mosquitoes will provide the critical 
knowledge for determining the change in the viral infectivity of the mutants. As the mutants with 
single point mutations only resulted in the significantly lower infection rate up to 10 d.p.i., the 
quantification in the number of antigen-positive epithelial cells especially prior to 7 d.p.i., when 
the infection rate of both mutants was significantly lower than the wildtype controls, will answer 
the critical question whether the mutations in the E protein of YFV 17D strains cause the 
significant loss of the viral infectivity via the less efficient viral entry and subsequently result in 
the focal distribution of viral antigens. The period required for the transition of the focal 
distribution of antigens into the widespread distribution of antigens in the infected midguts will 
provide the information to assess the potential impairment in the capacity of viral dissemination 
from the primary target cells of YFV. Such observations will be particularly important for the 
YFV E M299I mutants because the previously published mutagenesis studies in the 
corresponding region of DENV-2 E protein have suggested the mutants were associated with the 
lower efficiency of viral particle assembly (de Wispelaere and Yang 2012). Finally, the 
comparison on the length of the time required for the wildtype controls and the mutants to 
disseminate into salivary glands will be helpful in determining the differences in the length of the 
potential extrinsic incubation periods and the likelihood of being transmitted by the arthropod 
vectors. The characterization of viral dissemination into the secondary tissues described in this 
dissertation provided the fundamental understanding in whether the mutants are able to 
disseminate into any of the secondary tissues from the infected midguts. Further examination of 
the antigens of the mutants in the salivary glands will provide the direct assessment in the 
likelihood of transmission because the location viral replication in the salivary glands is required 
prior to the release of infectious virions into the saliva. 
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Similarly, the further histological examination comparing Ae. aegypti between the 
wildtype controls and the E T380R mutants will be helpful to determine the mechanism for the 
higher infection rate due to the T380R mutation in the E protein. Although it has been 
demonstrated as a determinant for the binding affinity with the cellular GAG molecules, the 
actual phenotype of the YFV E T380R mutants and the other GAG-binding variants of 
flaviviruses have not yet been characterized in orally infected arthropod vectors except for the 
oral infection experiments described in this dissertation (Lee and Lobigs 2002, Lee, Hall et al. 
2004, Lee and Lobigs 2008). The characterization of the YFV T380R mutants in chapter 3 
demonstrated that the T380R mutation in the FG loop of EDIII enhances the infectivity of YFV 
which carry the sequence of the E protein derived from the Asibi strain. The gap of knowledge 
prior to the full understanding of how the T380R mutation assists the establishment of infection 
still exists as the actual mechanisms of the increased infectivity remains unknown. The analyses 
on the differences in the primarily infected cells and the density of viral antigens in the mosquito 
midguts will provide the critical knowledge in how the accumulation of the positively-charged 
mutations in the serially passaged flaviviruses can alter the viral infectivity in the arthropod 
vectors (Lee and Lobigs 2000).  
With the histological evidence, one can anticipate the knowledge can also provide the 
information regarding to the attenuation of other mosquito-borne flaviviruses because the 
mutations in the EDI-EDII molecular hinge region in DENV-2, DENV-3, JEV and MVEV and 
the mutations in the EDI-EDIII linker region of DENV-2 all led to the phenotypic changes that 
reduce the viral infectivity or virulence (Lee, Weir et al. 1997, Hurrelbrink and McMinn 2001, 
Monath, Arroyo et al. 2002, Butrapet, Childers et al. 2011, de Wispelaere and Yang 2012). The 
knowledge is not only critical for the mapping and characterization of attenuation determinants 
for YFV and other flaviviruses but also potentially applicable to the development of the approach 
to attenuate other RNA viruses, which share the structure of class II fusion proteins. 
 6.7 Future directions 
 A. Characterization of the mutations in the E protein of YFV 17D strains 
The results in this dissertation have provided the mechanistic knowledge for viral 
attenuation caused by four of the eight conserved amino acid substitutions in the ectodomain of 
the E protein among YFV 17D vaccine strains (Hahn, Dalrymple et al. 1987, dos Santos, Post et 
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al. 1995). The remaining uncharacterized mutations in the ectodomain of the YFV E protein 
include the A170V in EDI, the K200T in EDII, and the S305F and the K331R in EDIII.  The 
A170V in the EDI G0 β-strand and the K331R mutation in the Cx β-strand are the conservative 
mutations that are expected to maintain the local structures and biochemical properties of the E 
protein. The minimal influence of the K331R mutation was reported by McArthur et al. and has 
been discussed in section 3.1 (McArthur, Xiao et al. 2005).  
As described in section 4.4, the K200T mutation in EDII is the other non-conservative 
mutation remain uncharacterized in EDI and EDII of the YFV 17D strains and shared by the 
17D-204 and 17DD substrains (Hahn, Dalrymple et al. 1987, dos Santos, Post et al. 1995). To 
achieve the more comprehensive understanding in the mechanisms that lead to the significantly 
lower infection rate of the Asibi+17D EDI-II in Ae. aegypti, the evaluation of the K200T 
mutation should be performed individually by introducing the single K200T mutation and 
collectively with the G52R mutation, which has been identified as an attenuation determinant in 
this study, in the Asibi strain and 17D+Asibi M-E chimera. 
The other additional mutation that is biochemically non-conservative and remains 
uncharacterized is the S305F mutation in EDIII. The S305F mutation is conserved in the 17-204 
and 17DD substrains. The structural change by substituting the Ser305 residue with phenylalanine 
is shown in Figure 6.13 The sidechain of the phenylalanine substitution is exposed on the 
surface of the first β-sheet of YFV EDIII in the upper portion of the structure. 
 
Figure 6.13 The S305F substitution in the A β-strand of YFV EDIII (PDB ID: 2JQM) 
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(a) The Ser305 residue is displayed with the sidechain containing the hydroxyl group 
highlighted in red. (b) The S305F substitution is displayed with the aromatic ring structure. 
Clearly, the phenylalanine substitution in the amino-terminus of the A β-strand creates a 
structure that is unique among all the known structures of flavivirus EDIIIs. In all the known 
NMR structures of flavivirus EDIIIs, the EDIII of the members under the DENV-, YFV- and 
TBEV-serocomplexes only contain one amino acid with the aromatic-ring sidechain, which is 
usually packed in the space between the first and third β-sheets, at the first residue of the A β-
strand. The EDIII of the members under the JEV-serocomplex contains two amino acid residues 
with the aromatic-ring sidechain packed in the space between the first and third β-sheets, at the 
first and third residues of the A β-strand. The amino acid residues containing the sidechain with 
the aromatic ring in the A β-strand of EDIII are shown in Figure 6.14. 
 
Figure 6.14 Locations and configurations of amino acid residues containing the aromatic-
ring sidechain in the A β-strand of flavivirus EDIII (PDB ID: 2JSF;1PJW;1S6N;1Z3R) 
The NMR structures of flavivirus EDIIIs are listed in the following order, (a) DENV-2 
EDIII, (b) JEV EDIII, (c) WNV EDIII and (d) OHFV EDIII. The first, second and third β-
sheets are colored in yellow, orange and magenta, respectively. The amino acid residues 
containing the aromatic ring sidechain are colored in cyan and the structure of the 
sidechain is displayed in sticks structure. 
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Based on the available structure of flavivirus E proteins, it is clearly demonstrated that 
the A β-strand structure is part of the upper portion of EDIII, which is exposed on the surface of 
virion and likely to interact with the cellular receptors. Due to the lack of the crystal structure of 
YFV E protein, the S305F residue is shown in the corresponding region of the crystal structure 
of DENV-2 E dimer in Figure 6.15.Whether the unique structure caused by the phenylalanine 
substitution will result in the changes in the phenotype remains to be characterized. 
 
Figure 6.15 Diagrammatic representation of the location of the YFV S305F mutation in the 
corresponding region of DENV-2 E protein dimer (PDB ID:10AN) 
The three domains are colored in red as EDI, yellow as EDII and blue as EDIII. The S305F 
mutation is shown in green spheres. 
 B. Characterization of the attenuation mechanism of YFV FNV 
Although the parental Asibi strain and the FVV strain were isolated in the same outbreak 
in the West African coast, the different strategies of attenuating the virulent viruses led to the 
difference in genetic loci which contribute to the attenuated phenotypes of the 17D strains and 
the FNV strain (Wang, Ryman et al. 1995). Although the FNV strain has been found to be not 
only more immunogenic in humans and but also non-disseminating in Ae. aegypti, the 
understanding of the attenuation mechanisms for FNV remains limited (Strode and Rockefeller 
Foundation. International Health Division. 1951, Deubel 1981). After the manufacture and use of 
FNV in disease control were discontinued, the characterization on the genetic mutations in the 
FNV strain is limited to the conserved genetic mutations between the 17D strains and the FNV 
strain. Both the L36F mutation in the prM protein and the I95M mutation conserved in both 
vaccine strains in the NS4B protein resulted in the significantly lower infection and 
dissemination rate in Ae. aegypti (McElroy, Tsetsarkin et al. 2006, McElroy, Tsetsarkin et al. 
2006).  
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Currently, the mutations in the E protein of the FNV strain have not yet been 
characterized for viral attenuation. Interestingly, the genetic heterogeneity exists extensively 
among the FNV stocks derived from difference sources potentially due to the heterogeneous 
nature of the FNV strain and the variation in passage history (Wang, Ryman et al. 1995). As 
reported by Vignuzzi et al., the greater genetic diversity of RNA  virus may be associated with 
the higher virulence (Vignuzzi, Wendt et al. 2008). Therefore, the greater genetic diversity of 
FNV may also contribute to the high incidence of neurological symptoms reported in vaccinated 
individuals. However, it is clear the continuous propagation of the FVV strain resulted in the 
accumulation of mutations, which ultimately lead to the change of phenotypes. In the study 
reported by Wang et al., the phenotypes of the variants of the FNV strains in four different 
laboratories, FNV-FC, FNV-IP, FNV-NT and FNV-CT, showed the different phenotypes in 
mouse neurovirulence, mouse neuroinvasiveness and primate neurovirulence. The amino acid 
sequences of the E protein from the four FNV variants suggested there are only three consensus 
mutations which distinguish the four FNV variants from the FVV strain (Wang, Ryman et al. 
1995). Among the four variants, the FNV-IP strain was reported to resemble the phenotype of 
FNV, which was used in the vaccination in French-speaking regions, with the loss of 
viscerotropic diseases and the increase of neurovirulence in non-human primates and mice 
(Strode and Rockefeller Foundation. International Health Division. 1951). Therefore, the FNV-
IP strain will be used as a model to discuss the potential attenuation caused by the mutations 
located in the E protein of FNV.  
There is a total of five amino acid mutations in the ectodomain of the E protein including 
the A54V mutation in the EDI-EDII molecular hinge region, the Q142R mutation and the 
N153K mutation in EDI and the G227E mutation and the N249D mutation in EDII between the 
FVV strain and the FNV-IP strain. Interestingly, there was no amino acid substitutions located in 
YFV EDIII (Wang, Ryman et al. 1995). The comparison of the locations of the mutations in the 
17D strains and the FNV strain in the corresponding regions three-dimensional structure of 
DENV-2 E protein dimer is shown in Figure 6.16. 
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Figure 6.16 The locations of the mutations in the E protein of the 17D strains and the FNV 
strain in the crystal structure of DENV-2 E protein dimer are highlighted in spheres. (PDB 
ID: 1OAN) 
The structurally central EDI is labeled in red. The dimerization EDII is labeled in yellow. 
The receptor-binding EDIII is labeled in blue. The mutations in the E protein of the 17D 
strains are shown in pink and labeled in bold-phased letters and numbers. The mutations 
in the E protein of the FNV strain are shown in green and labeled in bold-phase and 
underlined letters and numbers. 
The most notable similarity in the locations of the mutations in the 17D strains and the 
FNV strain exist in the EDI-EDII molecular hinge region, which contains the G52R mutation in 
the 17D strains and the A54V mutation in the FNV strain. In contrast to the A170V and T173I 
mutations in the EDI G0H0 loop structure on the surface of the viral membrane facing G0H0I0B0 
β-sheet, the Q142 mutation and the K153R mutation in EDI of the FNV strain are located in the 
E0F0 loop on the external surface of the A0C0D0E0F0 β-sheet. The G227E mutation is located in 
the disordered linear structure between the h and i β-strands of EDII. The region is at the 
interface of the gfeah β-sheet in the center of EDII and the ij β-sheet forming the elongated 
structure containing the fusion loop (Rey, Heinz et al. 1995). The likelihood of the G227E serves 
as a attenuation determinant for viral attenuation is limited because the residue 227 of the E 
protein in the Asibi strain utilizes the glutamate residue, which is the same as the Glu227 residue 
in the FNV-IP strain (Wang, Jennings et al. 1997). Finally, the corresponding residue of the 
N249D mutation in DENV-2 E protein is located in the pocket 1 structure of the three pockets 
providing the interactions between the M protein and the E protein in order to form the E-M-M-E 
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heterotetramer on the surface of the virion. The structure of three pockets is stabilized largely by 
the hydrophobic interactions between the M protein and the E protein (Zhang, Ge et al. 2013). 
The aspartate substitution in the asparagine residue in the N249D mutation reduced the 
hydrophobicity of the residue but it is unclear whether the attenuation is caused by the 
destabilization due to the decrease of the hydrophobicity. 
In summary, the difference in the locations where the mutations belonging to the 17D 
strains and the FNV strain are located suggests the potential attenuation caused by the mutations 
in the E protein of the FNV strain may depend on different mechanisms except for the A54V 
mutation in the EDI-EDII molecular hinge region. The identification of the attenuation 
determinants in FNV is likely to provide a different subset of mutagenesis targets for the 
rationale-based design of live-attenuated flavivirus vaccine candidates. The reverse genetics 
system of the Asibi strain can be considered as an appropriate tool for the characterization of the 
mutations in the FNV E protein because the sequences of the E protein between the Asibi strain 
and the FVV strain only differ at two residues at residue 227 and 331. The characterization of the 
A54V mutation will lead to the better understanding in the importance of the EDI-EDII 
molecular hinge region for viral attenuation because the A54V mutation is not only a 
biochemically conserved mutation and situated in the highly conserved hydrophobic region in 
the H1 peptide described in Section 4.1. The characterization of the N249D mutation in the M 
protein-binding pocket structure is expected to evaluate the potential of the selective 
destabilization of the hydrophobic interactions between the heterodimer of the M protein and the 
E protein as an approach to attenuate flaviviruses. In contrast to the 17D strains, which contain 
four amino acid substitutions in the ectodomain of EDIII, the sequence of the E proteins among 
the FNV variants suggested the lack of the mutation in the same region. The T380R mutation 
distinguishing the Asibi strain and the 17D strains has been characterized as the genetic 
determinant to increase the viral clearance and limit the viremia, which is required for the viral 
dissemination into the brains of intravenously challenged AG129 mice (Lee and Lobigs 2008). It 
will be particularly interesting to test if the introduction of the T380R mutation will further 
decrease the neurotropism of FNV. The mechanism will be potentially applicable to ensure the 
safety of the live-attenuated vaccine candidates that may require the further attenuation of the 
neurotropism. 
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 C. Characterization of the attenuation mechanism of YFV Asibi HeLa-p6 variant 
Although the mechanisms remain unknown, the attenuation of various mosquito-borne 
flaviviruses can be facilitated by the serial passage in HeLa cells (Dunster, Gibson et al. 1990). 
The serial passage of YFV in HeLa cells led to the Asibi HeLa-p6 variant that shows the 
different antigenic structures, which can potentially be attributed to the amino acid substitutions 
in the ectodomain of the E protein, and the significantly lower virulence in mice and monkeys 
(Converse, Kovatch et al. 1971, Dunster, Wang et al. 1999). The comparison with the porcine 
kidney (PK) cells-passaged YFV suggested the intrinsic factors in the HeLa cells are critical for 
the attenuation because the PK-cell-passaged YFV remained virulent to the vertebrate hosts 
(Converse, Kovatch et al. 1971). The nucleotide sequences of the E gene of the Asibi HeLa-p6 
variant identified five mutations in the ectodomain (Dunster, Wang et al. 1999). In order to 
compare with the mutations determined in the 17D stains and the FNV-IP variant, the five 
mutations, Q27H, D155A, M228K, K331R and H390P, are mapped in the available crystal 
structure of DENV-2 E protein dimer and shown in Figure 6.17. The comparison of the 
mutations in the Asibi HeLa-p6 variant with the 17D strains and the FNV-IP variant is 
summarized in Figure 6.19 and Figure 6.20, respectively. 
 
Figure 6.17 The locations of the mutations in the E protein of the Asibi HeLa-p6 variant in 
the crystal structure of DENV-2 E protein dimer are highlighted in spheres (PDB ID: 
1OAN) 
The structurally central EDI is labeled in red. The dimerization EDII is labeled in yellow. 
The receptor-binding EDIII is labeled in blue. The mutations in the E protein of the Asibi 
HeLa-p6 variant are shown in green and labeled in bold-phase letters and numbers. 
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In the structurally central EDI, the Q27H mutation and the D155A mutation are located 
in the B0C0 loop and the E0F0 loop structure on the external A0C0D0E0F0 β-sheet. The 
A0C0D0E0F0 β-sheet of EDI harbors the Q27H mutation and the D155A mutation above the inner 
G0H0I0B0 β-sheet. The M228K mutation is identified as part of the disordered structure between 
the h and i β-strands of EDII. The two regions have not been reported to contain any mutations in 
the E protein of the 17D strains.  In EDIII, the K331R mutation in the small Cx β-strand is the 
conserved substitution between the 17D strains and the Asibi HeLa-p6 variant (Volk, May et al. 
2009).  The H390P mutation in EDIII is located at the carboxy-terminus of the ectodomain in the 
“stem” region prior to the H1 perimembrane helix structure (Zhang, Ge et al. 2013). The stem 
region was recently found to be packed against the disordered structure between the h and i β-
strand, where the M228K mutation is located (Klein, Choi et al. 2013).  
Among all the mutations identified in the E protein of the Asibi HeLa-p6 variant, the 
Q27H mutation in the B0C0 loop is located in the unique region between the His244 residue in 
EDII and the His282 residue in EDI (Stiasny, Fritz et al. 2011). The relative locations of the 
mutations and the histidine residues are shown in Figure 6.18. Both of the histidine residues are 
the conserved histidine residues that are subjected to protonation required for the destabilization 
of the dimer structure prior to the conformation change in the acidic endosome.  Interestingly, 
the Q27H mutation between the His244 residue and the His282 residue results in the additional 
histidine residue between the two recipient residues of protons. It is unknown whether the 
substitution with histidine may influence the structural or biochemical properties.   
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Figure 6.18 The locations of the mutations in the E protein of the Asibi HeLa-p6 variant 
and the conserved histidine residues as the protonation targets in the crystal structure of 
DENV-2 E protein dimer are highlighted in spheres (PDB ID: 1OAN) 
The structurally central EDI is labeled in red. The dimerization EDII is labeled in yellow. 
The receptor-binding EDIII is labeled in blue. The mutations in the E protein of the Asibi 
HeLa-p6 variant are shown in green and labeled in bold-phased letters and numbers. The 
conserved histidine residues in the E protein are shown in cyan and labeled in bold-phase 
and underlined letters and numbers. 
The mapping of the mutations in the E protein of the 17D strains and the Asibi HeLa-p6 
variant suggested the potentially distinct attenuation determinants may exist. The location of the 
D155A mutation is distinct from the A170V and T173I mutations in EDI of the 17D strain, 
which are located at the G0H0 loop structure on the inner G0H0I0B0 β-sheet facing the viral 
membrane (Rey, Heinz et al. 1995). The presence of the K331R mutation is likely to be the 
conservative mutation, which has the limited contribution to viral attenuation similar to the 
phenotype from the variant of the Asibi strain derived from the passage in Syrian hamster 
(McArthur, Xiao et al. 2005).  
 
Figure 6.19 The locations of the mutations in the E protein of the 17D strains and the Asibi 
HeLa-p6 variant in the crystal structure of DENV-2 E protein dimer are highlighted in 
spheres (PDB ID: 1OAN) 
The structurally central EDI is labeled in red. The dimerization EDII is labeled in yellow. 
The receptor-binding EDIII is labeled in blue. The mutations in the E protein of the 17D 
strains are shown in pink and labeled in bold-phased letters and numbers. The mutations 
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in the E protein of the Asibi HeLa-p6 variant are shown in green and labeled in bold-phase 
and underlined letters and numbers. 
The locations of the mutations show the similarity between the FNV-IP variant and the 
Asibi HeLa-p6 variant. The D155A mutation in the Asibi HeLa-p6 variant and the Q142R 
mutation and the N153K mutation in the FNV-IP variant are all located in the E0F0 loop on the 
external A0C0D0E0F0 β-sheet. However, the significant difference in the biochemical properties 
exists because the D155A mutation in the Asibi HeLa-p6 variant removes the negative charge on 
the side chain of the glutamate with the substitution of hydrophobic methyl group on the 
sidechain of alanine but the FNV-IP variant contains two mutations which both lead to the 
increase of the positive charges with the Q142R mutation and the N153K mutation. The M228K 
mutation in EDII is located at the junction of the gfeah β-sheet and the ij β-sheet. The local 
structure consists of the disordered linear structure, which also harbors the G227E mutation 
conserved in FNV and the FNV variants (Rey, Heinz et al. 1995, Wang, Ryman et al. 1995). It is 
unclear whether the two mutations in the same region result in the similar phenotypic changes. 
 
Figure 6.20 The locations of the mutations in the E protein of the FNV-IP variant and the 
Asibi HeLa-p6 variant in the crystal structure of DENV-2 E protein dimer are highlighted 
in spheres. (PDB ID: 1OAN) 
The structurally central EDI is labeled in red. The dimerization EDII is labeled in yellow. 
The receptor-binding EDIII is labeled in blue. The mutations in the E protein of the FNV-
IP variant are shown in orange and labeled in bold-phased letters and numbers. The 
mutations in the E protein of the Asibi HeLa-p6 variant are shown in green and labeled in 
bold-phase and underlined letters and numbers. 
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The analysis and comparison of the mutations in the E protein among three attenuated 
strains of YFV based on the structural biological information suggest dissimilar mechanism for 
viral attenuation may exist. The mutations in the FNV-IP strain and the Asibi HeLa-p6 variant 
share the similarity in the locations in the E protein. The further characterization on the similarity 
and the distinctions among the attenuation mechanisms will provide the knowledge required for 
a significant advancement in the capacity of generating the candidates of live-attenuated 
flavivirus vaccines by rationale design strategies. Additionally, the mechanistic characterization 
of the attenuation mechanisms requires not only the platform for mutagenesis based on the 
molecular virology tools but also the available crystal structures. In contrast to the available 
crystal structures for the E protein of flaviviruses under DENV-, JEV- and TBEV- 
serocomplexes, the crystal structure of YFV E protein has not yet been available. The importance 
of the available crystal structure of YFV E protein has become critical for the determination of 
viral attenuation and the virulence since the first attempt of characterizing the genetic 
determinants for neuroinvasiveness of the neuroadapted 17D variants published by Nickells et al. 
(Nickells, Cannella et al. 2008). The study correctly identified the genetic mutations at the 
Phe305, Lys326 and Arg380 residues for the phenotypic change in vitro and further characterized 
the E326K mutation as the critical mutation for the neuroinvasiveness in mice. Although the 
study correctly predicted the locations of the three mutations based on the crystal structure of 
WNV E protein, the E326K mutation was later found in the BC loop of YFV EDIII, where the 
high diversity in the sequences and structures exist among flaviviruses (Volk, May et al. 2009, 
Zhang, Bovshik et al. 2010). The critical role of the crystal structure also can be exemplified by 
the clustering of mutations in specific regions of the E protein. Using the structurally 
homologous DENV-2 E protein in this dissertation, one can notice the A170V mutation and the 
T173I mutation in EDI and the M299I mutation and the T380R mutation in EDIII are located in 
the neighboring region. The precise determination of the structural change due to multiple 
mutations can only be achieved by the crystal structure of YFV E protein 
D. Genetic heterogeneity of YFV in Ae. aegypti 
Recently, the available deep sequencing tool further demonstrated the genetic 
heterogeneity of YFV is significantly lower in the 17D strains than the Asibi strain (Beck, Tesh 
et al. 2014). Such observation and the experiments of Polio virus suggest the diversity of the 
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viral population is critical for the disease pathogenesis and the attenuation (Vignuzzi, Wendt et al. 
2008, Beck, Tesh et al. 2014, Tangy and Despres 2014).  
In contrast to the discovery that the DENV-2 rapidly accumulated in the vertebrate hosts, 
the replication in arthropod vectors was reported to result in a less frequent occurrence of 
attenuation (Chen, Wu et al. 2003, Vasilakis, Deardorff et al. 2009). The current gap of 
knowledge in the process for the accumulation of mutations in the genomes of arboviruses is that 
the characterization has been performed with the highly-passaged neurovirulent DENV-2 New 
Guinea C strain in vitro. The experimental conditions may not necessarily reflect the selective 
barriers in the arthropod vectors (Hardy, Houk et al. 1983). Additionally, the highly-passaged 
neurovirulent virus may have resulted in the pre-selected viral populations based on the specific 
phenotype and the lack of the comparison with distinct phenotypes in mosquitoes further limits 
the likelihood of identifying critical mutations which result in the phenotypic changes in 
arthropods (Bray, Men et al. 1998).  
The techniques used in this study to characterize the YFV mutants in mosquitoes can also 
be applied to the characterization of YFV derived from tissue culture, which not only exhibits the 
distinct phenotypes but also contains the genetic heterogeneity among different viral populations. 
The competition assay can be performed between the infectious-clone-recovered virus and the 
tissue-culture-derived virus by the insertion of specific genetic marker in the infectious-cloned-
recovered virus, the simultaneously challenge of Ae. aegypti and the detection of the viral 
genomes in various mosquito tissues for the characterization of infection and dissemination. 
Such characterization will be helpful in providing answers to two critical questions regarding to 
the lifecycle and evolution of arboviruses, if the genetic heterogeneity is required for the 
infection and dissemination of YFV and if the replication of arboviruses in arthropod vectors 
results in the slower accumulation of mutations.  
In conclusion, the study described in this dissertation has provided the evidence that the 
genetic determinants which limit the infection of YFV in Ae. aegypti. The understanding in the 
attenuation of YFV has been further improved from the characterization of the individual 
antigenic domains of the E protein to the identification of single attenuation determinants.  
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Appendix A -  Screening of viable YFV mutants 
The cDNA infectious clones of the YFV mutants were generated with the materials and methods 
described in Section 2.2. To confirm the viability of YFV mutants, the growth curves in the 
electroporated BHK-21 cells were monitored for at least two independent electroporations. The 
average titers of the wildtype Asibi strain and the 17D+Asibi M-E chimera were obtained from 
four independent electroporations. Viable YFV mutants were selected for the per os infection of 
Ae. aegypti. 
Due to the adaptation which arises from the process of serial passage in tissue culture conditions, 
the propagation 17D+Asibi M-E chimera  reached insignificantly higher titers in electroporated 
BHK-21 cells than the Asibi strain. However, the Asibi strain has been reported to be 
significantly more infectious and disseminating than the 17D+Asibi M-E chimera in spite of the 
lower average titers of the recovered viruses. 
 1. T380R mutation in EDIII 
The recovery of the YFV E T380R mutants is summarized in Figure. 2.4. The T380R 
mutation increased the propagation of the Asibi strain and the 17D+Asibi M-E chimera in BHK-
21 cells. The Asibi E T380R mutant and the 17D+Asibi M-E E T380R mutant were recovered in 
two independent electroporations.  
  
Figure A.1 Replication of YFV E T380R mutants in electroporated BHK-21 cells 
(a) The titers of the Asibi strain and the Asibi E T380R mutant are shown in red and green 
lines, respectively. (b) The titers of the 17D+Asibi M-E chimera and the 17D+Asibi M-E E 
T380R mutant are shown in red and green lines, respectively. 
(a) (b) 
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The Asibi E T380R mutant showed the insignificantly lower titer at 1 (2.81 logTCID50/ml 
vs. 1.29 logTCID50/ml, p>0.05) and 2 (3.00 logTCID50/ml vs. 2.73 logTCID50/ml, p>0.05) d.p.e. 
than the Asibi strain. And, the viral titers of the Asibi E T380R mutant were higher than the 
Asiib strain at 3 (3.31 logTCID50/ml vs. 3.95 logTCID50/ml, p>0.05), 4 (3.84 logTCID50/ml vs. 
5.02 logTCID50/ml, p>0.05) and 5 (3.91 logTCID50/ml vs. 5.95 logTCID50/ml, p>0.05) d.p.e. 
with no statistically significant difference. 
Although there was no demonstrable difference, the 17D+Asibi M-E E T380R mutant 
propagated to the higher titers than the 17D+Asibi M-E chimera at 1 (2.92 logTCID50/ml vs. 
3.74 logTCID50/ml, p>0.05), 2 (2.78 logTCID50/ml vs. 5.02 logTCID50/ml, p>0.05), 3 (3.71 
logTCID50/ml vs. 6.74 logTCID50/ml, p>0.05), and 4 (5.57 logTCID50/ml vs, 7.02 logTCID50/ml, 
p>0.05) d.p.e. 
In summary, both the Asibi E T380R mutant and the 17D+Asibi M-E E T380R mutant 
were able to propagate to the relatively higher titers in electroporated BHK-21 cells. 
 2. G52R mutation in EDI-EDII molecular higne region and T173I in EDI 
The average titers of the YFV E G52R-T173I mutants are shown in Figure 2.5. The 
Asibi E G52R-T173I mutant and the 17D+Asibi M-E E G52R-T173I mutant were recovered 
from six independent electroporations. 
The Asibi E G52R-T173I double mutant showed the insignificantly lower titers than the 
Asibi strain at 1 (2.82 logTCID50/ml vs. 1.81 logTCID50/ml, p>0.05), 2 (3.00 logTCID50/ml vs, 
1.95 logTCID50/ml, p>0.05), 3 (3.32 logTCID50/ml vs. 2.79 logTCID50/ml, p>0.05), 4 (3.84 
logTCID50/ml vs. 3.02 logTCID50/ml, p>0.05) and 5 (3.91 logTCID50/ml vs. 3.43 logTCID50/ml, 
p>0.05) d.p.e. 
Similarly, the insignificantly lower titers were observed in the BHK-21 cells 
electroporated with the viral RNA of the 17D+Asibi M-E E G52R-T173I double mutant than the 
17D+Asibi M-E chimera at 1 (2.92 logTCID50/ml vs. 2.73 logTCID50/ml, p>0.05), 2 (2.78 
logTCID50/ml vs. 2.19 logTCID50/ml, p>0.05), 3 (3.71 logTCID50/ml vs. 3.43 logTCID50/ml, 
p>0.05) and 4 (5.57 logTCID50/ml vs. 4.01 logTCID50/ml, p>0.05) d.p.e. 
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Figure A.2 Replication of YFV E G52R-T173I double mutants in electroporated BHK-21 
cells 
(a) The titers of the Asibi strain and the Asibi E G52R-T173I double mutant are shown in 
red and green lines, respectively. (b) The titers of the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E G52R-T173I double mutant are shown in red and green lines, 
respectively. 
The titers of the YFV E G52R-T173I double mutants suggest the G52R mutation and the 
T173I mutation in the E protein result in the insignificantly lower titers for both the Asibi strain 
and the 17D+Asibi M-E chimera. 
 3. S305F, P325S and T380R mutations in EDIII 
The replication of the YFV E S305F-P325S-T380R mutants in electroporated BHK-21 
cells is summarized in Figure 2.6. The Asibi E S305F-P325S-T380R mutant and the 17D+Asibi 
M-E E S305F-P325S-T380R mutant were covered from two independent electroporations. 
Although there was no significant difference, the Asibi E S305F-P325S-T380R mutant 
propagated to the insignificantly lower titers than the Asibi strain in 1 (2.82 logTCID50/ml vs. 
1.06 logTCID50/ml, p>0.05), 2 (3.00 logTCID50/ml vs. 2.52 logTCID50/ml, p>0.05), 3 (3.31 
logTCID50/ml vs. 2.24 logTCID50/ml, p>0.05), 4 (3.84 logTCID50/ml vs. 2.74 logTCID50/ml, 
p>0.05), and 5 (3.91 logTCID50/ml vs. 1.52 logTCID50/ml, p>0.05) d.p.e. 
The replication of the 17D+Asibi M-E E S305F-P325S-T380R mutant in electroporated 
BHK-21 cells led to the comparable titers to the 17D+Asibi M-E chimera at 1 (2.92 
logTCID50/ml vs. 3.40 logTCID50/ml, p>0.05), 2 (2.78 logTCID50/ml vs. 3.74 logTCID50/ml, 
(a) (b) 
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p>0.05), 3 (3.71 logTCID50/ml vs. 6.02 logTCID50/ml, p>0.05) and 4 (5.57 logTCID50/ml vs. 
5.40 logTCID50/ml, p>0.05) d.p.e. 
  
Figure A.3 Replication of YFV E S305F-P325S-T380R double mutants in electroporated 
BHK-21 cells 
(a) The titers of the Asibi strain and the Asibi E S305F-P325S-T380R mutant are shown in 
red and green lines, respectively. (b) The titers of the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E S305F-P325S-T380R mutant are shown in red and green lines, 
respectively. 
The S305F, P325S and T380R mutations in the YFV E protein resulted in the 
insignificantly lower titer of the Asibi E S305F-P325S-T380R mutant than the Asibi strain. In 
contrast to the lower viral titers observed in the Asibi E S305F-P325S-T380R mutant, the 
replication of the 17D+Asibi M-E E S305F-P325S-T380R mutant in electroporated BHK-21 
cells showed the insignificantly higher titers at 1,2 and 3 d.p.e. than the 17D+Asibi M-E chimera. 
 4. G52R mutation in EDI-EDII molecular hinge region, T173I mutation in 
EDI and S305F and P325S mutations in EDIII 
The propagation of the YFV E G52R-T173I-S305F-P325S mutants is shown in Figure 
2.7. The Asibi E G52R-T173I-S305F-P325S mutant and the 17D+Asibi M-E E G52R-T173I-
S305F-P325S mutant were covered from three and six independent electroporations, 
respectively. 
The comparable yield in electroporated BHK-21 cells between the Asibi strain and the 
Asibi E G52R-T173I-S305F-P325S mutant was observed at 1 (2.82 logTCID50/ml vs. 2.91 
logTCID50/ml, p>0.05), 2 (3.00 logTCID50/ml vs. 3.07 logTCID50/ml, p>0.05), 3 (3.32 
(a) (b) 
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logTCID50/ml vs. 2.07 logTCID50/ml, p>0.05),  and 5 (3.91 logTCID50/ml vs. 3.72 logTCID50/ml, 
p>0.05) d.p.e. except for 4 d.p.e. (3.84 logTCID50/ml vs. 2.76 logTCID50/ml, p=0.038) 
There was no significant difference in the viral titers between the 17D+Asibi M-E 
chimera and the 17D+Asibi M-E E G52R-T173I-S305F-P325S mutant at 1 (2.92 logTCID50/ml 
vs. 2.99 logTCID50/ml, p>0.05), 2 (2.78 logTCID50/ml vs. 2.45 logTCID50/ml, p>0.05), 3 (3.71 
logTCID50/ml vs. 3.19 logTCID50/ml, p>0.05) and 4 (5.57 logTCID50/ml vs. 4.33 logTCID50/ml, 
p>0.05) d.p.e. 
  
Figure A.4 Replication of YFV E G52R-T173I-S305F-P325S mutants in electroporated 
BHK-21 cells 
(a) The titers of the Asibi strain and the Asibi E G52R-T173I-S305F-P325S mutant are 
shown in red and green lines, respectively. (b) The titers of the 17D+Asibi M-E chimera 
and the 17D+Asibi M-E E G52R-T173I-S305F-P325S mutant are shown in red and green 
lines, respectively. 
In summary, the replication of the YFV E G52R-T173I-S305F-P325S mutants in BHK-
21 cells resulted in the lower average viral titers without demonstrable difference from the 
average viral titers of wildtype controls. 
 5. G52R mutation in EDI-EDII molecular hinge region, T173I mutation in 
EDI and S305F, P325S and T380R mutations in EDIII 
The five mutations, G52R, T173I, S305F, P325S and T380R, are introduced in the E 
protein of the Asibi strain and the 17D+Asibi M-E chimera. The replication of the G52R-T173I-
S305F-P325S-T380R mutants and the wildtype controls is summarized in Figure 2.8. The Asibi 
(a) (b) 
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E G52R-T173I-S305F-P325S-T380R mutant and the 17D+Asibi M-E E G52R-T173I-S305F-
P325S-T380R mutant were recovered from two independent electroporations. 
The average titers of the Asibi E G52R-T173I-S305F-P325S-T380R mutant in the 
electroporated BHK-21 cells were insignificantly lower than the Asibi strain at 1 (2.82 
logTCID50/ml vs. 1.29 logTCID50/ml, p>0.05), 2 (3.00 logTCID50/ml vs. 1.29 logTCID50/ml, 
p>0.05), 3 (3.32 logTCID50/ml vs. 2.40 logTCID50/ml, p>0.05), and 4 (3.84 logTCID50/ml  vs. 
1.74 logTCID50/ml , p>0.05) d.p.e. 
Similarly, the 17D+Asibi M-E E G52R-T173I-S305F-P325S-T380R mutant propagated 
to the insignificantly lower average titers than the 17D+Asibi M-E chimera at 1 (2.92 
logTCID50/ml vs, 3.02 logTCID50/ml, p>0.05), 2 (2.78 logTCID50/ml vs, 2,95 logTCID50/ml, 
p>0.05), 3 (3.71 logTCID50/ml vs. 3.74 logTCID50/ml, p>0.05), and 4 (5.57 logTCID50/ml vs. 
3.52 logTCID50/ml, p>0.05) d.p.e.  
  
Figure A.5 Replication of YFV E G52R-T173I-S305F-P325S-T380R mutants in 
electroporated BHK-21 cells 
(a) The titers of the Asibi strain and the Asibi E G52R-T173I-S305F-P325S-T380R mutant 
are shown in red and green lines, respectively. (b) The titers of the 17D+Asibi M-E chimera 
and the 17D+Asibi M-E E G52R-T173I-S305F-P325S-T380R mutant are shown in red and 
green lines, respectively. 
Although there was no significant difference between the wildtype controls and the 
mutants, the five point mutations, G52R, T173I, S305F, P325S and T380R, led to the lower viral 
titers in both the Asibi strain and the 17D+Asibi M-E chimera. 
 6. Mutations in the E protein of the Asibi HeLa-p6 variant 
(a) (b) 
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The chimeras were generated by chimerizing the E gene derived from the Asibi HeLa-p6 
variant with the corresponding region in the Asibi strain and the 17D+Asibi M-E chimera. The 
recovery and propagation of YFV E HeLa-p6 mutants in BHK-21 cells are shown in Figure 2.9. 
The Asibi E HeLa-p6 mutant and the 17D+Asibi M-E E HeLa-p6 mutant were recovered from 
three independent electroporations. 
The propagation of the Asibi E HeLa-p6 mutant resulted in the similar titers to the Asibi 
strain at 1 (2.82 logTCID50/ml vs. 2.14 logTCID50/ml, p>0.05), 2 (3.00 logTCID50/ml vs. 3.14 
logTCID50/ml, p>0.05) and 3 (3.32 logTCID50/ml vs. 3.28 logTCID50/ml, p>0.05) d.p.e. The 
average titers of the Asibi E HeLa-p6 mutant were insignificantly lower than the Asibi strain at 4 
(3.84 logTCID50/ml vs. 2.47 logTCID50/ml, p>0.05) and 5 (3.91 logTCID50/ml vs. 2.47 
logTCID50/ml, p>0.05) d.p.e. 
The replication of the 17D+Asibi M-E E HeLa-p6 mutant and the 17D+Asibi M-E 
chimera led to the similar viral titers at 1 (2.92 logTCID50/ml vs. 2.58 logTCID50/ml, p>0.05), 2 
(2.78 logTCID50/ml vs. 3.00 logTCID50/ml, p>0.05), 3 (3.71 logTCID50/ml vs. 3.52 
logTCID50/ml, p>0.05), and 4 (5.57 logTCID50/ml vs. 4.52 logTCID50/ml , p>0.05) d.p.e. 
  
Figure A.6 Replication of YFV E HeLa-p6 mutants in electroporated BHK-21 cells 
(a) The titers of the Asibi strain and the Asibi E HeLa-p6 mutant are shown in red and 
green lines, respectively. (b) The titers of the 17D+Asibi M-E chimera and the 
17D+Asibi M-E E HeLa-p6 mutant are shown in red and green lines, respectively. 
The chimerization of the E gene between the Asibi strain and the Asibi HeLa-p6 variant 
resulted in the lower average peaked titer than the Asibi strain. Similarly, the 17D+Asibi M-E E 
HeLa-p6 mutant showed the lower average peaked titer than the 17D+Asibi M-E chimera. 
(a) (b) 
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In conclusion, the screening of the viable YFV mutant suggested the feasibility of 
utilizing the YFV E T380R mutant as the starting material to characterize the mutations in YFV 
EDIII because of the relatively higher average titers in BHK-21 cells electroporated by the RNA 
of the Asibi E  T380R mutant and the 17D+Asibi M-E E T380R mutant. Additionally, the 
propagation of the YFV G52R-T173I double mutants demonstrated the feasibility of using the 
mutants to characterize the two non-conservative mutations in EDI and EDII of YFV.  
 
